

ORIGINAL

T-1151

OFFICIAL TRANSCRIPT
PROCEEDINGS BEFORE

NUCLEAR REGULATORY COMMISSION

DKT/CASE NO.

TITLE

ACRS/SUBCOMMITTEES ON REACTOR RADIOLOGICAL
EFFECTS AND SITE EVALUATION

PLACE

WASHINGTON, D. C.

DATE

NOVEMBER 12, 1982

PAGES

1 - 295

TRO4
DELETE ACRS

8211160293 821112
PDR ACRS
T-1151 PDR

AR
ALDERSON REPORTING

(202) 628-9300
440 FIRST STREET, N.W.
WASHINGTON, D.C. 20001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

UNITED STATES OF AMERICA
NUCLEAR REGULATORY COMMISSION
ADVISORY COMMITTEE ON REACTOR SAFEGUARDS
SUBCOMMITTEES ON REACTOR RADIOLOGICAL EFFECTS
AND
SITE EVALUATION

Room 1046
1717 H Street, N.W.
Washington, D.C.

Friday, November 12, 1982

The Subcommittees on Reactor Radiological
Effects and Site Evaluation met, pursuant to recess, at

8:30 a.m., Dade Moeller, Chairman, presiding.

ACRS MEMBERS PRESENT:

- D. MOELLER
- J. RAY
- R. AXTMANN

ALSO PRESENT:

- R. MULLER
- R. KATHERN
- J. SHAPIRO
- H. PARKER

DESIGNATED FEDERAL EMPLOYEE:

- J. MCKINLEY

1 event of an accident at a nuclear power plant. That
2 will be presented by an official or representative from
3 FEMA. Then we will follow that with a briefing by a
4 member of the NRC staff on this same subject.

5 Next, we will discuss a proposed revision to
6 10 CFR Part 140, criteria for extraordinary nuclear
7 occurrences, and we will close out today with a
8 discussion of the de minimis concept from a regulatory
9 point of view, and that will include presentations by
10 the NRC staff, by EPA as they are looking at this
11 concept in terms of radioactive waste, and by
12 representatives of, I believe, the Edison Electric
13 Institute, and then a representative from the Oakridge
14 National Laboratory.

15 We will then recess for the evening, and the
16 subcommittee will resume its meeting tomorrow morning
17 with a discussion of two items. First of all, a
18 proposed amendment to 10 CFR Part 50 which is a proposed
19 ALARA rule for operating nuclear power plant licensees,
20 and then we will consider the possible impact of seismic
21 events as they relate to emergency planning for
22 accidents at nuclear power plants.

23 We have a variety of subjects that we are
24 going to try to cover, and we have a rather lengthy
25 agenda. But I hope we can move forward with it and

1 accomplish our objectives.

2 Our purposes are several. We are here to
3 listen and to be brought up to date on each of these
4 subjects, and in so doing we will seek also to foster
5 communications and to promote interchange among the
6 people involved in these issues, and that includes, of
7 course, the public, as well as the various Federal
8 agencies.

9 Where warranted, and where we believe we have
10 something useful to say, tomorrow, following the formal
11 portion of the meeting, we will consider the development
12 of written recommendations for submission to the
13 Advisory Committee on Reactor Safeguards for the
14 consideration of the full committee in terms of possibly
15 submitting written comments to either the NRC staff or
16 the NRC Commissioners.

17 This meeting is being conducted in accordance
18 with the provisions of the Federal Advisory Committee
19 Act and the Government in the Sunshine Act. Ms. R. C.
20 Tang, sitted on my right, is the Designated Federal
21 Employee for the meeting. We also have with us Mr. John
22 McKinley and Dr. Thomas McCone, Dr. McCone being an ACRS
23 fellow.

24 The rules for participation in today's meeting
25 have been announced as part of the notice previously

1 published in the Federal Register on October 25, 1982,
2 and then amended on November 8, 1982.

3 A transcript of the meeting is being kept, and
4 it is requested that each speaker first identify himself
5 or herself and speak with sufficient clarity and volume
6 so that he or she can be readily heard.

7 We have received one written statement
8 relative to the subjects being covered at the meeting,
9 and this written statement was submitted by Russell M.
10 Bimber from Paynesville, Ohio.

11 Mr. Bimber has commented on three topics being
12 covered at this meeting. First of all, the use of
13 potassium iodide as a thyroid blocking agent. The
14 second item is a comment on the revisions of 10 CFR 20.
15 The third item is a comment on the subject of the
16 extraordinary nuclear occurrence.

17 We are making copies of his written comments
18 available to all of the members of the subcommittee and
19 copies are additionally available for anyone who desires
20 them.

21 We have not received any formal request for
22 time from members of the public to make oral statements
23 at this meeting. Why don't I ask at this time if there
24 is anyone here who might desire a few minutes to make an
25 oral statement at any time in the next two days, other

1 than the people, of course, who are on the agenda.

2 I see no response, so we will not allow time
3 at the moment, but, again, if someone comes forward
4 later, we will certainly accommodate them.

5 Let me ask at this time if any of the members
6 of the subcommittee or our consultants have any
7 questions on how we will proceed.

8 Since at least one member of our consulting
9 staff is new, I will simply say that we will carry
10 through in our discussion in the formal presentations of
11 each of the comments of our various speakers. You are
12 free to interrupt and ask questions either while they
13 are speaking, or we can do that at the end.

14 We are here to become informed. " are here
15 to solicit and encourage you to provide the subcommittee
16 members with your thoughts, with your recommendations,
17 with your suggestions, with your comments on each of
18 these topics.

19 Tomorrow morning, as I said, following the
20 last formal presentation, we will meet in open session,
21 open to the public, but it will be an executive session
22 where we will simply discuss among ourselves what our
23 conclusions are and try to reach a consensus on each of
24 the items in terms of what our recommendations will be
25 that we will forward then to the full committee.

1 I see, after making that comment, that the DOE
2 people have asked that they be permitted to proceed
3 through their presentation and hold questions until the
4 end. We can certainly accommodate you in that request.

5 MR. VALLARIO: Mr. Chairman, would it be
6 possible to put EPA second on the list?

7 We have quite a bit of material to cover, and
8 I think it would be more prudent to have us as anchor on
9 the morning session, so that we could regulate ourselves
10 knowing how much time it would take. Would it be
11 possible to do that?

12 MR. MOELLER: We will certainly try to do
13 that, Ed. We will go ahead with the NRC, and then if
14 the EPA people are here, we will move forward with
15 them.

16 MR. VALLARIO: Thank you.

17 MR. MOELLER: Any other comments or requests?

18 There being none, let's move forward with the
19 initial presentation, which is the current status of the
20 NRC proposed revision of 10 CFR Part 20, and I will call
21 on William Mills.

22 MR. MILLS: Where would you like me to be?

23 MR. MOELLER: I think up here would help.

24 Let me repeat that although it is, in a sense,
25 sort of a formal meeting, I want to get to the facts, I

1 want comments, I want us to really get into these
2 subjects and discuss them. So don't stand on
3 formality. Raise your hand, and I will recognize you.

4 We can have comments from the DOE people
5 during the NRC presentation, and vice versa.

6 MR. MILLS: Thank you, Mr. Chairman, members
7 of the subcommittee, and consultants.

8 What we would like to do today, as you have
9 mentioned, is to give you a status report of where we
10 are with the revision of Part 20, and to fill you in on
11 some of the contacts that we have had since our previous
12 meeting, and discussion on the issue.

13 We want to give you a feel for some of the
14 significant changes that we have made in the draft rule,
15 and then to tell you where we are relative to the status
16 of the rule and the accompanying information that we
17 must prepare to submit it as a proposed rule for
18 consideration within the NRC.

19 Let me touch first on the kind of meetings
20 that we have held since our last discussion.

21 We have met with the Edison Electric Institute
22 in a meeting in Atlanta, in which we went over in detail
23 the comments that they had, and some of the issues that
24 they raised, and this will be reflected in the changes
25 we have made.

1 We have met with the Atomic Industrial Forum
2 on two occasions here in Washington. On one occasion,
3 it a half-day meeting in which we discussed some of the
4 general topics. Then for two days, we sat down with a
5 ad hoc working group of the Atomic Industrial Forum in
6 which we went through line by line down the rule, and
7 heard their comments on the possibility of some the
8 practical problems they had with the implementation of
9 the rule.

10 We also participated in a conference sponsored
11 by the Atomic Industrial Forum in which we presented
12 three papers that dealt with the Part 20 issue in one
13 way or another.

14 Mr. Minogue gave a paper on the general
15 approach to 10 CFR Part 20 revision, as well as brief
16 comments on the de minimis concept. He also talked
17 about the source term research that is being undertaken
18 relative to that problem.

19 Mr. Guy Cunningham, from the Executive Legal
20 Office in NRC, gave a paper on de minimis, and you will
21 be hearing from that paper this afternoon. We gave also
22 a short presentation of the overall content of the
23 revision of Part 20.

24 We have met with the NRC Regions I and II, and
25 we had lengthy discussions in which we covered the focus

1 of the revision. This was particular important because
2 one of the questions that come up repeatedly will be how
3 we will translate the revision into the actual
4 inspection procedures, and what steps will we take to
5 inform the inspectors of what these changes are and some
6 of the intent. They have raised questions which we have
7 also fed into the revision.

8 We met with the Westinghouse people, I guess
9 their collective health physics program. Particularly
10 of interest to us, that we discussed in the earlier
11 meeting, was the fuel fabrication. I think we have
12 worked something out with these people.

13 As a follow up to a meeting in which Dr. Denny
14 Ross met with Assistant Secretary Young in the
15 Department of Energy, we met with the DOE staff, with
16 Deputy Assistant Secretary, Mr. Bob Davies, and many of
17 the people who will be giving a report from DOE this
18 morning.

19 We have proposed to DOE, as a follow up to our
20 discussion, to sit down with them and discuss where we
21 are in agreement, where the major areas of disagreement
22 remain. We have such a meeting scheduled now for the
23 22nd or the 23rd of this month.

24 I am sure you will hear some of the problems
25 that DOE sees in the revision during the course of the

1 day, and that will be beneficial to us as well.

2 MR. MOELLER: There is a question, Bill.

3 MR. RAY: Excuse the interruption, please, but
4 maybe you can fill in the gaps in my background, in my
5 understanding of the procedures in the review of this
6 proposed rule.

7 I gather from your narration that the review
8 has been by organizations that have expertise and
9 interest in the industry. Has there been any formal
10 submission to the general public for comments, or will
11 there be?

12 MR. MILLS: Yes, sir. There will have to be a
13 formal proposal.

14 The intent, when we started out, in drawing up
15 a rule, was to meet with the licensees and other
16 interested parties. For example, we have met with the
17 National Resources Defense Council. We have met with
18 the hospital people. The idea was that we would develop
19 a rule in which we got early input on the practicality
20 and the problems that they saw in the revision of such a
21 rule.

22 In doing so, with the full understanding that
23 this was an evolutionary process in terms of revising
24 the rule, and that we were not asking for formal review
25 at this time. The formal review will of course occur

1 when we get the approval from the Commission, and then
2 it would in fact be published in the Federal Register.

3 MR. RAY: Mr. Mills, if you have the time to
4 do that, I think that it is a splendid idea myself,
5 because the thing you show the public then has more
6 support in the scientific area.

7 MR. MILLS: I guess it is not a unique
8 approach in the NRC, but it is certainly one that we
9 have found to be in the best interest of our work, not
10 to go to a formal review process prior to getting those
11 kinds of input.

12 I was going to cover some of this in the
13 status, but let me just say that what you are hearing
14 from us has not in fact received any formal review
15 within the NRC itself.

16 My colleagues here, Mr. Cool and Mr. Baker, if
17 you saw their version of the rule, you would see a
18 document which is continuously being rewritten and
19 significant changes are being made. So we are not at
20 that point where we have even asked for a review within
21 the NRC.

22 I must say that the sessions that we have had
23 by talking to licensees and other interested
24 individuals, we have in fact gotten significant changes
25 in our thinking, and we think it is resulting in a rule

1 that is better focused on what it is supposed to do, and
2 at the same time it meets the requirements that we see
3 in NRC.

4 There hasn't been any formal blessing of any
5 type. Of course that will be a long process, and we
6 recognize that.

7 We, of course, have tried to sharpen the
8 definitions. We have made a lot of editorial changes.
9 One of the things as a result of the discussions that we
10 have had, in the current version, probably the version
11 that you have seen which was written in August, we
12 continued to carry the SI units in the document, we now
13 are dropping the SI units from all areas except in the
14 definitions themselves.

15 It made the reporting requirements a little
16 bit complex as to whether or not there would report the
17 SI units or the conventional units that we have used up
18 to date. So we don't ask that they make that they make
19 that conversion. That was of particular concern to the
20 unions people, because to try to explain to them a new
21 system of units was a very difficult problem, and others
22 as well.

23 One other thing that we changed is the photo
24 conversion factors. We had in the table a long list of
25 conversions from rads to rems as a function of energy.

1 The reason we changed it was that we never intended for
2 the licensee to actually try to determine the small
3 changes in the photo spectra. That was not the intent.
4 The intent was to address the problem of calibration of
5 his dosimeter, so that his dosimeter was responsive to
6 the air filters.

7 What we have done, we have tried to simplify
8 that. We never intended that the licensee have a
9 continued spectrometer problem, so we dropped a lot of
10 the conversion.

11 We modified the controls for the very high
12 radiation areas. We had a lot of conditions in those
13 requirements that the licensee would have to do three
14 additional activities. We found that that constituted a
15 lot of unnecessary redundancy, and without jeopardizing
16 the control on the high radiation areas, instead of
17 making them "and" clauses, we have made them "or"
18 clauses. We don't feel that this is in any respect
19 going to jeopardize the control that the NRC will have
20 over those radiation areas.

21 One of the things that, of course, is of major
22 interest to us is the requirement for the summation of
23 the internal and external exposure. After a lot of
24 discussion on this issue, we have arrived at what we
25 consider to be a tentative position that we find, at

1 least acceptable, and that is to allow the licensee to
2 list his external exposures separate from his internal
3 exposures.

4 This will also provide us some information
5 relative to the summation. We will have a place on the
6 form, the record that he submits as well as keeps on the
7 workers, a place to sum these if, in fact, he would like
8 to do so. In doing so, we think we have helped
9 particularly the situation of those few licensees in
10 which the requirement of two entries or the summated
11 entry, it is new information for us as well as them. So
12 we have allowed both the record of the internal and the
13 external exposures.

14 Also relative to that issue, we allowed
15 greater flexibility in how one addresses the problem of
16 50-year dose commitment. He can list it as a fraction
17 of the annual dose limit, or he can list as a fraction
18 of the annual limited intake. He can also list it as a
19 fraction of the DAC, the derived air concentration, in a
20 year of exposure.

21 The latter, of course, is the same requirement
22 we now have relative to the reporting of the maximum
23 permissible concentration per year. So there is really
24 no change in the DAC in terms of the reporting than the
25 present Part 20.

1 We think that this will add greater
2 flexibility in the operation. This will be of
3 particular value to the fuel fabrication industry, which
4 is very much concerned about this problem.

5 We have also been discussing with the fuel
6 fabrication. One of the problems they have, of course,
7 is how to use individual data that they might have on a
8 worker to correct the records. That is perhaps not the
9 true recording of the worker exposure, and we ask that
10 at the end of the year the record be submitted to us.

11 One of the things that they raised with us was
12 whether or not some delay of that record could be
13 allowed, so that if they were to gather two more
14 quarters of data on an individual worker, they could, in
15 fact, get a better feel for what the yearly component of
16 the annual dose was, and not have to make an
17 inappropriate correction in that.

18 We are still thinking about that, but we think
19 that this is perhaps one way to accommodate him without
20 sacrificing what our intent was relative to the 50-year
21 dose commitment.

22 One of the changes we have made relative to
23 the plant special exposures, and I might say that there
24 was concern when we went to the regions as to the
25 industry might view the plant special exposure. We have

1 taken that information from the regions. We have had
2 discussions with the Atomic Industrial Forum. We think
3 we have a plant special exposure requirement that is, in
4 fact, implementable. The industry doesn't see any
5 problem with it.

6 I might also say that they were very reluctant
7 to use the plant special exposure, and that is what we
8 were trying to get them to do. In the regions, they
9 have expressed some concern that it might be misused.
10 We as yet don't see that it will be particularly
11 misused.

12 One of the questions that was raised to us
13 relative to the plant special exposure was the reporting
14 being to the regional office. Some concern was
15 expressed as to what might be reported, if a journalist
16 wished to make a big case on the plant special
17 exposures. That was of some concern.

18 What we have said now is that the records on
19 plant special exposures would be held within the
20 facility and would be made available to the inspectors,
21 so that we could get a feel for that. It might be that
22 we will just require that a letter be sent with some
23 details if, in fact, they have used the plant special
24 exposure provision. But we didn't want to have a record
25 submitted to each regional office in such a way that

1 they might be misused.

2 In thinking about the medical exposures, one
3 of the concerns that we had was the number of areas in
4 which it occurred to us that we were writing a broad
5 radiation protection standard, but we were rather
6 focusing down on the medical exposures in a way that was
7 perhaps unnecessary, in appropriate, I should say, to
8 the Part 20 revision.

9 So what we are now considering is that we
10 would -- As some of you may or may not know, there is a
11 revision of Part 35 underway to give the control of
12 human exposures to byproduct materials. That revision
13 is underway, and it is a little bit further along than
14 Part 20. But it would seem to us to be more appropriate
15 for that regulation to address this rather special
16 requirement that we have put in relative to medical
17 exposures.

18 For example, the control of high radiation
19 areas associated with therapy patients, how to handle
20 the sewage disposal of the patient excrement. We feel
21 that these would be more appropriate if they were
22 incorporated into Part 35. So we will be looking at
23 ways to do that.

24 I will tell you a little bit about where we
25 are going. The status of the rule is that we are still

1 working on it. It still has a long way to go. We are
2 developing a viable alternative to the present Part 20,
3 we think, which we described some of the problems.

4 We will, of course, have to address the
5 overall question of the cost of implementing the rule.
6 We are addressing that. I don't recall if I brought it
7 up before, but we have amended or tied into an EPA
8 contract that they have been looking at relative to
9 their own proposals back early in 1981. But that
10 particular study did not address some of the NRC
11 proposals until we have been able to tie into that. I
12 am not sure, but I think it is Cohen Associates, which
13 is now part of another consulting firm.

14 We have gotten a lot of reports from Mr. Cohen
15 in which he has gone to licensees and sit down with them
16 and discussed at great length the cost of implementing
17 the revision to Part 20, as written in the some earlier
18 drafts and also in the August draft.

19 We have also contracted with Oakridge National
20 Laboratories for the value impact statement which we
21 will need when we go to the formal review process within
22 the Commission. They will evaluate Mr. Cohen's analyses
23 as well as the additional information that they have
24 collected relative to the cost and the benefits of the
25 revision as they see it.

1 We essentially have that part of the activity
2 underway. We will not have that information except for
3 Mr. Cohen's information. We will have not have a draft
4 value impact statement when we start through the review
5 within the NRC at the division level. After division
6 review, at that time it is sent out by Mr. Arsenault,
7 our division director, to other divisions at NRC to get
8 their views.

9 I might say, within the NRC, we have met with
10 NMSS and we have also met with NRR and discussed the
11 intent of the revision, and we have gotten feedback from
12 them. We did not ask them at that time for any type of
13 commitment either for or against the rule, but we did
14 get some valuable input from them.

15 I have sort of run through some of the
16 highlights of where we are. My colleagues and I, if you
17 have some questions, we will be glad to answer them. We
18 are looking forward to hearing both the DOE presentation
19 as well as EPA. We appreciate that it is one of your
20 objectives to get the interested parties to talk because
21 this is important.

22 Thank you.

23 MR. MOELLER: Thank you, Bill.

24 I have a couple of questions. You say that it
25 has a long way to go, and you have also commented that

1 it has not been formally reviewed by the other
2 components within NRC. Will it be reviewed totally
3 within NRC before you would plan to publish it?

4 They will all have to review and sign off, in
5 essence.

6 MR. MILLS: Yes. In the publishing of the
7 rule, I am not sure if they necessarily have to concur
8 in the content of the rule, but they would have to
9 concur in the publishing of the rule. I know that in
10 EPA, you could publish something with non-concurrence by
11 the Administrator, but I am not sure that that is true
12 in NRC.

13 MR. MOELLER: How long might that take?

14 MR. MILLS: We are shooting to get this
15 division review underway, so that in the month of
16 December, which is kind of a slack month, we hope to
17 give the reviewers a chance to enjoy their holidays with
18 our version of the revision.

19 We have discussed this already with many of
20 these people, and we think we have reflected their
21 comments already. I think that this next review will be
22 more or less addressing the broader issues rather than
23 the smaller details. I would not hazard a guess as to
24 how long within NRC such a review would take place.

25 As far as us getting a package which we are

1 satisfied with within our branch, we hope to get that
2 out, or we will get it out before the end of this year.

3 Herb Parker.

4 MR. PARKER: Bill, let me say first that I
5 come at this from a position of bias. I am a member of
6 the NCRP Subcommittee No. 1, and I feel that that group
7 very recently came to a solution which is far superior
8 to the wholesale swallowing of the ICRP system. I
9 realize that you cannot prepare a regulation on a system
10 that has not been published. I would have hoped that
11 you could wait about two years when it is available, but
12 I also appreciate that you have pressures in the other
13 direction.

14 So really the remaining question is, if we
15 support your going through with this, how willing would
16 you be to redo the whole thing to a far superior system
17 two years from now?

18 MR. MILLS: I appreciate those remarks, Mr.
19 Parker. I would hope that any time an improvement in
20 the system of radiation protection occurs that the NRC
21 would be flexible enough to recognize those changes and
22 to implement them into the rule. I would guess that it
23 is very likely that the hearing process for this
24 revision is going to be a very long one. Therefore,
25 some of the NCRP views have to be taken into

1 consideration for the scientific respect that they
2 have.

3 As to whether or not we would change the rule,
4 or how long it would take us to change after looking at
5 the NRC document, I would hope there would not be a
6 situation where the NRC would not take it into serious
7 consideration. If we have to go back to the drawing
8 board to get a better system, I personally would be in
9 favor of that.

10 The important thing, I think, at this stage of
11 the game is that we had a system to us by the ICRP in
12 1977. It has problems. We think we have taken into
13 account some of the problems. We feel that there are
14 some revisions that we have to make in the current Part
15 20, and we need to move the process along. Hopefully by
16 doing so, we might be able to step up the NRC to get
17 its report out.

18 MR. PARKER: Thank you.

19 MR. MOELLER: Any other questions? Jake
20 Shapiro?

21 MR. SHAPIRO: For many decades, we lived with
22 a cap of 15 rem as a single organ dose. Your revision
23 essentially increases that cap to 50 rem in those cases
24 where the statistic gives you a level above that. Have
25 you, in addressing this, received any input from the

1 industry or from other sources that in fact the 15 rem
2 was too low a limit to live with?

3 MR. MILLS: I will ask Bob and Walter to pipe
4 in, as they have done most of the discussion.

5 We have not seen nor heard that that was a
6 particular problem. I think what it amounts to is the
7 fact that the 15 rems is calculated as an annual dose on
8 the old ICRP-2 model, or perhaps the recent one. But,
9 in essence, what it means is that with the ICRP 30 and
10 32 models, the doses would appear to be much larger. I
11 have not looked at it in terms of what the overall risk
12 differences are, if you look at the 15 rems under the
13 old system.

14 We have not received any indications that the
15 industry has any difficulty in meeting the 15 rems. But
16 I am not so sure. For example, in the case of the fuel
17 fabrication situation, they don't actually report to us,
18 but they give us how many MPC hours during the year, and
19 it would depend on how we calculated that MPC as to
20 whether we use the new information or the old
21 information. But I don't think that they raised it as a
22 particular problem.

23 MR. SHAPIRO: As I read it, the shorter lived
24 materials, whether it is a few months or a couple of
25 years, your regulation would allow repeat a 50-year

1 working dose provided there as no external radiation.

2 MR. MILLS: Right.

3 MR. BAKER: To clarify that just a bit. The
4 new system, of course, is based on what Herb would call
5 a quasi-risk rationale, it is not a purist type system
6 by any means, but nevertheless what we believe to what
7 we believe to be very close to a risk system.

8 There are a number of changes. For example,
9 we are now adding, if you will, the external doses plus
10 the effective internal doses, I say effective because
11 the dose which is the surrogate of this is based on a
12 common risk internal and external.

13 So this is a whole new system. Some of the
14 values have gone up, some are down, and some stay about
15 the same. It is not as straightforward as comparing,
16 let's say, the permissible dose on the present system
17 for specific organs. In the new one, there is a cap,
18 but there is also a multiplicity of internal organs for
19 the doses which are weighted and summed.

20 So the two systems are so different that I
21 don't think a simple comparison like 15 rems as compared
22 to a 50 cap is truly valid. This probably doesn't
23 clarify your question, but it is more complex than a
24 comparison.

25 MR. SHAPIRO: What I am saying, as I read it,

1 though, it will result in higher organ doses than were
2 allowed before, especially with nuclides that tend to
3 concentrate in a single organ, perhaps the lung. What I
4 am asking is, have you had indications, aside from any
5 other changes, from any source whatsoever that a 15 rem
6 cap is in fact too low? That is the only answer I am
7 really interested in.

8 MR. BAKER: I don't know that that particular
9 question has been raised. More nearly, one compares the
10 MPCs in the current rule with the derived air
11 concentrations in the old rule. As I said, some of
12 these go up, some of them go down, and some stay about
13 the same.

14 That is really the only significant comparison
15 that has been made. One has not compared doses to a
16 particular critical organ now in the present system,
17 with the current analytical models, and so forth, that
18 are used, with the new models and new limits. But
19 rather it is one of comparing you recapitulations.

20 MR. MOELLER: Herb Parker, and then Jerry
21 Ray.

22 MR. PARKER: Bob, I think you put words in my
23 mouth when you say I have referred to the ICRP system as
24 a quasi-risk system. I would call it strictly erroneous
25 risk system based on what we had as knowledge in

1 approximately 1948, rather than the knowledge of 1982.

2 MR. MOELLER: Jerry Ray.

3 MR. RAY: Dr. Shapiro's question stimulates
4 one in my own mind, and it reflects my ignorance. I
5 think it was stated quite clearly.

6 Evidently you have increased some limits.
7 Could you give me the bottom line in the exposure, say,
8 to a worker over a 20-year career. When he walks away
9 from the plant, will he have significantly higher
10 biological damage incurred than under the new rules than
11 he would have had under the old rules?

12 MR. MILLS: My impression is, if he is working
13 in a situation where most of his exposure is due to
14 external, there will be no change.

15 MR. RAY: Even though certain limits of
16 exposure have been increased.

17 MR. MILLS: One could say that he will walk
18 away with a lower dose because of the fact that we no
19 longer rely, for example, on 12 rems as a year, which is
20 an operating kind of thing, or 3 rems a quarter. So
21 with the external, he probably walks away with a little
22 bit less.

23 In terms of the internal exposures, it is hard
24 to say because unfortunately we don't have a lot of good
25 data. Except for the MPC value, we really don't know

1 what the dose has been to the worker from the internal
2 emitter. It is highly variable with the individual.

3 What we are doing, I think, is giving more
4 assurance that, in fact, the limits are being met for
5 internal emitters.

6 MR. RAY: You mean that you are more
7 prescriptive now in the controls?

8 MR. MILLS: Yes. The controls, by requiring a
9 recording of the dose for the internal emitters in the
10 consideration of the 50-year dose limit, we in fact
11 require, I think, a much stronger requirement which we
12 can relate to relative to the what the worker's history
13 has been over 20 years. We think that that is where the
14 importance lies.

15 MR. RAY: In your discussions with the various
16 nuclear community organizations, do they reflect their
17 concurrence with this philosophy or this conclusion?

18 MR. BAKER: I think that our interactions with
19 the nuclear community have been pretty resolved the
20 philosophical as well as the operational problems for
21 the most part as they have existed.

22 I would like to say just a word on you other
23 question. One of the big changes between the old Part
24 20 and the proposed revision has been a requirement for
25 ALARA, that is sort of an admission that it should be

1 as low as achievable.

2 Then in order to truly cause this to happen,
3 you will find a series of requirements which would cause
4 things to happen, cause actions, cause reports, cause
5 different to happen below the limits. It might be an
6 evaluation to see why certain doses have exceeded
7 certain levels. These are not limits below the limits,
8 but rather action points below the limits.

9 So we think that these progressive pressure
10 points below the limits will indeed do what we wanted to
11 do to indeed find the levels that are as low as
12 reasonably achievable. This is done, as I said, with a
13 series of reference levels that are action points, or
14 reporting requirements, or whatever, that are below the
15 limits.

16 What happens then is that the MPCs then become
17 essentially conversion factors, and they should not be
18 looked upon as speed limits where it is all right to go
19 up to some point, as one could read in the current Part
20 20. Rather, indeed, the emphasis throughout is on doing
21 things as far below those limits as is reasonably
22 achievable, and we are trying to make that something
23 meaningful rather than just a phrase, and we think we
24 can do it.

25 MR. RAY: Let me see if I can say in words

1 that I understand, if I can indicate my comprehension of
2 what you just told me.

3 I gather that what you are saying is that you
4 are setting up a system such that you motivate the
5 licensee to insure protection of the worker, or
6 establish exposure conditions such that he would be
7 below the maximums, and thereby improve the working
8 conditions of the individual from the viewpoint of
9 exposure. Is that what you are saying?

10 MR. BAKER: We sincerely believe that we can
11 do that. We think that we can do it by setting these
12 reference levels which are actions levels. For example,
13 we will have levels where, if it is exceeded, the
14 licensee would not be cited for exceeding a limit
15 because it is not a limit, it is below the limits, but
16 it is a level which is exceeded which would cause the
17 licensee to be cited, for example, why he is, what he
18 is doing to keep things as low as is reasonably
19 achievable.

20 He would have reporting things so that we
21 could look over his shoulder, and it could be that he is
22 perfectly justified in being at that point. But he has
23 to look and verify this. We think that this is the
24 proper route to go.

25 MR. MOELLER: We will take one more comment,

1 and then we will move on to the next presentation.

2 Jack Selby, did you have a comment?

3 MR. SELBY: Yes.

4 I think that it also should be noted that this
5 discussion of the 50-rem cap, that not all limits have
6 been raised. One very important one, that is to the
7 extremities, has been lowered from 75 to 50. So it has
8 not all gone in one direction.

9 MR. MOELLER: Thank you.

10 Ed, the EPA people, I rather, are not here, so
11 if you don't mind.

12 Bill, excuse me, is this an okay place to move
13 on?

14 MR. MILLS: It is up to you, Mr. Chairman.

15 MR. MOELLER: I would like to because I think
16 many of the individual points to be raised will be
17 raised as the discussion progresses this morning.

18 So, thank you very much.

19 You have had so many meetings, I wonder if you
20 could meet with Herb's NRCP and pick their brains before
21 they publish what they are going to publish, so that you
22 know.

23 MR. MILLS: We have already met with NRCP
24 once.

25 I have talked to Lawrence Sinclair since then,

1 and we are very much interested in NRCP's view. We
2 appreciate your comment, and we certainly will continue
3 to do that. We are very interested in their help.

4 MR. MOELLER: Thank you again, Bill.

5 All right, we will move on.

6 Let me repeat, while Ed comes up, I am sure
7 the subcommittee members and consultants will have or do
8 have a variety questions, but I do believe that most of
9 these will come up during the course of our
10 discussions.

11 MR. VALLARIO: Mr. Chairman, members of the
12 panel, and members of the public.

13 My name is Edward Vallario, and I am the
14 Department of Energy's Group Leader for health physics,
15 and we represent some of the same views of the
16 Department on the proposed change by NRC to 10 CFR Part
17 20.

18 I would like to note that the Department fully
19 appreciates the opportunity to present these comments.
20 We think that it is quite constructive to get into a
21 forum like this and attempt, perhaps, to use it as an
22 umbrella to resolve some issues that we find really
23 quite significant.

24 We believe that there is a wealth of practical
25 experience out in the universities and laboratories, and

1 we think that this is indeed needed to assess the
2 technical adequacy of any basic emission detection
3 standards. I say this in the context of the practical
4 experience that people have in the laboratories, and so
5 forth.

6 In this context, present here today are the
7 principal health physics representatives from three
8 major DOE laboratories. From Savannah River-Dupont, we
9 have Mr. Rosco Hall. From Rockwell, International,
10 Rocky Flats, we have Mr. Robert Yoder. From Battelle
11 Laboratory, we have Mr. Corley, who will focus on the
12 operational experience as regards the environment
13 question.

14 Mr. Ken Heid is from Battelle also. Most of
15 you know him, he has been a principal in the area of
16 internal dose assessment. He will represent some views
17 that were expressed at an IAEA subcommittee meeting,
18 views reflecting the European concerns.

19 Finally, we have Mr. Selby, who most of you
20 know, who has a very broad background in health
21 physics.

22 These laboratory principals will provide the
23 operational backup data in support of the Department's
24 views. I will attempt to convey the concerns that we
25 have, and then proceed to have the people from the

1 laboratories present the data that I think you would be
2 interested in seeing.

3 First, to place our comments in proper
4 perspective, we wish to commend the NRC staff for some
5 very excellent features reflected in their revision.
6 These are the presentations on the de minimis levels and
7 the concept of setting both and internal and external
8 exposures, both of these have been overlong in coming.

9 We would note, however, that there are some
10 features of the revision that present some very, very
11 serious operational problems to the Department, which
12 really don't have any gain in safety.

13 I plan to cover these areas. They depict the
14 total position of the Department. In particular, the
15 application of retrospective versus prospective dose
16 limitation system, problems associated with the 50-year
17 effective dose equivalent as it relates to the
18 well-retained, long-lived nuclides, and any number of
19 problems in applying these concepts in terms of
20 radiation dose management.

21 We were a little surprised, and I will go into
22 this in some detail, to hypothesize that under the
23 proposed revision it is conceivable for the fetus to
24 receive a 3 rem dose. I will get into that.

25 Then, of course, the individual monitoring

1 requirements appear to go in the opposite direction from
2 where we feel monitoring requirements should be going,
3 and I will get into details.

4 Then, of course, the bottom line, and I was
5 pleased to note that Billy Mills said that one of the
6 things they are going to consider is the cost associated
7 with the system. We are here to convey to you that this
8 is a rather serious matter, and we are talking about
9 tens of millions of dollars. The operational people
10 will convey this.

11 With that, I would like to begin, the
12 department has a fundamental difference of opinion with
13 respect to the application of ICRP 26 dose limitations.
14 The stress appears to be on the work place rather, in my
15 opinion, on the individual. In this sense, the proposed
16 revision to 10 CFR Part 20 as an application of ICRP 26
17 is both a retrospective and prospective dose limitation
18 system.

19 Members of the ICRP Committee have gone on
20 record reinforcing the use of the ICRP 26 for planning
21 purposes, for prospective application, and noting that
22 the prospective dose limitation system is intended to
23 provide guidance for the derivation of secondary
24 standards, and the planning and control of work
25 involving potential radiation exposure.

1 However, by proposing the use of ALIs to
2 assess and record an individual's occupation exposure,
3 the NRC, we feel, has inappropriately applied ICRP-26.
4 In support of this, I would like to quote three
5 references.

6 The first one relates to a statement from 26,
7 which conveys the intent that air sampling as an
8 integral part of this dose assessment system, and it has
9 to be, and here ICRP 26 states: "Only in a few
10 circumstances can the results of programs of monitoring
11 of the workplace be used to estimate the dose
12 equivalents or intakes of individual workers. The use
13 of derived or authorized limits is essential in the
14 interpretation of environmental monitoring programs."

15 I would like to refer to another reference
16 from Dr. Bill Baer, whom all of you know, and this was
17 at a recent meeting of the ACRS on June 23rd, in which
18 the NRC discussed the 10 CFR Part 20 revision.

19 Dr. Moeller stated, "Let me put words in your
20 mouth, and correct me if I am wrong, the DACs are simply
21 a mechanism for controlling operation or looking at it
22 in terms of --

23 "Dr. Baer: For planning purposes.

24 "Mr. Moeller: Planning and designing
25 controlling operations.

1 "Dr. Baer; Exactly."

2 I would like to go further and refer to the
3 statements that came out of the IAEA working group.
4 This was a working group that was constructed to look
5 into the implementation problems of ICRP 26. Ken Heid
6 was the chairman of the working group of IAEA, and he is
7 going to get into this in some detail. But at this
8 point, I think it is sufficient to note that all members
9 of the committee, except for the NRC member, voted
10 against the use of the 50-year dose commitment.

11 I would like to get into the application of
12 perspective versus retrospective. There is some decided
13 advantage, as you all know, in the application of
14 ICRP-26 as a perspective application, and one of the
15 more significant things is that you can determine
16 occupational risk. But we see some very serious
17 problems associated with using this system for
18 retrospective applications.

19 One of the important problems is that the ALIs
20 are based on standard reference man, and as we know the
21 distribution of radionuclides in the body is dependent
22 on a number of individual parameters, such as age, size,
23 sex, and metabolic patterns, occupational exposure,
24 isthmus should be based on each individual's
25 metabolism. When ALIs are used to assess an

1 individual's exposure, this is difficult, if not
2 impossible.

3 In the case of long-lived, well retained
4 nuclides, the development of an individual model may
5 require years, and you may not be able to assign the
6 committed dose in the year of intake.

7 The problems associated with the long-lived
8 nuclides are related to the 50-year dose provision,
9 which I will now discuss, and in this sense, we turn to
10 the next viewgraph.

11 The 50-year dose commitment presents some
12 obvious problems. Clearly the issues are the
13 extrapolation of the 50-year dose to the first year,
14 where we feel that affords no greater protection at
15 all. What you are doing essentially is assigning for
16 exposure to the first year of intake, an exposure that
17 has not been received.

18 My comment related to the the 50-year
19 committed effective dose equivalent is specific only to
20 the long-lived nuclides. For the short-lived nuclides,
21 the system works quite well.

22 There are some obvious measurement problems
23 associated with this. Frankly, the measurement systems
24 are inadequate. In this sense, let me talk to first the
25 air sampling mode. There are two ways of doing this.

1 One is, of course, the continuous rapid response
2 systems.

3 This is material that was prepared by
4 Livermore. Lawrence Livermore conducted a study and
5 they found that typically for plutonium, for example,
6 the continuous air monitors are really quite
7 inadequate. The integration time that is commonly used
8 is five minutes.

9 If you will note the particle size in the
10 respirable range from 0.6 micrometers to 2.4
11 micrometers, we are talking anywhere between 7.3 and to
12 95 MPC hours. So that is clearly not a system that
13 could be used for purposes of monitoring in the sense of
14 air.

15 With respect to the other mode of air
16 sampling, you can achieved sensitivities of 0.10 of DAC,
17 but here again you are talking about for over a week in
18 the case of plutonium, for example.

19 If you take an eight-hour sample, you pull it,
20 you count it, and you wait 24 hours for decay, and you
21 count again, and then you wait another week and you
22 count it again. so you are talking about assessments
23 well after the fact.

24 Going back to my original point, if your focus
25 is on the control of the workplace, the system works

1 fine. But if your concern is the individual worker,
2 this system does not work at all. So that is the
3 problem that we have there.

4 With respect to the next area, in vivo
5 assessment, levels to which you have to conform are well
6 below detection capability by a factor of ten or more,
7 and you have similar problems with bioassay.

8 One of the very serious problems that we see,
9 and Dr. Yoder and Rosco Hall will be focusing on this
10 quite a bit from the operational experience point of
11 view, so it is sufficient to say that the control
12 treatment of low exposures is going to change
13 dramatically with this system.

14 We can see that in cases where someone
15 receives 200 millirem, and this is quite common when we
16 are talking about intake, you may have some minor load
17 breaches or things like that, what happens in this new
18 system is that 200 millirem becomes 10 rem. So low
19 exposures are now going to become technical
20 over-exposures.

21 Then, of course, you have got the next
22 problem, and that is the management of subsequent years
23 exposure. This is a problem. You use, according to the
24 Part 20 revision, the metabolic models, unless you have
25 other means, and in the case of plutonium, as we all

1 know, it takes years before you can come up with
2 accurate information. But the system that is being
3 proposed dictates that you find some exposure in the
4 first year of intake.

5 What do you do, years later you come up with
6 another number, then you come back and you retrofit the
7 exposure. I can't begin to tell you the problems that
8 this represents.

9 What is the effect on health physics practices
10 as we see it today. Clearly, we think there is going to
11 an ineffective utilization of the workforce. The
12 program today is based on true exposure, actual
13 exposure.

14 The system that is being proposed, in the case
15 of long-lived nuclides, in in-take you would be talking
16 about a management system based upon exposures yet to be
17 received, if you will. In the case of workers, some
18 will have to be removed for the year.

19 So we end up with ineffective utilization of
20 workers based on the system that we don't quite
21 comprehend.

22 Of course, the credibility of detection
23 control is the thing that bothers me. The current
24 program is based on, as I said, actual exposures. In
25 fact, there must be millions of dollars being spent in

1 enhancing accuracy of dosimetry. NRC is involved in a
2 certification program, we are too, to try to refine our
3 measurement system, to try to learn more about these low
4 dose exposures, and so forth and so on. Then we come up
5 with a system now where we are talking about holding the
6 line, and maybe going a little higher in terms of
7 monitoring requirements, and forgetting about data with
8 reference to rem. We have a problem with that.

9 Of course, the net effect of the 50-year dose
10 commitment, as I indicated before, our cost estimates
11 are in the tens of billions of dollars, this is
12 certainly not reasonable cost, and we don't believe
13 there is any gains from the safety point of view.

14 The next area I want to talk to is radiation
15 dose management. I will not go through this again. I
16 did talk to the problems of handling non-routine
17 exposure data, which is a severe problem.

18 I believe the revision states that if you have
19 a technical over-exposure, if you have 25-rem once in a
20 lifetime dose, you charge it against. But in our
21 exposure experience, we see where that would be wiped
22 out immediately, and then where do you go. So the
23 problem of technical over-exposure is a real one, and we
24 don't know how to handle it under the new system.

25 The fetus dose thing is an interesting one,

1 very interesting. The monitoring requirements state
2 that you monitor where the deep dose is greater than 500
3 millirem, and where your intake dose is greater than 1.5
4 rem. I can postulate a situation, when we are talking
5 about a group of workers now, who will not be required
6 to be monitored, and this group of workers will include
7 women.

8 I could postulate a situation where clearly a
9 female worker, who is pregnant, unaware of it for the
10 first couple of months, working in a non-monitored
11 environment based on the monitoring rule or the
12 criterion in the proposed rule, could receive, where the
13 age specific parameters are known, 0.49 and 1.0 rem, you
14 could possibly come up with 1.49 exposure, and this is
15 not known, but she is not monitored.

16 Then she declares herself, and based on the
17 proposed revision, she is then restricted to 500
18 millirem during the period of gestation. So you are
19 talking, in the case where age-specific parameters are
20 known, conceivably a dose of 2.00 rem to the embryo.

21 In the case where the age parameters are
22 unknown, as you indicated in the revision, the embryo is
23 twice sensitive, so the effects on the embryo are twice,
24 so you multiply the committed effective dose by two, and
25 it is conceivable, in this particular case, where the

1 age-specific parameters are unknown, that the embryo
2 would have received something on the order of 3 rems.

3 I submit that the control in the case of the
4 gestation dose needs to be reassessed in this context.

5 Going back to radiation dose management,
6 clearly another problem we can see is that the records
7 will reflect the anomalies in data, with the 2.0 rem
8 monitoring rule and the 500 deep dose, and the 1.5
9 intake dose. There will be a body of data that will be
10 unreported, that will not be reflected in the exposure
11 records of individuals.

12 Again, it is interesting, the revision states
13 that if an individual, coming from one nuclear plant and
14 going to another, and there is no exposure data, that
15 individual will be charged 1.5 rem per year. So there
16 is a tremendous inconsistency. Now we are face with the
17 problem of a fellow being charged 1.5 rem, and we don't
18 know what his exposure is.

19 So we see quite a disruption in the data that
20 goes into the records, and this of course will impact on
21 epidemiology. ALARA focusing has been in the area of
22 less than 1.0 rem in the Department of Energy. If you
23 have been observing our annual summary report, there was
24 something like 98.6 percent of our radiation workers
25 received less than 1.0 rem, and we are trying to improve

1 in that area.

2 The ALARA application is in the less than 1.0
3 rem region, and if we were to implement a system such as
4 that proposed by the Nuclear Regulatory Commission, it
5 would have a detrimental effect on ALARA, and they would
6 no longer be focusing on an area in the low dose
7 region.

8 Now to the individual monitoring requirements,
9 these are the things that are presenting problems to
10 us. There is a 30 percent monitoring criterion that we
11 have problems with. Of course, the effect on the
12 management requirements, and I will get into that in
13 detail with the next slide, but the effect is, of
14 course, in eliminating a lot of information and creating
15 a lot of anomalies, exposure trend analysis is going to
16 be impacted upon.

17 The Department at the present time does not
18 have any such criterion. They record any positive
19 exposure intake and we track this, and it becomes a part
20 of the exposure status of the individual, and our
21 control system is a positive one and reflects this type
22 of practice. Of course, the impact on the monitoring
23 requirements, as I indicated before, is the ALARA.

24 I am hoping that this is correct because we
25 had a heck of a time trying to focus on the monitoring

1 requirements with the use of the various terms, and that
2 is another problem.

3 In the case of the monitoring requirements,
4 the problem here is that good practice, in our opinion,
5 dictates that you report all measured exposures. The
6 system doesn't require that. Implementing the 30
7 percent criteria and the 500 millirem deep dose criteria
8 will effectively eliminate about 50 percent of the total
9 man-rem estimates in current information.

10 I would like to tell you that the Department
11 has been going in an entirely different direction. We
12 do have this 10 percent limit, and Billie properly
13 mentioned that the reporting requirements are not that
14 much different from what they had in the past.

15 Now that may be true, but I think there is a
16 need to reassess monitoring requirements in light of
17 many things, the recent activity of the Office of
18 Workmen's Compensation Program, the Hatch Act, the
19 off-site litigation problem. There is a tremendous
20 focusing on low dose, and the compensation cases are
21 being litigated at levels below 1.0 rem.

22 We, in the Department, have been looking into
23 this in connection with our RIRS upgrade program. This
24 is the radiation information record system. One of the
25 very important considerations in the Department that we

1 are looking at is lowering the monitoring requirements
2 to 100 millirem per year.

3 It is true that we need to get away from
4 monitoring everyone because of the cost associated with
5 this. But, we believe we can effectively accomplish
6 this end, not by raising the limits, but simply by
7 lowering them from 10 percent of the limit to 100
8 millirem per year.

9 So we are going in an entirely different
10 direction because we are interested, beyond the subject
11 of data, in enhancement of data for epidemiology
12 studies. We are interested in reflecting a more
13 positive control in the workplace, and I believe when
14 you do this and you record all positive exposures, you
15 are effectively accomplishing this. I think when you
16 rule out exposures less than 2.0 rem, you are not
17 accomplishing this, and so forth.

18 We want to make you aware of the fact that our
19 position on the monitoring has to do largely with the
20 opinion that we feel that the monitoring requirement
21 levels should be effectively lowered.

22 The bottom line of all this is that we are
23 concerned about. Of course, there is programmatic cost
24 and that has to do with the workers. In the case of the
25 plutonium production facilities, you are talking about

1 curtailment, to a large extent, of operation, to go
2 through some sort of transition period, to remote, or to
3 modifying the remote systems to be able to comply with
4 the 50-year dose commitment.

5 This is a very serious matter because you are
6 talking about plants oriented toward defense programs
7 and national security, and you are talking about
8 retrofit costs on the order of tens of billions of
9 dollars.

10 This is not an off-the-shelf number. We did
11 look at this for the second time in connection with this
12 NRC petition. They are attempting to reduce the
13 dose equivalent to 500 millirem, if you recall that
14 business a couple of years ago. But a new assessment
15 has been made and these are the dollars we are talking
16 about. So the facility costs are quite high.

17 Let me get down to the litigations. I have an
18 affection for the attorneys and the lawyers because this
19 radiation business can get you into a lot of trouble.
20 You always feel more comfortable when they are around.

21 This business of compensation, as I mentioned
22 before, is a very serious matter. We can see, for
23 instance, someone coming into court, alleging cancer, if
24 you will, or some physical manifestation associated with
25 radiation, and the judge says, "Can you produce the

1 records of the individual." We find that that
2 individual, while he worked in a radiation area, he was
3 not required to be monitored and there is no record
4 associated with the individual. This problem could be a
5 serious one.

6 The technical overexposure is again another
7 problem. In the case of the long-lived, well-retained
8 nuclides, when you make this extrapolation, you go from
9 low exposure to something that is higher, and the fellow
10 develops cancer. Incidentally, that technical
11 overexposure becomes the dose record of the individual,
12 as we understand, and that is the number you work with.
13 We can conceive that that could be used in a court of
14 law to litigate a claim, and it is not really reflecting
15 the true exposure of the individual.

16 I have taken an awfully long amount of time to
17 go through this. Let me now turn this over to Dr.
18 Yoder, who will present some operational data.

19 MR. AXTMANN: I have a question, Mr.
20 Chairman.

21 MR. MOELLER: Could we ask a few questions at
22 this point?

23 MR. VALLARIO: Their data is in support of
24 what I have been saying, so you may get the answers from
25 these gentlemen, and it will save time.

1 MR. MOELLER: Are you willing to wait, Bob?

2 MR. AXTMANN: Sure.

3 MR. MOELLER: All right we will withhold.

4 MR. PARKER: Could we dispatch an emissary to
5 battle with the vacuum cleaner.

6 MR. MOELLER: We have done that, Herb, and
7 what we have been told is that the air conditioning
8 system is on the fritz, and they are in there trying to
9 correct it. We will try to obtain a projection as to
10 how long it will take. I know it is disturbing, but I
11 hope you will bear with us.

12 Roughly, how long will each person require?

13 MR. VALLARIO: About 15 minutes.

14 MR. MOELLER: That is for five people. You
15 are talking then of another hour and 15 minutes.

16 MR. VALLARIO: Yes.

17 MR. MOELLER: Let's get started, but try to
18 keep it as short as you can.

19 MR. VALLARIO: Alan Richardson said that we
20 could have the time.

21 MR. YODER: Mr. Chairman, and members of the
22 panel. I am pleased to be here. My name is Robert
23 Yoder, and I am Director of Health Safety Environment
24 for Rockwell International, the operating contractor for
25 the Department of Energy's Rocky Flats site.

1 We will discuss with you this morning that
2 some issues that have developed as we have reviewed the
3 NRC's proposed 10 CFR 20 document dated in August.
4 Because their thinking is continuing to evolve, so the
5 comments that I may make may be changed or may have
6 already changed. However, that is the last draft that
7 we do have.

8 I would like to show you a few slides with
9 regard to a comparison of the information regarding the
10 ICRP 30 and the 10 CFR 20 document. The derivation of
11 the information came from codes that at Oakridge which I
12 presume are owned by the ICRP, and anyone can make
13 calculations on them.

14 However, we noticed that due to the rounding
15 factor there are changes with regard to the annual
16 limiting intake, with regard to plutonium 239, based on
17 our calculations. While that may not look too important
18 for Class Y materials, which are the ones that are
19 retained for a long time in the body, this represents
20 about a 30 percent change or reduction in the limit.

21 When one takes this ALI and looks at the
22 information which one can obtain from the calculation on
23 the dose to the bone surface, one finds that ALI would
24 have a committed dose of 32 rem to the bone, rather than
25 the 50 rem that is actually stated in the limit, because

1 of the way the values are rounded and the way one
2 actually can make the calculations.

3 If one looks at the whole body effective dose,
4 and I apologize for the terminology in the sense of
5 dose, this is the weighted annual dose for the Class Y
6 materials, and the value would be about 2.9 rem for the
7 soluble materials, and the value would be 2.2 rem per
8 year for the total dose commitment for the ALI.

9 The amount of material in the lung from an
10 acute ingestion -- I will restrict my remarks to acute
11 ingestion, because most of the intake is from acute
12 events rather than chronic exposures. These also are
13 the ones that are the easiest to measure. If I had
14 problems with these, the problems were more severe with
15 the chronic measurements.

16 In terms of the initial long-term deposition,
17 one is talking about for the Class Y material it is
18 about 1.4 nanoCuries, and for the Class W material it is
19 about 0.7 nanoCuries, and at the end of the year the
20 amount of material that has already been transferred to
21 the bone represents about 0.9 nanoCuries for the
22 insoluble and about 0.5 nanoCuries for the soluble
23 material. So the material is moving.

24 MR. PARKER: Bob, are these the new ICRP
25 numbers you are talking about?

1 MR. YODER: Yes, these are the values that
2 come out of ICRP 30, which is the calculation from
3 ICRP-26.

4 MR. PARKER: 10 CFR 29, are those new numbers,
5 too. those are not old numbers?

6 MR. YODER: Those are the numbers that are in
7 the August draft.

8 If we look at our ability to measure plutonium
9 in air, we find in the air of the MPCs, the DACs are
10 approximately the same, in fact it is relaxed just a
11 little bit for the insoluble material. The ability to
12 detect this material in the air for long-term sampling
13 is about one-tenth, roughly, of the DAC. So one can
14 measure the material in the air.

15 As Ed mentioned, it takes perhaps a week in
16 order to be able to analyze one of those samples to come
17 back and determine what was the value at some previous
18 point in time.

19 If we look at our experience, we take about
20 60,000 air samples per year in the work environment, and
21 on a monthly average we have about 58 of those samples
22 that would show -- 58 events, rather, that would have
23 air samples associated with above the DAC or above the
24 MPC level.

25 Of those, 46 are those that we have

1 anticipated at above level air samples, so we have taken
2 precautions, we have provided air suits, or respiratory
3 protection, or other requirements, to minimize or
4 eliminate the possibility of intake. We are then left
5 with 12 events per month in which we have to conduct an
6 investigation in order to determine was there a
7 potential exposure.

8 If we look at our ability to measure in vivo
9 radioactive material, particularly plutonium, for of
10 initial long lived activity in the lungs of about a one
11 micron particle size, the 10 CFR 20 numbers that I
12 referred to a moment ago are these. We can infer from
13 our lung counting at Rocky Flats about 1.3 nanoCuries of
14 plutonium. That is an inferred measurement based on our
15 ability to measure americium which goes with plutonium
16 in most cases, and if that americium is at a thousand
17 part per million.

18 If the level is lower in americium, our
19 ability to determine plutonium or inferred plutonium is
20 less. If one has no americium in the exposure -- in the
21 material, then we are well above 16 nanoCuries in order
22 to measure plutonium in the lung, and that 16 nanoCuries
23 is the present value for the lung burden to get 15 rem
24 per year.

25 This problem is compounded somewhat if we say,

1 at previous burden, or no previous exposure, we can have
2 a limited detection from 1.3 nanoCuries. If we have 10
3 percent or 25 percent of the existing values in the
4 lung, our limited detection goes up because we are
5 trying to measure a very small increment on a background
6 that already exists. So one has the statistical problem
7 of evaluating a true change in the deposition level.

8 We have, in this case, 10 percent of lung
9 burden, and we have about 170 employees in that
10 category, we have about 72 in the category of 25
11 percent.

12 If we look at our ability to use bioassay as a
13 technique again these particular materials, the proposed
14 ANSI standard has a minimum detectable performance of a
15 minimum detectable activity of 0.16 deeper rem in a
16 liter of urine in a 24-hour sample of urine. We find
17 that for the class Y materials, at 90 days or 180 days
18 following an ALI, this would assume you had an ALI and
19 now know about it until your program caught up with that
20 individual, and you would be unable to detect it from
21 the class Y materials. You would be able to measure it
22 for the class W materials, or the relatively soluble
23 materials, up to about 180 days.

24 Again, for periods of time of one, two, or
25 three years following the intake, one has an decrease in

1 sensitivity with regard to the ability to monitor that
2 material that is there on top of an existing burden.

3 We do not have very good experience with
4 regard to using bioassay, particularly urine samples for
5 insoluble materials in terms of inferring how much
6 material is in the body. Here we are showing the
7 estimated urine analysis of how much plutonium was in an
8 individual versus the extrapolated tissue analysis that
9 was obtained through trans-uranium registry program for
10 these individuals. Notice that our estimates, in every
11 case, are higher than the actual material there, and in
12 some cases, the deltas are quite large.

13 The impact to use these data that we may have
14 with this type of an error, we would be assigning a
15 committed dose quite a bit higher than that which may
16 actually be the estimated dose to the individual.

17 With regard to the problems we are having in
18 terms of our technical matters is that the detectability
19 depends upon how much is already in an individual and
20 what that level is in the individual. New uptakes will
21 be very difficult to interpret and to get a good and
22 accurate measure of the change in the system.

23 Urine measurements have not been successful to
24 infer lung deposition, and we have some problem, but
25 this is really an administrative problem, of trying to

1 figure our when you start and stop the year. You cannot
2 handle 5,000 urine samples on January 1, and be able to
3 maintain an operation. So there are some problems with
4 that, but those are really administrative problems.

5 We believe that the sensitivity of measurement
6 is not yet adequate to measure the very small increments
7 of intake that are associated with the ALIs. The values
8 here are calculated based upon acute exposures rather
9 than a chronic exposures.

10 I would like to show you one viewgraph --

11 MR. AXTMANN: Before we go any further, I am
12 not sure, after you compared urine samples with tissue
13 analyses.

14 MR. YODER: Yes.

15 MR. AXTMANN: Analyses of what tissue?

16 MR. YODER: One was the data from the
17 trans-uranium registry in which we estimated how much
18 was in the body. This would be from the autopsy samples
19 of lung, liver, and bone, where one determines from the
20 urine sample how much is there. The question is, from
21 autopsy what can you infer is there. So this is a
22 composite for each individual of how much we thought was
23 there.

24 MR. AXTMANN: There are that many autopsies
25 every year?

1 MR. YODER: We have 50-some autopsies, and
2 these are 12.

3 MR. MOELLER: This was representative sample,
4 then, or is this all of your sample?

5 MR. YODER: We have 50-some samples, not all
6 were exposed to soluble materials. Some were exposed to
7 soluble, and some combination. What is tough is to get
8 into the analysis of that data, this is trying to
9 reflect some of the difficulties in inferring how much
10 is in the individual by urine sample.

11 I am going to show you a curve that is in the
12 ICRP 2 documents of a number of years ago, and I have
13 put committed dose up here, which I really don't care
14 whether the number is 50 or 30, it is the concept that I
15 am looking at, for a short lived or for a material that
16 assimilates fairly rapidly in the body, such as some of
17 isotopes of calcium, for example, calcium-40. In a year
18 or so, the committed dose that you are assigning is in
19 fact the dose that the individual is receiving.

20 In this period, however, the dose that you are
21 assigning has not been received. When one looks at
22 plutonium as a material, the assigned dose, of course,
23 goes on, and for every year we are assigning a 50-rem
24 dose to the lung, when in fact the dose that is actually
25 being received is represented by the small area located

1 right here, and after 50 years of exposure at the ALI,
2 the dose does reach the 50 rem committed dose. After
3 the individual leaves work, this curve should drop off
4 as no more intake occurs.

5 The point I want to make is, with our
6 difficulty in making measurements in this range, and our
7 difficulty in making very small measurements of the
8 change, we are assigning very large exposures to
9 individuals that we have questions with. So we are
10 forced to go back and ask the question, since I don't
11 feel comfortable in assigning a dose that I don't know
12 is there, what options does one have to deal with this
13 particular issue.

14 Until we look at the operational impact of our
15 environmental measurements, the room samples, our in
16 vivo, our bioassays, I have not mentioned wounds, but
17 the new document does at least give us some insight as
18 to how one would handle events of that nature, we have
19 some alternatives which improve the technology.

20 I was informed by a member of the NRC staff
21 that we are going to have some major improvements in our
22 urine bioassay measurement technique, which I look
23 forward to seeing. However, they are still in the
24 laboratory and have not been tried out in the field with
25 regard to the applicability on a routine basis. We may

1 be able to improve that.

2 Our lung counting and measurements of
3 materials on the lung, we are not seeing much
4 opportunity in the next few years for major advancement
5 in being able to reduce our MDA. Therefore, I have to
6 look at the option of the modifications that can be done
7 with regard to the activities we are now engaged in.

8 I do not feel it appropriate to assign a
9 significant dose based on an air sample, taken several
10 days before, with which we are kind of uncomfortable in
11 terms of making a dose assignment. Therefore, we look
12 to operations or activities in order to remote or
13 automate those operations with which the employee is in
14 close proximity to the radioactive material. We would,
15 in effect, have to look at that option of removing the
16 worker from the actual glove-box activity, free him in
17 the control room or in more remote areas so that it can
18 be separately contained and controlled.

19 Looking at the cost of these types of options,
20 assuming we even know how to do the remoting of very
21 complex activities, I estimate that at Rocky Flats we
22 are talking in terms of \$4 to \$5 billion in order to
23 achieve that. If I extrapolate that over the Department
24 of Energy, to other plants that they may have which will
25 require similar modifications, the costs will certainly

1 be in the neighborhood of \$10 billion-plus, if one has
2 to use that option.

3 Thank you very much.

4 MR. MOELLER: Thank you, Bob.

5 I think we will go ahead with the five
6 individual presentations, and then we will have our
7 general discussion session. So let's go ahead. We will
8 have one more and then take a break.

9 MR. HEID: Mr. Chairman, members of the
10 subcommittee, and consultants, I want to thank you for
11 the opportunity to be here today to make a few
12 comments.

13 Name is Ken Heid. I have 34 years of
14 experience as a professional health physicist, all of
15 which in the applied health physics end of the
16 business. Included in that 34 years is 16 years as
17 Manager of a Personnel Dosimetry Section. For the last
18 two years, I have been Associate Director for the U.S.
19 Trans-Uranium and Uranium Registries, responsible for
20 the health physics aspects of these studies.

21 My comments today will be mine. I am not a
22 spokesman for either Battelle nor the Department of
23 Energy. Further my comments essentially will be aimed
24 at the long-lived, well-retained radionuclides because,
25 in my opinion, that is where the problem is, or one of

1 the main problems.

2 I will start out, I would like to read a quote
3 from Dr. HUGH Dell, who is a member of the main ICRP
4 Committee. In a recent publication, he stated: "In the
5 practical application, release protection will be
6 governed by national laws and regulations. There is a
7 risk of confusion or conflict if those responsible for
8 drafting or enforcing such laws and regulations are not
9 fully aware of the original purpose of the basic
10 recommendations, the assumptions behind them, and the
11 significance of the concepts employed." I believe this
12 statement is very prophetic.

13 Many groups have been involved in discussions
14 and presentations or documents involving the ICRP 26
15 concepts that we are discussing -- No, we are discussing
16 the 10 CFR 20 that uses as a basis, primarily, the ICRP
17 26 concepts.

18 I have two slides.

19 The proposed changes for internal dosimetry
20 that have I have listed are 1977, when ICRP 26 came out,
21 1979 when ICRP 30 was published, and in 1980 IAEA
22 convened a group of experts, so-called, to discuss this,
23 and they formed Technical Committee 334 that talked
24 about that.

25 In 1981, we discussed the EPA proposal. Now

1 we are talking about the NRC proposal for 10 CFR 20. In
2 addition, we heard Dr. Parker mention the activities of
3 the NCRP, and I am sure we are all looking forward to
4 this, but so far they haven't published anything.

5 Shortly after the ICRP 26 concepts came out,
6 they were mandatory in the European community, at least
7 to the extent that they were told to begin the
8 transition period. Each of them were given a date by
9 which they had to comply.

10 During this transition period, the health
11 physicists were desperately trying to figure out how
12 they could implement these concepts. It was very easy
13 to implement the concept on a prospective basis, but to
14 try and come up with respective method for dose
15 assessment, a meaningful and practical assessment, and
16 one which they could compare with these requirements
17 that were laid down on the 50-year dose commitment
18 basis, was very difficult. They immediately set out a
19 call for help, "Because we have to do it, now somebody
20 tell us how we can?"

21 In response to their cry for help, the IAEA
22 set up a committee in 1980. This panel was given the
23 problem of trying to come up with some meaningful,
24 factual, and reasonable method to measure or evaluate,
25 assess the internal loads, and then compare with the

1 limits.

2 The group took the concepts of ICRP and found
3 that they were acceptable for control purposes. I would
4 like to elaborate a little bit on what Ed was saying
5 earlier about the one negative vote. Everybody was in
6 agreement that we could use it for control purposes,
7 that is for management of the worker exposure.

8 As Jake Shapiro pointed out earlier -- I am
9 sorry, I think it was Billie Mills pointed out earlier,
10 there is basically little difference for control basis
11 prospective use between the old system and the new
12 system. We are still trying to divide up the
13 permissible internal exposure and say, let's try not to
14 get more than one-fiftith of that in any one year. That
15 is what the MPCs did and that is what we are doing now.
16 The numbers may vary a little bit, but the concept is
17 not too dissimilar.

18 For dosimetry for short-lived emitters, the
19 dose commitment and the annual dose are basically the
20 same. There is very little difference. The real
21 problem, and where everybody but the one agreed that it
22 was totally unacceptable was for dosimetry for
23 long-lived, well-retained radionuclides.

24 Here basically we are comparing a prospective
25 limit with a dose assessment, and we are trying to

1 assess that dose at what it is going to be in 50 years,
2 and this 50 rem for stochastic, which is really
3 plutonium, is 50 rem over a 50-year period, or one rem
4 per year as the limit. For the non-stochastic the high
5 rem committed dose equivalent is 5 over a 50-year
6 period, or one-tenth of a rem per year.

7 To further supplement the European picture, I
8 might make a few comments about a meeting I attended
9 just last week. Ron Kathren was there. There were
10 three representatives from the UK, a representative for
11 the Department of Defense, Ron and I, and then Bill Baer
12 and Wright Thompson were in this meeting.

13 At that time, the UK representatives described
14 their effort to try and make some progress. They had
15 actually put lapel samplers on a few thousand people for
16 a couple of year period and tried to see if there was
17 any correlation between intakes as measured by the lapel
18 samplers and uptakes based on measurements made for the
19 individuals. They found absolutely no correlation, and
20 I think that should not be surprising. Without a lot of
21 additional data, intake does not relate to uptake.

22 MR. MOELLER: Excuse me on that. You are
23 assuming that the lapel monitor did indicate intake, and
24 you are saying that if it did, there was no correlation
25 between the intake and the uptake.

1 MR. HEID: In some cases they did, and in some
2 cases there was no activity there, but they did find
3 some in fecal samples. They were collecting fecal as a
4 primary means because that is a more sensitive measure
5 for the bioassay.

6 MR. RAY: Why would it indicate positively in
7 some cases and not in others? Do the different nuclides
8 react differently?

9 MR. HEID: This was all plutonium work.
10 I think that probably the difference is
11 particle size and ingestion. There are a lot of reasons
12 you could have.

13 MR. RAY: The circumstances under which the
14 ingestion took place.

15 MR. HEID: There are just a whole bunch of
16 parameters that have to take to relate uptake to
17 intake.

18 MR. MOELLER: Jack Selby.

19 MR. SELBY: I would like to respond a little
20 bit more on that.

21 The lapel air samplers that we currently have
22 available to us sample at the rate of one or two liters
23 per minute, that is a very, very low flow rate.

24 There have been studies that have demonstrated
25 that perhaps the lapel air sample is only looking at a

1 stagnant volume of air located near the surface of the
2 protective clothing, and not the true air concentration
3 that he is breathing.

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 MR. HEID: Their conclusion from the studies
2 they ran was, they prepared lapel samplers and room
3 samplers with the human data, worker data, was that air
4 sampling was an excellent trigger for a diagnostic
5 evaluation using in vivo and bioassay measurements for
6 the individual, period. I totally concur with this
7 conclusion.

8 When this was presented to the other members
9 from ICRP, Bill Barren, Roy Thompson, their response was
10 that ICRP had put out 26 as a prospective tool for
11 management, for planning for design of new facilities,
12 for planning and management of the worker exposure. It
13 was not intended to be used on a retrospective basis.
14 They were considering issuing a second document which
15 would be for retrospective dose assessment.

16 They did not give us any indication of if or
17 even when this might be published. They had run into
18 problems, and we don't know where that stands. I hope
19 that the NCRP will come through and give us some help.

20 The 10 CFR 20 proposal provides probably -- I
21 think it does -- provides better capability for
22 prospective control of worker exposure. However, again,
23 I repeat it is not valid for dose assessment. They are
24 throwing out 40 years of experience where we use the
25 critical organ dose concept. This has proven to be

1 effective in control, and I see no need to rush into
2 this Why don't we wait until the experts come up with
3 their findings and recommendations on how to do it on a
4 retrospective basis?

5 The previous speaker went into the details, so
6 I will just kind of recap the point I wanted to make.
7 He was saying on his slides that an uptake of less than
8 one nanocurie, I believe the number was .5, .6, in that
9 range, nanocurie uptake, not intake but uptake, would
10 result in a committed dose equivalent of 50 rem for
11 bone. For plutonium, that is 50 rem for 50 years.

12 The committed effective dose equipment would
13 be five rem. Both of these are from an uptake of less
14 than one nanocurie of plutonium. The strict application
15 of the 50 year committed dose will present the five
16 health physicists with the following problems. These
17 have been touched on, but I would like to repeat them
18 for emphasis.

19 Often years are required to collect the data
20 necessary for a meaningful dose assessment, especially
21 when chelation therapy has been administered. This, if
22 administered promptly, benefits the worker, but it sure
23 is not a benefit to the health physicist trying to
24 evaluate the deposition.

25 So, I can take one extreme case where the

1 treatment continued for several years, and we still
2 don't have a meaningful measurement that we have been
3 able to make through in vivo techniques.

4 Also, the chelation therapy will change the
5 distribution throughout the body. What the chelation
6 tends to do is remove -- still talking about plutonium,
7 keep that in mind. It tends to remove the plutonium
8 from the blood and the liver. It has very little impact
9 or effect on the bone. It will block any additional
10 deposition from going to the bone, but what already had
11 been deposited there, most of it will stay there, so
12 that now you end up with a case where the bone has a
13 deposition, the liver doesn't.

14 When you try to apply this standard model to
15 all of them, it is a very confusing result that you
16 get. Also, the previous speaker mentioned that the
17 state of the art does not permit assurance or detection
18 at these reduced limits.

19 Just a few words on the impact on epidemiology
20 studies, and I will broaden that out to include the
21 impact on the U.S. transuranium industry, since I am
22 involved in that. If we were to get health physics data
23 expressed in committed effective dose equivalent for the
24 internal exposure, forget it. There is no way we can
25 try to compare the health physics data without working

1 backwards, making assumptions on what assumptions they
2 used to arrive at that figure.

3 So, it is really going to cast doubt on the
4 credibility that might be made in any such study as
5 these.

6 One quick word on uranium. Basically, the
7 same kinds of concepts would apply for uranium, but to a
8 much lesser degree. Most of the uranium clears very
9 rapidly from the body. Thus the annual dose and the
10 50-year committed dose are comparable. However, there
11 appears to be a small fraction of the uranium that is
12 well retained in the body. We have seen in vivo
13 measurements for years after a person was removed. The
14 clearance rate is much lower than anticipated.

15 In this particular fraction, it would fall
16 into the same ball park as plutonium. The 50-year
17 committed dose equivalent just does not apply.

18 In conclusion, let me just stress again that I
19 would hope that we are not in such a big hurry to get
20 this done that we don't wait for the experts to give us
21 an answer that might end up with a much better product
22 than what is proposed by the NRC in 10 CFR 20.

23 Thank you.

24 MR. MOELLER: Thank you.

25 Let's now take a break until a quarter of

1 11:00. And then we will resume.

2 (Whereupon, a brief recess was taken.)

3 MR. MOELLER: Let's resume the meeting,
4 please.

5 For those who are wondering about the
6 schedule, the people from EPA tell me that they will
7 need roughly about a half-hour, so we are not as bad off
8 as it might appear. Above all, though, when we have had
9 people who have so obviously devoted a lot of time to
10 preparation and who come here at great personal
11 sacrifice to be with us today, my objective is to hear
12 them out and to give them the time that they need.

13 So that will be the premise on which we will
14 continue. We will move ahead then now.

15 MR. HALL: Mr. Chairman, members of the
16 committee staff, consultants, I consider it an
17 opportunity for me to come and express my views on the
18 implementation of the proposed 10 CFR 20. I was with
19 DuPont at the Savannah River plant during the startup of
20 the production reactors, separation facilities, fuel
21 fabrication facilities, the laboratories, and I have
22 worked in those facilities protecting the health of
23 DuPont employees and other DOE employees for the last 30
24 years.

25 I am currently the staff health physicist with

1 the primary responsibility for monitoring and
2 determining the dosimetry or the dose equivalent
3 received from radiation sources, both external and
4 internal to the body, for approximately 10,000 employees
5 at the Savannah River plant, the Savannah River
6 laboratory, and other DOE facilities at the site.

7 This proposed revision to the 10 CFR Part 20
8 will certainly have a major impact on the Savannah River
9 plant if an attempt is made to implement it in the form
10 of the August, 1982, draft. Health protection for DOE
11 contractors' employees can be improved significantly by
12 the practical application of the prospective dose
13 limitation system recommended by ICRP and Publication
14 26.

15 (Slide.)

16 MR. HALL: But, however, without some major
17 changes in some of the proposed concepts and as 10 CFR
18 Part 20 is currently drafted, it is unacceptable for the
19 assessment of employee committed effective dose
20 equivalent and the effective control of some of the
21 significant occupational radiation exposures.

22 (Slide.)

23 MR. HALL: On this slide, I have listed some
24 of the operational problems that Mr. Vallario has
25 presented earlier, the plutonium intakes, air sampling,

1 bioassay, and 50-year dose commitments. I will briefly
2 show some of the examples of how these are problems at
3 the Savannah River plant operations.

4 The primary operational problems with the
5 proposals are monitoring for the possible assimilations
6 of radio nuclides into the body and the compliance with
7 the dose limitation systems that are listed in Section
8 20.205.

9 (Slide.)

10 MR. HALL: We show here all of the confirmed
11 assimilations of radio nuclides in the body of employees
12 since 1972 at the Savannah River plant. These do not,
13 except for the blue ones that indicate tritium, do not
14 indicate any minimum amount. If we confirm an intake it
15 is listed there, whether it be one millirem dose
16 equivalent or ever how high.

17 Now, the blue ones indicate the tritium
18 assimilations, and they indicate the ones that are above
19 a limit, an administrative limit of 20 microcuries per
20 liter, that would result in a total integrated dose to
21 the whole body of approximately 100 m-rem.

22 The purple ones are for fission products. I
23 guess the main reason our production reactors do not get
24 any induced activity or fission products in the bodies
25 of people is that our moderator is duterium that

1 contains tritium. When you project for tritium, there
2 is no way to assimilate fission products.

3 By the same token, we have plutonium in our
4 separations area, and the only way to keep plutonium out
5 of the bodies of our employees is to keep the fission
6 products that are associated with those. So, these
7 uptakes result from accidents.

8 The green ones, for example, are for uranium,
9 and it is primarily depleted uranium. These intakes are
10 not necessarily above the TLV of the .2 milligrams per
11 liter. In fact, if you expose the worker to one-tenth
12 of 1 percent of that TLV for eight hours, he would
13 exceed the ten micrograms per liter of uranium, which
14 would be recorded on these incidents.

15 So the effective control that can be used and
16 that is used is to preclude the intakes of radioactive
17 materials into the body. However, you can see some
18 worrisome red colors that have to do with plutonium and
19 some orange colors that might have to do with the
20 americium and curium. At least a couple of these orange
21 curiums are californium 252 rather than curiums, but
22 that is the same sort of transuranium nuclides involved
23 in that particular case.

24 But all of the employees with potential
25 intakes are investigated and the measured dose received

1 is placed in the employee's record. All radiation
2 workers that are potentially exposed to radioactive
3 airborne contamination are not only monitored, they are
4 identified as radiation workers, and all radiation
5 workers are monitored for both external and internal
6 intakes into the body.

7 I think that the thing that may be shown is
8 that with tritium, the DOE's guidance and requirements
9 requires both the external and internal be added
10 together, and we add the dose from all tritium
11 assimilations. We detect tritium down to five-tenths of
12 a microcurie per liter, which would be less than an
13 m-rem or so exposure, but we take a sample of each day,
14 some 60,000 a year, and if the dose is measured, it is
15 added to the external exposure and placed in the
16 employee's record so that we know either how much or how
17 little exposure each employee has.

18 We figure that it is important to not only
19 identify but to record what the individual exposure may
20 be.

21 (Slide.)

22 MR. HALL: These are the confirmed tritium
23 assimilations that have occurred during 1982. As you
24 can see, the maximum approach is about .25 rem, the
25 level at which the proposed 10 CFR 20 requires us to

1 begin monitoring, so I suppose from this, if we had been
2 under this instead of those 60,000 samples, we would
3 have had to monitor one employee if we could have
4 identified him prospectively.

5 In the power reactors, the total exposure for
6 some 1,000 employees during 1981 was 150 rem total
7 collective dose equivalent to the whole body. Of that,
8 about 60 rem was due to tritium assimilations, and of
9 those tritium assimilations, most were below the
10 required measuring level.

11 As a matter of fact, for this year, the total
12 dose at the Savannah River plant, if we had neglected to
13 measure and add in these tritium internal doses we are
14 approaching the 100 rem collective dose equivalent to
15 the whole body of the 10,000 employees that we monitor
16 at Savannah River.

17 So, that just points out the salient
18 importance of measuring what the employees get.

19 (Slide.)

20 MR. HALL: This shows a picture of where the
21 1,000 were. It says the plutonium assimilations can
22 occur by inhalation and be deposited in the lung, the
23 bones, or the liver. We also have ingestion. At least
24 at the Savannah River plant, ingestion is not an
25 occupational hazard, but puncture wounds is an

1 occupational hazard.

2 If puncture wounds occur, there is some
3 guidance in 10 CFR 20, but none of the ALI's or DLI's
4 can be applied to a puncture wound. Those are applied
5 only for inhalation or ingestion because they were not
6 calculated to get the factors that would make them
7 applicable for puncture wounds, and the concept for --
8 needs to include all routes of entry into the body.

9 (Slide.)

10 MR. HALL: What we are saying is that as far
11 as inhalation of airborne contamination goes, we have
12 much experience with monitoring airborne contamination
13 in the form of tritium exposure which is a gaff. It may
14 be in the workplace, and yes, at low levels we permit
15 employees to breath tritium atmospheres if they will
16 receive less total external exposure by picking up
17 tritium without the respiratory protection.

18 We have thousands of people each day for the
19 past 30 years where they have estimated their tritium
20 assimilations from airborne samples that were taken at
21 the time of their work. However, we found that it is
22 necessary to collect samples daily if they work daily
23 and three times a week if they work intermittently to
24 correct those estimates.

25 The estimates for tritium assimilations are

1 usually on the conservative side, and the employees will
2 estimate a factor of two or three higher than they
3 actually receive. However, it is a different case on
4 the unplanned exposure, where the person is involved in
5 a protective equipment failure, where you have a torn
6 plastic suit, or the loss of containment, or where there
7 is a procedure violation, and the proper protective
8 measures were not taken.

9 Estimates based on air sampling in those
10 conditions are meaningless. You know, yes, they had
11 one, you had better evaluate. They are immediately
12 removed from work until -- of course, with tritium,
13 there is no problem to evaluate. It reaches equilibrium
14 in the body in two hours. Obtain a sample of body
15 fluids, and you know the real answers that you can put
16 in the employee's records.

17 (Slide.)

18 MR. HALL: As Dr. Yoder indicated earlier,
19 that when he has an assimilation, and I at this point
20 would like to indicate that I personally concur with the
21 statements made earlier by Mr. Heid and Mr. Yoder, that
22 if you have an assimilation or a potential assimilation
23 from an unplanned incident, that these are the steps
24 that are taken to evaluate that. Yes, first, you have
25 to know how it occurred. Was it a puncture wound or was

1 it inhalation? Then you would need to know what radio
2 nuclides were involved.

3 Now, we have no problem identifying small
4 quantities of plutonium in our waste tank or in a waste
5 farm where we are processing radioactive waste, because
6 for every nanocurie of plutonium, there are hundreds of
7 nanocuries of cesium 100 or other gamma-emitting radio
8 nuclides emitting plutonium, so therefore from the air
9 sample you can get the ratio of the two, and if you are
10 counting in vivo immediately after the incident when he
11 still contains all the fission products and the
12 plutonium, you can assess updates down to the fraction
13 of a nanocurie level.

14 And of course the airborne contamination is a
15 consideration. It just gives you the extent of the
16 release and how long the men were there, which is how
17 worried you get, and then you look at the clothing
18 contamination, the skin contamination, was his hair
19 contaminated, nasal contamination, the whole body in
20 vivo count comes early.

21 However, those particular assessments are, as
22 was pointed out, do not have the sensitivity needed, and
23 you have urinalysis, fecal analysis, and for long-lived
24 nuclides like plutonium, this has to occur by not only
25 months but years after the intake. So, this

1 investigation must begin immediately when it occurs.
2 There is no way to investigate this thing with a long
3 chronic exposure with any success.

4 (Slide.)

5 MR. HALL: Both Mr. Vallario and Mr. Yoder
6 have addressed air sampling to some degree. Here, I
7 merely show a comparison between what the personal air
8 samplers are. These are the operational state of the
9 art air samplers that are available at the Savannah
10 River plant, the normal room air sample, where we assess
11 and compare them with the 10 CFR proposed Appendix B
12 levels for ALI's.

13 As you can see, the amount that can be
14 detected when you compare it with the amount of the
15 DAC's, the methods are very marginal, if you only had a
16 pure sample of plutonium 238 with only one plutonium
17 isotope. Unfortunately, if you will read the proposed
18 10 CFR Part 20, and I think it is well that they
19 recognized that you can have mixtures, with plutonium
20 mixtures, the DAC is 3×10^{-13} .

21 (Slide.)

22 MR. HALL: At Savannah River, our plutonium,
23 except in the fuel fabrication facilities, where
24 plutonium 238 is produced to provide power sources for
25 satellites, it is a plutonium mixture. Here is a

1 typical mixture that we may encounter. You will notice
2 that in this mixture, you have both beta-emitting
3 isotopes, the plutonium 241, and alpha-emitting
4 isotopes.

5 We normally just measure the alpha-emitting
6 isotopes on air samples. In a reprocessing facility or
7 in a laboratory, you can have separations of the
8 americium 231 daughter from this mixture. Immediately
9 after separation, the ingrowth of americium 231, I am
10 sure that many of you are familiar with, changes hourly
11 and daily and weekly by orders of magnitude.

12 Therefore, if the identity of each radio
13 nuclide is known, but the concentration of one or more
14 of the nuclides or the isotopes in the mixture is not
15 known, the DAC is 3×10^{-11} and the ALI is .7
16 nanocuries.

17 (Slide.)

18 MR. HALL: On that basis, a brief review of
19 some of the data shown earlier as far as in vivo
20 counting with the state of the art Foswick detectors.
21 This shows that for plutonium 239, plutonium 238, you do
22 not see a small fraction of what we consider the lung
23 burden now, and these do not compare very favorably with
24 the .7 for the annual assimilation, and in operational
25 you would like to be able to measure a small fraction of

1 that.

2 (Slide.)

3 MR. HALL: I would like to use this
4 assimilation of plutonium that occurred in the spring of
5 1982 to show you what effect the 50-year committed
6 effective dose equivalent would have on this employee.
7 The employee was working in a facility. He was
8 protected with cabinet -- processed cabinet gloves.

9 During the work, inadvertently the glove
10 failed at constant air monitor high volume sampling that
11 40 CFM alarmed immediately, and when he left the work
12 location, we monitored him and did not detect any
13 activity in the in vivo. The initial urinalysis, even
14 though the man was treated with DPTA, that enhances a
15 factor of 50 with only a fraction of a deep rem per day.

16 However, the nine fecal samples collected a
17 week after the accident contained measurable quantities
18 of plutonium and the assessment of his retained lung
19 burden was 2.9 nanocuries. You can see that this
20 represented about 2.3 rem, a 12-month committed dose
21 equivalent to lung organ dose.

22 Now, if you evaluate this with -- you would
23 have to look back and say, well, now, the intake was 19
24 nanocuries, and you would say, well, now, we are lucky,
25 because 10 CFR Part 20 says the annual ALI is 20

1 nanocuries. We are home free.

2 However, with that typical plutonium isotope
3 about 12 percent or 160 nanocuries of that was plutonium
4 241, so you have to add to that 4.8 rem that you would
5 calculate 1.1 rem from the plutonium 241, and the
6 americium 241 daughters, and immediately you have 5.8
7 rem, and we would have had to have gone to this
8 employee, whose lung dose was not more than 15 percent,
9 which is half the value that the new 10 CFR 20 says you
10 would have to measure if it were the organ dose, it says
11 30 percent, if this was 15 percent of that organ dose.
12 For some short-lived compound, it would be half of that.

13 Suddenly, we have to disrupt the individual
14 and say, well, you are overexposed, we must remove you
15 from work, we must upset your family, all other
16 psychological impact that goes with this, and after
17 several conferences, we may be able to look at the other
18 socioeconomic problems.

19 (Slide.)

20 MR. HALL: In summary, we have identified some
21 of the shortcomings and pitfalls that we have seen in
22 the proposed monitoring and records system, and the
23 problems associated with the 50-year committed dose
24 equivalent are more severe for the Savannah River plant
25 than they are -- than for what the licensees may

1 anticipate for themselves today.

2 However, in the future, many licensees will
3 face the same problems that we have been facing because
4 of prolonged storage of spent reactor fuel, reprocessing
5 of fuel, and the breeder program.

6 I mentioned the isotopic content of my typical
7 plutonium, breeder plutonium, power reactor plutonium.
8 The dose from the plutonium 241 data that you are not
9 measuring will probably be at least equal to that of the
10 alpha.

11 Thank you.

12 MR. MOELLER: Thank you.

13 Let's see. Jack Selby is going to be the next
14 presenter.

15

16

17

18

19

20

21

22

23

24

25

1 MR. MULLER: There were several of those
2 slides that it would be nice to get copies of.

3 MR. MOELLER: I'm sure we will.

4 MR. SELBY: Mr. Chairman, members of the
5 Subcommittee, and NRC Staff: I appreciate the
6 opportunity to participate in your Subcommittee meeting
7 on the proposed draft 10 CFR Part 20. I am Jack Selby,
8 Manager of Health Physics Technology at Battelle
9 Northwest.

10 For the past five years I have been the
11 project manager of an extensive health physicist support
12 and assistance program which we conduct for the
13 Department of Energy at the headquarters level. It
14 should be noted that my comments represent my opinions
15 and not my employer nor DOE.

16 As an operational health physicist for 28
17 years, I share with you the dedication to the three
18 basic principles governing radiation protection of
19 workers, namely, occupational exposure should be: one,
20 justified; it should be kept as low as reasonably
21 achievable; and it should be subject to upper limits of
22 individual risk.

23 However, these principles require careful
24 balancing to ensure that no one segment of the worker
25 population nor the public is required to bear a

1 disproportionate share of either the dose or the
2 financial burden in order to satisfy a regulatory agency
3 position which may have little or no justification.

4 There are several problems associated with the
5 draft guidance that concern me. These include, but are
6 not limited to: the apparent treatment in the recording
7 and reporting of effective dose equivalent for radiation
8 workers; number two, the implication and stigma that a
9 worker has received an effective dose equivalent orders
10 of magnitude greater than the annual limit of 5 rem by
11 adopting the committed dose equivalent for 50 years.

12 This can result from assigning all of the 50-year
13 committed dose to the year the worker was exposed to a
14 minute quantity much less than the long-lived emitters.

15 The alternate approach would be to assign to a
16 particular year only the dose received during that year,
17 regardless of when the intake occurred.

18 Finally, the continued emphasis on the
19 measurement of percent, rather than the actual uptake in
20 the individual, and the relative impact of identical
21 acute deep dose equivalent external and committed
22 effective dose equivalent internal exposures.

23 I will try to touch on all of these as we go
24 along.

25 (Slide.)

1 I intend to touch briefly on three major
2 points in my discussion: the Department of Energy
3 experience, the impact on worker protection, and the
4 apparent legal implications.

5 (Slide.)

6 A very useful document on occupational
7 exposure to ionizing radiation in the United States, EPA
8 520/4-80-001, was produced by the EPA. This document
9 illustrated what many of us have been aware of, namely
10 that the nuclear industry, through its flexible
11 radiation protection program with emphasis on ALARA, has
12 been effective in lowering individual and collective
13 doses, even though the jobs are becoming more complex
14 and the worker population is increasing.

15 I would like to show a little bit of the
16 experience we've had in the Department of Energy along
17 this line.

18 (Slide.)

19 In this figure we have slotted for selected
20 years the numbers of individuals in the various exposure
21 ranges, zero to one, one to two, two to three, and so
22 on. It should be noted that beyond 1968 any points that
23 you see on this represent unplanned exposures, because
24 the Department of Energy contractors and the Department
25 of Energy adopted the philosophy that we would not use

1 the banking concept but we would limit our exposures to
2 five rem.

3 If you will note, in 1976 we had approximately
4 five people in the four to five rem range. Now, that is
5 in a worker population of approximately 100,000
6 workers. In 1977 we had a few more. We had in the
7 neighborhood of 20.

8 (Slide.)

9 To further characterize this, I would like to
10 show the breakdown of the most recent year to illustrate
11 a point that I want to touch on later. Here again, we
12 have shown the ranges, zero to one, one to two, two to
13 three, and we have plotted the collective dose
14 equivalent that has been recorded for the radiation
15 workers.

16 As you can see, the single greatest
17 contributor to the collective dose equivalent in the
18 Department of Energy and its contractor organization is
19 in the zero to one rem range. If I further break that
20 down and showed you the zero to .5 and the .5 to one,
21 you would see that the majority of it was in the zero to
22 .5, and therein lies one of the problems that we have
23 with the current draft of 10 CFR 20, that is, to
24 encourage not measuring exposure at .5 or less.

25 (Slide.)

1 Showing this in yet a different way, we
2 believe that if you identify a worker to be monitored, a
3 radiation worker, that you should record all
4 measurements whether they are negative or positive. And
5 in fact, some people feel perhaps the negative values
6 are even more important. I know Ken would take
7 exception with that, because he challenged me last
8 night. But we certainly do not believe there should be
9 holes in the occupational exposure record for values
10 that are below a measurement level, and I'll get into
11 that a little bit more.

12 Now, as you can see, last year in our
13 radiation worker population, which was approximately
14 83,000 according to the statistics we received, 54
15 percent were less than measurable. That means that the
16 dose recorded on the dosimeters was background. 44
17 percent were in that range that I pointed out, zero to
18 one rem. Only 1.5 percent of that worker population was
19 above one rem.

20 I would submit that we should concentrate a
21 great deal of attention in this area and not throw the
22 data out and not forget about that particular aspect of
23 the worker population.

24 (Slide.)

25 Referring back again to the study that the EPA

1 did -- and it should be noted that the report failed,
2 however, to present several important data points.
3 These include the actual magnitude of workers' total
4 exposure, external plus internal, and its relationship
5 to a perceived limit of 250 rem dose equivalent for a
6 worker employed for 50 years in the nuclear industry.
7 It failed to identify the magnitude of internal
8 exposure. It failed to identify the magnitude of
9 forearm exposure.

10 And one additional one now that comes out as a
11 result of one of the requirements in 10 CFR 20 -- and it
12 may have been modified, as we heard this morning from
13 Dr. Mills, but one would wonder how the application of
14 the F conversion factors that are contained in Table 1
15 of the August draft will impact on the current reported
16 deep dose equivalent, since these values vary from 1 to
17 1.5 depending on the energy of the photons.

18 I would like to note that for a plant such as
19 Rocky Flats involving worker plutonium if you look at
20 the levels we're talking about you would probably have
21 to multiply the current reported doses by approximately
22 1.4, and that impact I do not believe has been
23 reviewed.

24 (Slide.)

25 To further take a look at the internal part of

1 this, we have prepared a slide which represents 168
2 depositions, plutonium depositions that we currently
3 have at Hanford. We have attempted to place these in
4 the ranges based on the maximum permissible body
5 burden. We have 114 workers with less than five percent
6 of the maximum permissible body burden of
7 plutonium-239. We have 4 in excess of 50.

8 Over here we have attempted to calculate the
9 50-year committed dose equivalent using the requirements
10 of ICRP 26. It should be noted, however, that these
11 numbers when we did it were based on the weighting
12 factors in the EPA document, and therefore if we used
13 the current numbers these would increase by
14 approximately 25 percent.

15 (Slide.)

16 In order to make a point, I wanted to show a
17 list of our highest external radiation exposures at
18 Hanford. It should be noted that the first on the list
19 is the separations operator with 144 rem of external
20 exposure, and the majority of this was received during
21 the Recouplex accident. We do not choose to take resort
22 in the one-time accidental exposure and neglect it. So
23 it has been included and he has been controlled
24 accordingly.

25 Now, looking at the rest of the group, where

1 unplanned exposures exceeding limits have not occurred,
2 you will see the average age is -- I'm sorry, the
3 average length of service is somewhere around 25 to 30
4 years, and the average annual exposure is someplace in
5 the 2 rem range. Now, in this particular group there
6 are four individuals who are also deposition cases.

7 (Slide.)

8 Again, looking just at their external exposure
9 situation, we have three separations operators and a
10 reactor operator who are in the highest exposure group
11 at Hanford and who have also plutonium depositions. As
12 you can see again, the average service is somewhere in
13 excess of 30 years and their average annual exposure is
14 approximately 2 rem.

15 (Slide.)

16 Now, looking at that group and calculating for
17 the 50-year committed dose, this is what their total
18 whole body risk would be assumed, based on the ICRP 26
19 model. Again, it should be noted that these numbers are
20 25 percent low because they were based on the weighting
21 factors in the EPA document and not on the current
22 guidance.

23 So you can see that for worker A, with 68 rem
24 external exposure, with a deposition of less than 50
25 percent of the body burden, he's now set it at

1 approximately 25 rem.

2 MR. KATHERN: Jack, can you put that up
3 again?

4 MR. SELBY: I should mention, this should be
5 A, B, C, D. Was that what you were catching on?

6 MR. KATHERN: Yes, that was the question.

7 MR. MOELLER: And you're also going to show
8 us, Jack, what their actual dose has been up to this
9 time?

10 MR. SELBY: No, I didn't.

11 MR. MOELLER: It's much less?

12 MR. SELBY: It's much, much less, yes.

13 (Slide.)

14 For the sake of time, I'm throwing out a few
15 of these things here.

16 MR. DAVIES: Jack, would you mind putting that
17 slide back that you just took off, the one with the two
18 C's? Did you get the total accumulated dose?

19 MR. SELBY: This one right here or the second
20 column?

21 MR. DAVIES: The second column.

22 MR. SELBY: That is their external dose.

23 MR. DAVIES: Okay.

24 MR. SELBY: This is what you would calculate
25 using the 50-year calculated dose equivalent, and this

1 then would be the calculated effective dose equivalent
2 (Indicating).

3 MR. MULLER: That's the sum of the two.

4 MR. KATHEEN: Yes.

5 (Slide.)

6 MR. SELBY: Quickly, I would like to hit a few
7 points that Ed Vallario has already hit, but I just
8 would like to hit them once more. I have five
9 concerns. I had four when I made this slide and I came
10 up with a fifth one, which is design of the radiation
11 protection program.

12 The occupational exposure history we feel is
13 extremely important in not only protection of the
14 individual, but also in the protection of the company
15 and any organization that is associated with that
16 history. I think we are seeing now efforts to try to go
17 back, for example, and to calculate or estimate
18 exposures to military personnel who are involved in test
19 site shots, who worked at plants where there was
20 radioactive material, and their records were either not
21 kept or they were lost or what have you.

22 So we feel that occupational exposure history
23 is extremely important. If you review ANSI N.13.6, I'll
24 admit it's out of date, but it does have a message.
25 That message is that you should use good business

1 practices and all actions should be auditable. All
2 actions should be auditable.

3 That is, you shouldn't be throwing out data.
4 You should be putting in whatever you measure. You
5 should be justifying what you measure. And if you will
6 refer to 20.1103 in the draft standard, it says that if
7 you are exposed to two DAC hours in eight hours, to ten
8 DAC hours in a week, you can go ahead and escalate that
9 out to a year, you're talking about 25 percent that you
10 do not have to record. So you could in effect, one day
11 because you are above that two DAC hours in eight hours
12 you record it, the next day you're below it and you
13 don't.

14 If you're going to use that concept, you
15 should be recording everything you measure or estimate.
16 That same point goes to an incomplete data base. You've
17 got holes in your records. If you're monitoring for the
18 individual, report what you're monitoring. If you're
19 not going to monitor, then don't play games of that
20 sort.

21 However, when you go on down to the next
22 point, calculation of assumed exposure, if you read the
23 guidance, you do not have to monitor for an individual
24 if you assume that he is going to receive less than half
25 a rem per year or he is going to be exposed to less than

1 30 percent of an ALI in a year. So you do not have --
2 it's a perfectly good judgment.

3 However, when you come to Form 4 and the
4 instructions as to how you fill that out and each
5 employer, when he hires somebody who has worked at
6 another facility that involved radiation exposure, has
7 to fill this Form 4 out, and he is required to fill in
8 any gaps where the exposure has not been measured with
9 1.5 effective dose equivalent rem.

10 So therefore the exposure, as we have seen on
11 the earlier charts with the DOE experience, much of our
12 exposure is down in the zero to one rem range. In fact,
13 it's down in the zero to a half a rem range. And all of
14 a sudden we're going to start putting in exposure that
15 doesn't exist. I think that's going to raise a lot of
16 questions on the part of the individuals and on the part
17 of the legal records, et cetera.

18 ALARA, the exposure records, serve another
19 purpose. That is that they are very, very useful in
20 comparing results of the radiation protection program
21 within facilities in a given plant, between plants
22 having similar operations. It provides an important
23 base to look at worker group problems and to look at
24 important exposure categories.

25 We feel that when you have a set of data that

1 you are accumulating, that it should not be added
2 together in one final number. That is, the relationship
3 to the effective dose equivalent of five rem per year.
4 You should maintain all of the parts so that you can
5 continue to do the comparison of the results and look at
6 important worker groups and important exposure
7 categories.

8 That encouragement has to come out of
9 organizations like the Department of Energy and the
10 Nuclear Regulatory Commission.

11 (Slide.)

12 I mentioned that I had one other point I
13 wanted to make or put on this graph. That's design of
14 the radiation protection program. We feel that
15 continued emphasis on total dependence on air sampling,
16 rather than encouragement to involve good internal dose
17 measurement programs, is not a good service to the
18 radiation worker.

19 That is something that is not new. It was in
20 the existing 10 CFR 20, and we would hope that when a
21 change is made in 10 CFR 20 and we talk about improving
22 worker protection that a strong consideration would be
23 given to encouraging the development of a good internal
24 dosimetry program.

25 Now, it turns out that that requirement in 10

1 CFR 20 seems to be counterproductive with what is going
2 on in other parts of the Nuclear Regulatory Commission
3 and also in the Department of Energy. As was mentioned
4 earlier this morning, there is a great deal of effort
5 going on to improve the quality of the measurement
6 program.

7 The Nuclear Regulatory Commission sponsored
8 the study by the University of Michigan, which should
9 lead to the certification of dosimetry processing. I
10 think that is a very, very valuable exercise that they
11 have supported and I think it is very useful to all of
12 the industry.

13 The Nuclear Regulatory Commission and the
14 Department of Energy jointly are looking at a
15 certification program for bioassay, again to improve the
16 quality of the measurement program, and I think that's
17 the way we should be going. We have heard that we have
18 a great deal of problems in terms of sensitivity -- or
19 perhaps I shouldn't say sensitivity, but minimum
20 detection levels -- in our current measurement program,
21 and we should be attempting to take care of that.

22 At the same time, we should be encouraging the
23 use of good internal dosimetry programs.

24 (Slide.)

25 My last slide, I'm not going to belabor this

1 since Ed has covered it so well already. We feel that
2 many aspects in the draft that we reviewed, the office
3 draft of 10 CFR 20, carry legal implications. To name
4 three of them: the 50-year committed dose; the
5 implication of technical overexposures, applying this
6 concept; and the encouragement of an incomplete data
7 base.

8 Again, let me thank you for allowing me to
9 appear here today. I'd be happy to answer any questions
10 when we get to the question period.

11 MR. MOELLER: Thank you, Jack.

12 Let's see. We'll finish up then with the DOE
13 presentations, presented by Jack Corley.

14 MR. CORLEY: I suppose I could almost save
15 everybody a little bit of time by just reading my
16 introduction and my summary and let us get to lunch a
17 little bit earlier.

18 I am John or Jack Corley and a staff engineer
19 with the Radiological Science Department of, in spite of
20 what's on the program, Battelle's Pacific Northwest
21 Laboratory. I've been a health physicist for 35 years
22 for 8 of which I was in charge of the Environmental
23 Surveillance Program at the Hanford site. For the past
24 eight years I've been responsible for the technical
25 assistance project in the area of environmental

1 radiological protection for first the AEC and now the
2 Department of Energy, and as such I've had primary
3 responsibility for the preparation of guides of good
4 practice for radiological environmental surveillance and
5 effluent monitoring.

6 Like my cohorts, I have to make it clear that
7 I am going to give you my views and not DOE's or
8 Battelle's position.

9 Practical application of the ICRP
10 recommendations to population groups introduces
11 different problems and constraints than it does for
12 occupational exposure. In large part, it's due to the
13 lack of specific identification of the exposed
14 individuals in the environment, the fact that those
15 individuals are a mixed heterogeneous group and
16 continually changing, and because we don't really have
17 the ability to control as individuals future exposures
18 to those same population groups. We do of course have
19 control by remedial actions at the source or by
20 intervention in exposure pathways for groups as such.

21 Several aspects of the proposed 10 CFR 20
22 regulations then generate similar concerns for
23 environmental surveillance as for occupational
24 protection responsibilities. Others engender some
25 different responses and I'll try to point this out.

1 It is noted that several of the concerns that
2 we are addressing are inherent in the adoption of ICRP
3 Publication 26 recommendations, for example the
4 assignment of a 50-year dose commitment to the year of
5 intake and the use of weighting factors to calculate an
6 effective whole body dose equivalent.

7 But others have been introduced in the NRC
8 drafting process: the use of factored ALI's for
9 population dose estimates and a directed ALARA
10 emphasis. In principle, the use of 50-year committed
11 dose equivalence from radionuclides with long biological
12 half-lives seems more appropriate for assessment of
13 population exposures than for occupational doses. The
14 latter capability will exist to substantiate a priori
15 estimates through external and internal monitoring
16 procedures, however sensitive they might be.

17 For members of the public, use of the
18 committed dose equivalence may be necessary to
19 demonstrate compliance as well as for predictive
20 purposes. As a matter of fact, a number of our DOE
21 sites are currently calculating 50-year committed dose
22 equivalence for plutonium.

23 As noted earlier, however, the acceptance of
24 the principle of calculating committed dose equivalence
25 does not necessarily imply, and in fact in my view does

1 definitely not imply, acceptance of the principle of
2 calculating and basing our controls strictly on
3 effective committed dose equivalence. And even the
4 acceptance of the 50-year dose equivalent requires an
5 additional caveat or two: The conversion of health
6 effects to individual --the conversion of risk health
7 effects to individual body organs to an equivalent body
8 risk and control purposes certainly is just as valid for
9 uncontrolled area populations as for occupational
10 exposures.

11 The practice may indeed be even more useful
12 for comparison of collective health risk as an aid in
13 design analysis, or even to provide a trend indicator
14 for a given facility or for a group of similar
15 facilities.

16 However, loss of the pertinent individual body
17 organ dose estimates, whether it's for epidemiological
18 purposes or for potential legal protection, inevitably
19 will occur if no other record is maintained than the
20 effective collective committed dose equivalent.
21 Especially where nuclide pathways population exposures
22 are limited, one wonders if this is really the right way
23 to go.

24 The masking of probable risk of health effects
25 to specific body organs especially, as well as the

1 actual genetic risk is especially questionable where
2 specific nuclides are highly concentrated in one body
3 organ. And of course, you've already been given
4 examples, I believe, by Jack Healy of plutonium bone
5 doses and the other obvious example is thyroid doses
6 where the only releases are radioiodines.

7 One would find it difficult to evaluate a
8 claim of excess cancer incidence solely on the basis of
9 effective dose equivalence. The weighting factors
10 recommended by the ICRP and incorporated by the NRC in
11 proposed 10 CFR 20 involve so many assumptions as to
12 physiological parameters and relative risks which for a
13 diverse population group, I would certainly expect to
14 see large deviations from standard values for which
15 adequate data is almost always lacking to some extent.

16 Perhaps no ready alternative is available if a
17 single coefficient of risk must be derived for
18 assessment of total public health risk. However,
19 determination of an effective committed whole body dose
20 equivalent may well involve increases in effluent and
21 environmental monitoring programs. Unfortunately, the
22 potential need for and cost of extending specific
23 radionuclide measurements and accumulating other
24 necessary components of the data base has not really
25 been evaluated for the broad variety of licensees, nor

1 even all the variety of DOE facilities.

2 I would in addition raise one additional point
3 of concern about potentially misplaced emphasis in an
4 effluent reduction program or an ALARA application
5 program if we were looking only at effective committed
6 dose equivalent rather than specific nuclide releases.
7 Of greatest concern, however, to me and I think to
8 others concerned with evaluating population doses is the
9 proposed use of the proposed ICRP's ALI and DAC tables
10 with constant factors to adjust for lower limits,
11 different exposure periods, and an assumed age
12 distribution.

13 Aside from the the fact that the ICRP
14 specifically warns against this practice, application of
15 the standard factors for all nuclides and for all the
16 diverse critical groups to be found at the various
17 licensee facilities will largely negate any claim to
18 more precise controlled population exposures. If all
19 such calculated annual intakes were equivalent to less
20 than the de minimis values, obviously one could ignore
21 the weakness of the assumptions used. I am not
22 confident that that is the case.

23 As one example only, I will flash on one flip
24 chart here.

25 (Slide.)

1 This I stole from Roy Thompson, who all of you
2 know. It was in a paper given at a meeting, and it
3 simply demonstrates the range, some of which are orders
4 of magnitude, for two age groups only, the adult and the
5 infant. Now, the factors for the infants, of course,
6 apply presumably for only one or at most two years of
7 life. Then we get into childhood for which we have
8 still different ratios.

9 Then the teenage years, which at least in our
10 current dose models we are using still different
11 factors, and then finally into the adult years. So the
12 period of time over which the different factors apply
13 continues to change as the exposed population ages
14 change.

15 I suggest that the ability to adjust ALI's for
16 all nuclides and all factors of that kind -- and that is
17 by no means all -- is some years away. I understand in
18 fact that the Committee too, the ICRP has been
19 struggling with the problem for some time without
20 success to date. Maybe Herb has indicated the NCRP may
21 now have some solutions to some of these problems. I'm
22 not sure.

23 In the interim, I suggest the ICRP in its more
24 recent publications has certainly provided some guidance
25 as to calculating some specific organ doses for some

1 specific nuclides, without recourse to ALIs and the DAC
2 tables. To the extent these models can be realistically
3 adapted to the different age groups and the mixtures of
4 age groups and exposure patterns, I suggest that that
5 could at least be attempted.

6 This Committee and the other people here in
7 this room are probably aware of the considerable
8 uncertainty that now exists as to the adequacy of the
9 data base for doing so, however, and at least for many
10 of the radionuclides and certainly to the extent that
11 any better precision of dose and risk calculations can
12 realistically be claimed.

13 Let me say a word about ALARA prioritization,
14 which is of some concern to me. Section 20.102 of the
15 proposed regulations addresses this prioritization of
16 ALARA effort. With due respect to my colleagues
17 primarily concerned with occupational doses and
18 occupational worker protection, I submit that the
19 general public in no way would accept in an either-or
20 situation a principle of minimizing occupational doses
21 at the expense of greater public exposures. This I do
22 not think has been addressed in the proposed
23 regulations.

24 As a matter of fact, the members of the public
25 most apt to be affected by releases from any of the

1 licensee facilities and to which your population dose
2 limits are addressed, the maximally exposed individual
3 or critical group, is not even mentioned in terms of
4 ALARA.

5 Proper implementation of this principle then
6 requires consideration of all categories of exposure and
7 indeed involves some social and political judgments
8 which presumably the NRC has to take. But I hope that
9 if they do take them they will consider both collective
10 and individual doses, and also to the worker and to the
11 public.

12 I have to say something about proliferational
13 limits and I'll wrap this up just as fast as I can. The
14 use of reference levels or action levels for special
15 reporting for initiating the investigative action is
16 basically sound and generally accepted as good radiation
17 protection practice. We can all agree to that.

18 For those responsible for reporting to the
19 public, we must be concerned with the continuing
20 proliferation of such levels, which leads only to
21 additional public confusion and misunderstanding as to
22 the differences between reference levels, ALARA values,
23 and limits. As a matter of fact, I'm not sure it's only
24 the public that gets confused on this at times. But
25 this is just a few I pulled out, and I'll put up my

1 single chart if you can all see those.

2 (Slide.)

3 I would warn you at the outset, I think you
4 recognize these are not necessarily the same base, but
5 here if we look here at the whole body dose equivalent
6 or committed whole body dose equivalent, as the case may
7 be, in several of these limits but not in others, then
8 we have the stated 10 CFR 20 limit of 500 millirem per
9 year.

10 We have a reference reaction level at 100,
11 which is relatively new. At 25 we have the light water
12 reactor uranium fuel cycle, the limit proposed by EPA
13 CFR 190. Down here we have the EPA Safe Drinking Water
14 Act limit, on drinking water supplies now not on
15 releases, of 40 CFR 141, at 4 millirem per year. We
16 have a range of 3 to 15 from 10 CFR 50, Appendix I,
17 depending on the nuclide and the pathway. And then down
18 here -- and thank you, gentlemen -- we have a proposed
19 de minimis level.

20 Anywhere from the 500 to one, as we all
21 recognize, we say is ALARA. We have some design
22 objectives. Now, we have in some cases attempted, and
23 that of course is what 10 CFR 50 is all about, we have
24 attempted to apply numerical values to define ALARA. At
25 the present time we don't have those numerical values

1 and I don't think, unless I have missed something in 10
2 CFR 20, that's being attempted here, and it probably is
3 not appropriate for 10 CFR 20.

4 Turn the lights back on. That's my last
5 slide.

6 I had hoped until I got here -- I'm sorry,
7 Bob. I had hoped that not only this Committee, the NRC
8 Staff, would really recognize that in practice any
9 reference level becomes an action level; an action level
10 becomes a working limit, and to the public that's the
11 limit. Now, in the proposed regulations this situation
12 is reinforced by the language of Section 20.301, which
13 states that the basic annual limit to the public is 0.5
14 rem, and presumably that's the effective committed dose
15 equivalent intended. This applies to some of all the
16 sources of exposure, licensed and unlicensed, other than
17 natural radioactivity and medical exposures.

18 Now in Section 20.303 it's quite rightly
19 recognized that it's impractical, if not impossible, to
20 determine an actual dose to individual members of the
21 public precisely, and this is because of the presence of
22 mixed sources from all of the sources. So now we will
23 substitute the reference level as a means of
24 demonstrating compliance with the NRC's intent.

25 I have to say, to me it's a questionable

1 practice to claim a limit for the licensee which is not
2 really a limit you're asking them to live with, which in
3 essence will be the 100 millirem.
4 Now in Section 20.401(c) I find that, "a licensee
5 engaged in the uranium fuel cycle operations subject to
6 the provisions of 40 CFR 190" shall comply with its
7 requirements. In addition to the limits on releases of
8 specific radionuclides -- and that particular section is
9 referring to the subject of releases -- but in addition
10 to that 40 CFR 190, it specifies annual dose equivalent
11 limits for members of the public. Not only different
12 numerical values, which I showed you on that last
13 vugraph, but with a different basis, because that indeed
14 is an annual dose and not an effective committed dose
15 equivalent.

16 Fortunately, very few of the better than
17 10,000 licensees for the NRC and Agreement States are
18 going to have to worry about that double bookkeeping
19 because they are not going to have to face up to truly
20 the effective committed dose equivalent or the 50-year
21 dose equivalent, in fact.

22 Our studies by Battelle of the releases from
23 the power reactors for example show that some 80 percent
24 of the dose to the public appears to be from atmospheric
25 releases, and nearly all radio-xenons and

1 radio-kryptons. So our annual dose is our annual dose
2 equivalent.

3 There are other reference levels potentially
4 available, but I won't bother you going into those.
5 They've been previously addressed. But I do hope you
6 will keep that point in mind, that the reference level
7 is a limit.

8 On the basis for risk estimates, I can only
9 shake my head. I don't claim any special expertise in
10 this area of assessing public health risks from
11 radiation exposures. All I know is what I read in the
12 manuals. However, it does seem to me from what I've
13 read that there is a valid question as to whether an
14 assumed distribution of risk for a particular worker
15 population should be used to determine some assumed
16 level of risk for a mixed public with varying ages,
17 habits, periods of exposure, and status of health and
18 health care.

19 I mentioned several times before the need for
20 a significantly expanded data base as a proposed system
21 of dose regulation to achieve truly better estimates of
22 population doses. I wish I could give you real data. I
23 can't. We've asked for lots of money and lots of time
24 to determine what that is, but we haven't gotten it
25 yet. Unfortunately, I can -- not unfortunately; I beg

1 your pardon. I can foresee steady employment for a
2 number of years for computer programmers for some time
3 to come, adapting all our dose calculation models to the
4 new models, and maybe that's inevitable.

5 I would like to pass on to you a quote from my
6 co-worker Joe Soliat, who many of you know at least by
7 reputation. Joe's reaction generally to the ICRP system
8 now incorporated in 10 CFR 20 is: "My overall
9 impression is that the elegance of the mathematics far
10 exceeds the availability of the basic data needed to
11 make it work."

12 Thank you.

13 MR. MOELLER: Thank you, John.

14 MR. CORLEY: You can call me "Jack," Dade.

15 (Laughter.)

16 MR. MOELLER: Herb, you had a comment?

17 MR. PARKER: Before I ask a question, Mr.
18 Chairman, I would like to refer to the fact that at your
19 table you have two Battelle-related people and
20 presenting data you have three Battelle people. And
21 while I applaud this high concentration of quality, I
22 think it could raise questions of possible conflict of
23 interest.

24 So for the record, I would like to stipulate
25 that I for one have not consulted with any of these

1 gentlemen on the matters before your Committee, Mr.
2 Chairman, and during the last year or so. I have worked
3 with Ron Katheron on a book review which I think was
4 clearly unrelated.

5 MR. MOELLER: Fine. Thank you for that.

6 MR. PARKER: I would like to ask a question
7 after that.

8 MR. MOELLER: Sure.

9 MR. PARKER: May I address Ken Heid. Ken,
10 this is not directly on the details that you gave us
11 today, but you did say that you had been working with
12 personnel records for something over 30 years and
13 presumably know something about it.

14 Jack Selby gave us four cases where there was
15 a very serious overlap between external dose and
16 internal dose. It used to be in the old days that by
17 and large you either got the one or the other, with a 10
18 or a 20 percent overlap. How does that separation stand
19 in today's practice in the business?

20 Is it still largely true that you could take
21 one and if you added 20 percent you would have a safe
22 upper limit for what the man's risk was?

23 MR. HEID: I think the trend is still true.
24 Of the 10,000 employees at Hanford, perhaps 5 percent
25 are exposed to plutonium. Of this 5 percent, only a

1 small fraction are exposed to -- well, they are all
2 exposed to the photons and neutrons that come from the
3 plutonium. But only a very few, way less than one
4 percent of these, are exposed to levels in excess of one
5 rem.

6 So that the number that we have an overlap
7 significantly different from the past trend you could
8 almost count on your two hands. Other than that, the 20
9 percent overlap is still appropriate today.

10 MR. PARKER: Thank you.

11 MR. MOELLER: Thank you.

12 Ed, does that complete your formal
13 presentation?

14 MR. VALLARIO: Yes. I would just like to make
15 one final comment here. We are appreciative of this
16 participation and we would like to make the
17 recommendation that the ACRS continue to function as a
18 forum in examining the considerations and the
19 resolutions to these important issues during the tenure
20 of the Part 20 development.

21 In this context, of course, we would be
22 looking forward to perhaps some scheduled meetings such
23 as this one in the near future.

24 Thank you.

25 MR. MOELLER: Thank you.

1 I think we will move ahead then now to hear
2 from EPA. And I understand their presentation will be
3 shortened. We will see then how that goes and make our
4 decision about when to break for lunch.

5 The presentation will be by Glen Sjoblom.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 For the record, and he will probably tell us,
2 he is Director of the Office of Radiation Programs for
3 the Environmental Protection Agency.

4 MR. SJOBLOM: In early June I became the
5 Director of Office of Radiation Programs. When I became
6 familiar with what the functions and ongoing tasks were
7 shortly after coming, I realized that one of the very
8 important ones was the resumption of the EPA's efforts
9 towards updating the 1960 Federal radiation guidance.

10 As you know, in January or thereabouts in
11 1981, EPA published a proposed update of that guidance
12 and held hearings a few months later. There were a lot
13 of comments. I have with me Alan Richardson here today,
14 who will give you a little bit more of detail on some of
15 the issues that were raised during the public comment
16 period.

17 We are now in the process of determining just
18 where to go from here on this. Basically it is my intent
19 that we reconvene the interagency process. There is
20 something like 14 or 15 agencies in the government, not
21 just DOE, not just NRC and not just EPA, that are
22 interested in occupational radiation exposure.

23 So I believe that it is appropriate and
24 essential that we derive what may be the Federal
25 radiation guidance that lasts for the next 20 years

1 through the most open and discursive measures that we
2 can. I believe it is appropriate for the ACPS, of
3 course, to be involved with any major update of a major
4 NRC regulation.

5 As you know, the 10 CFR Part 20 derived from
6 the original Federal radiation guidance. I have
7 discussed with senior NRC people like Bob Minogue and
8 have received assurance that NRC plans to function and
9 participate fully in this interagency process that we
10 anticipate resuming shortly. I plan to do this by
11 sending a letter to each of the agencies, convening an
12 initial meeting at the policy level, identifying in that
13 meeting what the issues are that we believe need to be
14 resolved, taking any recommended additional issues that
15 the agencies feel need to be resolved, perhaps breaking
16 up into smaller groups on individual issues and trying
17 to resolve each of those, and then reconvening later the
18 interagency group again to attempt to ratify or amend
19 and subsequently ratify the recommendations which would
20 subsequently go forward.

21 Our schedule, as I hope to do it, would end up
22 about September, we hope, with a final package of
23 recommendations.

24 I would like at this time to introduce Alan
25 Richardson, who could perhaps give some more detail on

1 what we intend to do.

2 MR. RICHARDSON: I am pleased to be here. The
3 last time I spoke to you was before we had proposed new
4 guidance. I am glad this time to be able to report that
5 it has been proposed. We have made some progress. I
6 would like to review a little bit of the history first.

7 I would like to remind you that the Federal
8 Radiation Council was created way back in 1959 and that
9 the present guides that we now operate under were
10 established in 1960, and in 1961 there were some
11 additions. Those guides were derived, as you probably
12 all well know, mainly from NRCP and ICRP recommendations
13 that were in existence at that time.

14 Just to review what those guides were, the
15 essence of them was that the whole body limit was 3 rems
16 per quarter and 5N minus 18 rems to the average worker.
17 The protection scheme was based on the critical organ
18 approach. There were a variety of critical organ
19 limits, 5, 15, 30, depending on the organ involved or
20 the tissue.

21 There were two principles set forward in that
22 guidance. One is that radiation exposure needed to be
23 justified before it occurred at all and the second was
24 that exposure should be as low as practicable, which is
25 what we now call ALARA. Most of those things have stood

1 the test of time. Certainly the justification and the
2 ALARA principles are still the principles that we are
3 dealing with today.

4 The major change is in the expression of the
5 actual dose limits themselves where there is now under
6 ICRP 26 proposed a weighted dose scheme to replace the
7 critical organ approach. Late in 1970 the functions of
8 the Federal Radiation Council were transferred to the
9 administrator of the EPA, as you all know, and the
10 Council was abolished. About two years later, the first
11 BEIR -- not the BEAR, the BEIR -- report was issued in
12 1972.

13 In 1974 we began to review occupational
14 exposure guidance. We formed an interagency working
15 group. It had a large membership back in 1974. The
16 agencies represented were the Department of Energy --
17 well, then in those days the AEC, Department of Defense,
18 the NRC, Department of Transportation. Bureau of
19 Standards was involved, NASA was involved. HEW and DOL
20 were not initially members, at their choice. They later
21 joined the group as full members, and the Conference of
22 Radiation Control Program Directors was also a member of
23 the program.

24 Later in 1973 BIER-2 was issued, and then as
25 Mr. Sjoblom just mentioned, in January of 1981 we

1 finally came to the end of this long process and
2 proposed for public comment new guidance, which you have
3 a copy of. The handouts that I gave you were, first,
4 the now 22-year old Federal radiation guidance that we
5 still operate under that was published in 1960 and 1961;
6 the second handout was the Federal Register notice of
7 these proposed revisions; and the third handout is the
8 one that I will use in talking a little later about the
9 changes that were proposed.

10 After publication in January of 1981, we held
11 many days of public hearings in Washington, in Houston,
12 in Chicago, because that is where a lot of the medical
13 societies are centered, and on the west coast of San
14 Francisco. We accumulated a very large record. And
15 since people who don't like what you are doing are the
16 people who come and talk to you at your hearings, most
17 of that record was negative. There is about 4 feet of it.

18 Well, so much for history. I am going to try
19 and be quick and just take about 10 or 15 minutes. I am
20 going to summarize the proposals that we made briefly
21 because you may not remember them a year and a half
22 later, almost two years later. I will say a little bit
23 about what kind of public comment we got, what we have
24 been doing in the intervening years since public
25 hearings, and then review once again what Glen outlined

1 in terms of what our future course would be.

2 First, to review what the proposals are.

3 (Slide)

4 This is a very poor Vu-graph, but you have a
5 copy of it in front of you. My apologies to the back of
6 the room.

7 There were nine major elements of the
8 proposal. The first one was that exposure should be
9 justified. It was required by 1960 guidance. There is
10 no real change proposed in that except that alternatives
11 to exposure were explicitly called out for consideration.

12 Let me just make some parenthetic remarks
13 about ICRP 26 and 10 CFR 20 so you can get a picture of
14 where there is a discrepancy and where these things are
15 essentially the same. ICRP 26 is basically the same as
16 what we are proposing here, and 10 CFR 20 I don't
17 believe addresses the question of justification.
18 Optimization of exposure was required under 1960 guides,
19 was required under the proposed new guidance, and
20 explicitly called out was the point that this means to
21 minimize the collective dose because individual doses is
22 dealt with separately under limitation of exposure.

23 That is identical to what ICRP 26 requires,
24 and the translation in 10 CFR 20 proposed is kind of
25 mixed. I guess I won't talk about it in much detail.

1 There is a requirement for ALARA. There are things like
2 de minimis doses for collective exposures which are
3 departures from ICRP 26.

4 Under limitation of exposure we distinguish
5 whole body from partial body exposure. I mentioned
6 earlier what the existing limits are under Federal
7 guides. The new proposal was for 5 rems a year, which
8 is identical to both ICRP 26 and the proposed 10 CFR 20.

9 For partial body the 1960 guides -- this is a
10 fundamental difference -- involved individual critical
11 organ limits. The proposed guidance was the limit on
12 sum of organ risks, as is ICRP 26 and 10 CFR 20
13 proposed, but there is a fundamental difference. In the
14 ICRP 26 system, somatic risk is lumped together with
15 genetic risk, and in the EPA proposal the genetic limit
16 of 5 rems which we have been operating under for 20
17 years is retained as an independent limit, and therefore
18 it dropped out of the combined limit on sum of organ
19 risk. There are also some other small numerical
20 differences, but that is the essence of the
21 differences.

22 On the question of combining internal and
23 external exposure, under the existing 1960 guides the
24 limits are applied independently of each other. In both
25 the proposed new guides and ICRP 26 and, I believe, 10

1 CFR 20, they are combined, using the weighting factors
2 for individual organs.

3 The proposal contained a new element, which is
4 that there should be minimum radiation protection
5 requirements. These dealt with matters such as
6 monitoring, recordkeeping, supervision of workers and
7 instruction of workers in very broad generalizations,
8 and we propose in the new guidance three different
9 levels, that this be divided into three different
10 levels: highly exposed workers over several rems, a
11 group of workers falling between the population limit of
12 a half-rem, and then highly-exposed groups and then
13 people exposed below the limits of the general
14 population.

15 ICRP 26 has some of those elements but in two
16 exposure ranges, and I can't speak for 10 CFR 20 in
17 detail. In the 1960 guides this just was not specified
18 at all. Regulatory limits lower than the RPGs for
19 specific job categories was addressed by the proposed
20 guidance. It was not addressed in the 1960 guides. The
21 proposed guidance simply recommended that the regulatory
22 agencies do this when it is appropriate.

23 ICRP 26 provides for just this sort of thing
24 and leaves it to the regulatory bodies. 10 CFR 20, I
25 believe, does not address that.

1 The next element was intake guides. I am not
2 going to address the differences there. It is all
3 coupled back to implementing the scheme, whichever one
4 you have, on limiting internal exposure, and the
5 recommendations were consistent with what had been
6 recommended up here in the various cases.

7 Exposure of minors has been at one-tenth of
8 the RPGs under all of these proposals. There are no
9 changes. Exposure of the unborn was not addressed under
10 the 1960 guides and is not addressed now in current
11 Federal guidance.

12 We proposed four alternatives. Both the ICRP
13 and the proposed 10 CFR 20 make specific recommendations
14 which happen to be different from each other but not
15 terribly different. The ICRP 26 and the 10 CFR 20
16 proposal are consistent with some of the proposals
17 proposed for public comment in the proposed new guides.

18 Exceeding the radiation protection guides is,
19 of course, permitted under the 1960 guides at the
20 discretion of the agencies involved. There was proposed
21 no change in that except there was added an explicit
22 requirement for disclosing that it was taking place
23 unless defense purposes precluded that. I don't
24 remember what ICRP 26 and 10 CFR 20 say about that.

25 Well, so much for what was proposed in rough

1 general form and how that compares to ICRP 26 and 10 CFR
2 20 proposed. Let me go on now to the question of the
3 reaction to our proposal.

4 Well, I think probably the most important
5 thing to say about the reaction to our proposal was that
6 our proposal was really the first time in this country,
7 I think, that something like the ICRP system was
8 actually proposed for public comment and we heard what
9 people thought about it. There were other things in our
10 proposal that weren't exactly ICRP 26, but we did get a
11 strong response on the question of ICRP 26-type schemes,
12 including these basic principles based on justification
13 of exposure and optimization of exposure, which, if you
14 will recall back in 1960, were developed privately by
15 the ICRP and the NCRP, and the Federal Radiation Council
16 made the recommendations to the President without public
17 involvement.

18 This is the first time all of these principles
19 have been put forward for public comment. One of the
20 things that really surprised us was we get a lot of
21 objection to the idea that radiation exposure should
22 have to be justified and that there should be ALARA in
23 the public comment. This proposal was set forth at a
24 time when the country was reacting to regulatory
25 requirements, was very conscious of paperwork burdens

1 imposed by government, and I think part of the reaction
2 we got was coupled to that heightened awareness.

3 Nonetheless, what came through loud and clear
4 is that you can't make motherhood statements like the
5 1960 guides did about justifying exposure and keeping
6 exposures as low as reasonably achievable without people
7 getting very worried about the paper requirements that
8 would be put on them to do that. So one of the clear
9 messages we got was we would have to find ways to
10 express the guidance in ways that make it clear that the
11 guidance itself is no an imposition of paperwork
12 requirement, that that is a regulatory decision.

13 A second kind of major reaction disclosed had
14 to do with the concentrations, minimum-maximum
15 permissible concentrations, the changes in all the
16 values that result from the adoption of ICRP 30 models
17 and the new values for either the weights or the
18 critical organs or whatever. What emerged from that is
19 that there is very little understanding in the radiation
20 protection community itself of the distinction between
21 changes that are caused by new scientific information
22 and changes in the models and changes that are due to
23 the selection of the weighting factors or the limits
24 themselves.

25 The fact of the matter is that most of the

1 changes that come about from the adoption of the ICRP 30
2 models plus new guides, most of the changes are due to
3 the models, not to the choice of the numerical limits.
4 There are order of magnitude changes in many of the
5 values and there have not been proposed order of
6 magnitude changes in the limits by any stretch of the
7 imagination. Most of them stay about the same. Yet the
8 changes were ascribed to the new guidance, the proposed
9 new guidance; and that was simply not the case.

10 One of the remaining areas of controversy that
11 is still not resolved, we still haven't resolved the
12 basic controversy of whether this country should go
13 forward with a weighted dose system or with critical
14 organ limits. There was no clear answer coming out of
15 the comment that we got. There are people on both sides
16 of that issue, and that is going to be one of the major
17 things that we will have to resolve in the interagency
18 group as soon as we get it back together again.

19 Some commenters felt that health risk was a
20 factor and we should wait for the results of the
21 reevaluation of the Hiroshima-Nagasaki data. That,
22 surprisingly, was not a very strong message in the
23 public comment. I think there is a growing realization
24 that the detailed health estimates are not all that
25 important for choosing what the occupational limits

1 should be. I think there is a growing awareness that
2 although these health risk factors bounce around a
3 little bit, they don't bounce around by orders of
4 magnitude, which is what would be required to really
5 change the dose limits.

6 One area which is a real problem which emerged
7 from the public comment was this question of committed
8 dose for long-lived radionuclides and the need to look
9 carefully at making distinctions between prospective
10 application of dose limits, and in that case perhaps the
11 committed dose and retrospective application possibly on
12 an annual basis when you have major body burden and you
13 are dealing with a specific worker. That is another
14 thing we will be looking at in the interagency working
15 group.

16 We have done a few things in the past year.
17 As one of the speakers this morning mentioned, there was
18 a comprehensive survey of occupational exposure in the
19 United States published by the EPA a couple of years ago
20 about the time this guidance was proposed. Its cut-off
21 date was 1975 because it takes a long time to accumulate
22 and evaluate comprehensive data for the whole country's
23 radiation workforce.

24 We are in about six months, I think, going to
25 complete an update of that for 1980. As an indication

1 of how difficult it is to do this, let me just point out
2 that over half of all exposure is to medical employees,
3 and the availability of records is much, much worse for
4 medical employees than it is, for example, for nuclear
5 power employees, which is something like 7 percent, and
6 DOE employees, which is another small percentage.

7 We have done a detailed survey of the costs
8 that would be associated with these proposed new guides
9 here for implementation. That work is almost complete.
10 As a sort of baseline for departures for the final
11 guidance, we have been developing alternatives and
12 reviewing the comments. I mentioned the size of the
13 record.

14 Let me just finish by reiterating what it is
15 we have ahead of us. We have essentially completed but
16 we are not quite finished yet identifying and fleshing
17 out a statement of the major issues that have to be
18 resolved before this guidance can go final. We are in
19 the process of reconvening the interagency working
20 group, which, by the way, will also include in addition
21 to those agencies the NCRP, a representative from the
22 NCRP.

23 When that group reconvenes, we will be
24 probably assigning individual issues to small groups of
25 agencies so that we can work more quickly and

1 efficiently so that we can propose back to the main body
2 resolutions which the main working group will then deal
3 with. We expect to get that process completed in a
4 matter of months, hopefully. Then will come a decision
5 on whether we can move this forward as final
6 recommendations or whether they will have to be
7 repropose. It will depend upon the magnitude and the
8 character of the changes that develop out of this
9 process, and then we will do that. We propose to go
10 final.

11 MR. MOELLER: Thank you.

12 I have a couple of questions. I think now we
13 should open it up to general discussion. One question.
14 You mentioned that you are preparing cost estimates of
15 the implementation of your proposed guides.

16 MR. RICHARDSON: Yes.

17 MR. MOELLER: Do you have any numbers?

18 MR. RICHARDSON: Not at hand, no. That
19 contract report hasn't been delivered. We just have it
20 in draft form. There are a couple of case histories --
21 we are doing it as case studies, and a couple of those
22 aren't completed yet. But we should have them in a few
23 months.

24 MR. MOELLER: Another question. You
25 mentioned, of course, I guess it was the 1970 law that

1 transferred the functions of the Federal Radiation
2 Council to the EPA. When President Carter was in
3 office, he established the Federal Radiation Policy
4 Council. How did that relate to the Federal Radiation
5 Council?

6 MR. RICHARDSON: In many ways it was similar,
7 and in other ways it was different. The purpose of
8 that policy group was to deal with questions of policy
9 involving radiation generally. What that group did not
10 do, and I guess this is the key part of the answer to
11 your question, it was not the Federal guidance function
12 to make direct recommendations on radiation protection
13 matters. It was not transferred to that group. It
14 remained with the administrator.

15 MR. MOELLER: And then I guess when President
16 Reagan abolished the Federal Radiation Policy Council,
17 did everything transfer back to EPA? Is that the idea?

18 MR. RICHARDSON: I don't think anything was
19 transferred away from EPA. That was a group which was
20 created to deal with radiation policy issues in general
21 between the agencies. The, if you will, statutory
22 function that is in the Atomic Energy Act of making
23 recommendations to the President was not affected by the
24 creation of that group.

25 MR. MOELLER: I see.

1 Are there questions from our committee or
2 consultants? Ron Kathern.

3 MR. KATHERN: I would just like to ask: when
4 you went out for comment and received the objections
5 about the protection schemes and adoption of the ICRP
6 values, were these objections from a general
7 cross-section of those who appeared or were they from
8 one particular area?

9 MR. RICHARDSON: I would say they are pretty
10 general. We got those kinds of objections from, for
11 example, the medical community, who for the first time,
12 perhaps, thought about Federal guidance and how it
13 applied to them. We got it from the power industry. In
14 1960 when those things were originally set forth as
15 Federal guides, we didn't have environmental impact
16 statements. People have had a long painful history with
17 what may be required as the result of a simple statement
18 like that. Since 1960 I think we were hearing a lot of
19 that.

20 MR. MOELLER: Jack Shapiro.

21 MR. SHAPIRO: I notice that you did make a
22 statement in the Federal Register that you chose the
23 limiting annual dose to most single organs to be 30 rem
24 rather than the internationally adopted value of 50 rem
25 "but we do not see a need for a value higher than any

1 now used in this country." Why did you use 30 rather
2 than just retain the 15?

3 MR. RICHARDSON: There is also a value of 15
4 in the current -- there are two reasons for that, to be
5 brutally frank about it. I don't have a copy of the
6 guide, the 1960 guide that you have in front of you.

7 MR. SHAPIRO: This is y ur 1981 Federal
8 Register notice.

9 MR. RICHARDSON: If you would look in the 1960
10 guides, you will find the value of 30 applies to some
11 organs, and I've forgotten precisely which ones. So
12 that is the highest value which was in current use. If
13 you adopt a value as low as 15, then you might as well
14 not bother weighting the organ doses.

15 What happens when you do that in the ICRP 30
16 models is that the 15 limit to the most exposed organs
17 becomes controlling for almost every isotope, and there
18 just didn't seem to be any point in doing that. The
19 values that you get for the MPCs in air, for example,
20 scatter fairly evenly on both sides of the old values
21 for a choice of 30 or 50. As equal a number goes up as
22 go down.

23 MR. MOELLER: Herb Parker, and then Ed.

24 MR. PARKER: I am confused about item seven.
25 That is the exposure of minors that you have on the

1 chart, Mr. Richardson. Is this some occupational kinds
2 of exposure of minors? What are we talking about?

3 MR. RICHARDSON: In the classroom only.

4 MR. PARKER: In the classroom only; that's not
5 spelled out. Because in the 1960 guides, one of the
6 purposes of the 5 into N⁻¹⁸ accumulated dose formula
7 was specifically to exclude employment of minors in
8 radiation tasks.

9 MR. RICHARDSON: But the 1960 guidance also
10 included that one-tenth.

11 MR. PARKER: As an exception to the 5 into
12 N⁻¹⁸.

13 MR. RICHARDSON: I guess as an additional
14 requirement.

15 MR. PARKER: Otherwise there was an
16 inadvertent contradiction in the rules. I am worried
17 about this.

18 MR. RICHARDSON: I guess once you get to be
19 18, and no longer have the 1/10th rule applying to you,
20 then the 5 into N⁻¹⁸ then picks up.

21 MR. PARKER: It doesn't matter where they have
22 the 1/10th rule applying. If 5 into N⁻¹⁸ applies, it
23 doesn't matter what you say about the other; it has to
24 be zero. Isn't that correct?

25 MR. RICHARDSON: I see what you're saying. If

1 you apply it --

2 MR. PARKER: And that is why I am worried. I
3 ask this question because I am worried about the new
4 intention. We have eliminated the 5 into N⁻¹⁸ for a
5 reasonable cause because it was misused in the banking
6 thing, which was never intended, but we have now opened
7 that up wide to the employment of minors at some
8 specified level. It is totally unnecessary to do that.

9 MR. RICHARDSON: I have not thought of the
10 implications of allowing "N" to become less than 18. I
11 guess you could interpret that as a requirement to save
12 natural background dose.

13 MR. PARKER: I happen to be the originator of
14 the 5 into N⁻¹⁸. That is why it was 18, because the
15 law at that time for employment of minors specified a
16 lower age limit of 18. It was subsequently lowered to
17 16, I think.

18 MR. SJOBLUM: Do you think that should be
19 explicitly stated in the new guidance?

20 MR. PARKER: I think it should be explicitly
21 stated: Employment of minors should not be contemplated
22 in the radiation industry.

23 MR. MOELLER: Ed Vallario.

24 MR. VALLARIO: Alan, two questions. One, will
25 the interagency committee have the benefit of obtaining

1 a summary of all of the comments received as a
2 consequence of the public hearings on the last EK draft,
3 number one. Number two, in view of the rapid initiative
4 on the part of the EPA to proceed in reconvening the
5 interagency committee, do you view this in your
6 discussions with the NRC as obviating the need for the
7 NRC revision and proceeding and focusing on the EPA
8 draft, or is this going to be a parallel development
9 function?

10 MR. SJOBLON: Let me take the latter one. I
11 view the two as being a co-current process. I think we
12 can and should be able to do the two together. Whether
13 or not the specific details are exactly consistent with
14 another will be part of the discussion. But as I
15 mentioned, there are 14 agencies involved in one way or
16 another with radiation protection in the country, and we
17 feel the need to involve them all, and the NRC is
18 certainly right up there as one of the more important
19 ones, as is DOE.

20 I don't feel that the NRC should stop what
21 they are doing, because I think many of the implementing
22 decisions, the practicality of implementing certain
23 parts of the guidance, we would be very much interested
24 in. We want the guidance to be practically
25 implementable, so I think it is essential that the

1 implementing agencies look at what it will mean to them
2 and to their licensees, not only the NRC, but I would
3 presume that the other agencies will want to do
4 likewise, will want to consider from their constituent
5 groups just what the results are in terms of
6 implementation.

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 MR. VALLARIO: That question was raised
2 reflecting on some comments that were made at the
3 Richland Health Physics Contractor meeting. At that
4 time this question was raised in the interest of concern
5 over the possibility ultimately of having two separate
6 standards in the country. This was the reason for the
7 question.

8 MR. RICHARDSON: Ed, I think a corollary to
9 what Mr. Sjoblom just said is we need to distinguish
10 between "regulations" and "guidance." They are
11 different things and they both need to go forward. That
12 is the program that we are engaged in.

13 To answer the first part of your question,
14 yes, there will be a summary of the comments that were
15 made. And of course, anybody who wants to come and read
16 that whole shelf of comments is also encouraged to do
17 so. But there will be a summary of the major comments
18 by commenter or commenter group.

19 MR. MOELLER: Other questions or comments on
20 anything now that has been presented this morning?

21 MR. KATHERN: On anything that's been
22 presented?

23 MR. MOELLER: We're now going to discuss the
24 three presentations: DOE, NRC and EPA. Yes, Ron
25 Kathern?

1 MR. KATHERN: I would like to ask a general
2 question of the NRC presenters. The bottom line is
3 simply, to me this system that is proposed in 10 CFR 20
4 revised, does this really provide any better protection
5 for the worker than the existing 10 CFR 20? I listened
6 to particularly the DOE arguments and I see what the EPA
7 has proposed, and really I think this may be a
8 rhetorical question, that you don't want to answer
9 because it takes a long time.

10 But I really ask that question in a generic
11 sense. There are some specific things that I think are
12 not addressed where improvement really should be
13 sought. One of these is related to the question of
14 exposure from what I will call nontraditional
15 occupational exposures. Perhaps the required medical
16 X-ray as a condition of employment needs to be addressed
17 a little more completely than you have done so, I think,
18 in the introductory statement.

19 The travel -- people who travel as a condition
20 or a requirement of employment may incur significant
21 exposures, and perhaps this needs to be addressed,
22 perhaps exempted or what have you as well. I would also
23 ask about the transient worker problem. I am not really
24 sure you have fully resolved that problem in my mind.
25 Maybe you have and perhaps you would like to comment on

1 these items that I raised.

2 MR. MILLS: Bill Mills.

3 Let me take the last one first. As far as the
4 transient worker is concerned, that has been a very
5 important part of our discussion, for example, with the
6 Atomic Industrial Forum. And in fact, what we've been
7 encouraging them to do, somewhat at their own
8 initiative, is in fact to consider the possibility of a
9 centralized recordkeeping system whereby the transient
10 workers would in fact use some of the current computer
11 technology to transfer the records. This offers a
12 benefit for the industry in that -- and it applies as
13 well to temporary workers, such as some in the
14 industry.

15 What the advantage to them of course is, is
16 they don't have to -- with the centralized system they
17 don't have to sit around waiting for a couple of days
18 for the record to be transmitted. They think they can
19 work it out so that in fact there will be some cost
20 savings to them.

21 So we have sort of encouraged them to do so
22 and have been working with them. So we think the
23 transient worker problem and our requirement of a Form 4
24 will be in fact considered in that vein. So we have not
25 pushed our own recordkeeping for that reason. We would

1 much prefer a voluntary system of keeping track of
2 records, but still require them to report on an annual
3 basis.

4 The inclusion of the exposures that arise from
5 air transport, for example, or the requirement for
6 medical X-rays pre-employment, we have not addressed
7 either one of those problems. We think that it is
8 something that perhaps we should consider, but it's also
9 probably outside of what we can really regulate.

10 Now, that doesn't mean that we would be
11 opposed to the licensees keeping a check of those
12 exposures. However, we could not require such exposure
13 to be recorded.

14 MR. KATHERN: Maybe it should be addressed
15 from the standpoint of exclusion.

16 MR. MILLS: Basically, they are excluded,
17 because we exclude exposures for medical reasons. We
18 also exclude natural backgrounds. So I would think that
19 both of those would be excluded already. But if you
20 ask, should the licensee keep records of those
21 exposures, I think that's something that we cannot
22 regulate.

23 As to whether or not -- I'll not try to answer
24 completely as to whether or not we are providing more
25 protection to the worker. That question was referred to

1 earlier, I think, in my presentation. The point is, I
2 think, that we can get better assurance of the
3 protection by the separation of external and internal
4 exposures and the recognition of such, for those few
5 licensees who have a problem with both.

6 While I have the podium, let me make a point
7 relative to the monitoring. Perhaps one of the areas of
8 disagreement or misinterpretation of what we propose for
9 monitoring requirements, it is in fact a requirement of
10 ten percent of the external and ten percent of the
11 internal in situations where you would expect the worker
12 to be exposed above those limits. It does not say that
13 you do not do any monitoring of the area or what have
14 you.

15 The one example that was shown of the one
16 worker who might be over the limit, if there is a
17 potentiality, we say, for the licensee that individuals
18 could be exposed above those limits, then we ask that
19 the individual monitoring be applied. But it is not
20 correct to assume that there is no monitoring at all of
21 the situation. The licensee would have to do area
22 monitoring, air sampling, and that sort of thing if he
23 can expect that dose to be 30 percent.

24 MR. MOELLER: Are there other questions? Jack
25 Selby?

1 MR. SELBY: Could I make an observation in
2 connection with area monitoring? The data that you get
3 from that, we have one situation -- I also was in the
4 exposure evaluation program at Hanford for a number of
5 years, and as a result I took all the telephone calls
6 when we had suspected plutonium deposition cases. I can
7 remember one vividly where the health physicist, who is
8 probably the best informed person at the plant, called
9 and asked for our help. He said, I don't have any real
10 information to indicate that we've got a problem. All
11 the air sampling data was negative, the surface
12 contamination was negative, and there were several other
13 aspects that he followed that were also negative.

14 And he would never ever explain to us why he
15 felt that we should be investigating this, but we did
16 respond to it. We sampled 19 people. 13 of them came
17 up with minor depositions. As a result, the area
18 monitoring gave absolutely no information. This was
19 usually in the air sampling at a number of locations in
20 the workplace, and using a high flow rate, not the very
21 low flow rate.

22 I think the other example of this -- you're
23 getting closer to personnel monitoring -- is the use of
24 pocket dosimeters as a backup to a good dosimeter in
25 cases where you have high exposure, not uniform, for

1 example during maintenance outages at reactors.
2 Historically, the sum of those pocket dosimeter
3 readings, which are reviewed daily, end up much higher
4 than the actual recorded exposure with the dosimeter.

5 So area monitoring can only be one tool for a
6 good health physicist and it cannot be the end-all for
7 explaining what the individual is exposed to. I've
8 heard the statement made that it can be the upper
9 bound. I would submit that it's not even the upper
10 bound in many instances, that what you have recorded
11 based on your monitoring results may very well be less
12 than what the individual was exposed to.

13 MR. RAY: Two questions. I learned this
14 morning that your revision of 10 CFR 20 is based
15 principally to a great degree on ICRP 26. It was
16 indicated that the ICRP changes would be forthcoming
17 within a two-year period.

18 What would be the impact on industry and any
19 disadvantages they might incur if you deferred the 10
20 CFR 20 until that time?

21 MR. MILLS: Well, I won't attempt to speak to
22 what the full impact is on the industry. This is
23 something we would have to discuss with them. As I
24 tried to point out this morning, as we go through the
25 process, the public process, we would expect that after

1 we proposed it we would be in a process of two years of
2 trying to address the public comments.

3 MR. RAY: From where you are today?

4 MR. MILLS: From where we are today, Mr. Ray,
5 I suspect we are three years from any final -- it would
6 be my guess we are three years from anything final.

7 MR. RAY: The implication here is that you
8 would possibly have the NCRP input before you were ready
9 to publish?

10 MR. MILLS: Yes, sir. If they came out within
11 two years, we would have it. We are continuing, as I
12 pointed out this morning, to continue the discussions
13 with the NCRP.

14 MR. RAY: Would I be optimistic if I were to
15 conclude that the NCRP releases would probably influence
16 what you finally publish?

17 MR. MILLS: Certainly they would be a system
18 that we would have to take under strong consideration
19 and give reasons why not, I think. But as Mr. Parker
20 pointed out, they have been working for some time on the
21 NCRP approach. That too has to go through a vote within
22 the NCRP, which I would imagine would be in itself a
23 point of controversy.

24 So you've got all of these deliberations that
25 will have to take place, I think, before. So while I do

1 not disagree that it would be possible that they would
2 have a report in two years, I think we also have to
3 recognize they may not have a report.

4 MR. RAY: Well, I would feel that it is highly
5 desirable that the regulatory requirements on the
6 American industry, to benefit the American public, would
7 be well advised to consider the viewpoints of the
8 national organization rather than the international
9 organization, particularly since that's the latest view
10 of the NCRP.

11 MR. MILLS: Well, as a member of the NCRP, I
12 assure you we will do so.

13 MR. RAY: Another question. We've heard what
14 I consider rather substantive comments from DOE and the
15 DOE contracting organizations. I would like to know if
16 the NRC Staff is considering these comments and will
17 reflect on them and be objective about them as to how
18 they might influence the final copy.

19 MR. MILLS: Yes, sir. We certainly -- as I
20 mentioned earlier this morning, we are certainly willing
21 to sit down with the DOE and go over their comments.
22 Let me make a point, however, that some of the data you
23 have seen today, this is the first time I've seen that
24 data.

25 MR. RAY: That was the second part of my

1 question. So you really haven't assimilated in any
2 degree these comments yet?

3 MR. MILLS: No, sir.

4 MR. RAY: Excuse me, Mr. Mills. You said, we
5 would like to or we would be willing. Are you going to
6 sit down with DOE?

7 MR. MILLS: We have made the offer to sit down
8 with DOE the 22nd and 23rd of November. We think they
9 have taken our offer up and we certainly intend to
10 follow through.

11 MR. RAY: Good. Thank you.

12 MR. MILLS: There is one point that I would
13 like to make. These are discussions which we hope will
14 take several days, so that we fully understand where
15 they are coming from, that they fully understand what
16 our intent is, and that there is no misunderstanding of
17 what the rule really says.

18 As I pointed out, I think there are areas of
19 misunderstanding and misinterpretation of what we
20 intended.

21 MR. RAY: Thank you.

22 MR. MOELLER: That's very helpful.

23 Herb, you have a question, I'm sure. May I
24 ask you one, and if it is improper for you to answer
25 just say so.

1 MR. PARKER: Try me.

2 MR. MOELLER: You are, of all of us probably
3 in the room, you're more aware and more involved in
4 terms of what the NCRP is proposing to do, and I'm not
5 asking you to tell us what they propose because that's
6 improper. But could you comment and tell us whether the
7 exercise that the NRC is going through in revising 10
8 CFR 20, if it will be easy to blend in the newer
9 recommendations of the NCRP, or is it so different that
10 it would require going back to square one and starting
11 over?

12 MR. PARKER: Well, it's very difficult to
13 answer that question precisely. On the whole, it could
14 be said to blend in, although there will be some amazing
15 simplifications, such as throwing out the whole dose
16 equivalent system, which is totally unnecessary and
17 wrong. That's one of the reasons for the forthcoming
18 changes, so there would be some radical changes that
19 would be in the direction of simplification as far as I
20 can foresee.

21 Is that responsive to your question?

22 MR. MOELLER: Yes. That's all we need.

23 MR. PARKER: Let me make two other comments.
24 First let me support what Bill Mills said in this
25 questioning on the NCRP. I in no way meant to imply

1 that he or his colleagues had been delinquent in the
2 relationship for NCRP sources. They are indeed slow and
3 cumbersome, and in my view the real progress was not
4 made until the meeting about a month ago in Denver,
5 which radically changed the current outlook and made me
6 much more optimistic than I was before.

7 So I think we will just about beat that two
8 years, Bill, although the review process is simply a
9 mess.

10 If I could go to another subject --

11 MR. MOELLER: Yes, sir.

12 MR. PARKER: As a matter of clarification,
13 when the NRC talked with us this morning they were
14 really very brief and just explained their actions since
15 the August draft. In the meantime, your consultants
16 have been busily tearing that draft apart.

17 I am assuming that this is not the occasion
18 where you want the benefits of all those comments.

19 MR. MOELLER: No, that's correct.

20 MR. PARKER: Yes, because there are some
21 idiocies, if I can use that word, in the present draft.

22 MR. MOELLER: We may call upon you to either
23 let us have the benefit or let the NRC Staff have the
24 benefit of your notated copy or write them out
25 separately. By all means we want that.

1 Ed Vallario and then Frank Arsenault next.

2 MR. VALLARIO: Two points apropos to Billy's
3 comment regarding the interface with DOE -- I guess that
4 is the 22nd and 23rd of this month -- to advise the
5 Committee here that the 22nd and 23rd meeting we
6 construe as a preliminary meeting. The last Friday
7 meeting with the NRC, we made it clear that we needed
8 some time to evolve an abundance of operational data.
9 We will not have this completely by the 22nd.

10 So the scoping of the meeting, as I
11 understand, Billy, the 22nd and 23rd is to address the
12 periphery issues and perhaps touch on the main issues.
13 But indeed, that is supposed to be one of several
14 meetings as we understand it.

15 The second point I would like to make is that
16 there are many things going on with respect to ICRP 26
17 because of the unsettling feeling regarding its
18 application. In particular, you heard Ken Heid refer to
19 Technical Committee 334 and the results of that
20 Committee's deliberations and their unanimous decision
21 that the 50-year dose commitment was inappropriate. I
22 think that the IAEA Technical Committee's comments
23 should be considered and the results should be
24 considered by the NRC in their revision and their
25 consideration regarding the 50-year dose commitment.

1 Further, to advise you that the NEA is quite
2 steeped at this present time into the whole question of
3 the implementation of ICRP 26, and it would seem
4 appropriate to be plugged into these groups as well as
5 the NCRP to gain the benefits.

6 Further, we were advised also today that the
7 ICRP is structuring a group to come up with guidance on
8 the retrospective application. So it would seem that to
9 try to apply ICRP 26 at this time, with all these
10 unsettling views, seems ill-timed, and perhaps what is
11 needed is to follow the Committee very carefully in your
12 deliberations.

13 Thank you.

14 MR. MOELLER: Thank you, Ed.

15 Frank Arsenault?

16 MR. ARSENAULT: Thank you, Mr. Chairman. I
17 would just like to make a few general observations that
18 may put together a few of the things we have heard
19 previously this morning.

20 First of all, I would note that we gained a
21 great deal from the EPA experience. It was the extent
22 of the comments received by them that emphasized for us
23 the need to solicit from a very broadly based source
24 comments on the applicability of regulations and
25 standards such as they had published and such as are the

1 basis for the revision of Part 20.

2 As a consequence, you heard the Staff describe
3 the contacts they've made and the discussions they've
4 had with a wide variety of sources. I think it is ample
5 evidence that we are interested in receiving the benefit
6 of comments and criticisms of that type. So I think
7 there is evidence that we are receptive to the type of
8 information that the DOE has provided us today and we
9 look forward to analyzing the data they provided and
10 discussing at some depth with them the points that they
11 have made.

12 Now, I would expect fully in the discussions
13 with them to have experiences similar to what we have
14 had in industry, in which some of the comments go to
15 parts of the revised Part 20 that are more or less
16 immutable, inherently part of Part 20, and can't be
17 changed in any major way without violating the very
18 principles that underlay the draft. Other comments
19 called our attention to places in the draft where our
20 proposals could be significantly improved, simplified
21 and clarified, and we will be delighted to make changes
22 where those are possible.

23 Still a third category of comments made us
24 realize that, however carefully we wrote the document,
25 people would interpret it in light of their own

1 predilections and concerns. And for the record I would
2 like to refer to at least two examples of that type of
3 comment that were made this morning and to point out
4 that Part 20 revision is getting a bad rap by being
5 saddled with those criticisms.

6 I refer in the one case to comments made by, I
7 think it was, Mr. Selby in that relieving the licensee
8 of the requirement for individual monitoring below
9 certain levels was contrary to the interests of the
10 employer in that he would not have recorded data that he
11 might need to protect himself in the event of charges.
12 I don't think there's anything in revised Part 20 that
13 could be read to preclude more accurate, more detailed,
14 or more individual monitoring than is required by Part
15 20. So if the employer considers it to be in his best
16 interest to implement personnel monitoring techniques
17 that are more detailed than those we require, we
18 certainly would not object.

19 I think generally in the revised Part 20 the
20 best data available to reflect the exposure to workers
21 is what we recorded. We simply have provided that in
22 some areas more stringent requirements would not be
23 necessary.

24 Another example where I think Part 20 was said
25 to require something that indeed it does not require was

1 in the comment by, I think, Dr. Hall when he said that
2 the application of the 50-year effective dose commitment
3 might drive an employee over the limits in Part 20,
4 where the current practice of DOE would not do so, and
5 he would not be required to tell the employee he was
6 overexposed and to remove him from his work and upset
7 his family. That comes as close to a quote as I can
8 come.

9 Part 20 doesn't require any of that. In fact,
10 we would regard the calculated effective dose equivalent
11 for that year as reading above the limits and would not
12 represent necessarily an overexposure. We know the
13 difference between a calculated and an actual dose.

14 Secondly, Part 20 does provide for the man
15 being retained in radiation work with, however, some
16 additional and more stringent limits applied to the
17 incremental doses he would be permitted to get that
18 year.

19 So neither of the two requirements that were
20 inferred from Part 20 I think are valid. As far as
21 upsetting the man's family, I would think that would in
22 fact be an effect from the first two factors and not
23 something that would be done as a matter of actual
24 practice.

25 So I think a lot of clarification can be

1 offered to DOE regarding the intent and content of
2 revised Part 20. And for our part, we expect to receive
3 a great deal of additional information and data to allow
4 us to understand more clearly the causes of some of the
5 concerns that were expressed this morning.

6 MR. MOELLER: Thank you, Frank.

7 Rags Muller?

8 MR. MULLER: I just had one question maybe
9 Frank can answer. If after all of these discussions are
10 over it is apparent that DOE has requirements which
11 extend beyond, because of some of the special work that
12 some of those labs are doing, beyond what you normally
13 would get in the electric power generation industry, is
14 it possible there might be a bifurcation or two separate
15 parts to cover the two separate areas?

16 I think you know what I mean.

17 MR. ARSENAULT: I think we are developing a
18 revision of Part 20 based on the principles of the ICRP
19 system of dose limitations. We intend however to
20 accommodate wherever we can, without violating those
21 principles, the practical difficulties of the
22 implementation of the system within the industry. By
23 that I mean to include all people who are required to
24 exercise occupational radiation exposure.

25 If in the discussions with the DOE we find

1 difficulties that are real and substantive and suggest
2 to us an additional modification of Part 20, we would of
3 course introduce such modifications. If, however, we
4 find the difficulties they feel are not real but are in
5 fact, what should I say, unique and would not in our
6 view justify a revision of the regulation which applies
7 to licensees, it seems to me that it is within the power
8 of DOE to develop an alternative approach and to justify
9 it.

10 It is obviously to everyone's advantage if
11 radiation protection systems and practices can be more
12 uniform, but I think the question you ask is one that
13 they will have to make a decision on.

14 MR. MOELLER: We have used up the morning and
15 even used up a little bit of the afternoon, and we could
16 go on for quite some time longer. But I think we have
17 heard what we came here to hear, and we will have
18 tomorrow for the Subcommittee to discuss this more in
19 detail and decide what our possible role or
20 contributions might be.

21 So let me wrap up this session with an
22 expression of appreciation to the NRC group, Bill Mills
23 and his group, for coming and talking to us, and to Ed
24 Vallario and the DOE group for coming, particularly all
25 their laboratory people who are here, and to Glen

1 Sjoblom and the EPA group for coming and sharing your
2 thoughts with us.

3 With that, I will declare a recess and we will
4 reassemble at five minutes after 2:00.

5 (Whereupon, at 1:05 p.m, the meeting was
6 recessed, to reconvene at 2:05 p.m. the same day.)

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

AFTERNOON SESSION

1
2 MR. MOELLER: It is now 2:05, as I have been
3 taught, and so we will resume our meeting.

4 The next topic on the agenda is a discussion
5 of the draft federal policy statement on the
6 distribution and use of potassium iodide for thyroid
7 blocking in the event of an accident in a nuclear power
8 plant.

9 Mr. R. Krimm, who was the scheduled
10 representative from FEMA who was to discuss or simply
11 place in the record the draft federal policy statement,
12 was here at 1:00 o'clock, at the proper time, to offer
13 his presentation, but then we were behind schedule and
14 went to lunch, and he had to go to another meeting.

15 So, I would ask that we have placed in the
16 record of the meeting a copy of the complete draft
17 federal policy statement.

18

19

20

21

22

23

24

25

1 MR. MOELLER: I think, too, I would like to
2 simply enter into the record the questions or comments
3 that I would have offered him or would have asked of him
4 had he been here to make his presentation.

5 This is not a criticism at all of FEMA,
6 because this is a joint effort of federal agencies, but
7 it was my conclusion after reading the draft federal
8 policy statement, and particularly checking carefully
9 the last paragraph, I found very little in the way of
10 policy guidance in it.

11 In other words, it says, whether KI should be
12 stockpiled and distributed depends on local conditions,
13 and its use should be evaluated by each state or local
14 jurisdiction based on the specific conditions and
15 environment for each operating nuclear power plant, and
16 that the local people will make the decision.

17 Well, that is non-policy guidance in my
18 opinion, if you just simply -- maybe that is a decision,
19 that we will leave it to the local people, but I
20 personally, in looking through the policy and looking at
21 the whole subject, have found that if I were a local
22 authority and was faced with such a decision, that I
23 don't have the guidance I need to know when and if I
24 would require the distribution of KI and under what
25 circumstances.

1 So, not knowing any more about it than I do, I
2 would certainly recommend that some of the federal
3 agencies consider offering more in the way of guidance
4 to the state and local groups.

5 Do any of you have comments on the general
6 policy statement?

7 MR. AXTMANN: Well, it seems to me that they
8 decided that they didn't want -- for a while their neck
9 was way out, saying, we are all ready to implement a KI
10 distribution plan, and then found there was confusion in
11 the ranks, and decided to bail out, and they did it that
12 way. They might have also said, this is up to the
13 utility to do it, or the NRC, or somebody else.

14 I don't see anything sinister.

15 MR. MOELLER: No, not at all. It was simply
16 apparently a way that they handled the situation.

17 MR. MOELLER: I just had two comments on it.
18 One, I think I want to call everybody's attention again
19 to that German paper I ran across, which I think was
20 distributed, wasn't it? Wasn't that German paper
21 distributed to everybody?

22 MS. TANG: Last time.

23 MR. MOELLER: Since the last time, because I
24 sent in something else.

25 MS. TANG: Since the last time you added some

1 tables to the last paper.

2 MR. MOELLER: Was that distributed?

3 MS. TANG: It is not in this current package.

4 We can make some copies of it. The gist of it was, that
5 was a discussion of some of the impact of plain iodine
6 on the thyroid in the human system, and apparently it
7 isn't at all clear that iodine isn't a problem,
8 especially under certain conditions.

9 The other comment, I mean, last time we heard
10 the American Thyroid Association indicate that there
11 wasn't any known effect at any levels below 100 R to the
12 thyroid, and it made me wonder why you would want to
13 block it at any lower level, at one of the lower
14 levels. Suggested, I think, was 25, and then there were
15 some other papers last time that even suggested
16 considerably lower than that.

17 MR. MOELLER: Okay. Why don't we move on,
18 then, with the agenda, which calls for comments from the
19 NRC staff on their views and positions on the draft
20 federal policy statement?

21 For that presentation, I will call on Brian
22 Grimes.

23 MR. GRIMES: Thank you.

24 As you pointed out, there has been an
25 interagency working group which did work with FEMA to

1 develop a draft federal policy statement on the
2 distribution of potassium iodide and in particular for
3 the general public.

4 I would just note that the statement does set
5 out the advantages and disadvantages of using potassium
6 iodide, some of the logistical difficulties which might
7 be encountered if one were to try to put that sort of
8 thing in place.

9 As you correctly noted, the paper takes no
10 federal position for or against the distribution of
11 potassium iodide to the general public, and leaves the
12 matter to the state or local groups to make a decision.

13 With respect to the NRC's status, the NRC
14 staff sent this draft statement to the Commission for
15 its review in SECY 82-396. After that statement was
16 provided to the Commission, the NRC Office of Research
17 indicated that they believed that the previous
18 contractor cost benefit analysis done by Sandia could be
19 refined at this point, and perhaps a firm position
20 against the distribution of potassium iodide to the
21 general public could be developed.

22 The paper sent by the staff to the Commission
23 was therefore withdrawn by SECY 82-396A pending the
24 promised research study which is due approximately
25 January 1. We would anticipate after that study becomes

1 available deciding on a course of action at that point,
2 and they are working with FEMA and other federal
3 agencies after they digest the results of that study.

4 That's all the comments that I had to make.

5 MR. MOELLER: Yes, Jerry Ray?

6 MR. RAY: I have a question that is once again
7 an elementary sort. Do we know, or has it been
8 established whether there are any adverse radiological
9 reactions on the part of some humans to the injection of
10 KI?

11 MR. GRIMES: I believe we know that there are
12 some adverse reactions in some segments of the
13 population. There is a statement by the FDA which
14 weighs those adverse effects and makes a conclusion that
15 the drug -- that the benefits of taking the drug would
16 outweigh the risks from taking the drug at an exposure,
17 a projected exposure of about 25 rem to the thyroid.

18 MR. RAY: So even in the case of someone who
19 was unresponsive to it, it would be an overriding
20 consideration?

21 MR. GRIMES: No. I'm sorry. If an individual
22 were known to have an adverse reaction, then that
23 individual under the policy statement would be cautioned
24 against taking it.

25 MR. RAY: Thank you.

1 MR. SHAPIRO: I might say we discussed that at
2 our isotopes meeting at Massachusetts General, where we
3 to have research workers, and the question was brought
4 up as to whether they should be given potassium iodide,
5 and our own thyroid specialist there recommended against
6 it. He said you could have problems. So I think one
7 has to determine at what level the benefit does outweigh
8 the risk, because there is a risk.

9 MR. MOELLER: Thank you.

10 MR. PARKER: But that would be repeatedly
11 different in your practice rather than the one-shot
12 accident application.

13 MR. SHAPIRO: I don't know whether it would be
14 considered one shot versus multiple use, but I think
15 that is certainly a point.

16 MR. MOELLER: Do you have that paper that was
17 written by K-a-l-l-e-e? I think you don't Ms. Tang
18 can provide you with a copy of it with the charts and
19 everything. It is very interesting.

20 MR. RAY: Does that bear on this subject?

21 MR. MOELLER: Yes.

22 MS. TANG: I got you a copy, but I will try to
23 get another one.

24 MR. AXTMANN: I have a question for Mr.
25 Grimes. SECY 82-396A says, in the second paragraph of

1 the discussion, I am now informed by our Office of
2 Research that in light of information available on the
3 behavior of radio iodine during a reactor accident, a
4 technical paper would show that the use of potassium
5 iodide for the general public is significantly less cost
6 beneficial than previously assumed.

7 What was the information, and where is it
8 written down?

9 MR. GRIMES: I believe the office of research
10 is now writing down the information which they have
11 stated is available. I think they are referring to the
12 general information that has been brought forward on
13 source terms to date, and they believe that while they
14 cannot come up at this point with a new general source
15 term recommendation, that they do know enough to refine
16 some of the assumptions that were made in the cost
17 benefit study by Sandia which were done with respect to
18 potassium iodides.

19 So they have in mind refining some of those
20 things which were stated to be conservatisms, but not
21 directly factored into the cost benefit calculations at
22 that time.

23 MR. AXTMANN: I keep looking for written, not
24 spoken, confirmation of what I have deduced from what
25 you are saying, and you are saying that there is

1 significant new information on the degraded core reactor
2 source term, and I have simply not seen any hint except
3 SECY 82-396A and something I got in the mail one week
4 ago NSAC 50, dated May, 1982, which says that EPRI
5 studies concluded that the degraded core accident source
6 term is lower than previously considered.

7 Now, we all realize that the TMI 2 source term
8 was less, but there have been studies done that examine
9 not TMI 2 but the whole spectrum of conceivable
10 degraded core accidents.

11 MR. GRIMES: It is my understanding that the
12 Office of Research has such studies under way. I have
13 not seen the material myself, and am awaiting myself to
14 get the paper which the Office of Research has
15 promised.

16 MR. AXTMANN: So there is no such paper. Is
17 that what you're saying?

18 MR. GRIMES: I am saying I don't have it.

19 MR. MOELLER: I have the same problem that Dr.
20 Axtmann does in that the implication in the SECY 82-396A
21 is that there is new information and therefore we are
22 going to ask them to recalculate it, and we know it is
23 going to show that there is no need for KI pills to even
24 be distributed, and I have read Mr. Minogue's paper he
25 presented at the AIF meeting, October 3 to 6, 1982, in

1 New Orleans, Louisiana, and the paper covers three
2 subjects.

3 The first one is the source term, and it says
4 that -- it traces the history and then it says, "Our
5 research program now is looking both experimentally and
6 theoretically at the chemistry and physics involved in
7 all phases of severe accidents, that is, accidents in
8 which there is fuel damage such that fission products
9 escape from the fuel."

10 Well, the Committee has been told, and we
11 review it twice a year in terms of the reactor safety
12 research program. We are thoroughly familiar -- I hope
13 we are -- with all of this planned research, but I have
14 yet to see the first numbers coming out of it.

15 How can you reach all of these decisions when
16 the research has not been completed? Had SECY 82-396A
17 said -- Had it been a recommendation to the
18 Commissioners that you hold up on the policy statement
19 on potassium iodide until such time as the results of
20 this research are in, I would have understood that, but
21 that wasn't what it said at all.

22 MR. GRIMES: Well, I will bring to the Office
23 of Research's attention your concern and urge them in
24 their January 1 paper to include the appropriate
25 documentation. SECY 82-396A was rewritten based on

1 comments from the Office of Research on SECY 82-396,
2 the submission of the reactor policy paper, and it was
3 based on those initial offers that 396A was written.

4 MR. MOELLER: Are there any other comments on
5 this subject?

6 Excuse me. Herb Parker?

7 MR. PARKER: I think one of the problems is,
8 we have no concept of the shelf life of the potassium
9 iodide. We have been told that the iodate is a
10 catastrophe, and you give that up. Then the paper I've
11 read so far simply says it is left to the manufacturers
12 to determine the shelf life of their potassium iodide
13 product, but surely someone knows whether this is on the
14 order of one year or ten years, which might be the very
15 factor that persuaded you whether the thing was feasible
16 or a pain in the neck.

17 Is that number known?

18 MR. AXTMANN: I am told that the potassium
19 iodide that showed up at TMI 2 came from a chemical
20 manufacturing company whose name escapes me that is just
21 outside of Princeton University -- pardon me, five miles
22 outside of Princeton, New Jersey, and that they ginned
23 up several tons of this in a few days because they had a
24 process going, but they have no way of establishing a
25 shelf life in the absence of orders, you see.

1 Up until that time, they had a few capsules,
2 and I don't know what it takes to establish a shelf life
3 of a chemical that apparently requires tonnage
4 quantities and some kind of sponsorship which this
5 rather small chemical company is not willing to
6 undertake. So it's a Catch 22. The shelf life
7 presumably is long, but there is so far no motivation or
8 financing to establish what the FDA would accept as a
9 shelf life.

10 MR. MOELIER: Dr. Bernard Schlein is here from
11 the Food and Drug Administration Division of -- Is it
12 Division or Office? -- Office of Devices and --

13 MR. SCHLEIN: National Center for Devices and
14 Radiological Health.

15 MR. MOELLER: Why don't you take the floor,
16 Bernie, and just solve our problems here? I would like
17 for you to comment both on the shelf life of different
18 forms of iodide as well as to repeat what you told us
19 last time on the selection of 25 rem as the dose.

20 MR. SCHLEIN: Let me say something about the
21 shelf life. I think it has been pointed out the FDA
22 does not set shelf lives. The manufacturer has to
23 submit samples that have been sitting on the shelf or
24 having been tested under accelerated conditions and then
25 an assay is done, and if the material is still up to

1 potency, the shelf life is that long.

2 The FDA does not go out and solicit a shelf
3 life. The manufacturers thus far have submitted
4 material that permits it to set a three-year shelf life
5 on that particular drug. Until they care to submit
6 material that is five years old, we can't do anything
7 about it. It is just the matter of the law.

8 MR. AXTMANN: So that will be two years down
9 the road?

10 MR. SCHLEIN: I am afraid so, yes.

11 MR. MOELLER: So you have no idea?

12 MR. SCHLEIN: We have no control over that,
13 and neither do we have any data beyond what the
14 manufacturers have submitted.

15 MR. MOELLER: Okay.

16 MR. SCHLEIN: I don't exactly know what you
17 would like. I would prefer not to go back over my
18 presentation from last year. Several questions have
19 been raised, one concerning the German study, which I
20 did take back and I did review.

21 MR. MOELLER: Would you comment?

22 MR. SCHLEIN: Germany is an area where there
23 is an iodide deficiency. Consequently, one would expect
24 a higher number of problems with the use of stable
25 iodide that you would expect in the United States, which

1 is not an endemic goiter, not an endemic area where
2 there is an iodide deficiency.

3 Also, I really do hesitate to go through my
4 previous presentation or through the 20 or 30 pages in
5 the FDA recommendations. Quite honestly, we weighed
6 everything we knew about the carcinogenesis, and we
7 weighed very heavily a paper which will appear in
8 Aviation Research where we compared doses of radio
9 iodine and external radiation to the thyroid, and found
10 that the ratio of carcinogenic risk is one to one.

11 Therefore, we felt, given this particular
12 factor which we feel is a new research factor, and given
13 the fact of numerous external radiation studies that
14 show increased induction of thyroid cancer down to nine
15 rads, the Modan study, the 25 rem was a reasonable
16 proving ground.

17 MR. AXTMANN: I have forgotten. How do the
18 Germans make up their iodide deficiency? Do they do it
19 through salt, like we do in the states? Or do they take
20 pills? Do they take potassium iodide pills?

21 MR. SCHLEIN: Frankly, I have no idea. Some
22 areas use -- for example, the diet in the United States
23 has about 300 micrograms of iodide each day just from
24 material that is used in bread baking, from vitamins.
25 Some contain iodides.

1 MR. AXTMANN: Well, iodide salt.

2 MR. SCHLEIN: Well, then, of course, iodide
3 salt. I don't know what the Germans do, frankly.

4 MR. AXTMANN: I thought maybe they might have
5 a tablet that had been sitting around for 14 years
6 perhaps.

7 MR. SCHLEIN: Interestingly enough, they did
8 an independent study, and if I remember correctly, it
9 was reported at the last meeting in Stockholm, the
10 meeting that was held in Scotland last year, the
11 Radiation Protection Society over there, and I believe
12 they came up with, because they had this particular
13 problem, that they came up with a number of around 100
14 rem where they would give potassium iodide.

15 As I say, given the difference in the risk
16 factors, I don't think that's inappropriate.

17 MR. MOELLER: Thank you very much, Bernie.
18 That is helpful.

19 Brian, I think about the only --

20 MR. SCHLEIN: Could I just make one other
21 point?

22 MR. MOELLER: Certainly.

23 MR. SCHLEIN: In addition, they did not
24 consider that particular animal study which I think very
25 much influenced our deliberations.

1 MR. MOELLER: Thank you again.

2 Back to Brian. I think our only comment of
3 significance is the one that Dr. Axtmann has made that I
4 reinforce. That is, we would like to see the data that
5 support the decision that was made.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 All right, let's move on, it now being 2:30,
2 and we will take up the proposed 10 CFR Part 140, the
3 criteria for extraordinary nuclear occurrences, and Hal
4 Peterson is going to be the NRC Staff spokesman on this.

5 MR. PETERSON: Now that I am wired up, thank
6 you, Dr. Moeller.

7 The extraordinary nuclear occurrence
8 definition is one that the Commission itself did not
9 develop but was developed by Congress. Basically, as
10 you can see, it has two substantial parts.

11 (Slide)

12 It requires a finding by the Commission that
13 radioactivity has been released from its intended place
14 of confinement in amounts offsite or levels offsite that
15 the Commission finds to be substantial, and then it also
16 requires that the Commission determine that those
17 releases have caused damages which the Commission has
18 determined are substantial.

19 I think it is very important here to recognize
20 that what is substantial is a value judgment. It is not
21 arrived at by any scientific analysis or so forth.

22 (Slide)

23 The reason we are revising the regulations,
24 which I will come to, is that during the Three Mile
25 Island accident, the Commission actually did go through

1 for the first time and ENO determination. It found that
2 the Three Mile Island accident was not an ENO, primarily
3 because of the fact that there were not substantial
4 releases or doses, offsite doses. The damages were a
5 difficulty in evaluating in terms of the magnitude.
6 That was the primary purpose that we decided to redo the
7 ENO definition, because the original phrasing included
8 total damages, some of which the magnitudes could not be
9 assessed without a court resolution, yet the Commission
10 was required to make a prompt determination in order to
11 provide a speedy processing of claims as a result of any
12 reactor accident.

13 I might point out that the Commission's ENO
14 determination, if positive, has three primary effects,
15 all of which are legal. It removes the necessity of a
16 claimant to prove negligence on the part of the reactor
17 operator. That is implied. Once an ENO determination
18 has been made, the claimant only has to prove damage.

19 Secondly, it consolidates all of the claims
20 for a particular reactor accident within the nearest
21 U.S. district Court without having multiple law suits
22 wherever the claimant happened to be.

23 Thirdly, it extends any statute of limitations
24 of the states out to 20 years, which would cover
25 radiation-induced injuries.

1 Those are the three primary roles that an ENO
2 determination has. They do not affect the availability
3 of Price-Anderson liability funds, and they do not
4 trigger the disbursement of the nuclear industry's own
5 insurance payments. Those took place, at least the
6 private funds, at Three Mile Island without any ENO
7 decision.

8 MR. MOELLER: Has there every been an ENO?

9 MR. PETERSON: No. The current criteria for
10 substantial releases are based in part on doses.

11 (Slide)

12 In fact, they use doses right here. As you
13 can see, it is a 20 rem dose to the whole body, 30 rem
14 to the thyroid, 60 rem to the skin. I took somewhat
15 pleasure in reading the comment that came in this
16 morning addressed to this issue simply because the
17 suggestion was that we take into account the protective
18 action guides in developing the ENO criteria. That, in
19 fact, was the source of the 30 rem thyroid dose. This
20 was the original protective action guide for an
21 individual, not a suitable sample of the population that
22 was specified by the Federal Radiation Council back in,
23 I believe it was, 1965. That was the source of that
24 number.

25 At that time there were no equivalent PAGs for

1 other organs except the bone. I should say that. The
2 whole body did not have its own, nor did the skin, so
3 they took a multiple of the occupational exposure. In
4 the case of whole body it was four times the 5 rem per
5 year limit.

6 The point is, I should point out, with regard
7 to both the original selection and our modification it
8 is the substantial release in the sense of being
9 substantially above what we would expect from normal
10 operation.

11 MR. RAY: Maybe I wasn't listening hard enough
12 when you first addressed this slide. Are these
13 either/or? Must they all be present in order to have a
14 substantial release, or any one of them?

15 (Slide)

16 MR. PETERSON: Let me show you a logic table.

17 MR. RAY: I hope I can understand it.

18 MR. PETERSON: The event, this essentially
19 always takes place. Any accident would be -- TMI, for
20 example, did fit the event one, so that goes into this
21 "and" box. The amount of radiation levels offsite,
22 which is substantial, is an "or." It can be one or the
23 other or both. So that finding must be made. That was
24 one of the three.

25 Then with regard to the damages, the damages

1 to persons and damages to property, they either have
2 resulted or will result and all of those are "or's." So
3 any combination, anything that leads along one of these
4 three paths will give an ENO. The first one almost
5 always happens.

6 MR. RAY: Let's dwell on the second block.
7 Commission determines that amounts offsite are
8 substantial.

9 MR. PETERSON: That is correct.

10 MR. RAY: Now come back to this slide. Must I
11 have each of one of these levels in that particular area
12 of exposure or any one of them would determine
13 substantial releases?

14 MR. PETERSON: Any one. You also don't even
15 have to have a dose to anybody; you can just have
16 substantial contamination. It refers here to amounts
17 offsite.

18 MR. RAY: Are the levels quantitative levels
19 to determine substantial contamination and you will come
20 to that?

21 MR. PETERSON: Yes.

22 MR. MOELLER: And this is getting ahead, but
23 will the proposed change in the definition of an ENO
24 make TMI-2 an ENO?

25 MR. PETERSON: You are jumping ahead, but the

1 answer is no.

2 MR. MOELLER: It still won't do it?

3 MR. PETERSON: No.

4 MR. RAY: Do we have a copy of that slide?

5 MR. PETERSON: Sure.

6 MR. RAY: It wasn't in the handout.

7 MR. PETERSON: It was a backup slide.

8 [Slide.]

9 These are the contamination levels presently
10 existing. You can see that they are fairly gross
11 numbers. They concern alpha from transuranics,
12 non-transuranics, beta or gamma emission of 4 MR per
13 hour, 1 centimeter, .1 milligram per centimeter
14 absorption. So they are really rather gross levels.

15 Now, we did look at -- I should point out
16 there is another set that is ten times larger that
17 applies to land which the licensee or the person
18 indemnified owns. So I didn't clutter up the slide with
19 that, but that is a minor point which we are dropping.
20 We figure if the licensee's land is the only land
21 contaminated, there is no reason for the ENO
22 determination to be made.

23 MR. KATHERN: This is contamination outside of
24 some boundary?

25 MR. PETERSON: The boundary is covered in the

1 indemnification agreement.

2 MR. MOELLER: I am pretty sure it is land
3 beyond the border of the facility.

4 MR. KATHERN: Okay.

5 MR. PETERSON: These numbers are definitely --
6 the numbers I mentioned that were ten times higher would
7 apply to land that was perhaps separate. One could see
8 like a switching station that was separate from the site
9 but was contaminated by the event.

10 MR. MOELLER: Hal Parker has a question on
11 that same slide.

12 MR. PETERSON: Certainly.

13 MR. PARKER: I was trying to read what you
14 said about beta or gamma. How are you going to measure
15 the beta emission that way?

16 MR. PETERSON: With a very thin window.

17 MR. PARKER: You don't get roentgens out of it.

18 MR. PETERSON: The site is wrong, the rule is
19 right. It is 4 MR.

20 MR. KATHERN: They read the scale.

21 MR. PARKER: That is one way of doing things.

22 MR. KATHERN: I hope not.

23 (Slide)

24 MR. PETERSON: What we are proposing is a 5
25 rem effective whole body dose, so that the effective

1 change is a 20 rem whole body dose and goes down to a 5
2 rem dose. This is still significant in terms of being
3 far above normal release limits. Well, at the time the
4 original limits were proposed, the operable number was
5 the 500 millirem per year dose limit for the members of
6 the public, so that the ratio was 40 between the 20 rem
7 whole body dose and the normal release limit.

8 What we are proposing, you should bear in mind
9 that the current release limit is based on EPA's 40 CFR
10 190 and is .025 rem. So that we actually are proposing
11 a number where the difference between the normal
12 operation and the ENO limit is a factor of 200, even
13 though we are reducing that down.

14 I should also point out that at the current
15 time we have a factor of 800 between the .025 and the
16 current 20 rem ENO criterion, but essentially where we
17 are coming down in terms of the total numerical value,
18 we are still maintaining a substantial distance above
19 what would be a normal operating level of a reactor for
20 triggering this.

21 The basis we are using in part is the fact
22 that both the FDA and the EPA have recommended proposed
23 protective action guides that deal with whole body doses
24 from either gaseous emissions or foods, and the FDA has
25 proposed a two-level scheme using a preventive PAG of

1 half a rem and an emergency PAG of 5 rem, at which point
2 you would start considering confiscation of foods. EPA
3 has proposed a scale of 1 to 5 rem, the higher number
4 being more mandatory.

5 We believe that the ENO concept is in fitting
6 with the higher mandatory action level so that you would
7 consider an ENO if you had to have taken protective
8 action, and that is essentially what we are proposing as
9 the equivalent of a substantial dose, is one that you
10 would have had to take protective action to avoid.

11 I might add that the way the rule is worded on
12 this, we are not requiring that protective action has
13 been taken or what happens with regard to a particular
14 actual event. Whether the authorities call for an
15 evacuation or do not does not affect the ENO
16 determination; it is whether they should have, because
17 the ENO is going back. It is not a radiation protection
18 limit per se; it is an internal number for the
19 Commission's use in evaluating an accident that has
20 already happened. I think that is an important
21 viewpoint in viewing what the significance of this
22 number is.

23 (Slide)

24 Now, the damages in the existing rule are five
25 or more people killed with objective clinical evidence

1 of radiation injury, or \$2.5 million of damage sustained
2 by one individual, or \$5 million of damage sustained in
3 the total, or \$5,000 sustained by 50 or more persons,
4 and at least \$1 million in total. I think you can see
5 why the Staff has made recommendations to change some of
6 those.

7 Actually, when you plot these you get an
8 interesting effect that one person gets \$2.5 million but
9 the 50 people only need \$1 million, and any number of
10 people would take care of \$5 million. So that there is
11 no apparent proportionality between the total amount
12 required to satisfy the physician and the people
13 affected.

14 MR. MOELLER: Again, at TMI -- and I realize
15 you have had these formulae where you allow, what, \$100
16 a day while you are gone for loss of employment, and \$25
17 a day for your expenses to shelter?

18 MR. PETERSON: What is the insurance
19 industry's figures. Those are not the Commission's.

20 MR. MOELLER: Okay. You are saying to me
21 there were not 50 people at TMI that incurred \$5,000 or
22 more loss in business or farming or anything?

23 MR. PETERSON: Well, loss of business is not
24 covered. Maybe it would be --

25 MR. MOELLER: Loss of business is not covered?

1 MR. PETERSON: What was covered were
2 evacuation costs.

3 MR. MOELLER: Why didn't we make it in ENO?

4 MR. PETERSON: Because of the first finding,
5 the either/or. You have to have both substantial
6 releases and substantial damages. If you have
7 substantial damages without the releases, it is not an
8 ENO.

9 MR. RAY: That did not come through in your
10 first slide.

11 MR. PETERSON: I am glad Dr. Moeller raised
12 the question, then, because now it is clarified. The
13 damages that are covered in this part include the
14 protective action, and this includes the evacuation
15 costs. It also includes the cost necessary to put
16 property back into use, or if it has lost its value, the
17 cost of the loss of use. But it is hard to say that
18 this arose from the toxic or explosive levels.

19 MR. MOELLER: Have you arrived at a value for
20 psychological damage yet?

21 MR. PETERSON: You know that is a sore point.
22 We did consider putting it in as a criteria to the
23 revision. The big problem there is that our conclusion
24 was that the damage, the magnitude of the damage was not
25 necessarily proportional to the magnitude of the

1 accident, and without saying anything about certain
2 agencies who perhaps added to that concern, that it is
3 too hard to evaluate.

4 I think the psychologists could measure it.
5 They could measure it at TMI, the anxiety, but is it
6 related to the accident in terms of proportionality, or
7 did some other incident that wasn't quite related to the
8 accident, such as media coverage or something that got
9 put out of proportion.

10 MR. KATHERN: I don't quite understand. Dr.
11 Moeller asked a question about loss of business, and you
12 said that wasn't a damage or injury. Did I hear you
13 correctly?

14 MR. PETERSON: The loss of business per se was
15 not. It says loss of use of affected property. In
16 other words, if you had a business that got so
17 contaminated that you had to close for a while.

18 MR. KATHERN: But if you evacuated the area so
19 that people couldn't come to my place of business, that
20 is the same thing, effectively, as contaminating it. In
21 other words, the bottom line in either case is I lose my
22 business.

23 MR. PETERSON: I think that is true, but there
24 are certain expenses that were considered when the rule
25 was initially formulated and some that weren't.

1 MR. MOELLER: Frank Arsenault is waving his
2 hand.

3 MR. ARSENAULT: I think I am hearing something
4 back here that may not be carrying up there. The
5 distinction is between loss of use of property,
6 including having to close down a business, either by
7 reason of contamination or evacuation, as distinct from
8 the loss of business occasioned by the nervousness of
9 your customers, which is not loss of use, merely loss of
10 business. I think that is the distinction he is trying
11 to make here. The former, loss of use, either by
12 evacuation or contamination, would be a loss, a damage.
13 If people don't come to your front door, that is the
14 criteria.

15 MR. KATHERN: That is the question I had, the
16 actual physical prevention of people from coming to the
17 front door.

18 MR. PETERSON: Thank you, Frank. I wish I had
19 said that.

20 (Slide)

21 Finally, we are preparing to revise these
22 two. We will call a substantial injury a 500 rem dose
23 or greater to five people. This gets around the present
24 restraint to identify clinical objective evidence of
25 radiation injury, which we have --

1 MR. RAY: Excuse me. I didn't hear you read
2 that the way it is printed. You said a 500 rem dose to
3 five people.

4 MR. PETERSON: 100 rem. I'm sorry. It is
5 printed right. The point that I am making here is that
6 the previous criteria called us to find five people who
7 were killed outright or who were hospitalized with
8 objective clinical evidence of radiation injury. One of
9 the psychological aspects of Three Mile Island, to me,
10 was to point out a lot of the symptoms of stress are
11 exactly the symptoms of the acute radiation syndrome:
12 the nausea, the vomiting, the clammy hands. A lot of
13 the symptoms are very much the same.

14 So I said now what do we use for clinical
15 objective evidence of radiation injury? Chromosome
16 aberrations could be used for small numbers of people,
17 but there you don't have proof of injury. You have
18 proof of maybe radiation exposure, but most physicians
19 say it is not known how that relates to actual injury to
20 the person.

21 So we decided that instead of trying to
22 develop a better definition of objective clinical
23 evidence of radiation injury with regard to that, in the
24 old days I would have said just list the symptoms of
25 acute radiation syndrome and we would have it, but it

1 looks like in fact that may just be a general stress on
2 the body. The stress reactions have very similar
3 symptoms and therefore would not be very useful in the
4 kind of an accident where you would expect the
5 population that was exposed to the radiation to be
6 somewhat stressed.

7 So we are proposing a dose limit of
8 substantial injury and then smaller doses to larger
9 numbers of people in terms of the linear threshold
10 approach, and then the definitions of damages would be
11 only in three categories: contamination or loss of
12 offsite property due to contamination, lost employment,
13 and evacuation of at least 100,000 person days
14 duration. These we figure we can get very good early
15 readings on without waiting for court cases in order to
16 decide what total damages would be. That is why we
17 picked them. And yet they are representative of the
18 types of things we would expect in the case of a very
19 serious radiation accident.

20 MR. MOELLER: Excuse me. Before you take that
21 down, I want to call to the attention of the
22 Subcommittee that there are many ramifications in the
23 first item. The 100 rem is 100 rem effective dose
24 equivalent, and if you read the details, then, you are
25 using ICRP 26's weighting factors. And in a sense, this

1 is then identical to our whole discussion this morning
2 on the revision of 10 CFR 20. So we will have to keep
3 that in mind.

4 MR. MULLER: So if that doesn't fly, then this
5 doesn't fly.

6 MR. MOELLER: Correct. And this should not
7 fly right if it doesn't, or else they could get around
8 it by simply using a term something like whole body
9 equivalent without giving the formula.

10 MR. PETERSON: Are there any other questions?
11 If not, I am done.

12 [No response.]

13 MR. MOELLER: Okay. Any more questions? Let
14 me just ask: how long is NUREG-0637, which gives the
15 details of NRC's decision that TMI was not an ENO?

16 MR. PETERSON: I guess it is about an inch
17 thick.

18 MR. MOELLER: I guess we have seen it. Has
19 the Committee? If it went by, it went by real fast.
20 Could you just -- or we can get someone here to get us a
21 copy.

22 MR. PETERSON: I can probably send you a copy.

23 MR. MOELLER: But it simply took the criteria
24 and laid them out, and it didn't work or it didn't fit.

25 MR. ARSENAULT: Mr. Chairman.

1 MR. MOELLER: Yes, Frank.

2 MR. ARSENAULT: A few additional observations
3 of a more general character. First, I made the comment
4 when we started on this paper that it would be hard for
5 me to accept that an ENO could be caused by a reactor
6 that had less substantive impact on people than I could
7 create driving my Volkswagen bus home, and I suspect
8 that if I tried real hard, that I could kill more than
9 five people on the way home. So we really need to put
10 the concept of an extraordinary nuclear occurrence in
11 perspective.

12 The second observation is I think Congress did
13 exactly that when it drafted the definition. It
14 required that there be a substantial release of
15 radiation or radioactive material and asked the
16 Commission to define what that meant, and indicated that
17 this release should result in substantial damage. I
18 think the Congress conveyed in that definition what its
19 intentions were with respect to the definition of the
20 ENO.

21 So I have heard the question, well, why
22 wouldn't TMI be an ENO? The fact is that there were
23 damages or injuries, both psychological and practical,
24 at the facility, but one must ask if they were in fact
25 caused by the accident or the psychological environment

1 surrounding the accident and the way in which the
2 accident was handled by different individuals. So these
3 are additional perspectives I think the question has to
4 keep in mind.

5 One final note. When we talked to the EDO's
6 office on this point, one of the EDO staff raised the
7 question, should the definition be changed? That is a
8 question of legislative recommendations and was not one
9 which the Staff addressed in attempting to revise the
10 criteria so they would be more workable.

11 Obviously, if the Commission chooses to seek
12 legislative adjustment or if the Congress itself chooses
13 to modify its definition, then we would have to go back
14 to square one. We have only addressed the question of a
15 workable criteria under the current definition.

16 Thank you.

17 MR. MOELLER: Thank you.

18 I think for the Subcommittee the main point
19 that I want to make is that this item and the previous
20 item on the potassium iodide and thyroid blocking, those
21 are two items in which the Committee has been
22 specifically requested by the Commission to offer
23 comment. So the previous one, I think I know what we
24 will say, which I will repeat: that is, to request the
25 data that support the decision that was made. On this

1 one I think we will have to discuss exactly what it is
2 that we want to say.

3 Well, there being no other questions and that
4 having completed that particular presentation, I will
5 declare a 15-minute recess.

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 MR. MOELLER: The meeting will resume.

2 The next item on our agenda, and in fact for
3 the remainder of the afternoon, is to discuss the de
4 minimis concept. We are going to begin with a
5 presentation by the NRC staff on the de minimis concept
6 from a regulatory standpoint. That presentation will be
7 made by Joanna Becker. Joanna?

8 MS. BECKER: Thank you.

9 I am subbing for Guy Cunningham, who had to go
10 to another meeting, but I wrote the speech that he was
11 going to give anyway, so I am quite familiar with the
12 general subject.

13 MR. MOELLER: Maybe we had better harness you
14 up with the microphone, because I want to be sure
15 everyone can hear.

16 Excuse me. Before you begin, and this may be
17 jumping the gun, but did you have then the major input
18 into the section on de minimis that is in the draft 10
19 CFR 20? Or is this a separate thinking?

20 MS. BECKER: I had some input into the de
21 minimis section in Part 20, but this really goes into
22 the legal aspects.

23 MR. MOELLER: Good. Thank you. That will
24 help me.

25 MS. BECKER: As I am sure you all know, or

1 maybe you don't, the so-called de minimis concept more
2 properly referred to as de minimis non curat lex, means
3 the law doesn't concern itself with trifles. I should
4 point out that whether the term de minimis is used or
5 not, the concept doesn't have the same legal
6 connotations as a license exemption or a general license
7 since those concepts are inherently recognize the
8 existence of radioactive material and usually qualify
9 the exempt or generally licensed activity to particular
10 uses or characteristics.

11 Nor is the de minimis concept the same as the
12 "as low as reasonably achievable," the ALARA concept.
13 Persons interested in the NRC regulatory process have
14 tended to equate the de minimis concept with the license
15 exemption, general license or ALARA concept erroneously
16 in the legal staff's opinion.

17 The NRC regulation of radioactive materials in
18 the interest of protection of the general public may be
19 characterized as a series of requirements in descending
20 order relating to risk to the general population. At
21 the top of the regulatory list, maximum permissible
22 levels are presently set forth in Sections 2105 and 2106
23 of Part 20. Section 2105 provides that permissible
24 levels of radiation in unrestricted areas shall be such
25 that no individual is likely to receive a dose to the

1 whole body in a calendar year in excess of .5 rem.

2 Two, that radiation levels shall be such that
3 no person continuously present in an area could receive
4 a dose in excess of two millirems in any one hour or 100
5 millirems in any seven consecutive days.

6 And Three, licensees in uranium fuel cycle
7 operations shall be in compliance with EPA's 40 CFR Part
8 190.

9 Section 2106 provides that licensees shall
10 assure that radioactivity and effluence to unrestricted
11 areas shall not exceed the concentrations in Appendix B,
12 Table 2 of Part 20 except as specifically authorized or
13 as authorized pursuant to Section 2302 relating to waste
14 disposal, and that licensees engaged in uranium fuel
15 cycle operations also comply with 40 CFR Part 190.

16 These permissible levels of radiation in
17 unrestricted areas and discharge of effluents containing
18 radioactive materials to unrestricted areas involve
19 doses above which the Commission considers the risks
20 unacceptable or at least unreasonable to expect under
21 normal circumstances.

22 Below the levels established by license
23 conditions imposed under Section 2105 and 2106 is the
24 ALARA range of releases and or doses. Releases or doses
25 permitted in the ALARA range are based upon

1 consideration of cost, benefits, and other
2 considerations related to practicability. Paragraph
3 20.1(c) of Part 20 defines ALARA as follows:

4 The term "as low as is reasonably achievable"
5 means as low as is reasonably achievable taking into
6 account the state of technology and the economics of
7 improvements in relations to benefits to the public
8 health and safety and other societal and socioeconomic
9 considerations, and in relation to the utilization of
10 atomic energy in the public interest.

11 Keeping doses ALARA is not presently stated as
12 a general requirement in Part 20. However, the concept
13 is frequently incorporated in materials license
14 conditions by reference to commitments in license
15 applications. Facility licenses contain technical
16 specifications for keeping releases ALARA as provided in
17 Sections 50.36a or Part 50.

18 ALARA quantities or concentrations in releases
19 are not necessarily at or below a de minimis level.
20 While licensees are not presently required to operate at
21 lower than the ALARA level, the Commission does not by
22 the very fact of consideration ignore the risk from
23 ALARA releases.

24 The Commission has also established in its
25 regulations exemptions from licensing requirements for

1 unspecified quantities or concentrations. forms or uses
2 of radioactive material which may be below the ALARA
3 range but which are not still necessarily de minimis.

4 The exemptions in Commission regulations
5 usually permit use or disposal of exempted products or
6 quantities without regard to their radioactivity.
7 However, exemptions are issued by the Commission in
8 rulemaking proceedings in which cost benefit
9 considerations are the primary consideration.

10 A recent example of an exemption may be found
11 in the recent amendments to Part 20 in 20.306, which
12 permits disposal of liquid scintillation media and
13 animal carcasses containing tracer levels of tritium or
14 carbon 14 without regard to their radioactivity, and
15 raises the annual limits of those materials that can be
16 disposed of by release to sanitary sewer systems by
17 amendment of 23.303(d).

18 Section 20.306 specifically provides, however,
19 that such disposal under the section does not relieve
20 the licensee from maintaining records showing receipt,
21 transfer, and disposal of such material as required by
22 Part 30.

23 As the notice of rulemaking demonstrates, the
24 Commission considered costs in terms of radiation hazard
25 to sewage system workers and expected radiation doses to

1 the public as well as the savings in elimination of
2 burial in radioactive materials in terms of cost to
3 licensees, problems in transportation, and shortage of
4 radioactive waste burial capacity.

5 By contrast, the de minimis concept, the
6 lowest level in this hierarchy is not based on the ALARA
7 concept or the cost-benefit considerations involved in
8 the issuance of an exemption through rulemaking.
9 Rather, the de minimis concept as used in the revision
10 of Part 20 being drafted by the NRC staff is that any
11 health risk to the members of the general public due to
12 the presence of radioactive materials or radiation is so
13 low that the radioactivity in such releases may be
14 regarded as trifling.

15 The de minimis risk can be expressed in terms
16 of dose rate as a surrogate for specification of
17 quantities of radioactive material. As the ICRP said in
18 Publication 22, "The use of the concept of population
19 dose in the process of decision-making should ... be
20 supplemented by consideration of the dose to
21 individuals. At low levels of individual dose, e.g.,
22 those small by comparison with variations in local
23 natural background, the risk to the individual is so
24 small that his health and welfare will not be
25 significantly changed by the presence or absence of the

1 radiation dose."

2 As an aside, it might be noted that the term
3 "de minimis" which has been used in the notice of
4 proposed rulemaking of the new Part 61 dealing with low
5 level radioactive waste is somewhat misleading in that
6 the term was used to refer to the possible development
7 of an exemption for de minimis amounts of specific
8 waste.

9 Thus, we have a regulatory scheme that has as
10 an upper limit above which the calculated health risk is
11 generally unacceptable and a lower bound value that
12 implies a risk that, if it exists at all, we believe
13 fully acceptable without further consideration.

14 In between these two values, regulatory
15 requirements are based on the application of the ALARA
16 concept, and any risk is judged acceptable on the basis
17 of not only the magnitude of the health risk, but also
18 social and economic factors that are involved. If the
19 Commission adopts a de minimis concept in Part 20, NRC
20 and its resources would be relieved of the burden of
21 licensing activities relating to releases and disposal
22 of de minimis quantities of radioactive materials, and
23 also of enforcement activities relating to such
24 quantities.

25 The Commission and its staff could thus avoid

1 the complex calculating of doses integrated over the
2 entire population and over all time which would be
3 inherent in the process of taking the "exemption from
4 licensing" route rather than reflecting the de minimis
5 concept in Part 20.

6 To express the concept in quantities, which is
7 the usual form for an exemption, would involve the
8 further calculational problem of considering the
9 infinite number of pathways to man. Accordingly, the de
10 minimis concept would be based upon risk and its
11 surrogate dose, not quantities. The NRC staff, and I am
12 sure that Dr. Mills will go into this further, is of the
13 view that of necessity the de minimis quantity can only
14 be applied to doses at very low levels. The concept
15 would not likely be of help to the nuclear industry in
16 easing the regulatory burden relating to waste streams.

17 Any relief in that area would have to be
18 accomplished by the exemption route, as in the case of
19 the exemption for carbon 14 and tritium wastes. A
20 problem in NRC's incorporating the de minimis concept in
21 Part 20 is the danger that doses above the de minimis
22 level might be perceived by members of the public as
23 unacceptable or even dangerous. This would result from
24 the definition of "de minimis" which is that such
25 matters, that is such doses, are a trifle.

1 Accordingly, higher doses might be perceived
2 as more than trifling and perhaps even substantial.
3 Such a perception could lead to unwarranted opposition
4 to exemptions, general licenses, and operations under
5 license conditions. From the standpoint of the
6 licensee, adoption of the de minimis concept would
7 relieve them of the burdens associated with licensing
8 and regulation of releases or disposal of de minimis
9 quantities which are de facto ALARA quantities.

10 Licensees would, of course, have the burden of
11 establishing by calculation or otherwise that
12 radioactive material released was in fact within the
13 limits established by the Commission by regulation. The
14 same result could be achieved if the Commission used its
15 authority to exempt de minimis quantities from the
16 licensing requirements of Sections 53, 62, and 81 of the
17 Atomic Energy Act and 10 CFR Parts 30, 40, and 70.
18 However, the difficulty of defining de minimis doses in
19 terms of quantities or forms appears to preclude that
20 regulatory approach as a practical matter.

21 The de minimis concept, in those words or
22 equivalent, has formed the basis for some judicial and
23 regulatory decisions in the United States. Cases in
24 areas most analogous to the NRC statutory
25 mission--protection of the public health and safety--are

1 those arising under sections of the Federal Food, Drug
2 and Cosmetic Act, are not particularly relevant because
3 of differences in interpretation of the statute. I will
4 not go into those, although a discussion of them is
5 included in the printed material.

6 A better analogy is found in the Food and Drug
7 Rulemaking proceeding to implement an amendment to the
8 so-called "Delaney Clause," which provides that "no
9 [food] additive shall be deemed to be safe if it is
10 found to induce cancer when ingested by man or animal,
11 or if it is found, after tests which are appropriate for
12 the evaluation of the safety of food additives, to
13 induce cancer in man or animal, except that this proviso
14 shall not apply with respect to the use of the substance
15 as an ingredient of feed for animals which are raised
16 for food production, if the Secretary finds (i) that,
17 under the conditions of use and feeding specified in
18 proposed labeling and reasonably certain to be followed
19 in practice, such additive will not adversely affect the
20 animals for which such feed is intended, and (ii) that
21 no residue of the additive will be found (by methods of
22 exemption prescribed or approved by the Secretary by
23 regulations, which regulations shall not be subject to
24 subsections (f) and (g) of this section) in any edible
25 portion of such animal after slaughter or in any food

1 yielded by or derived from the living animal, ..."

2 The notice of proposed rulemaking pertaining
3 to the use of DES in cattle feed which followed the
4 amendment which was published in the Federal Register
5 March 20, 1979, discussed at length the linear theory of
6 carcinogenesis, and adhered to the "no threshold"
7 theory analogous to that used by the NRC. However,
8 without using the term de minimis, the FDA concluded
9 that a risk level of one DES-induced cancer in one
10 million people was so low that the FDA could conclude
11 that the risk level should not significantly increase
12 the human cancer risk.

13 It should be noted, however, that the Delaney
14 clause as amended speaks in terms of "no residue" being
15 found, avoiding such words as "occur" or "remain." As
16 pointed out by the FDA, the amendment emphasized
17 detectability rather than non-existence. Thus the FDA
18 has approved for use a carcinogenic compound if
19 examination of edible tissues by an assay reveals no
20 residue, and noted implicit approval of its
21 interpretation in case law.

22 It should be noted, however, that the FDA
23 regulations to which I referred were in proposed form.
24 It was anticipated that substantial changes would be
25 made in the effective rule on the basis of comments from

1 the meatpacking industry urging that a higher risk level
2 be used. I am not aware that the FDA has taken any
3 further action on the proposed rule. Although there are
4 a number of judicial decisions in which the concept of
5 de minimis is either determinative or discussed, most of
6 those decisions are not particularly pertinent to the
7 use of the concept by a regulatory agency, since most
8 involve use of the concept in matters resulting in
9 private litigation.

10 On individual occasions, and this is really
11 ancient history, the old AEC permitted equipment
12 contaminated with small traces of special nuclear
13 material which could have been sold under Manual
14 Chapters 5170 or 5182, if exempt contractors had been
15 involved, to be transferred without a license required
16 of the transferee. This determination was made because
17 at that time there was no statutory authority for the
18 Commission to exempt SNM from licensing requirements
19 which was enacted in the omnibus bill of 1974.

20 In a memorandum prepared by the AEC's Office
21 of the General Counsel, it was stated that on the basis
22 of information that the traces of SNM on such
23 contaminated equipment would not be economically
24 recoverable, and would not subject personnel to
25 radiation exposures as high as limits in Part 20 for

1 nonradiation workers, it could be concluded that the
2 quantity of SNM involved was de minimis and without
3 health or safety significance, that in these respects
4 the contaminants would not be considered special nuclear
5 material within the meaning of the Act, and that no
6 licensing would be required.

7 The initial legal obstacle in the use of the
8 de minimis concept in NRC regulations is the fact that
9 the Atomic Energy Act does not provide for such a
10 concept. However, the use of the concept in other
11 agencies administering the laws mentioned above was also
12 not specifically authorized by the governing statutes.
13 The fact that the Act in Sections 57d, 62, and 81, on
14 the other hand, provides for issuance of exemptions from
15 licensing requirements suggests that the Congress
16 intended that the AEC and its successor, the NRC, use
17 the exemption mechanism to provide relief from the
18 requirements for a license.

19 It might be argued that the line of NRC
20 Licensing Board and Appeal Board decisions arising from
21 the Perkins decision constitutes a recognition of the de
22 minimis concept by the Commission and its application to
23 licensing under the Atomic Energy Act. However, the
24 issue in those cases was one arising under the National
25 Environmental Policy Act considering the health effects

1 of a release of radon from uranium mill tailings piles,
2 not one cognizable under the Atomic Energy Act.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 As noted above, the NRC has authority to
2 exempt from licensing requirements unimportant
3 quantities of source material and quantities of special
4 nuclear material and byproduct material that would not
5 be inimical to the common defense and security and would
6 not constitute an unreasonable risk to the public health
7 and safety. Historically, neither the AEC nor the NRC
8 has generally used its exemption authority to permit
9 unrestricted releases or distribution of radioactive
10 material.

11 Exemptions codified in NRC regulations
12 ordinarily specify the form and/or use or user of the
13 exempt materials, with the exception of the exemption in
14 Section 40.13(a) for source material in chemical
15 mixtures, components solutions or alloys in which the
16 source material is less than .05 percent of the
17 mixture. In view of the historical use of the exemption
18 provisions in the Atomic Energy Act, it may be
19 considered inappropriate to include the de minimis
20 concept in the regulatory process through the exemption
21 route.

22 On the other hand, because of the availability
23 of statutory authority to exempt nuclear materials from
24 licensing requirements, it might be argued that this
25 authority indicates that the exemption route, rather

1 than the de minimis concept, should be used. To some,
2 use of the de minimis concept may seem inconsistent with
3 the "no threshold" or "no zero risk" concept applicable
4 to carcinogenesis, which has always been the underlying
5 premise of AEC and NRC regulation of radioactive
6 materials.

7 However, it seems that as a practical matter
8 the exemptions in Parts 30, 40 and 70 also run counter
9 to that concept. Further, the so-called "consumer
10 product criteria" published on March 16, 1965, indicate
11 that in evaluating proposals for the use of radioactive
12 material in consumer products, not only are potential
13 doses to be considered, but also the potential benefit
14 that will accrue or be denied the public because of the
15 utility of the product by approval or disapproval of a
16 specific product.

17 As I have noted above, the Food and Drug
18 Administration in its rulemaking proceeding to implement
19 amendments to the Delaney clause seems also to have
20 reconciled the "no threshold" concept with unrestricted
21 distribution of foods containing carcinogens.

22 The need for a de minimis feature in this Part
23 20 has long been recognized in order to avoid extending
24 regulatory actions beyond what are needed to adequately
25 protect the public health. Applied to radiological

1 protection, de minimis can be of a level of risk or a
2 dose rate as a surrogate measure so low that it would be
3 trivial in comparison to the risks which the individual
4 is subjected to daily as a part of normal living habits
5 and activities. It would constitute a level of risk so
6 low that no resources could be justified to control it
7 or to be further concerned with it.

8 There are a number of ways to establish a de
9 minimis level where exposures to radiation are
10 concerned. Suggestions have been made to select a value
11 based on variations in the naturally occurring
12 background radiation from cosmic and terrestrial
13 sources.

14 Background levels are highly dependent on
15 local geology and altitude. Background levels in the
16 United States varying from less than 100 millirems to
17 over 200 millirem per year can be found. Reference to
18 natural background radiation levels provides a good
19 perspective on radiation exposures, but it is not clear
20 how this range could be used to select a de minimis
21 level that has unique advantages over a judgment on risk
22 in terms of serious health detriment.

23 Consistent with the Commission's proposed
24 policy to use quantified risk as an important factor in
25 decisionmaking, reflected in its Proposed Policy

1 Statement on Safety Goals for Nuclear Power Plants, in
2 the current Staff draft of the revision of Part 20 the
3 de minimis level would be based on considerations of an
4 "acceptable" lifetime risk of one in one million of
5 dying from radiation-induced cancer.

6 Since the total risk coefficient is about 1.65
7 $\times 10^{-4}$ per rem for whole body deep dose equivalents, a
8 risk to one in one million persons in a lifetime, about
9 70 years, would be about 0.1 millirem per year. I will
10 leave the justification of these figures in the draft of
11 Part 20 to Dr. Mills.

12 A de minimis value of one millirem per year
13 for an individual has tentatively been selected by the
14 Staff in its draft revision as mentioned above. When
15 radioactive materials are more widely dispersed, there
16 is some possibility, but it is still not likely, of an
17 individual receiving dose contributions from multiple
18 sources, each at a de minimis level of 1 millirem per
19 year. Consequently, a de minimis value of 0.1 millirem
20 per year might be selected for consideration of
21 collective doses to populations.

22 Some have correctly noted that the de minimis
23 level in the August 1982 draft of Part 20 is too low to
24 permit measurements with generally available survey
25 instruments. Since the de minimis levels have been

1 selected on the basis that the risks are trifles, the
2 associated dose values are indeed too low to be measured
3 as a practical matter. The levels would therefore have
4 to be derived from calculations.

5 Application of the de minimis level would,
6 among other things, limit both the size of the
7 population and the time over which collective dose would
8 need to be considered in evaluating activities
9 associated with release of radioactive materials to the
10 environment. It appears that with the two de minimis
11 values -- that is, one millirem per year for individuals
12 and 0.1 millirem per year for determining collective
13 doses -- no need is anticipated to constrain other
14 parameters such as person-rem increments or quantities
15 of radionuclides.

16 The de minimis level would be a lower limit
17 which would be applicable to any licensed activity. The
18 establishment of a de minimis dose level should not
19 imply that at higher levels it is necessary to spend
20 resources for radiation protection purposes. Indeed,
21 when an ALARA level for a specific activity is
22 determined, additional resources for radiation
23 protection are not required beyond that level, but an
24 ALARA level is not a de minimis level since such a level
25 is not necessarily at or below the de minimis level.

1 Of course, should any licensee operate in a
2 manner that the de minimis levels are satisfied, those
3 operations are by definition ALARA, because to go lower
4 would be unreasonable from a health protection
5 standpoint.

6 I might mention in closing that by reason of
7 Reorganization Plan No. 3 of 1970, EPA has the
8 responsibility for setting generally applicable
9 environmental standards for the protection of the
10 general environment from radioactive material covered by
11 the Atomic Energy Act, that is, limits on radiation
12 exposure or levels, concentrations or quantities of
13 radioactive material in the general environment outside
14 the boundaries of locations under the control of persons
15 possessing or using radioactive materials.

16 The plan, as you know, also transferred to EPA
17 all the functions of the FRC under Subsection 274h. of
18 the Atomic Energy Act. Those functions include advising
19 the President with respect to radiation matters directly
20 or indirectly affecting health, including guidance for
21 all federal agencies in the formulation of radiation
22 standards.

23 These provisions of Reorganization Plan No. 3
24 of 1970 do not transfer responsibility for promulgation
25 of Part 20, including de minimis provisions, to EPA.

1 However, the NRC's draft revision of Part 20, which
2 includes the de minimis concept, is not in conflict with
3 40 CFR 190 and existing federal guidance. It can be
4 expected that NRC will work with EPA in formulating the
5 de minimis concept.

6 Are there any questions?

7 MR. MOELLER: Thank you.

8 Do we have questions for Ms. Becker? Yes, Ron
9 Kathern?

10 MR. KATHERN: I just have one quick question.
11 If you set a de minimis level for a whole series of
12 operations, is each of these considered independently,
13 as say in the case of drugs, where you have a de minimis
14 level for aspirin and whatever, or do you somehow have
15 to look at the collective aspects of all of these de
16 minimis actions?

17 MS. BECKER: It's my understanding -- and Dr.
18 Mills will correct me if I'm wrong -- that there would
19 be one level. The de minimis level would not be
20 selected selectively, is that right, Billy?

21 MR. MILLS: Right. To that point, Ron, one of
22 the things we are engaged in right at the moment as the
23 replacement for the Radiation Policy Council, the
24 President has given to the Office of Science and
25 Technology Policy the responsibility to establish -- I

1 don't know the name exactly, but it's the Committee for
2 Radiation Policy Coordination, I think. Is that close?

3 One of the -- in accepting membership on that
4 committee for Mr. Minogue, one of the things he
5 specified was that all these agencies would consider as
6 a priority item the de minimis concept. So I would
7 imagine that even though we have attacked it only from
8 the radiation standpoint, that any agency engaged in
9 that activity would also reflect on it in terms of the
10 other control that it has. For example, in the case of
11 EPA I am sure it would apply to the control for air
12 pollution as well.

13 MR. MOELLER: Thank you.

14 Other questions or comments?

15 (No response.)

16 MR. MOELLER: I think, Ms. Becker, you have
17 started us off on a very good -- in a very good way.
18 And now as we listen to the other people we can begin to
19 put it together. Will you be with us for a while?

20 MS. BECKER: Oh, yes.

21 MR. MOELLER: That will be helpful, and then
22 we can come back.

23 Why don't we move ahead, then, with our
24 agenda. And the next presentation in this series will
25 be the EPA program to develop standards for "below

1 regulatory concern" levels. Floyd Galpin is here to
2 lead us in that discussion.

3 MR. GALPIN: One has to be careful when you
4 interact with Dade. We had him over for a briefing on
5 our activities in the waste area in general, and often
6 one interaction with Dade leads to another and you don't
7 know where you're going to be appearing. I believe what
8 prompted his invitation to me to come here today was
9 that I had mentioned to him in the course of that
10 discussion that we were looking at setting a level below
11 regulatory concern -- some people would call that de
12 minimis -- for the radioactive waste area.

13 I further mentioned that it perhaps was not
14 indeed a panacea and it perhaps raised more questions
15 than it answered, and he replied later he was very
16 curious as to how I came up with that and if I would
17 follow up. So when I wrote this paper for an AIF
18 presentation which I have had passed out, why, I sent a
19 copy to Dade and got this invitation. I don't know
20 whether he's laying for me or what the intention is.

21 MR. MOELLER: No, we simply want you to share
22 your thoughts with us, and we appreciate your coming.

23 MR. GALPIN: Thank you.

24 I feel like there has been rather a series.
25 Joyce Davis and I were both on the program at the AIF

1 meeting, and Billy Mills was there too. I think maybe
2 we could put a dog and pony show on the road for
3 different people's consideration of de minimis.

4 But let me just go into what EPA is doing.
5 Its present activity regarding the de minimis or
6 regulatory cutoff is restricted to the area of
7 radioactive waste. Let me just go over a few things we
8 are not doing.

9 We are trying to stay away from even using the
10 term "de minimis." The reason that is so is it has come
11 to mean different things to different people. There are
12 those who are constituents of EPA who have gotten the
13 idea that anybody that uses the term "de minimis" or "de
14 minimis non curat lex," I believe is the Latin, is
15 talking about legal care or we're not concerned, we
16 don't give a damn. And they react to that.

17 So rather than confront people's already
18 preconceived notions and therefore cause reactions, we
19 are using terminology we hope is more descriptive of
20 what we are actually trying to do. At the moment we are
21 settled on something that we would call a level below
22 regulatory concern. This is a level below which
23 regulation is not warranted or may be minimal.

24 Now, we have tried to come up with different
25 acronyms or different terminology to replace "de

1 minimis." I asked my staff to do this at one time, and
2 I suspect highly that they first picked the acronym and
3 then tried to fit words to it. The last one, they
4 wanted to call it LAID waste. This was to be "levels
5 allowed in dumps."

6 (Laughter.)

7 I think, however, we set that aside and
8 charged them with working more along their bent.

9 Another thing we're not doing is, we are not
10 attempting, as was discussed just a moment ago, to set
11 an overall cutoff or even an overall truncation. We
12 believe that those two levels, as NRC has pointed out,
13 should appropriately be different levels, because one
14 could calculate some level of population exposure that
15 is beyond, let's say below or smaller than, the cutoff
16 that one would make for an individual dose.

17 But this particular activity that we're
18 involved in at the present time does not attempt to do
19 either one of those. We looked at that. I admire Billy
20 and his people for taking that on. We could not see it
21 as something we would tackle in the near future, nor did
22 it seem to us like the sort of thing that was most
23 significant, that being the case with the waste
24 disposal.

25 You will hear an excellent paper or a

1 summarization of a paper when Mrs. Davis gets up next,
2 and probably the most complete listing of different ways
3 that one can consider setting an overall level,
4 including the biological aspects and such things as
5 background considerations. So I will leave that to
6 Joyce and her excellent work.

7 Also, there has been some work done by Hoyt
8 Whipple which would not only combine the background and
9 its variability, but the variability of disease
10 incidence, and Hoyt and I have exchanged some
11 conversations over that. One of the things that
12 bothered us in that area is that background's
13 variability even is not constant over the eastern United
14 States, nor is the disease incidence. If you will adopt
15 one of those as a national basis for criteria, we can
16 see certain problems there.

17 Although we are limiting this present activity
18 to low level radioactive waste, we do see that it has
19 some implications for some other things that EPA is
20 involved in. Let me just mention those. One is, any
21 consideration that we would make of setting standards
22 for decontamination and decommissioning. Certainly the
23 same kind of thinking that you get into when you talk
24 about a regulatory cutoff for waste or exposure level
25 below which there is no further concern has to become

1 involved when you look at what you are going to leave
2 behind, what exposures that might entail when you get
3 into decontaminating and decommissioning a facility.

4 Another activity that we are involved in that
5 will be related is in setting protective action guides
6 for the case of re-entry into any area that should be
7 contaminated by an accident. Again, the same kinds of
8 considerations arise there: What basis do you make for
9 that cutoff?

10 One of the reasons that the numbers themselves
11 might be different in all these cases, at least we feel,
12 is that the cost-effective analysis which we would plan
13 to use very well could show differences. We would
14 suspect that to clean up an area, to take remedial
15 action -- we certainly have found this in the case of
16 mill tailings -- is going to be a much more expensive
17 job than it is to take an action in a preventive mode.
18 So it is making some type of cost-effective or cost
19 versus risk balancing, and you might have so much more
20 tremendous cost in the case where you're considering a
21 remedial action versus something like low level waste,
22 where you're trying to prevent something, that indeed
23 you might allow different exposures as cutoffs in these
24 two types of cases.

25 So we feel that we want to go through the

1 analysis, we want to look at the cost, we want to look
2 at the effect, and hopefully come up with an evaluation
3 of a level that just plumb doesn't warrant further
4 expenditure or control.

5 Now, in the paper I passed out there is a
6 section there on authorities that EPA has. I heard that
7 just covered in the paper I was listening to when I came
8 in. They are generally applicable radiation protection
9 standards. Just to summarize that, such standards could
10 establish numerical limits on the radiation exposure or
11 levels or concentration or quantities of radioactive
12 materials in the general environment outside the
13 boundaries of locations licensed for low level waste
14 disposal.

15 It's the same authority we used in setting 40
16 CFR 190. One perplexing part about the definition is,
17 as it reads in the Reorganization Act, when you look at
18 a low-level waste facility and you look at it after such
19 time as institutional control is deemed to no longer be
20 active, where is the boundary? That is one aspect that
21 we are trying to fold into our consideration, that
22 actually the boundary considerations may change as time
23 goes on and you may be looking at a different set of
24 boundary conditions.-

25

1 The second authority we could use to set a de
2 minimis is that of the Federal Radiation Council. At
3 the present time we haven't locked in on using either
4 one of those authorities. In fact, we might use
5 possibly both. As we have gotten into this, we are
6 certainly aware that the Radiation Policy Council made a
7 statement on setting de minimis, or at least one of
8 their committees made a statement on setting de minimis
9 for waste disposal.

10 To quote them, they said, "An overall generic
11 de minimis level is not a practical solution to a
12 portion of the waste management problem because without
13 knowing physical and chemical parameters of the waste
14 involved, it is difficult to establish pathways to
15 humans and resulting doses. Therefore, in order to
16 establish a generic de minimis level, extremely
17 conservative assumptions are dictated which are likely
18 to lead to levels that are so small that they have
19 little practical value in disposing of low activity
20 waste. As an alternative, the task force endorses the
21 approach of evaluating waste streams on a case-by-case
22 basis. ..."

23 We believe that considerations of specific
24 categories of waste streams and methods of disposal must
25 be part of the analysis and we are proceeding in that

1 manner. We are pursuing those kinds of analyses as we
2 go on with out effort. We are even quite clear that
3 there probably will be part of that analysis that ought
4 to be made in the licensing realm.

5 One of the things that is needed and we are
6 going to do is carry out negotiations and discussions
7 with the NRC as to where who does what ought to stop or
8 that line ought to be. I have been talking with Ross
9 Grunnel, who is the Low Level Waste Licensing Branch
10 chief now, and we are both very interested in pursuing
11 this and doing it jointly.

12 I think that my own consideration is that EPA
13 can develop a context or an umbrella that will provide a
14 lid for that source-by-source or case-by-case licensing
15 evaluation to be done. As to how we may express our low
16 level concern, there are several we have considered.

17 Probably a leading contender would be for an
18 annual individual exposure rate, which a cost-benefit
19 analysis has determined to not warrant further
20 reduction. This could also be expressed as a collective
21 population exposure. Any time you start doing that, I
22 think you run into real implementation problems. We
23 could express it in terms of concentrations or specific
24 activities of radionuclides or define mixtures that
25 could go into a disposal place. Again, I have a

1 question there as to whether that wouldn't be more
2 appropriate for the NRC to do. This is certainly
3 something we will be considering over the months ahead.

4 I have outlined in the paper some of the
5 technical analysis that we are going to do, and I don't
6 believe I will get into that. I know it is late in the
7 day for all of you. Let me just briefly say we are
8 going to do a cost-effectiveness analysis and a risk
9 assessment for disposal of various low level waste waste
10 streams, and we are going to do that for eight different
11 methodologies of disposing of low level radioactive
12 waste. This includes low level, shallow land burial,
13 improved shallow land burial, sanitary landfills such as
14 you have in the municipal sanitary landfill, and on down
15 to such things as hydrofracturing, deep well injection,
16 some type of engineered storage, eight different methods.

17 We plan to look at each of those in terms of
18 examining what would happen if we took various streams
19 that are presently identified by NRC, and there are 36
20 waste streams, and see what kind of risk, what kind of
21 cost effects you would have if you took them stream by
22 stream.

23 A more difficult problem and one we are really
24 struggling with and hope to work with both DOE and NRC
25 on is the matter of segregation of streams. I think in

1 that area, at least in the hard core nuclear industry,
2 is where our hope might lie. In the institutional
3 waste, why, we probably hope to be able to consider a
4 whole stream. When you get into the nuclear power
5 cycle, why, I think we are going to be in a mode where
6 we want to look at the segregation of streams. There is
7 really very little information on that. The only place
8 I am aware of where it is documented as being
9 successfully done has been with the Navy, and it took a
10 lot of tooth pulling and head pounding to force some of
11 their services into doing that.

12 So that is a real rough area that we are going
13 to be spending a good deal of time on, and it is that
14 area where we will need specific assistance as to where
15 those volumes could be reduced, as to where measurements
16 need to be made about those segregations, and I will
17 raise some problems on that in just a minute.

18 In looking at the sanitary landfill case,
19 where we are talking about either going to a sanitary
20 landfill or being incinerated first and then the ash
21 going to a sanitary landfill, we also look at the
22 trade-offs on transportation. As you reduce volume,
23 certainly you will be reducing transportation. On the
24 other hand, you are going to -- that stuff evidently
25 goes on to a low level waste site and you will be

1 increasing concentration of that because you are taking
2 out the lower levels of that. Whether that is going to
3 have any effect in terms of the NRC's Class A, B and C
4 -- in other words, will we be enforcing more material
5 into Class C by virtue of having taken out the diluting
6 uncontaminated trash -- that is a question to be
7 answered.

8 We have several uncertainties in terms of the
9 waste volume. In that area the institutional and
10 industrial waste probably are the greatest uncertainty
11 as to what those volumes will constitute. There are
12 several efforts going on that we are trying to get a
13 handle on that. DOE has contracted with the Conference
14 of Radiation State Program Control Directors to try on a
15 state-by-state basis what comes out at the generator
16 level, and that is going to be very useful but I am
17 afraid it will be too late in terms of what we want to
18 do in terms of a time schedule.

19 There are industrial data bases, one for the
20 Hanford site in Washington, that unfortunately is only
21 about seven or eight months old, that has a
22 barrel-by-barrel inventory. That is where most of the
23 institutional waste has been going over that six or
24 seven-month period. We are working with DOE to capture
25 that data base and put it into the DOE overall data

1 base, and we will have access to it.

2 The State of Massachusetts has made a survey
3 of their generator level low level waste. That is
4 another thing we can go to to try to get some better
5 feel. However, how to extrapolate from Massachusetts to
6 the United States of America is a problem that may be
7 very perplexing.

8 Anyway, through this evaluation, this
9 cost-effective analysis and these risk assessments,
10 which will consider both the risks of the sanitary
11 landfill and its associated incineration as well as the
12 licensed and regulated options for disposing of waste,
13 we hope to come up with some basis to make a judgment.
14 Because we consider this activity to be very important
15 and potentially a most meaningful thing in terms of
16 solving the problem with regard to low level waste that
17 EPA may be doing, we are looking at going at it in an
18 accelerated mode and actually slowing down the rest of
19 our development of the low level radioactive waste
20 standard so that we can throw those resources into doing
21 this activity and go ahead and get it out of the way and
22 go on the street with it and then come back and develop
23 the upper limit.

24 There are several considerations we must
25 resolve before we decide to do that. One will be

1 whether we have an adequate analysis to describe the
2 impact, both for the case of the population and
3 individual risk before we complete the analysis for the
4 overall standard. The other will be establishing the
5 level below regulatory concern, whether it will rule out
6 any viable options we should be considering for the
7 standard itself. Will the additional administrative
8 requirements in hearings and public interactions delay
9 the actual upper limit standard so far that it is
10 meaningless? We targetted May 1983 to make this
11 decision as to whether to go with an early-on
12 consideration of this level below regulatory concern.

13 The last area I wanted to get into and the one
14 that I think prompted some of the concerns or questions
15 that Dade raised in the first place is the reasons that
16 we are continuing vigorously to get with some skepticism
17 that a de minimis or regulatory cutoff as applied to
18 level waste disposal may not be a panacea that some
19 people consider it might be. You have got a very
20 limited data bank or history basis to look at. But what
21 we have seen gives us this skepticism.

22 One of the questions we raise is is there a
23 willingness on the part of the institutions and the
24 industry to do that segregation that would be necessary
25 to utilize a regulatory cutoff? Now, our information

1 base on this is limited. Probably the best example we
2 have to look at is when the NRC deregulated the
3 carbon-14 and the tritium associated with animal
4 carcasses and scintillation vials.

5 What we do know is that there are still people
6 sending animal carcasses and scintillation viles to low
7 level waste burial grounds rather than to sanitary
8 landfills and to hazardous waste sites. Now, I know
9 there are some reasons for that. There have been
10 problems with incompatibility between DOT regulations
11 and what they require to be labeling and what the NRC
12 has done. I know that when a truck rolls up to a
13 sanitary landfill with radioactive material on the side
14 of it, they may not be too thrilled at the sanitary
15 landfill to take it on or even at the hazardous waste
16 site.

17 It also turns out relative to the hazardous
18 waste site that even with all of the costs that you have
19 in a low level radioactive waste site, some of the
20 hazardous waste sites cost more. So for both of those
21 reasons, I can see that this may not be a complete
22 answering data base as to whether it will work or not,
23 but it does allow us some skepticism.

24 Another question we had is the willingness of
25 the operators, the institutions and the industry to take

1 the responsibility for possibly making an error. Not
2 only have the regulators in the past been accused, and
3 sometimes rightfully so, of being overly conservative,
4 but the industry people themselves have been deathly
5 scared of making an error and putting something out that
6 they should not have.

7 Now, how willing are they going to be to take
8 the chance to do that? Another one is how willing are
9 they going to be to face the municipality and its
10 operator of the landfill, its operator of a town
11 incinerator and suggest to them what they are doing?
12 Will those municipalities be willing to accept a
13 national EPA-NRC agreed upon level of below regulatory
14 concern?

15 We have in my own backyard or very close to my
16 own backyard a sanitary landfill that is now being put
17 in. From everything I can find out from our people who
18 are in land disposal of garbage, why, it is an
19 excellently designed facility removed from population
20 centers, and you wouldn't believe, or maybe you would
21 believe, being in the business you are in, the amount of
22 public uproar that facility has received and the demands
23 for liners to be put in the bottom and people laying
24 themselves down across the roads so the trucks can't
25 drive in, and nobody suggested putting any radioactive

1 or hazardous material there.

2 So, you know, what happens when you raise the
3 spectre of having radioactive waste placed in such
4 facilities. It might create an even greater issue, and
5 as the generator, I don't want to face that. I don't
6 know of any way to absolutely answer those questions. We
7 are going to try to get some feel for what they are.

8 Dave Harwich is locked in the back of the
9 room. It reminds me that Ross Garano and I were just
10 talking today. We plan to go to AIF and see if we can't
11 get some assistance from them in looking at the
12 segregation of waste streams and its practicality. We
13 are hoping that something can be worked out there.

14 MR. MOELLER: Very good, Floyd. We thank you.

15 Floyd has asked for specific comments from us
16 on the question as to whether -- well, he would like
17 general comments, but specifically he has asked that if
18 a regulatory cutoff were established for the low level
19 rad waste, should they express it in terms of a dose
20 limit or should they express it in terms of waste
21 concentration limits or quantities that can go in to the
22 disposal area?

23 I guess I am a little bit in a quandary as to
24 what to say. Do any of the members here have any idea?
25 Herb.

1 MR. PARKER: First, I would like to applaud
2 you not staying with the specific term "de minimis" for
3 semantic reasons that I might talk about later. You are
4 groping for an acceptable term all around, and I think
5 you haven't found one, if I read you right, Floyd, your
6 LAID proposal? We don't want rape waste in here yet,
7 but we have been trying to do the same thing. The
8 closest we came to it was a negligible dose level.

9 If someone could find a term like that that
10 was acceptable, then you could play it either way in
11 terms of what the Chairman asked for. You could say
12 quantities of radioactive materials reflecting
13 negligible dose levels under such and such conditions.

14 So I think the prime need is to find some
15 reasonably agreeable term, on the order of "indifference
16 level," "negligible dose level," put the best one on the
17 market and go with that, I would suggest.

18 MR. GALPIN: IAEA in the ocean waste disposal
19 area has gone so far as to set individual dose exposure
20 several years ago, which they called de mimimis. They
21 have been struggling for the last three or four years
22 with how do you implement that. I feel that it is
23 certainly something both agencies need to work on, and
24 together, on where the line gets drawn. I'm not sure.

25 MR. MOELLER: Jack Shapiro.

1 MR. SHAPIRO: The best way to see what to do
2 is to do it and see what happens. I think the
3 Massachusetts example so far is an excellent one to look
4 at. From our own experience, the minute you deregulate
5 it as the NRC deregulated scintillation vials, we sent
6 them out through our chemical waste disposal contractor,
7 who burns them locally, and everything has been
8 completely uneventful, which means that you are not
9 dealing with the technical problem at all. If there is
10 someone here who finds you can get mileage out of a
11 waste disposal problem, however de minimis you get, you
12 may be in trouble. If no one is concerned, then the
13 problem never appears. But the experience at
14 Massachusetts has been very, very good so far.

15 MR. GALPIN: Take a look at New York City.

16 MR. SHAPIRO: New York is different. Maybe
17 the air is so dirty in New York that you feel guilty
18 trying to put anything else into it. I think that is a
19 problem. I would be very, very careful about burning
20 anything in the middle of Boston. I think we might have
21 problems if we tried that. And yet if you go up to some
22 town that had an industrial area outside of
23 Boston -- Wait, erase that from the record.

24 [Laughter.]

25 I don't know just what the term is.

1 You just have to jump and hope things work out.

2 MR. GALPIN: We argue upon the head of an
3 analysis. One thing I didn't mention. We have TRW on
4 the Board as a contractor working with this -- it is the
5 first time we have been able to buy a body of that
6 magnitude or any proportion of such a body -- which is
7 working with us on the low level radioactive waste
8 area. We are trying to get them a little bit in bed,
9 you know, with the big boys like EG&G and others that
10 are dealing in this area.

11 MR. SHAPIRO: I think the most important task
12 is to try to get some perspective and equate radioactive
13 hazards with the other hazards. The economy does accept
14 waste disposal. It accepts burning of certain
15 materials. It accepts burning just in connection with
16 industrial operations. I think you have to realize that
17 if you are going to have an economy, you are going to
18 have to have waste, and if it is accepted in other
19 areas, it will be accepted perhaps with radioactive
20 materials if you can get the hazard impaired without
21 having an absolute risk. Maybe a relative risk would be
22 accepted.

23 MR. MOELLER: Ron Kathern.

24

25

1 MR. KATHERN: I think of your question on how
2 do you evaluate this on the basis of concentration or
3 dose or whatever, and I am struck with the Oregon
4 example, which I think we should all learn from. You
5 are laughing, so you are familiar with it. The state of
6 Oregon, in what had to be a fit of legislative wisdom or
7 passion or whatever, defined radioactive waste as
8 anything that contained radioactivity, and these could
9 not be disposed of in the state of Oregon.

10 Of course, that was a little difficult on the
11 undertakers, because human bodies, of course, contain
12 radioactive waste.

13 There appears to be -- I think Herb made the
14 point very well, perhaps inadvertently, Herb. There
15 appears to be a psychology associated with the term
16 "waste" and "radioactive," and put together. I would
17 like to suggest that perhaps the best approach might be
18 on the basis of concentration rather than dose or dose
19 equivalent if you want to go that route, because I think
20 that concentration is very much simpler to measure, very
21 much simpler to define, and it could eliminate if set
22 appropriately, could eliminate natural, I won't say
23 normal natural levels of radioactivity as opposed to
24 technologically enhanced things or perhaps radioactive
25 sources, so that's my sources, o-a-r-s.

1 MR. GALPIN: Somebody is going to have to set
2 concentration levels just as an implementing procedure.
3 Even if we, EPA, doesn't, NRC or somebody is going to
4 have to do it to make the thing work.

5 MR. KATHERN: When we start playing around
6 with doses, it seems we go through a big mathematical
7 exercise that ends up in the implication that we can
8 actually calculate these to insignificant figures, and I
9 doubt seriously that we can do it to even one
10 significant feature.

11 MR. SHAPIRO: I think again you go back to the
12 concentrations in the areas.

13 MR. KATHERN: If you set them appropriately,
14 you would have categories like alpha emitting and beta
15 emitting, so it would be independent of whatever
16 nuclides were in there. You might exclude tritium,
17 because obviously tritium is a different state of
18 affairs, but you could have, say, one concentration
19 value for alpha emitters and one for beta emitters.

20 MR. GALPIN: That's very difficult. You would
21 almost have to go isotope by isotope, like Part 20
22 tables do.

23 MR. AXTMANN: Which is what a lot --

24 MR. KATHERN: You could probably categorize
25 them into a half a dozen or so categories.

1 MR. GALPIN: That could be.

2 MR. SHAPIRO: I think the liquid scintillation
3 is a real triumph for the regulatory process. There,
4 you went with concentrations, and it has worked very
5 well.

6 MR. KATHERN: I might point out that the
7 liquid scintillation things are actually a category in
8 and of themselves. What are you dealing with mostly?
9 Carbon 14 and tritium. So they are both low energy beta
10 emitters, and there is perhaps a precedent in that is
11 the first cut.

12 MR. GALPIN: I commend NRC for taking that
13 step.

14 MR. AXTMANN: That would work for general
15 waste.

16 MR. MOELLER: Frank Arsenault has a comment.

17 MR. ARSENAULT: On the question -- I don't
18 have the answer, but I would like to make a few
19 observations about it. When you ask which way to frame
20 the level, the standard, that is the solution, but I am
21 not sure we have yet formulated the problem correctly.
22 If we use the term, and I want to come back to something
23 you said and ask a question about this, but if we use
24 the term below the level of regulatory concern, the
25 first question is, what is the nature of the regulatory

1 concern.

2 If it is public risk or individual risk or
3 whatever it is, you can find within that some level at
4 which you say, below that I am not concerned. Now,
5 having established that, and if it is risk, you express
6 it, you then translate that into whatever surrogate you
7 will find practical, but to lead right to a
8 determination of whether you use concentration or dose
9 or what level without asking in what way they are
10 related to the nature of the concern that we are below
11 is in my view a mistake we have been making for many,
12 many years, and the type of intuitive jump that has
13 caused us a great deal of difficulty in dealing with the
14 public.

15 The question I wanted to ask was, earlier you
16 indicated the trouble you have with the phrase de
17 minimis. You said you are terming what you are going
18 for is a level below regulatory concern. Well, below
19 concern is not clear no matter what you are talking
20 about. But then you talk about the possibility of
21 deriving the benefits by doing a cost benefit analysis.

22 That, it seems to me, comes very close to make
23 your level below level of regulatory concern an ALARA
24 response.

25 Joanna mentioned that if you are working at a

1 de minimis level or ALARA level, you are at a de minimis
2 level, but the opposite is not true. I can see where a
3 cost benefit analysis can be used to derive ALARA, but
4 not how it could be applied to establish de minimis. I
5 will use my term.

6 MR. GALPIN: It would be a reverse cost
7 benefit if you would, or the inverse. You would be
8 looking at an evaluation of levels where it clearly
9 didn't even warrant the cost that might be called for
10 within an ALARA band to be considered or applied. There
11 would be an evaluation that absolutely not one nickel
12 would be warranted below that level, as in contrast to,
13 say, when we set up something like 40 CFR 190, where you
14 were looking at a broad span of overall what it would
15 take in terms of engineering controls to bring something
16 down to a level.

17 One concern I have with the term de minimis
18 for another reason other than what I mentioned before
19 is, I'm afraid if you tag that number on or that value
20 issue onto something, people will begin to think that
21 anything above that is of concern. That could also now
22 happen with the value we're talking about, the level
23 below regulatory concern, except that you have that
24 advantage that saying something is below regulatory
25 concern, it's all right to say that things above that

1 are to the extent that ALARA ought to be applied.

2 I certainly don't claim to have the magic
3 answers or vernacular at this stage.

4 MR. MOELLER: Floyd, you mentioned comparing,
5 you know, rad waste to other types of waste, meaning
6 toxic chemicals and so forth. Within EPA, are you
7 working with your toxic chemical people? Are they
8 looking at these same types of questions?

9 MR. GALPIN: We are probably closer to the
10 thinking processes and rationale of the NRC low level
11 people as we are our own toxic people. They are putting
12 things like putting liners in hazardous waste trenches
13 and trench drains and calling for continuous pumping,
14 and I asked the question of them, how long do you plan
15 to continue pumping, and how do you know when you are
16 done, and I don't get good answers to that kind of
17 question, and I don't think we can afford that kind of
18 obligation to potential perpetual care in the nuclear
19 area, and I don't think that they know that they are
20 doing that.

21 MR. MOELLER: I agree. Well, thank you for a
22 very interesting presentation. We will move on, then,
23 to the next item, where Dr. Joyce Davis will talk to us
24 about the feasibility and methodology for establishing
25 de minimis levels, and Joyce is with General Physics

1 Corporation.

2 MS. DAVIS: Good afternoon, ladies and
3 gentlemen. I am very happy to be here.

4 I guess I am here because of a project I am
5 connected with at the Edison Electric Institute. As Mr.
6 Galpin said, we have been giving talks around. The last
7 one was at the AIF meeting in New Orleans, where this
8 topic of de minimis had a half-day on the program.

9 I am using the word de minimis in its very
10 broad sense, and I will try not to use it, but I am
11 afraid I will from now on.

12 What I am really talking about is the concept
13 of a regulatory cutoff. The concept I am talking about
14 is a little broader, for example, broader than the
15 concept that Ms. Becker talked about, the legal de
16 minimis. It is broader even than radiation regulation.
17 It is really as broad as the whole field of regulation,
18 but I will concentrate on how it applies to the
19 radiation area.

20 This started about a year ago. Sol Harris was
21 then at the Edison Electric Institute, and for several
22 years had been collecting information on the concept of
23 de minimis. He talked to people about it in the
24 radiation protection community. The idea of a dose of
25 no concern has been floating around for quite a few

1 years.

2 He suggested that a short study be done by EEI
3 to see what the feasibility of the concept was and where
4 it stood. So, I was the consultant who prepared the
5 report. It was just a short two-month review of the
6 literature. Because I also have a background in law, I
7 looked at some of the legal aspects as well as the
8 technical part.

9 As a result, we came up with a feasibility
10 study that I believe has been distributed to everybody.
11 It's a General Physics report that is feasibility of --
12 Today I am really talking about some of the ideas in
13 that report, some of the things that have happened since
14 then in the EEI program. I prepared a little outline
15 which I also guess was also distributed just describing
16 some of the things I will try to get to talking about
17 today. I may not get to all of them, but most of the
18 things are discussed in the feasibility report.

19 First, I wanted to start out talking about the
20 full de minimis concept. First of all, as Ms. Becker
21 has very ably presented earlier, there is a legal
22 concept of de minimis, something that is negligible. I
23 found that in talking about this idea and applying it to
24 radiation or anything, lawyers really understand it
25 better than the technical people because they have

1 worked with it. The courts are very familiar with the
2 concept, and she mentioned some of the cases. There is
3 a Supreme Court case, benzine case, which I have in my
4 paper, where in a concurrence Justice Burger cited an
5 appeals court case that talked about de minimis. He
6 even gave some limits on where the area of regulatory
7 concern should cut off as far as risk is concerned.

8 This was in the benzine and OSHA case, but he
9 said somewhere between a risk of one in 1,000 and one in
10 a billion an agency should be able to do a cutoff. That
11 is a very broad range, of course. He used something
12 like the regular correlation, the linear correlation,
13 something between ten rem and less than 100th of a
14 millirem. So, somewhere in there someone could draw a
15 line, and actually anywhere in there it's possible.

16 So, that brings us to the regulatory concept
17 of below regulatory concern. The courts recognize de
18 minimis, and they recognize that regulatory agencies can
19 cut off their regulation, that the purpose of regulation
20 is to achieve some end, and it is necessary in the
21 practical world to cut off where you regulate at some
22 point when you are not having much of an effect, even
23 though theoretically there may be an effect out there.

24 That brings us to another concept that gets
25 involved in the negligible risk. Again in the nuclear

1 area, this has been floating around for many years.
2 People have compared risks to many things, acceptable
3 risks, negligible risk, and done it on a comparative
4 basis, so that works its way into this de minimis idea.

5 Finally, there is this concept of radiation
6 doses of no concern which the radiation people have been
7 talking about for a while. Putting this together in my
8 report, I sort of divided it into the scientific and
9 legal approaches. The de minimis program of the Edison
10 Electric Institute, after we did the initial feasibility
11 study, the next thing, early last year I prepared a few
12 documents to illustrate what a radiation cutoff policy
13 statement would look like, for example, if the President
14 would want to give one, and also an implementing
15 statement by an agency, what that would look like, and
16 perhaps some possible criteria.

17 Now, I think the idea is that first you have a
18 policy, then you have guidelines for how you want to
19 implement that policy, and based on that you develop
20 criteria and methodologies, and as a result of using
21 those criteria and methodologies, you would be able to
22 derive their regulatory cutoff level each of the
23 different places where you want the regulatory cutoff
24 level.

25 Then the next thing we did, we sent out a

1 questionnaire to all of the nuclear utilities, the
2 utilities that have nuclear plants, asking for their
3 opinion on whether this was a concept that they felt
4 would be useful, feasible, and try to get from them some
5 indication of how it would be useful and what benefits
6 they see. Also, whether they had any what we called
7 horror stories of cases where things either went right
8 because somebody came up with a cutoff or they went
9 wrong because there was no cutoff limit set. And we got
10 some of those back. In fact, I am giving a paper next
11 week at ANS at one of their reactor sessions on the
12 results of that survey.

13 It turned out that most people think it's a
14 good idea, but a lot of people think it will never get
15 through. But we did get some good information on it and
16 a few horror stories.

17 Currently, we are talking about the concept.
18 I commented personally on the de minimis aspects of the
19 Part 20 regulations, and I have given out a copy of
20 that. We have been talking to people in the regulatory
21 agencies and the industry trying to develop a feeling
22 for where the concept is going and really what is needed
23 to support it. It was decided, for example, that it
24 might come up in the Part 20 rulemaking, and we intend
25 to do that in the future. EEI is still supporting this

1 project, and is using my services to continue working on
2 this subject.

3 All right. The nature of a regulatory cutoff
4 policy for low level radiation doses. I said that the
5 first thing is, you have a policy statement. We
6 originally thought it would be wonderful to get a policy
7 statement from the President, go right to the top and
8 have a statement, that actually the most general
9 statement would be something that says, all regulations
10 should have a low cutoff. All regulations for
11 everything ought to have a lower cutoff. That really
12 makes sense, and I think it would be nice if that
13 happened.

14 But we are not putting all our eggs in one
15 basket. We are also working with the agencies that are
16 developing regulations to try to develop it on a local
17 level, for example in Part 20. So, if you were doing it
18 from the policy level down, you would have a policy
19 statement. Based on that, you develop guidance for
20 implementation. For example, that is where you decide
21 what it is that is negligible when it is of no
22 regulatory concern. And you decide what you are going
23 to use as the basis.

24 For example, are you going to use the concept
25 of risk and say it's a negligible risk to an

1 individual? Are you going to use the concept of
2 comparison to something else like background? That
3 really has to be developed before you work out the
4 individual levels. Then you can develop criteria based
5 on that for setting the de minimis levels.

6 For example, if you decide that it's
7 comparison to background that you want to use as your
8 basis, then you would in your criteria set up what
9 measure of background you are going to use. For
10 example, if you are going to use a standard deviation of
11 the background averaged over a population, or something
12 like that. And then you would have to develop
13 methodologies for setting particular cutoff levels.

14 Now, that is working down from the top. It
15 may be that the best way rather than trying to work from
16 the top is to come in from an intermediate level where
17 there is a chance to do something, for example, as the
18 Part 20 rulemaking, to come in sort of on the guidance
19 and criteria level and develop some good guidance and
20 criteria for that particular rulemaking which then could
21 be carried over to other places.

22 In this report that I have done, I describe
23 some of the ways people have suggested to set cutoff
24 levels. The first part I call scientific approaches.
25 In the report, for the scientific thing I used de

1 minimis. I said, setting up a hypothetical case, a de
2 minimis dose is one that a reasonable expert in
3 radiological health would not consider of concern for
4 his own or his family's health and day to day life.

5 Other people have postulated, for example, the
6 dose that a person wouldn't worry about, a person would
7 find of no concern. The trouble is that people aren't
8 really aware. The ordinary person isn't aware of
9 background or its variability or anything like that. So
10 I think that the scientific level, what I call de
11 minimis or negligible dose really has to be set in
12 relation to experts.

13 In the report I list some of the things the
14 experts have suggested. Dr. Eisenbud gave a paper
15 several years ago at the NRCPC conference where he
16 discussed some of these possibilities. He talked about,
17 for example, the practical threshold of latency based on
18 the work of Dr. Evans with the radium dial painters
19 where it appeared that eventually the latent period got
20 so long at the lowest doses that the cancer wouldn't
21 occur during the person's lifetime, so therefore you had
22 a practical threshold.

23 He said it would be nice if we could get
24 enough radiobiological information on that to actually
25 use that kind of threshold, and that is the nearest

1 thing we have to a biological threshold, something that
2 would be scientific. For most things, we really don't
3 have that much information yet. Dr. Eisenbud among
4 other things recommended a lot of effort be put into
5 that area of research.

6 Other effects -- there is another way to get a
7 practical threshold which I don't know if anybody
8 recommended, but just logically I came up with it. If
9 you're thinking about dose to a large number of people,
10 you can get a practical threshold by saying there shall
11 be less than one health effect in this population, and
12 that is sort of a cutoff thing. Once you get to below
13 one, zero. That is also not too useful unless for a
14 specific case where you are talking about a specific
15 population.

16 So, if you can't derive a threshold, you are
17 sort of stuck with comparative approaches. The kind of
18 comparative approaches I included were things like
19 non-detectability of the radiation level, or
20 non-detectability of health effects. In other words, if
21 it doesn't turn up in the epidemiological study, or one
22 which also relates to non-detectability of the
23 background risk.

24 Now, Dr. Whipple, for example, proposed that
25 kind of criteria. He said he plotted the effect against

1 -- compared to the background risk of cancer in the
2 United States with its standard deviation, which is
3 quite wide, and said, if you are within that plus or
4 minus standard deviation, then that would be a radiation
5 level that should be of no concern.

6 One problem with that is, he came out with
7 quite large levels. He came out with 500 millirem per
8 year for beta gamma radiation, which is in effect saying
9 if you look at it that way the upper limit is de
10 minimis, and I don't know if people are ready to go that
11 far, but using the numbers he used, that's where he gets.

12 Another approach is to look at background
13 radiation. I have some slides but I don't know whether
14 it's worthwhile showing them. I gave out the list.

15 MR. MOELLER: These are in your paper?

16 MS. DAVIS: Yes, most of them are from the
17 paper. I guess I ought to backtrack to catch up with
18 the slides. This one I just put together. This is
19 something like what Ms. Becker was talking about, the
20 hierarchy of levels that we're talking about, to put
21 this thing in perspective. I have on the left side the
22 characterization of the risk, and on the right side the
23 characterization of the dose rate.

24 It is not meant to be to scale. It is just
25 meant to try to put things in an order. There are no

1 numbers connected with it. It is decreasing risk and
2 decreasing regulatory concern as you go down the chart,
3 and down here, here is zero, theoretical absence of
4 radiation, since in this world we don't get the absence
5 of radiation. Zero dose. I put zero question mark
6 risk, because we really don't know what the risk at zero
7 is. There are people that say that you're better off
8 with some radiation than with none. So some identified
9 value of risk, probably close to zero down at zero
10 dose. If you are down at the background level, you have
11 zero incremental risk over background zero incremental
12 dose.

13 Up here is some level that is hazardous, and
14 naturally this is all in the area of regulatory
15 concern. Here is the ordinary limit. That is
16 permissible dose and under the Atomic Energy Act, the
17 inference is that that is no undue risk. In exceptional
18 cases, the Commission can grant exceptions from the
19 regulations, and then there are emergency things. Where
20 you might be up to a somewhat higher level that's an
21 allowable risk and a permissible dose in an exceptional
22 case. Somewhat below that we might have an
23 administrative limit or action level. Part 20 added
24 that action level dose the new Part 20 proposed.

25 Then, down here in this region between the

1 limit and down here (indicating) is the ALARA region,
2 and that is the ALARA level for a specific case. That
3 can be anywhere between here and down to this exemption
4 level, and that is the risk that is as low as reasonably
5 achievable. The exemption level which Ms. Becker
6 mentioned are these levels that NRC sets on a cost
7 benefit basis, which can be looked on as sort of a
8 generic ALARA.

9 I would call that a minimum practical dose and
10 a minimum practical risk. So your ALARA can be anywhere
11 in this level.

12 Now, there haven't been exemption levels set
13 for everything, so in some cases these levels exist for
14 some particular type of limit; for some they don't.
15 Anyway, below that somewhere is our friend the de
16 minimis level: negligible dose, negligible risk. If
17 there is no exemption level, it acts as a floor for
18 ALARA. Otherwise, the exemption limit is the floor of
19 ALARA. This ALARA, depending on specific circumstances,
20 could be anywhere around here, but it never goes below
21 the de minimis level. That is because, by definition,
22 there is no more benefit in going below de minimis.

23 (Slide.)

24 Ms. Becker said all that. I am just showing
25 the picture. I have listed some of the people who have

1 made suggestions about de minimis levels or doses, the
2 scientific type doses of no concern. Dr. Eisenbud gave
3 a level below which exposures are ignored, and he -- in
4 his paper he didn't recommend any particular level, but
5 in the discussions he made it looked as if it would be
6 something whole body external between 20 and 100
7 millirems per year would be a level that he thought was
8 of no concern.

9 Dr. Rossi had a letter in the Health Physics
10 Journal a few years ago saying that there should be a
11 cutoff for ALARA because he can keep putting wet sheets
12 in front of his source forever, and someone can tell him
13 to stop and he can decide that it should have been just
14 one more. So he suggested something like 30 percent of
15 background would be an appropriate number for that.

16 Dr. Whipple, who I mentioned, his criterion
17 was no observable effects on health, and he got, using
18 the cancer statistics, got 500 millirem per year for low
19 level radiation.

20 Drs. Webb and McLean in England looked at this
21 problem, and they got -- they determined the level that
22 an individual does not consider in decision-making.
23 They really based it on risk levels in correlating the
24 dose, and they came up with ten millirem per year to an
25 organ and to the whole body. Then they went beyond

1 which was their scientific value negligible dose, and
2 then they said, we want to apply this to a regulation,
3 make it a regulatory cutoff for ALARA, where under the
4 ICRP and so forth for each practice you want to maximize
5 it to ALARA.

6 This came down. They said, well, let's take
7 100th of that, assuming somebody could do 100 practices
8 in a year and make it a tenth of a millirem per year for
9 a cutoff like that. Dr. Weinberg and Adler had a chart
10 that was presented in the health physics data on
11 variation of background, and they calculated the
12 standard deviation of state by state background,
13 weighted average background, state by state weighted
14 with background. They came up with a standard deviation
15 of 20 millirems a year. They have proposed that as a
16 low dose radiation standard for individuals in the
17 population. They didn't really talk about de minimis or
18 negligible dose, but the way they derived it, and other
19 people have used it in that sense, is that would be an
20 approach to getting a de minimis or negligible dose
21 level.

22 NCRP, and I talked to Dr. Kasserett last year
23 when I was writing the report. At that time his
24 Committee 1 was debating the possibility of establishing
25 a de minimis dose. It has been reported in the NCRP.

1 The year before they were talking about ten millirem a
2 year. I don't know whether that stands today. Some of
3 you probably know more than I do.

4 ICRP doesn't, at least in the publications I
5 reviewed, didn't express the concept of de minimis
6 negligible dose per se, but they do have the statement
7 that says, we are doing a dose effect calculation impact
8 assessment. You can stop when -- to go any further
9 would not change your results by more than a factor of
10 two or three, so that's a way to cut things off. It's a
11 different kind of cutoff, but it's the same idea that
12 you can cut things off that way.

13 MR. MOELLER: Do you have any rough idea as to
14 what dose would be associated with that for the ICRP?

15 MS. DAVIS: It really depends on the
16 distribution of what you are looking at. It depends on
17 -- I think that's a purely relative one.

18 MR. MOELLER: Ron Kathern?

19 MR. KATHERN: Kathern. I just wanted to ask
20 if you looked at the DOE ALARA guide which suggests that
21 one millirem is an ALARA dose, the ALARA threshold, if
22 you will.

23 MS. DAVIS: I haven't seen that specifically.

24 MR. KATHERN: Based on the work of Roger
25 largely 1 percent of the background level in the United

1 States and also the fact that that gives a somewhere
2 around ⁻⁶ 10 probability of a health effect, that's a
3 little lower than these other scientifically based
4 studies.

5 MS. DAVIS: Well, yes, that's what I wanted to
6 get to, the next thing. These are the kind of numbers
7 that the scientific community sort of throws around.
8 When you get to the regulatory, when you get to applying
9 it in the regulatory context, you probably don't want to
10 use -- you may not want to use exactly the same number.
11 You want to take into account what the scientific
12 community thinks, but they are really talking about an
13 actual exposure to an actual person, whereas in the
14 regulatory concept you are talking about predictions,
15 evaluations, and safety factors, you are talking about
16 things where you have to -- you don't know what the
17 uncertainties are, so in the regulatory context you may
18 have to step back from, say, as far as I'm concerned, I
19 would think something like 50 millirem is of no concern
20 to me.

21 But I might not necessarily say that I think
22 therefore that the ALARA cutoff for everybody should be
23 50 millirem. The regulatory people have to apply
24 additional criteria to derive their particular
25 regulatory level based on the particular case in

1 question. Some things, for example, some things that
2 will only happen once in a lifetime will be evaluated
3 differently than if you get the dose year after year.

4 That's why I say this regulatory concept
5 should really be a set of criteria and methodologies and
6 not just a level, such and such is the de minimis dose.
7 I don't think it should be approached that way. Among
8 the ways you can derive it from a regulatory approach,
9 derive it from current standards, in the report I have a
10 whole list of what some of the standards are that could
11 be used as a basis. For example, do you want to use
12 something like the Appendix I levels, or the levels, the
13 EPA environmental levels, and some of these other levels.

14 Just take somebody's current number. For
15 example, you could define radioactivity. Maybe you
16 should start off adopting the Department of
17 Transportation definition of radioactivity if you wanted
18 to get a quick level. You can derive it from current
19 standards. You can derive it from the safety goal, a
20 safety goal or some quantitative risk guidance value.

21 One thing the President could do or the
22 Department of Health or the NRC or somebody could set a
23 number saying a risk of such and such is negligible for
24 all uses. Then you could derive your de minimis dose
25 level from that kind of number. The NRC is proposing a

1 safety goal. In my comments on the safety goal
2 separately, I pointed out I think that what they
3 proposed is really a de minimis level, because in effect
4 they said, for accidents, this is a negligible risk.

5 So, that same kind of level then, maybe that
6 should be the same level for a negligible risk from
7 radiation in general, or maybe it should be some
8 fraction of that, or bear some other relation to it, but
9 maybe there should be a relationship, and it should be a
10 reasonable relationship.

11 MR. MOELLER: Excuse me. I thought on that
12 though that the Commissioners in their footnotes were
13 quite clear in stating that the death of even one person
14 is unacceptable, and so forth, and that these goals were
15 simply the degree of safety that they would require, not
16 saying additional safety is not necessary, but it is
17 simply what would be required by regulatory
18 requirements.

19 MS. DAVIS: Well, depending on whatever form
20 the thing takes from it, you should be able to get some
21 indication of what risk is acceptable for this kind of
22 thing, whether it's this number or some other related
23 number.

24 MR. MOELLER: I agree.

25 MS. DAVIS: I am just giving you the kind of

1 guidance you might be able to use. You might be able to
2 derive something from the expert opinions that we're
3 talking about from the experts getting together and
4 helping out. You may be able to derive it from other
5 indications of acceptable risk through the studies that
6 have been done on what people deem acceptable, and so
7 forth.

8 You could also limit it to less than one
9 projected effect, have some level that, for example, the
10 whole population of the United States, there would be
11 less than one death if the whole population of the
12 United States were affected, and then you could also do
13 it by -- for something like what Ms. Becker called
14 exemption levels. You do a cost benefit balancing and
15 set levels for regulatory cutoff that might be somewhat
16 above an absolute de minimis level, but nevertheless
17 would give you a regulatory cutoff.

18 I list here, and we go through with the things
19 that are currently going on, Part 20, Part 61, where de
20 minimis may or may not be involved in the safety goal,
21 the EPA entry criteria, and also state regulation.

22 I want to mention that we spoke to the state
23 radiation program people. The states really need
24 guidance in this area. There is no guidance for them,
25 and they are faced with these kinds of decisions, just

1 like the NRC people in the regions are faced with having
2 to make these kinds of decisions in the absence of
3 guidance.

4 I spoke with someone who was involved in the
5 decommissioning of cyclotron. That is something the
6 state was responsible for. It was very difficult for
7 them to come up with criteria. The problem was, there
8 was a lot of copper that was very valuable, and mostly
9 not radioactive, but parts of it had been exposed enough
10 so parts of it were very hot. Most of it was not. And,
11 of course, there was an intermediate level, and they
12 wanted to be able to sell the copper as scrap, the part
13 that was acceptable as scrap, and there was no guidance
14 on that.

15 The health physicist and the state finally got
16 together and set up a county system, and agreed that if
17 the piece of copper showed twice as less background than
18 background in that particular arrangement, that could be
19 released, but that was developed totally ad hoc. There
20 is no guidance for that kind of thing.

21 So, something developed on the federal level I
22 am sure would be immediately adopted by the states,
23 because they need something like that.

24 Other areas where this is useful is setting
25 regulatory priorities. Even if this comes out and hits

1 the licensees, if things like that are used by the
2 regulators themselves, it may prove very useful. The
3 decommissioning area was mentioned. Other areas that it
4 may be used in can serve as a cutoff for determining how
5 wide an area you have to consider in deciding whose
6 interests might be affected as to whether they can be
7 let into the licensing cases. They might be put into
8 the compensation cases, both the ones against the
9 government and for any private case.

10 It may not be totally dispositive, but if
11 there were a level that was recognized as de minimis,
12 the courts would look very carefully at that in deciding
13 whether or not to accept that, and say, these levels are
14 de minimis, and clearly someone can't be liable for
15 exposure at that level.

16 I list some of the problems and I discuss them
17 in the report. The first I call opposition of
18 anti-radiation programs. There are people who are for
19 one reason or another afraid of radiation and opposed to
20 any kind of change in the regulations that would appear
21 to be a weakening of the regulation. I think that when
22 this de minimis idea gets into the rulemaking and the
23 regulatory arena, that certainly there will have to be
24 very good backup by the people who are proposing it, and
25 they will have to have a good case and a good, clear

1 explanation to try to have people understand that it is
2 a reasonable approach and that it really is protecting
3 them because it's putting the resources of the agencies
4 on the things that they really -- paying attention to
5 the things they really should pay attention to.

6 Regulatory ratcheting, that is my shorthand. I
7 have talked to people who now believe that the linear
8 non-threshold theory was handed down by God and cannot
9 be violated in any way, and that this would, by drawing
10 any line, you are being arbitrary. It is true you are
11 being arbitrary. I think that in the world, in the real
12 world, particularly in the legal world, one has to draw
13 lines at some point, and in the sense that on the one
14 side it's yes and the other side it's no is arbitrary,
15 but they can still have a rational basis, but that is
16 something that proponents of a cutoff policy are going
17 to have to counter.

18 Then there is the problem, once a policy is in
19 effect, there is a problem of what I call regulatory
20 ratcheting. This goes two ways. One is the agency
21 tending to accept the idea that, well, since this level
22 is certainly okay, the de minimis level, why don't you
23 go down to that level, and in effect lowering the limit
24 so that the limit and the de minimis level come
25 together.

1 The other problem is, as Ms. Becker mentioned,
2 the effect of interest groups trying to ratchet the
3 agency to do the same thing, and I think those are just
4 things that have to be guarded against, and both the
5 agency and the people involved have to very carefully
6 spell out what this cutoff level means, and that is not
7 necessarily a limit. Then, the problem, I think, the
8 logical and technical problem involved in this, which I
9 don't think -- in most cases doesn't turn out to be a
10 real problem, but it is very difficult to counter
11 theoretically, I guess it is impossible to counter, and
12 that is the idea that you can accumulate -- if you
13 accumulate enough de minimis doses or concentrations or
14 quantities, eventually you are going to reach some
15 significant level.

16 Part of this, the cure for that, I think, is
17 this hierarchy of levels where the agency, when they set
18 a regulatory cutoff, look to how it's going to be used
19 to make sure that it is not going to be -- there is not
20 going to be a high probability of accumulation to
21 significant levels.

22 The other thing is that because these proposed
23 levels are generally relatively small, this is not the
24 kind of thing where overnight the background is going to
25 double. The thing is, I think the answer to that is

1 vigilance. The EPA and the NRC have to monitor
2 backgrounds. We have to monitor what people are doing,
3 and certainly if the background in the United States all
4 of a sudden started increasing so that you saw a 10 or a
5 20 percent increase, you go back and re-examine your
6 policy and make sure that the de minimis is not getting
7 out of control.

8 But that is a very hard thing. Logically, you
9 cannot refute that. If you keep adding little things,
10 eventually you will have a lot, but if you look at it in
11 the real world context where one licensee can affect
12 everybody in the country, and the background is varying,
13 so a person can't really control what he's getting,
14 these numbers should be such that they are less than
15 background.

16 The benefits, I listed public assurance.
17 That's a question mark. If it's done the right way, I
18 think it is helpful for the public to know that there
19 are levels that the regulatory agency considers of no
20 regulatory concern, and there are levels that
21 radiological scientists consider of no threat to their
22 health and their family's health.

23 If this could be presented in the right way, I
24 think it could be beneficial to people and would
25 increase understanding. If it is based on background, I

1 think it is particularly helpful because people are not
2 aware of background, and it would be nice to show them a
3 way that it does exist and explain the relationship of
4 those levels to this natural stuff.

5 Economic savings. Some of the horror stories
6 have had to do with the shipment of practically
7 non-radioactive materials to radioactive waste sites
8 because they couldn't be -- they were licensed material
9 and they weren't able to -- they weren't able to get
10 them out from under, so \$100,000 was spent shipping the
11 stuff to waste sites, and they were utilizing some of
12 the scarce space at the waste sites with various lowly
13 contaminated stuff.

14 There was also savings in regulators' time and
15 energy. That is optimum use of resources. The time
16 that is spent on reviewing things that are not of
17 importance to health could be spent and the effort could
18 be spent on things that are. If you look at -- I want
19 to go back and look at some of the past calculations.
20 If you look at calculations, for example, of the total
21 dose from Three Mile Island or a lot of these
22 probabilistic risk assessments that are now being done,
23 an awful lot of those gigantic numbers of cancers coming
24 out are coming from the tail of the distribution.
25 People are getting 100th of a millirem, but there are

-9

1 millions of them, or they are getting 10 , but it is
2 integrated over 250 million years, and you start getting
3 a body count.

4 And a cutoff on that would save a lot of
5 effort, and it would also save a lot of misleading of
6 people who don't understand that. I think it would also
7 make the people who are doing it feel better, because
8 people who do things like this know, the technical
9 people know that it is not a real -- they are not really
10 solving the real problem when they are doing these kinds
11 of calculations.

12 Another benefit I just put in, the idea of
13 deregulation, you know, nowadays we are supposed to be
14 the right guys to have less government regulation and
15 free people from the yoke of government constraints.
16 This is one area. Certainly we are not going to
17 deregulate nuclear energy. The fission process and so
18 forth are inherently dangerous. But it is certainly
19 reasonable to deregulate the parts that are not
20 hazardous, and that is the approach that we think, at
21 least I am speaking for EEI at the moment -- EEI has
22 decided to go ahead and continue to support this kind of
23 approach.

24 As I said, I gave out the copies of that
25 report, and I would appreciate if anybody has any

1 comments. I would love to get them, particularly if you
2 know of any horror stories or any references where these
3 kind of levels have been talked about, and we could sort
4 of update that report and maybe have it as backup when
5 the de minimis comes up in rulemaking.

6 MR. MOELLER: Thank you.

7 MR. PARKER: Dr. Davis, let me compliment you
8 on an excellent paper. I think it is by far the best I
9 have heard. At the same time, let me bring you up to
10 date on the NCRP position to the extent I can without
11 violating committee confidences.

12 I think it is sure that the NCRP will not use
13 the term de minimis. That is a semantic issue that was
14 presented at the Denver meeting, and they wisely
15 listened. They will be seeking some substitute for the
16 same concept, negligible dose level, negligible risk,
17 not yet determined. The level, I think you will
18 accidentally find in part of your elegant conversation on
19 Page 3 of your document, and I do hope if you have not
20 already done so you will send a copy of both of these to
21 Dr. Kasserett.

22 MS. DAVIS: I actually have already done
23 that. I spoke to him.

24 MR. MOELLER: A question I have, and this
25 again, I'm sure, reveals my ignorance, but I don't know

1 how to grasp or to handle this particular problem that I
2 have with the concept. That is, for radiation there is
3 a natural background, so you have that situation. Well,
4 for food and carcinogens in food, I realize obviously
5 there are naturally occurring carcinogenic agents in
6 food, but I don't know or I am fairly certain with no
7 facts that the natural background level of carcinogens
8 in food is not as high relative to the de minimis level
9 for carcinogens in school.

10 How do you handle that?

11 MS. DAVIS: I think radiation in a way is, if
12 I want to use a little Latin, sui generis. It is sort
13 of one of a kind among these things, that it has this
14 relatively large natural background. I think for other
15 things, some things have no natural background at all.
16 They are totally manmade. I think you have to use
17 another approach if you are going to have an overall
18 policy that includes other things as well as irradiation.

19 You may have to use some kind of a comparative
20 risk approach estimation or detectability. I didn't
21 talk much about detectability. That could be somewhat
22 used in irradiation. It can also be used in some of
23 these other things.

24 Also, these things aren't really mutually
25 exclusive. Actually, with radiation, whether you use

1 comparison to background or risk, the kind of numbers
2 people are talking about, you always come out in the
3 region, say, between one and 100.

4 MR. MOELLER: Yes.

5 MS. DAVIS: So it may give you a good idea
6 that it is coming there regardless of what approach you
7 take, so you really can use a combination of
8 approaches.

9 MR. MOELLER: Yes. Jack Shapiro.

10 MR. SHAPIRO: Somehow or other, we have missed
11 the point here which hit me just as you were talking
12 again. That is that in this whole de minimis concept,
13 you haven't said a word about the fact that we are
14 getting benefit out of the radiation, and just because
15 you are killing just one in a million doesn't give
16 somebody the license to go around and kill 200 people
17 just because it is only about one out of a million in
18 the population. Even though we know it is a benefit.
19 We keep talking about de minimis without talking about
20 the benefit. All people end up thinking about is that
21 these people are going around just killing one in a
22 million, and that came across in Massachusetts when I
23 found that I got the most results in talking to our
24 Boston city council when we were talking about our
25 radioactive wastes.

1 I said, look, we are not in the business of
2 making radioactive waste. We are in the business of
3 doing research. Massachusetts is the world center for
4 research. It is the world center for medical therapy,
5 and therefore it generates the stuff because it is doing
6 this, and suddenly the light dawns on these people too
7 and they realize that this was the concept, that there
8 was a benefit, and you have to talk about the benefit
9 versus what is being done here.

10 We have come to the conclusion as far as low
11 level waste siting is concerned in Massachusetts that
12 the only way we will get it is to get a town that will
13 get enough economic benefit and enough sweeteners so
14 they will accept going down to a millirem or a half a
15 millirem or a 100th of a millirem is not going to
16 convince anybody if they are not going to get anything
17 out of it.

18 So, I think we have to keep pushing the
19 benefits that come along and weigh it against whatever
20 we are doing.

21 MS. DAVIS: I think that's right, and I think
22 that's why all the levels above the de minimis level are
23 really set on the basis that there is a benefit
24 associated with the irradiation. In a way, you can say
25 the de minimis level, that very small risk is balanced

1 against the benefit of sort of regulatory convenience,
2 even just the benefit of not having to -- freeing the
3 regulators to work on these more important things is
4 enough benefit to outweigh this extremely small risk.

5 I think it is that kind of outlook you have to
6 take on that, and that must certainly be the emphasis
7 when you are dealing with people.

8 MR. AXTMANN: I have a thought on the early
9 part of your talk in which you dealt with the question
10 of how you set the de minimis level. You had two
11 suggestions I wrote down. One was something a real
12 expert wouldn't worry about, and two, something within
13 the standard deviation of the risk from cancer from all
14 causes.

15 In the first case -- and you would publicize
16 the de minimis concept this way. Something that an
17 expert wouldn't worry about, I think experts are
18 increasingly distrusted in this society, particularly
19 nuclear experts, and I don't think that would be a
20 particularly convincing argument to the more vocal part
21 of the population that worries about such things. And
22 something within the standard deviation makes people go
23 numb. Standard deviation? What's a standard
24 deviation?

25 I think you have to --

1 MS. DAVIS: You are right, and the way you
2 present it to people can't be -- I was giving sort of a
3 scientific background. I think you're right. That's
4 why I say, when you are setting the regulatory level,
5 you really have a somewhat different approach than just
6 strictly the scientific approach, and you really have to
7 look at those kinds of things. On the other hand,
8 personally, I don't think that it is necessarily a total
9 given to the current feeling that only if it's done by
10 amateurs is it any good.

11 MR. AXTMANN: Oh, no, no, no. I am saying you
12 can't always explain to amateurs that their instincts
13 are wrong. The final thing is whether I should worry
14 about the whole thing at all. If something is de
15 minimis, then I flush it down the toilet, right? But I
16 keep creating de minimis quantities of material and I
17 keep flushing it down the toilet. Pretty soon it all
18 winds up in this one cesspool two miles from my house.
19 Then I begin to worry about the whole idea of de
20 minimis, if you follow me.

21 MS. DAVIS: Yes, that's what I said. The
22 concept of the accumulation of de minimis levels.

23 MR. KATHERN: What about concentration,
24 though? Do you base it on concentration unless it is
25 somehow concentrated later on? You don't have the

1 problem?

2 MR. AXTMANN: No, but then you are worrying
3 about it, and you are worrying about it in a regulatory
4 sense. If there are natural, as you put it, natural
5 concentration --

6 MR. KATHERN: There is.

7 MR. AXTMANN: Natural concentrations, perhaps
8 the concept is flawed, at least in some cases.

9 MS. DAVIS: Well, also, if somebody was
10 watching the background in general, you would pick up
11 that there was a major --

12 MR. AXTMANN: Oh, sure.

13 MS. DAVIS: You would get to a major increase,
14 but you certainly can't postulate that you are going to
15 get up to levels that are clearly above the de minimis
16 level.

17

18

19

20

21

22

23

24

25

1 MR. AXTMANN: I guess what I am worrying about
2 is you are putting something out of the regulatory
3 framework and therefore out of the observatory, if that
4 is the word, framework.

5 MR. MOELLER: Well, thank you, Dr. Davis. It
6 was good of you to come and to share your thoughts with
7 us, and certainly you show that you have given it a lot
8 of thought.

9 The last person to appear on our schedule for
10 today is John Auxier from the Oak Ridge National
11 Laboratory. Dr. Auxier is going to summarize all about
12 de minimis for us and just wrap it all up in a nice,
13 neat bundle.

14 MR. AUXIER: Dave, if you were as optimistic
15 about everything I was going to say, we could have
16 solved the de minimis problem a long time ago.
17 Actually, it is not too bad to be the last person on the
18 program because it means at least I am talking to a
19 bunch of real survivors today.

20 First of all, I would say that my definition
21 of de minimis is precisely that the NRC and everybody
22 else is using, the legalistic one, and I am not today
23 interested in what you call it later. I am talking
24 about the principle, and therefore to me de minimis is
25 the same as every other term I am talking to now.

1 Up until about two weeks ago, I would have
2 come in here with a stack of Vu-graphs about equivalent
3 to this to show you the facts and figures and graphs to
4 show you how to arrive at a de minimis. I will take
5 about three minutes to tell you what I would have told
6 you in a half-hour, and then I will spend the rest of
7 the time on something that may not be as productive but
8 what I find interesting and bears on some of the
9 observations we have had in the last few minutes.

10 First, there are a lot of problems with the de
11 minimis approach. I think almost all of them have been
12 mentioned this afternoon and some in the last few
13 minutes. There is a need for it, especially when you
14 consider the cost-benefit think that Jack Shapiro was
15 talking about.

16 We can't forget that there are advantages to
17 the use of radiation. That is what we are in the
18 business for, and therefore we can't lose that
19 particular thing. And the need for de minimis is
20 enormous when you do that equation, the cost-benefit
21 analysis, the risk-benefit analysis.

22 There is a big disadvantage, however, there is
23 a disadvantage not to have one, but there is a bigger
24 disadvantage in having one that is obscenely low. In
25 other words, if it gets down to where -- you can get

1 involved with the problems here this afternoon, the
2 perceptions of the public. If you set a tenth of a
3 microroentgen per year, anything above that will tend to
4 look worse to the public and therefore it would be
5 better to leave the issue alone.

6 But using three approaches over the year, I
7 started this business when Appendix I was first
8 drafted. Some of you remember those days back in about
9 1971. In those days the first thing that occurred to me
10 was a number that was well below the natural background,
11 and then we played on it and the number that Weinberg
12 quoted was something I calculated for him in those days
13 based on EPA distribution of dose by states. We just
14 did a root mean square deviation and we came out with 17
15 or 18 millirem, which we rounded to 20, which is in my
16 opinion a reasonable number and one approach. It is not
17 all together defensible with everybody, but
18 nevertheless, it has some logic to it.

19 Secondly I would talk about the risk. I would
20 start with a risk and compare them to the risks of
21 everyday living that people accept willingly and then
22 divide them by some number, and all of us love to play
23 with factors of 10's and 2's and 100's. So I divide
24 those risks by 100, by 10, and you come out with numbers
25 like for a given individual I chose to limit the risk to

1 ⁻⁴10 for a representative group of the population, the
 2 old NCRP 170 millirem thing. I would for de minimis
 3 talk about a risk of 10⁻⁵, and then for a large, large
 4 population, maybe one in a million.

5 On the other hand, I would resist strongly the
 6 tendency to take 200 million people, 2×10^8 , and
 7 multiply it by anything and come out with anything
 8 useful. In other words, measuring $2 \times 10^{-8} \times 10^{-6}$
 9 is not a meaningful number because the uncertainties in
 10 what you are multiplying are enormous, as you know.

11 Now, also everybody here is aware of the fact
 12 that how we reach numbers by consensus is in groups such
 13 as this and that is why we get together, but we also
 14 know that there are real problems. For instance, NCRP
 15 is made up of a bunch of committees of which several of
 16 us here have been involved in for many years, and so was
 17 ICRP and so is the BEIR committee and the INSCR
 18 committees.

19 When they sit around tables, it is not always
 20 science that ends up, it is consensus. And experts, as
 21 has been noted, have a wide range of opinions. So we
 22 take the best data we can and then we compromise. BEIR
 23 III gave us the numbers that are being used. They are
 24 the same as BEIR II, about, but you are familiar with
 25 the contortions they went through to get a number based

1 As a consequence, this business of saying,
2 okay, if we put in magic fencepost number of five, then
3 the whole world average of that is just nonsense. We
4 have tried every kind of mathematical manipulation and
5 if you take a number of -- well, Sternglass Goff talk
6 about the 170 millirem per year killing everybody.

7 Well, even if you take radiation and explode
8 it in nuclear weapons and spread it around the world the
9 best you can, you cannot get a uniform distribution such
10 that if you take 170 millirem as the highest, that the
11 average dose to the population will be more than a small
12 fraction of that. If you take a power plant and do the
13 same thing, it turns out that if you limit it to, say,
14 170 millirem to a representative part of the population,
15 or if you limit it to 20 millirem at the boundary, the
16 average dose to the population is a very small fraction
17 of that.

18 It depends on several things, but typically it
19 is from 100 to 1000th of that. So we are not talking
20 about giving everybody the number we list as de
21 minimis. Also in the de minimis concept when you are
22 talking about a de minimis dose, or a regulatory dose,
23 for that matter, you are talking about a dose that takes
24 into account the accumulation in the environment in the
25 biosystems.

1 We can release stuff in generally two ways:
2 through the air and through the water, if you take the
3 accumulation into account, so let's don't reiterate it
4 again to go the next step. Okay. That is one way to
5 take the risk. If you do that, I come out with a number
6 that varies between 10 and 20, and it is close enough to
7 the other one not to worry.

8 Finally, the easiest and the quickest to
9 explain, and I expect that a lot of people would use, we
10 take the ICRP, NCRP, 170 millirem to the representative
11 part of the population, divide it by 10, another safety
12 factor, and say 17 millirem, and they could round it
13 either way, it would be a reasonable number. You could
14 take three approaches, where you base two of them on the
15 prestigious committees of the past, or you could take
16 one and look at the natural background; but you always
17 come out with numbers of 10 to 20 millirem per year.

18 But when I was asked to do this and was
19 preparing these charts, someone mentioned to me that
20 they thought maybe I was a spokesman for the Health
21 Physics Society or for the health physics profession.
22 Well, I am not. I have no cloak for that at all. As a
23 matter of fact, in disclaiming it, I recognized then
24 that somebody might still perceive it that didn't hear
25 me say that, so just in case, I would see how far off I

1 was from the rest of the health physics community.

2 For the next few minutes, then, I will show
3 you the results of something I did. You have got copies
4 of all these, so I will only go through part of it. But
5 I decided in a very short scale, and this is not very
6 scientific -- those of you who have done polls know it
7 is extremely difficult to do it and do it right -- but
8 about 10 or 12 days ago I made up a little form, making
9 it as simple as possible recognizing there was a need
10 for several caveats, and then I transmitted this by
11 telephone to about 20-some peers around the country who
12 I thought might be willing to collaborate and help me
13 get data in a hurry.

14 (Slide)

15 I gave them this form, gave them the caveats
16 and some explanations and said I will call you back in
17 two days, give me a time; and in the meantime, transmit
18 this to some of the staff around you, and then when I
19 call you back, you can just read off, yes, no, two,
20 four, whatever to the questions and I can get data.

21 Now very crudely, but I got about 80 responses
22 to this poll. Now, this is the health physics
23 community, and for obvious reasons I left off regulatory
24 groups. Now, I wanted to know if education and training
25 sorts of things had any bearing on what people would

1 perceive of as a de minimis value -- and these are
2 health physicists. So I looked at highest academic
3 degree, years of experience in health physics, whether
4 or not they are certified with the American Board of
5 Health Physics, yes or no, the type of facility from
6 which they work -- university, DOE labs, plants,
7 utilities, other industry and so forth.

8 Then I said, okay, within the NRC definition
9 of de minimis, give me numbers for these three questions
10 as if you were playing God and could set these numbers
11 for individuals where the first one would be a single
12 individual, the old Appendix I magic fencepost sort of
13 individual, for B for the 170 millirem equivalent in the
14 ICRP, NCRP for the representative population but limit
15 it to five miles, and then see what you could do if you
16 could control the people out to 50 miles, a region that
17 shows up in all the NRC regulations, as you are aware.

18 Finally, I asked the question, this is what
19 takes caveats: Should person-rems be the governing
20 factor, yes or no? And, I said, give me your comments
21 there because that will probably be the most useful
22 thing, and surely enough, they were.

23 (Slide)

24 So with that in mind, I then got all these
25 data from 79 or 80 people. Actually I think I had 80

1 and then threw mine out so I wouldn't bias the data.
2 But I got this kind of a distribution of responses in
3 terms of degrees. So you can see that there are a few
4 health physicists, long-term trainees that have only a
5 high school education or so, but BS's, MS's and Ph.D's.
6 There is a pretty good representation. Most senior
7 health physicists in the country I thought were at the
8 MS level, but I got a distribution that was not as far
9 different as I had expected. But at least there are
10 some people with various degrees.

11 (Slide)

12 Then I looked at years of experience. The
13 percentage is still on the ordinate, abscissa, years of
14 experience. As you see, there are a few people with
15 two, three, four years, all the way out to a few with
16 33, 35 years of experience, and sort of a peak in the
17 middle around 15 to 17 years. But I had no
18 pre-expectation, or no expectation at all about how that
19 would be.

20 (Slide)

21 Then I had certified health physicists. As
22 you see, it is not a 50-50 match but surprisingly a good
23 representation from the CHPs.

24 (Slide)

25 By facilities: There are universities, DOE

1 labs, other, industry, and utilities. These two in the
2 middle are low because I didn't know many people,
3 actually in industry that worked with enough health
4 physics to give an opinion. I got a few. "Other"
5 included two people that accidentally got in from the
6 NRC because they were asked by utility guys, and it
7 turns out their numbers are not among the lowest by any
8 means.

9 Universities. We had quite a few, but
10 obviously a high bias from the DOE labs because I asked
11 three labs and all of them gave me lots of numbers and I
12 took them. But I was going to show you where they came
13 from so you could take into account your own idea of
14 biasing.

15 (Slide)

16 Then that first question, maximum exposed
17 individual, this is the raw data responses. Again, the
18 percentage of the responses, and you see there are some
19 down here at one, and some up here at 1000. As a matter
20 of fact, there was just one at 1000, I believe, one at
21 650, which I had no idea how the person got it.

22 MR. MOELLER: Excuse me. This is millirem per
23 year?

24 MR. AUXIER: Millirem per year, yes. Excuse
25 me. And that is the distribution (indicating). So you

1 can see it covers a wide spectrum. We mentioned big
2 numbers, a variation of numbers today. You can see, of
3 course, there are little spikes representing people's
4 tendency to round off, 5 and 10 and 25 and 100, and you
5 would expect there might have been a 500 and at 170,
6 that there might have been more, but I was surprised. A
7 lot of things about this surprised me. One was that
8 very few people picked the 170 or one-tenth of that.

9 (Slide)

10 Now you see a similar thing for within 5
11 miles, more of a bias toward the low end of the dose
12 curve, as you would expect. But again, it is a
13 completely wide spectrum with some people going up to
14 250 millirem, a few, one.

15 (Slide)

16 Out to 50 miles, more to the left, except not
17 remarkably so, with 5 being a little more of a choice
18 than usual, and 7 and 8, after all, and 2 are not round
19 numbers in the normal thinking. So, anyway, you see a
20 bias a little more toward the low end as you would hope
21 for and expect.

22 Now the final question, and this one I got
23 surprised on, too. I figured some people thought
24 person-rem's were more important, but overwhelmingly the
25 people thought that person-rem's shouldn't be a

1 consideration in setting de minimis levels in the
2 environment. But, as I say, the discussions, the
3 comments were extraordinarily enlightening, and they did
4 cover a lot of things we have mentioned today.

5 One is that for ALARA concepts then
6 person-remS can be quite important. And in doing
7 emergency planning, person-remS should be paramount.
8 But for setting de minimis levels in the environment,
9 the person-remS people said it shouldn't be. After all,
10 some plants like Indian Point may be close to large
11 population centers and the risk per person is what
12 counts; and some may be way out where person-remS would
13 be zero even with significant levels to a few
14 individuals. So that one they were quite clear on.

15 I won't show you these because you have got
16 them, but I have got two of these that list every single
17 case, the data that gives the degree, the whole thing.

18 MR. MOELLER: Excuse me. Hal Peterson has a
19 question.

20 MR. PETERSON: Yes, if I may. You made an
21 implication, I think, about the man-rem being useful or
22 not useful when in fact the questionnaire says: Should
23 man-rem be the governing factor?

24 MR. AUXIER: That's right.

25 MR. PETERSON: Okay. Just for the sake of the

1 record, I wanted to straighten out the difference
2 between implications and governing factor.

3 MR. AUXIER: You've got it precisely correct.
4 As I say, we asked them the question: Should it be the
5 governing factor? And they said overwhelmingly "no,
6 but." And that is where the clarification was
7 revealing. It actually told me more maybe than if we
8 had asked the question and had time to ask several
9 questions. Namely, the comment says, for the risk to
10 individuals, whether there is a few or a lot out there,
11 it shouldn't be important; but when you start planning
12 for accidents or when you worry about ALARA, actually in
13 this area the people, these HPs out there seem to have
14 done a lot more in-depth thinking than they did about
15 the other. I think that may be reflected more as they
16 go along. But you are correct.

17 MR. MOELLER: Rags Muller, did you have a
18 question?

19 MR. MULLER: I just had one question, John.
20 What significance do you attach to the fact that perhaps
21 a lot of the degrees that you checked are not in health
22 physics but in some other discipline?

23 MR. AUXIER: I put no significance in it
24 because my Ph.D. is in nuclear engineering, but there
25 was until recently no place you could get a Ph.D in

1 health physics, so we are all radiobiologists,
2 physicists, mathematicians. Walter Snyder was a
3 mathematician, K. Z. was a physicist. That is their
4 academic degree, but they call themselves health
5 physicists on the basis of training and experience. But
6 if I put importance on what their degree is in, I would
7 just have to throw them out. Now the master's degrees,
8 a lot of those are in health physics in the old AEC
9 fellowship program and in the Public Health Service
10 program. A lot of the BS's, Most of those, up until the
11 very recent ones of course, were in one of the
12 disciplines such as physics, chemistry, math or biology.

13 Okay, I will just go through a few of these.
14 You have already gotten them but I left off all the
15 statistical parameters at the bottom to keep from
16 cluttering it any more, but to show you how to use this
17 in case you decide you want to play with it.

18 (Slide.)

19 Question 1 was degree. Question Q4A is the
20 maximum exposed individual. This, then, is the degree
21 versus their chosen numbers, and this in there is the
22 percentages of people responding, and under that, right
23 in there is the number of actual respondents, the lower
24 number being percentage. As you can see, 79 responses
25 is the 100 percent, 2 is 2.53 responses, and so forth.

1 If you look at this, and of course I had the
2 computer playing with it, there is no correlation.
3 There is nothing statistically significant about
4 anything about the distribution that we can see here.
5 Now, we can go through one or two more, but if you look
6 at that Question 1 by Question Q4C, that is Q4C was the
7 50 miles. Again the same thing.

8 But if you go through them all by degree,
9 by -- well, I thought for certain that there would be a
10 difference between the people in the nuclear power
11 industry as opposed to those maybe in the national labs
12 or other places, and I thought maybe the difference
13 between certified HPs might be correlated to their
14 numbers. No correlation. No significant correlation.

15 [Slide.]

16 Anyway, if you look back, I thought the
17 university folks would be the lowest and the utility
18 would probably be the highest. As you can see, there is
19 no statistical difference between them. Now, where am I
20 leading with all this stuff? Simply -- that will be all
21 the slides.

22 Namely, I had over a period of years in
23 talking with other people arrived at numbers that I had
24 a feeling were sort of representative of the science and
25 that could be defended, at least qualitatively, on a

1 scientific basis. And I felt then that the HPs out
2 there using the same sort of approach with some science
3 would come out with numbers that wouldn't be too much
4 different. And lo and behold, as you see clearly, there
5 is no correlation between the most experienced and the
6 best trained HPs and the neophytes.

7 So I conclude, and I told Bill Mills, and
8 unfortunately Bill had to leave, but I wanted to tell
9 him that in this case I sort of have to change sides on
10 him and say that after all, it is the HP out there that
11 is as emotional about these issues as everybody else.
12 The only explanation is that people are reaching for
13 numbers intuitively, and any time you are talking about
14 intuition, you are talking about some impact on the
15 emotions or reflecting emotional status, and therefore
16 we are all in the same boat.

17 The HP is not going to be able, if you
18 involved the HPs in helping you arrive at numbers, they
19 are really not going to be much help to you, and that
20 includes me.

21 Thank you.

22 Are there any questions?

23 MR. MOELLER: Questions. Frank Arsenault.

24 MR. ARSENAULT: Yes. I am not sure whether
25 this is a question or an observation. I guess the

1 question I would like you to react to is this. There
2 was, in fact, a correlation I notice, though, of the
3 results you presented in that most of the people you
4 consulted did not see person-rem as a basis for the de
5 minimis level. I wonder if that is because they are
6 health physicists and not regulatory personnel. You
7 would think a regulatory body might have a societal risk
8 basis for its perspective as distinct from the
9 practicing health physicist who tends to think in terms
10 of the individual he deals with.

11 MR. AUXIER: That is a good observation. I
12 have no data from the other side, but it certainly
13 sounds reasonable.

14 MR. ARSENAULT : The other part of my
15 observation is closely associated. That is that if you
16 had asked the individuals responding what the objective
17 was for the regulation of dose, you probably would have
18 found as wide a scatter in the answer to that question
19 as you did in the levels of the proposed for de minimis.

20 MR. AUXIER: I think you are exactly right.
21 As a matter of fact, in a session like this I learn a
22 lot more than I feel like I could contribute, but on the
23 other hand, in a poll of this type where you are forced
24 to ask a few simple questions, you learn immediately
25 that you either asked the wrong questions or certainly

1 didn't ask the right questions. But it would be fun to
2 follow up. I may, if time permits, use the Health
3 Physics Society Newsletter with Jack Colen's
4 cooperation, I might with the help of a lot of people
5 design a simple form and do a better poll. I am not
6 sure at the moment, though, it would be useful. I need
7 the right input first. It wouldn't pay to go to a lot
8 of work and come out with the same thing unless we
9 thought that, gee, it is important to know just that.

10 MR. MOELLER: Well, I guess I had a question
11 in looking at this. You said you did it by telephone,
12 but did they really, like in Question 4A, the maximum
13 exposed individual at the fencepost, did they really
14 give you a number for de minimis dose or did they give
15 you an Appendix I type of ALARA answer?

16 MR. AUXIER: I will give you an example of how
17 I did it. Jim Watson of the University of North
18 Carolina. I called him, I explained this to him. I
19 said, now, to be clear -- everybody, by the way, was 100
20 percent agreeable. Nobody said, gee, they didn't have
21 time. Everybody helped. Some of them worked quite a
22 bit, including Jim. But I said, now, when you talk to
23 other people, make sure that everybody is as far as
24 possible talking about the same thing. He played back
25 to me the definition, NRC's definition of de minimis,

1 and I said, now -- as a matter of fact, it was after the
2 first call or two that I said light the magic fencepost,
3 because I wanted to make sure they knew the maximum
4 exposed individual. And I usually used 170 millirem
5 NCRP to indicate we are talking about men, women and
6 children and a representative population.

7 Everybody played it back to me quite well.
8 Now, I don't know how they played it to the other people
9 or how those people perceived it. From some of the
10 numbers, I think, from the same place, there was quite a
11 different perception, but I can only use what data I
12 have.

13 MR. MOELLER: Well, again following up on what
14 Frank said, and I realize this is simplistic and I'm not
15 saying it correctly, but you told us that by a high
16 percentage they said, no, that person-rem should not be
17 a governing factor, and yet the de minimis dose level
18 went down from the fencepost from 5 miles to 50 miles.
19 That means they are thinking collective dose.

20 MR. AUXIER: For certain they are saying that
21 if you --

22 MR. MOELLER: If you expose more people, you
23 have to have less dose, because we are looking solely at
24 individual risk.

25 MR. AUXIER: If you look at the raw data you

1 will find there are a few people who had the same number
2 all the way across but not many. I had expected that
3 there would be more. A lot of things about this
4 surprised me. That was one of them, that the same
5 person who would say no would also have a number that
6 would vary by an order of magnitude. But it is a
7 complex issue. But when an individual looks at it,
8 their own perceptions may get complex in a way different
9 from how you or I would look at it.

10 MR. KATHERN: John, you left us hanging with
11 some of the important comments that might have been made
12 free-handed. Is there anything that came out of those
13 that you would like to comment on?

14 MR. AUXIER: I am sorry, I did mean to put
15 those in. Number one -- I mentioned two of them. The
16 other is that even though the numbers didn't always
17 agree, people said there should be some de minimis
18 value, and nobody complained about the term "de minimis"
19 in this, but then they didn't have much room to,
20 anyway. But two or people, at least, several people
21 said it would be better not to have one than to have one
22 too low. Most people are convinced that we will have
23 lower standards, guidelines for population than NCRP by
24 far, independent de minimis. They are concerned about
25 how low they will go.

1 Those are the chief ones. I did have a list of
2 them but I didn't bring it up here with me.

3 MR. MOELLER: Well, I think that is a very
4 interesting way to end the day, with a poll such as that.

5 MR. MULLER: It would be interesting to get
6 medical radiologists to respond to a similar poll.

7 MR. SHAPIRO: Are you kidding? 1000 R.

8 MR. AUXIER: That is not a bad guess, because
9 I did talk to a number of them.

10 MR. MOELLER: Well, it has been a long day,
11 not only for us but for our reporter. We will resume
12 tomorrow morning at 8:30, so I will declare a recess.

13 [Whereupon, at 5:50 p.m. the meeting was
14 recessed, to reconvene at 8:30 a.m. the following day,
15 Saturday, November 13, 1982.]

16

17

18

19

20

21

22

23

24

25

NUCLEAR REGULATORY COMMISSION

This is to certify that the attached proceedings before the

in the matter of: ACRS/Subcommittees on Reactor Radiological Effects
and Site Evaluation

Date of Proceeding: November 12, 1982

Docket Number: _____

Place of Proceeding: Washington, D. C.

were held as herein appears, and that this is the original transcript thereof for the file of the Commission.

Patricia A. Minson

Official Reporter (Typed)

Patricia A. Minson

Official Reporter (Signature)

advance copy

RUSSELL M. BIMBER RECEIVED

10471 Prouty Road
PAINESVILLE, OHIO 44097ADVISORY COMMITTEE ON
REACTOR SAFEGUARDS, U.S.N.R.C. Nov. 4, 1982

Ms. R. C. Tang
Advisory Committee on Reactor Safeguards
NRC
Washington, D. C. 20555

NOV 8 1982

AM PM
7,8,9,10,11,12,1,2,3,4,5,6

The Combined Subcommittees on Reactor Radiological Effects and Site Evaluation will meet Nov. 12, per 47 FR 47343. I wish to comment on the agenda items Nos. 1, 3, and 7.

I'm a chemist with more than thirty years of industrial experience, including some work with radioactive materials. In addition to my regular job, I'm helping Lake County draft its Radiation Emergency Plan, related to the Perry Nuclear Power Plant.

1. I haven't seen FEMA's draft policy on potassium iodide as a thyroid blocker. But the FDA advice, that KI be used when the projected dose exceeds 25 rem, (47 FR 28158-9; 6/29/82) sounds reasonable; I urge that it be adopted as Federal Policy.
3. Please do not increase the permissible levels of radiation, especially for unrestricted areas (10 CFR 20.105). Although the higher Protective Action Guides of EPA 520/1-75-001, cited in NUREG 0654 FEMA-REP-1, Rev.1 may be acceptable for incidents occurring no more than once a decade, their justification has not been properly documented. See the enclosed three pages of my communications with EPA on this subject.
7. I haven't seen NRC's proposed 10 CFR 140, but urge that the requirements for declaring an Extraordinary Nuclear Occurrence be reduced. For example, an ENO might be declared whenever radiation from a nuclear power plant exceeds 10 CFR 20.105 levels offsite, or whenever EPA's PAGs lead to recommendations for offsite protective action. I understand the courts have declared that state and local government can't get reimbursement for their part in the TMI incident. I believe non-governmental agencies, such as the Red Cross, who are expected to participate in radiation emergency response, should be assured of reimbursement, preferably from the nuclear plant responsible. Making it easier to declare an ENO may make such agencies more cooperative.

Thank you for this opportunity to comment on these vital topics; I hope this helps.

Sincerely,

Russell M. Bimber

encl: 3 pp

RUSSELL M. BIMBER
10471 Prouty Road
PAINEEVILLE, OHIO 44077

July 30, 1982

To: A. Stewart, Lake DSA
W. Kulash, PRC Voorhees

EPA Response on Protective Action Guides

Harry Galley (spelling?) of the EPA phoned today in response to my letter to David Rosenbaum, 7/15/82, which I copied you on.

He said 10 CFR 20.105 applies only to routine operation of nuclear power plants, not to accidents.

10 CFR 20 does not explicitly exempt accidents, but 20.501 does allow the NRC to grant exemptions. But the Draft Environmental Statement on PNPP, NUREG 0884 (March, 1982) implies that its accidents are not exempt; page 5-16 says, "even under unusual operating conditions which may temporarily result in releases higher than (normal) but still well within the limits specified in 10 CFR 20.....". It goes on to state additional requirements of 10 CFR 51 and 40 CFR 190. (But again and again, the NRC can make exceptions, which are not mentioned in the DES.)

Appendix C of EPA 520/1-75-001, which was to summarize the technical bases for PAGs of 1-5 rem, still has not been developed. Mr. Galley agrees that Appendix C is the most important part of the entire Document, and personally would place a high priority on getting it done. But EPA has received few questions about it and does not even have a target date for getting it done. In 1975, EPA used three rationales for the PAGs:

1. PAGs should not allow anyone to get a dose large enough to produce an acute effect, manifested within 30 days, or perhaps even out to one year.
2. PAGs should limit long term injuries to an acceptable range. EPA still has no exact definition of what an acceptable range is.
3. EPA would not make recommendations that could not be implemented. EPA was asked by many people to consider lower PAGs, and did consider 0.1 rem. This would lead to recommendations to evacuate unmanageably large areas.

I cited CEI's adoption of a 5 rem PAG without saying why they didn't adopt the 1 rem favored by EPA 520/1-75-001. Mr. Galley said this conflicts with EPA's intent, and that we should challenge CEI's interpretation of PAGs and make them change to 1 rem, unless they provide convincing arguments.

I mentioned densely populated North Madison, only four miles downwind, and generally with low radiation protection factor housing. He said a lower PAG may be appropriate for special situations like this; the risks of evacuation are low relative to certain radiation injuries in part of the exposed population.

Mr. Galley welcomes phone calls (703-557-7390) in preference to letters, but will follow up this call with a letter, and I'll copy you when I get it. This should contain the same information, probably in more detail than his letter.

Sincerely,

Russ

(encl as p 2 of 3 with 11/4/82 letter)

RUSSELL M. BIMBER

10471 Preuty Road
PAINESVILLE, OHIO 44077

July 15, 1982

David Rosenbaum, Dep. Asst. Adm. for Radiation Programs
EPA
401 M St., SW
Washington, D. C. 20460

I'm a scientist-volunteer helping Lake County, Ohio draft its Radiation Emergency Plan for the Perry Nuclear Power Plant. The Cleveland Electric Illuminating Company, which is to operate the Plant, says it must comply with 10 CFR 20.105 which sets a limit of 0.1 rad/week for whole body radiation exposure in unrestricted areas. This appears to conflict with CEI's proposed adoption of Protective Action Guides of 1-5 rad/in incident W.B., based ultimately on EPA 520/1-75-001, Sept. 1975.

The EPA sent me a copy of that document in October, 1979, including Chapter 5, revised 6/79, and Appendix D (Jan. 1979), yet Chapters 6, 7, & 8, and Appendices A, B, and C were still "to be developed". I think Appendix C is the most important part of the entire document because it was to summarize the technical bases for the numerical values of the PAGs.

If Appendix C has been developed, I would like to have a copy, along with any other help you may be able to provide, or direct me to, for understanding why a PAG in excess of 0.1 rad may be acceptable.*

Sincerely,

Russell M. Bimber
Russell M. Bimber (MS, chemistry)

* P. S. I have NUREG -0396, EPA 520/1-78-016 (Dec. 1978) and NUREG -0610 (Sept. 1979) which both cite the earlier EPA 520 Document as the authority for the numerical values of the PAGs.

(encl see p 1 of 3 with 11/4/82 letter)

ACRS BRIEFING
U.S. DEPARTMENT OF ENERGY POSITION
10 CFR PART 20 REVISION

PRESENTED BY
E. J. VALLARIO, GROUP LEADER, HEALTH PHYSICS
OFFICE OF NUCLEAR SAFETY
NOVEMBER 12, 1982

DON POSITION
PROPOSED REVISION 10 CFR PART 20

- **RETROSPECTIVE vs PROSPECTIVE**
- **50 YEAR EFFECTIVE DOSE EQUIVALENT**
- **RADIATION DOSE MANAGEMENT**
- **GESTATION DOSE**
- **INDIVIDUAL MONITORING REQUIREMENTS**
- **IMPLEMENTATION COSTS**
- **OTHER**

PROSPECTIVE vs RETROSPECTIVE

10 CFR 20 APPLICATION OF ICRP-26

- **PROSPECTIVE ADVANTAGE**
 - **OCCUPATIONAL RISK**
- **RETROSPECTIVE PROBLEMS**
 - **STANDARD REFERENCE MAN**
 - **LONG LIVED NUCLIDES**
 - **TIME REQUIRED FOR INDIVIDUAL ASSESSMENT**
 - **DOSE ASSESSMENT BASED ON AIR SAMPLING**
 - **INCREASED MEASUREMENT SENSITIVITY REQUIRED BY 50-YEAR DOSE COMMITMENT**
 - **ACCIDENTAL EXPOSURE DATA**

PARAGRAPH 176 - ICRP 26

"Only in a few circumstances can the results of programs of monitoring of the workplace be used to estimate the dose equivalents or intakes of individual workers. The use of derived or authorized limits is essential in the interpretation of environmental monitoring programs."

50 YEAR COMMITTED EFFECTIVE DOSE EQUIVALENT

RE: §20.201

ISSUES:

- **EXTRAPOLATION OF 50 YEAR DOSE TO 1ST YEAR —
AFFORDS NO GREATER PROTECTION**
- **MEASUREMENT SYSTEMS ARE INADEQUATE**
 - **ENVIRONMENTAL AIR MONITORING**
 - **IN VIVO ASSESSMENT**
 - **BIOASSAY**
- **LOW EXPOSURES BECOME TECHNICAL OVER
EXPOSURES**
- **MANAGEMENT OF SUBSEQUENT YEARS EXPOSURE
DATA — A PROBLEM**

EFFECTED HEALTH PHYSICS PRACTICES:

- **EFFECTIVE UTILIZATION OF WORKFORCE BASED ON
TRUE EXPOSURE**
- **CREDIBILITY OF PROTECTION CONTROL**
- **MAINTAINING REASONABLE OPERATIONS COST
BASED ON OPTIMUM SAFETY PERFORMANCE**

AIR SAMPLING INSTRUMENTATION PROBLEM

CONTINUOUS AIR MONITORS ARE LIMITED IN SENSITIVITY BY:

- INABILITY TO ADAPT TO VARIABLE BACKGROUNDS
- ^{242}Cm AND ^{244}Cm ARE SPECIAL PROBLEMS
- POOR SAMPLING EFFICIENCY FOR LARGER PARTICLE SIZES

CAM ANALYSIS - MPC - HOURS

INTEGRATION TIME	0.6 μm	1.5 μm	2.4 μm
1.0 MIN	17.3 MPC-HR	24.8 MPC-HR	225 MPC-HR
5.0 MIN	7.3 MPC-HR	10.5 MPC-HR	95 MPC-HR
10.0 MIN	5.1 MPC-HR	7.3 MPC-HR	66 MPC-HR

INDIVIDUAL MONITORING REQUIREMENTS

RE: §20.502, WITH REFERENCE TO §20.201, APPENDIX B

ISSUE: INDIVIDUAL MONITORING OF WORKERS WITH A POTENTIAL FOR A DEMONSTRABLE, POSITIVE INTAKE WOULD NOT BE REQUIRED IN MANY CASES UNDER THE "30%" MONITORING CRITERION. CURRENT DOE PRACTICE REQUIRES THAT EACH INDIVIDUAL BE MONITORED AND RESULTS RECORDED OF ALL POSITIVE INTERNAL DEPOSITIONS.

EFFECTED HEALTH PHYSICS PRACTICES:

- **AVAILABILITY OF EXPOSURE TREND DATA**
- **POSITIVE WORK PLACE CONTROL**
- **ALARA**

PROPOSED NRC MONITORING-RECORDING REQUIREMENTS

1. Limits (20.201)

- a. Effective Dose Equivalent = Deep Dose Equivalent + Committed Effective Dose Equivalent = 5 rem
Or b. Dose Equivalent = Deep Dose Equivalent + Committed Dose Equivalent = 50 rem

2. Summation (20.203)

10% of the Deep Dose Equivalent (0.5 rem) and 30% of the Annual Limit of Intake (1.5 rem)

3. Individual Monitoring (20.502)

- a. External: 0.5 rem Deep Dose Equivalent or 30% of the limit for eye (15 rem), skin (50 rem), or extremity (50 rem)
b. Internal: 30% of the Annual Limit of Intake

4. Recording of Individual Monitoring Results (20.1103)

- a. Required to record if required to maintain records (internal or external)
b. Not required to record individual intakes less than ALI/1000 (2-DAC-hours) in a day, or ALI/200 (10 DAC-hours) in a week, provided that for any assessment in excess of these amounts the entire amount is included (equates to 1.25 rem per year or 25% of the ALI)

5. Occupational Exposure History (NRC Form 4) -- Where monitoring is not required--assume 1.5 rem per year

6. Current Occupational Exposure Record (NRC Form 5) -- Lifetime Effective Dose Equivalent (including assumed exposure-see NRC Form 4) shall be added to the current year Effective Dose Equivalent to obtain new lifetime exposure

RADIATION DOSE MANAGEMENT

RE: §20.207, §20.502, §20.1103, 20.102

ISSUES:

- **INFERRED HANDLING OF NON ROUTINE EXPOSURE DATA WILL A BE PROBLEM**
- **ASSURED COMPLIANCE WITH EFFECTIVE DOSE EQUIVALENT TO THE FETUS IMPOSSIBLE UNDER PROPOSED SYSTEM**
 - **LACK OF INDIVIDUAL MONITORING REQUIREMENTS (1.5 REM RULE)**
 - **EMBRYO AGE SPECIFIC PARAMETER IS IMPORTANT IN CONTROLLING FETUS DOSE BUT APPLICATION IS NOT POSSIBLE IN ABSENCE OF INDIVIDUAL MONITORING REQUIREMENTS**
- **RECORDS WILL REFLECT ANOMOLIES IN DATA (1½ REM MONITORING RULE)**
- **EPIDEMIOLOGY STUDIES WILL LACK LOW DOSE DATA BASE**
- **ALARA APPLICATION EFFORT TO LOWER INDIVIDUAL EXPOSURES WILL BE HAMPERED**

EMBRYO/FETUS - PART 20 APPLICATION

POTENTIAL UNMONITORED EXPOSURES

	<u>DEEP DOSE EQUIVALENT</u>	<u>COMMITTED EFFECTIVE DOSE EQUIVALENT</u>	<u>CALCULATED EFFECTIVE DOSE EQUIVALENT</u>
AGE-SPECIFIC PARAMETERS KNOWN	0.49 REM	1.00 REM	1.49
AGE-SPECIFIC PARAMETERS UNKNOWN	0.49	2.00	2.49

BOTTOM LINE (IMPLEMENTATION COSTS)

- **PROGRAM**
 - FACILITIES, WORKER, EQUIPMENT
 - TRANSITION PERIOD
- **FACILITIES**
 - FACILITY MODIFICATION
 - PLANT RETROFIT (REMOTE OPERATIONS)
- **LITIGATIONS**
 - NO INDIVIDUAL RECORDS BELOW 1½ REM
(EFFECTIVE DOSE EQUIVALENT)
 - "TECHNICAL" OVEREXPOSURE WILL BE COMMON

federal register

Friday
January 23, 1981

Part XV

Environmental Protection Agency

Federal Radiation Protection Guidance
for Occupational Exposures

(RH-FRL 1722-5)

Federal Radiation Protection Guidance for Occupational Exposures; Proposed Recommendations, Request for Written Comments, and Public Hearings

AGENCY: U.S. Environmental Protection Agency.

ACTION: Proposed recommendations for radiation protection of workers.

SUMMARY: We are proposing to make recommendations to the President for new guidance to Federal agencies for the protection of workers exposed to ionizing radiation. These proposals are based on a review of existing guidance in the light of scientific knowledge of radiation risks and of experience in the control of occupational exposure. The proposed recommendations include both qualitative guidance on radiation protection and numerical guides for maximum allowed dose equivalents (RPG's¹). The most significant changes proposed are (a) that a graded set of minimum radiation protection requirements be introduced in three levels; (b) that the RPG for maximum whole-body dose equivalent be reduced from three rem² per quarter to five rem per year, and that regulatory agencies establish lower limits for specific types of work situations; (c) that limitation of internal doses³ take into account the sum of the risks to all organs, rather than continue to be based only on the most significantly exposed organ; (d) that the RPGs for the whole body apply to the appropriately weighted sum of the doses from both internal and external exposures; and (e) that the dose to the embryo and the fetus be limited through one of several alternative recommendations.

We welcome written comments on these proposals and will hold public hearings as discussed below. We will carefully consider all oral and written comments in preparing our final recommendations to the President.

DATES: 1. All written comments in response to this notice must be received by us by April 24, 1981, in order to be used.

2. Public hearings will be held at the following locations, beginning no earlier

than 60 days following publication of this notice: Washington, D.C., Chicago, Illinois. San Francisco, California, Houston, Texas. We will publish the times and addresses for these hearings shortly.

3. Instructions of interest to those who wish to appear at the public hearings are given below under the heading "Public Hearings."

ADDITIONAL INFORMATION: We will be happy to send a copy of a background report which provides additional information on these proposed recommendations to anyone requesting it. Please send requests to Mr. Luis F. Garcia at the address below. This report is also available for inspection and copying at EPA's Central Docket Section and ten Regional Offices (addresses below).

ADDRESSES: Written comments should be addressed to the Director, Criteria and Standards Division (ANR-460), U.S. Environmental Protection Agency, Washington, D.C. 20460, Attention: Docket No. A-79-46. These comments and the public hearing record will be filed under the above docket number and will be available for inspection and copying at the U.S. Environmental Protection Agency's Central Docket Section, Room 2903B, Mall 401 M Street, S.W., Washington, D.C. 20460, and at the Agency's library in each of its ten regional offices: *Region I:* JFK Building, Room 2100-B; Boston, Massachusetts 02203 (Tel. 617-223-5791); *Region II:* 26 Federal Plaza, Room 1002, New York, New York 10278 (Tel. 212-264-2881); *Region III:* Curtis Building, 6th & Walnut Streets, Philadelphia, Pennsylvania 19106 (Tel. 215-597-0580); *Region IV:* 345 Courtland Street, N.E., Atlanta, Georgia 30365 (Tel. 404-881-4216); *Region V:* 230 South Dearborn Street, Room 1417, Chicago, Illinois 60604 (Tel. 312-353-2022); *Region VI:* First International Building, 1201 Elm Street, 28th Floor, Dallas, Texas 75270 (Tel. 214-767-7341); *Region VII:* 324 East 11th Street, Kansas City, Missouri 64106 (Tel. 816-374-3497); *Region VIII:* Radiation Program Office (in lieu of library), 1860 Lincoln Street, Second Floor, Denver, Colorado 80203 (Tel. 303-837-2221); *Region IX:* 215 Fremont Street, 6th Floor, San Francisco, California 94105 (Tel. 415-556-1841); *Region X:* 1200 Sixth Avenue, 12th Floor, Seattle, Washington 98101 (Tel. 206-442-1289).

FOR FURTHER INFORMATION CONTACT: Contact Mr. Luis F. Garcia, U.S. Environmental Protection Agency (ANR-460), Washington, D.C. 20460 (Telephone 703-557-8224), about these proposed recommendations or the public hearings.

SUPPLEMENTARY INFORMATION:

Statutory Authority

The Administrator of the Environmental Protection Agency (EPA) is charged under Executive Order 10831, Reorganization Plan No. 3 of 1970, and Public Law 86-373 to " * * * advise the President with respect to radiation matters, directly or indirectly affecting health, including guidance for all Federal agencies in the formulation of radiation standards and in the establishment and execution of programs of cooperation with States." This guidance has historically taken the form of qualitative and quantitative "Radiation Protection Guidance." The recommendations we propose here would replace those portions of existing Federal guidance that apply to radiation protection of workers, which were adopted in 1960 (25 FR 4402).

Previous Actions by EPA

We began this review of the 1960 radiation protection guidance for workers in 1974. The most recent notice of this activity listed the principal issues being addressed and announced our intent to hold public hearings on proposed recommendations (44 FR 53785, Sept. 17, 1979).

We have sponsored two major studies in support of this program. First, the Committee on the Biological Effects of Ionizing Radiations, National Academy of Sciences—National Research Council, has reviewed the scientific data on the health risks of low level ionizing radiation developed since its 1972 report. Second, we have carried out a study of occupational radiation exposures and published our findings in a report entitled: "Occupational Exposure to Ionizing Radiation in the United States: A Comprehensive Summary for the Year 1975." We have also considered recent recommendations of the National Council on Radiation Protection and Measurements.

In developing these proposals, we have also consulted with the technical staffs of the Federal agencies that regulate or influence the regulation of occupational exposure, and will continue this consultation in developing final recommendations. These agencies are the Occupational Safety and Health Administration, the Nuclear Regulatory Commission, the Mine Safety and Health Administration, the Department of Defense, the Department of Energy, the Department of Transportation, the Food and Drug Administration, the National Aeronautics and Space Administration, the National Institute for Occupational Safety and Health, and

¹Radiation Protection Guides.

²A rad is a unit of measure for dose, i.e., the amount of ionizing radiation energy absorbed per unit weight of tissue. Thus, the same energy absorbed by twice as much tissue gives only one-half the number of rads. The rem, a unit for dose equivalent, is a rad multiplied by factors which describe how damaging the type of radiation is.

³In this notice we henceforth use "dose" to mean "dose equivalent."

the National Bureau of Standards. These agencies, which have not formally endorsed these recommendations, will formally review final proposals when they are developed following public review.

Issues Addressed

The principal issues we addressed in formulating these recommendations were identified in the advance notice cited above. They were:

1. Are the doses currently received by workers and the maximum doses permitted under existing guidance adequately low? In this regard, a) how adequate is the basis used for estimating risks to health from radiation exposure, and b) what are the appropriate bases for judging maximum individual and collective radiation doses in the work force and the tradeoffs between these two indices of the health impact of occupational exposure?

2. Should the same guides apply to all categories of workers (e.g., dental workers, nuclear medicine technicians, nuclear maintenance personnel, industrial radiographers)? Should specific guides be developed for pregnant women, female workers who could bear children, and/or men?

3. On what time basis should the guides be expressed? Quarterly? Annual? Should the lifetime occupational dose be limited? Should the age of the worker be a factor?

4. Should the guidance reflect or cover medical, accidental, and/or emergency exposures?

5. Is existing guidance for situations that involve exposure of less than the whole body adequate? In this respect, a) what organs and parts of the body should have designated limits, and b) on what basis should guidance be expressed for exposure of more than one organ or portion of the body?

6. How should the radiation protection principles requiring a) justification of any exposure, and b) reduction of the dose from justified exposures to the lowest practicable or as low as is reasonably achievable level be applied to exposure of workers? Should the concept of lowest feasible level be applied to exposure of workers?

7. What, if any, relationship should be maintained between permissible levels of risk to health from radiation exposure and other regulated hazards of disease or accidents?

Additional issues suggested since publication of the advance notice include:

8. Should the guidance include numerical values for the factors (called "quality" and "modifying" factors) used to convert dose (measured in rads) to

dose equivalent (measured in rem)? If so, should this be developed now or issued later as supplementary guidance?

9. What guidance should apply to workers who do not use radiation sources, but who are exposed to radiation due to the activities of workers under the control of other employers?

10. Are there situations that may require doses higher than normally permitted? Should we provide special guidance for them?

Many of these issues are addressed below. However, for a more complete and extensive discussion please refer to the background report cited above under the heading "Additional Information."

Risks From Occupational Exposure

There are three kinds of risks from the low levels of ionizing radiation characteristic of occupational exposures. The most important of these is cancer, which is fatal at least half the time. Another risk is the induction of hereditary effects in descendants of exposed persons. The severity of these effects ranges from fatal to inconsequential. We assume that at low levels of exposure the risk of cancer and hereditary effects is in proportion to the dose received, and that the severity of any induced effect is independent of the dose level. That is, while the probability of a given type of cancer occurring increases with dose, such a cancer induced at one dose is equally as debilitating as that same type of cancer induced at another dose. Thus, for these effects we assume that there is no completely risk-free level of radiation exposure.

The third type of risk includes a variety of other effects on workers and on the children of women exposed during pregnancy. These effects range from serious effects on children, such as mental retardation, to less serious effects on workers, such as opacification of the lens of the eye and temporary impairment of fertility. For these effects we believe the degree of damage (i.e., the severity) depends to some extent on the dose level. At the dose levels allowed by current radiation protection guides, we believe that none of the effects on workers themselves occurs to a degree sufficient to be clinically detectable. At these levels, however, effects on children exposed in utero may be serious.

The risks of effects on health from low level ionizing radiation were reviewed for EPA by the National Academy of Sciences (NAS) in reports published in 1972 and in 1980. We have used these studies and others to estimate the risks associated with the current and proposed Federal guides for limiting

radiation dose. Details of these and other risk estimates we use are provided in the accompanying background report.⁴

A worker who received the largest lifetime dose allowed under present guides (5 rem per year from age 18 to assumed retirement at age 65, or 235 rem) would have a lifetime risk of about 3 to 6 in 100 of dying from radiation-induced cancer, and numerically comparable chances both of nonfatal cancer and, for male workers, of mutational effects in his descendants.⁵ Risks of mutational effects from exposure of female workers are assumed to be three to four times smaller. However, in our recent national survey of exposures for the year 1975, 99% of all workers received less than half of, and only 0.15% exceeded, an annual dose of 5 rem. Based on these and other data, we believe that only a few workers involved in accidents have received close to the current maximum allowed lifetime dose.

The average worker exposed to radiation sustains only a small risk of death from radiation. The estimated average risk of death due to radiation-induced cancer is smaller, for example, than the risk of job-related accidental death in the safest of all major occupational categories, retail trades, for which the annual death rate was 60 per million workers in 1975. We estimate that the collective dose to the more than one million workers potentially exposed to radiation in their workplace for that same year will not lead to more than 15-36 premature cancer deaths. Other ways of expressing this risk are that the exposure of an average worker to radiation in 1975 represented an average lifeshortening of about two to three and a half hours, or an average increase in his chance of cancer death of about one to three in 100,000. In 1975 about one sixth of United States deaths were from cancer.

The comparative time-loss associated with nonfatal cancer is also estimated to be very small. The average time lost by

⁴Our estimated ranges of risk for cancer death are based on absolute and relative linear risk models used by the 1972 BEIR Committee and the assumption that the risk of incurring most radiogenic cancers continues throughout the lifetime of exposed persons. The 1980 BEIR report, which was just published, gives estimates based on a variety of risk models, some of which yield lower and some higher values. Based on our preliminary review, we do not believe that the differences between these values and those we have adopted here would lead to any changes in these proposals.

⁵Mutational effects here mean those hereditary effects included by the BEIR Committee in their 1972 report as serious disabilities. Examples are congenital malformations leading to premature death, hemophilia, sickle cell anemia, cystic fibrosis, diabetes, schizophrenia, and epilepsy.

U.S. workers due to all occupationally-related injuries and illnesses over a working lifetime is one month. For radiation-induced nonfatal cancers it is estimated to be about four days for a hypothetical individual receiving the largest lifetime dose allowed (235 rem), and for the average worker it is about two hours.

Limitation of Whole Body (External) Exposure

Based on these observations, risks due to occupational exposure to radiation do not appear to be unreasonably high for the average worker. They are comparable to risks of accidental death in the least hazardous occupations. However, a worker exposed to the current maximum allowed dose year after year would sustain substantial risks. The proposed radiation protection guidance contains provisions to avoid the accumulation of large lifetime doses through reduction of the maximum allowed annual dose and through specific minimum radiation protection requirements for workers in high-dose work situations. These include on-the-job radiation protection supervision for high-dose jobs, maintenance of lifetime dose records, and an admonition that exposure of workers should be managed so that their lifetime doses do not exceed 100 rem.

Existing Federal guidance permits doses up to 3 rem per quarter (or 12 rem per year), within an overall cumulative limit of $5(N-18)$ rem, where N is the age of the worker. This flexibility, which allows annual doses greater than 5 rem, does not permit specific tasks that require doses to individuals of more than 5 rem (since the 3 rem per quarter limit prohibits this), but it does permit the same worker to accomplish several tasks requiring doses at or near this quarterly limit in a given year. In view of the risks, it is our judgement that repeated exposures in a year at such levels should not occur, and these recommendations would eliminate this flexibility. One appropriate solution in cases where workers with specific skills are in short supply is to train additional workers, rather than to impose higher risks on a few individuals.

Because we assume that any exposure carries some risk, we believe that it is important to avoid unnecessary exposures at any exposure level. Although more than 97% of all workers in our survey received annual doses less than one rem, these same workers accumulated about half of the collective dose received by the entire work force. Many of these workers, because their doses are low compared to the limits, may receive only minimal training,

supervision, and monitoring for radiation protection. Many also work in situations where there is no need for exposures to ever approach the existing or the proposed new RPGs. On the other hand, some exposures at higher doses are justified. The proposed recommendations, therefore, provide a graded system of radiation protection which would establish minimum radiation protection requirements for each of three different ranges of exposure within the basic guides for maximum allowed dose to all workers. We anticipate that maximum exposure of the vast majority of workers would be effectively limited to the lowest of these ranges (less than approximately 0.5 rem to the whole body per year) through the deterrent of requirements for increased justification, on-the-job radiation protection supervision, and monitoring in the two higher ranges. In addition, the recommendations encourage regulatory agencies to establish more restrictive regulatory limits for work situations not requiring the maximum doses allowed under the basic guides.

The proposed guidance leaves agencies considerable discretion in implementing the minimum radiation protection requirements for justification of exposure of workers in each of the various ranges. We are considering additional guidance which would recommend the establishment of more explicit requirements for the highest range (Range C). These requirements could include establishment of criteria for use of Range C, or prior application to and approval by the regulatory agency of Range C exposure (either for specific or more general job situations). We request specific comments on these and similar approaches to further restrictions on the exposure of workers at these higher levels.

We have considered both higher and lower alternatives to the proposed 5 rem/year RPG for whole-body exposure. This value is proposed because (a) it is the current internationally-accepted value, (b) there appear to be essential jobs requiring near 5 rem per year, and (c) the risks to the few workers in these jobs are not high compared to other industrial hazards. In addition, the costs for levels significantly lower (one rem/year or less) appear to be unwarranted, both in terms of increased collective dose to the entire workforce (in return for a few lower individual doses), and in terms of increased economic costs.

In 1975 the National Council on Radiation Protection and Measurements took the position that no change was required in the recommendation given by it in 1971. That recommendation is

that "The maximum permissible prospective dose equivalent for whole body irradiation from all occupational sources shall be 5 rems in any one year" (NCRP Report No. 39, Jan. 15, 1971). Likewise the International Commission on Radiological Protection in 1977 recommended a basic dose-equivalent annual limit of 5 rem for whole body exposures to ionizing radiation (ICRP Publication 26, Jan. 17, 1977). In support of its recommendation the ICRP states that "The Commission believes that for the foreseeable future a valid method for judging the acceptability of the level of risk in radiation work is by comparing this risk with that for other occupations recognized as having high standards of safety. . . ." The radiation risk factors given in ICRP Publication 26 in arriving at its recommendation were reviewed by ICRP in May 1978 and no changes were made (ICRP Publication 28, 1978).

Nevertheless, these recommendations are all value judgments; there is not now compelling evidence for any particular value and it is hard to get such evidence. In judging the acceptability of the risks involved, it is necessary to identify (a) activities that cannot be performed at particular maximum dose levels, (b) skilled professionals and workers in limited supply whose numbers would be difficult to quickly increase in order to reduce average annual doses, and (c) the costs for additional workers and equipment that would be needed to meet different limits. For example, we are aware of a small number of maintenance tasks at nuclear power stations that could not be done under some limits less than 5 rem/year. There may be many more examples of professions, principally in medical areas, with limited labor pools. These include cardiologists performing catheterizations using fluoroscopy; and radiologists, neuro-radiologists, and nuclear medicine technologists with large patient loads for special procedures. Finally, studies by the Department of Energy and the nuclear power industry report that large costs and many more workers would be needed to greatly reduce the dose limits for many operations. Their projections of costs and personnel requirements increase exponentially with decreasing limits. We therefore request, in addition to comment on reduction of the current RPG of 3 rem/quarter to our proposed recommendation of 5 rem/year, comment on the above factors for reduction of the current RPG to 0.5 rem/year, 1 rem/year, and 3 rem/year.

Limitation of Partial Body Exposures

Exposure of portions of the body can occur through localized irradiation of

extremities (such as hands in glove boxes), or by breathing or swallowing radioactive materials, which then migrate to different organs of the body.

Current guidance limits such exposures through separate numerical guides for organs and for individual parts of the body that are easily exposed, such as hands and feet or lens of the eye. Some organs recognized as easily subjected to high doses or as particularly sensitive to radiation have specific guides.

These current guides are applied separately. For example, even though a worker has received the maximum allowed dose to his thyroid, he may also receive doses to his lungs, skin, or any other organ, as long as no single organ receives more than the dose specified by its guide. We assume that the risks associated with such multiple doses are additive.

An alternative approach is to limit the total risk of fatal cancer in all exposed organs. This method has been adopted by the International Commission on Radiological Protection (ICRP). It is also adopted in these recommendations, but only when it leads to a greater degree of protection than limiting the dose to critical organs. Specifically, the recommended guidance provides that (a) either the combined risk of fatal cancer from all doses to individual organs not exceed the risk permitted under the whole body guide or (b) the dose to the most significantly exposed organ not exceed its guide, whichever is more restrictive. The recommendations also provide, when workers receive both external doses from whole-body exposure and internal doses from radionuclides, that the sum of the risks of fatal cancer from external whole-body doses and those due to breathing or swallowing radioactive materials not exceed the risk of fatal cancer allowed by the whole-body guide.

The numerical weighting factors chosen to relate risks to individual organs to whole-body risk are discussed in the background report cited above. In general, they are consistent with recent determinations of risk of fatal cancer by national and international scientific bodies, such as the NAS and the ICRP.

We have chosen the limiting annual dose to most single organs to be 30 rem, rather than the internationally-adopted value of 50 rem, because we do not see a need for a value higher than any now used in this country. The risk associated with 30 rem to any of these organs is equal to or less than that of 5 rem to the whole body. Additional differences from internationally-used values for gonads, lens of eye, and hands are discussed below.

It is usually impractical to directly monitor the dose received by a worker who breathes or swallows radioactive materials, but it is useful to be able to predict doses that may be received from breathing contaminated atmospheres or swallowing contaminated materials. To make decisions about radiation protection of such workers possible, it is necessary to calculate the amounts of different kinds of radioactive materials which, when breathed in or swallowed, give the maximum dose allowed by the RPGs. Those calculations require complex models of metabolism and dosimetry. We propose that these limiting amounts of radioactivity be designated the "Radioactivity Intake Factors" (RIFs), and that they replace the currently used "Radioactivity Concentration Guides."

Recent advances in modeling metabolism and dosimetry have produced significant changes in the doses calculated for radioactive materials in the body. For many radioactive materials the changes in the RIFs due to changes in the models are considerably larger than the changes due to the proposed new RPGs. These new models more often reduce allowable intakes than raise them. However, for those cases where the RIF for any specific radionuclide would be increased, the question arises whether regulations adopted by implementing agencies should retain existing values, in accordance with proposed Recommendations 2 and 6. We believe that, for existing applications, experience gained over the past two decades shows that current values can be reasonably achieved. Accordingly, in cases where the RIF for any specific radionuclide would be increased under the proposed guidance, we recommend that the value adopted in regulations governing existing applications be no higher than that now in use. A summary of the changes due to the new models and to the proposed new guides is provided for the more significant radionuclides in the background report.

Limitation of Risk From Mutations

The current guides for limiting dose to the gonads are identical to those for the whole body. For a given annual dose, the risk of mutational effects in all of a male worker's descendants combined is believed to be numerically comparable to his lifetime risk of fatal cancer. The risk to a female worker's descendants is smaller. The medical severity of these hereditary effects is usually less than, and, at worst, comparable to, death from cancer. For these reasons we do not believe that a more restrictive guide is required for the gonads than for the

whole body. The proposed new guide for gonadal dose is therefore identical to that proposed for the whole body. This guide is specified separately and not included in the scheme proposed above for weighting partial-body doses because the risks involved are of a fundamentally different nature: the affected individual is not the one exposed to radiation and the effects include different types of harm.

Limitation of Risk to the Unborn (Fertilized Oocyte, Embryo, and Fetus)

Protection of the unborn from radiation is an already well-established principle; the purpose of the guide for gonadal exposure is to limit mutational effects in children conceived after the exposure. However, those conceived but not yet born, the "unborn," are also at risk. Their risks are greater, for a given dose, than the risks to those not yet conceived. Current guidance does not contain a dose limitation to protect the unborn from these risks.

The risk of serious harm following in utero exposure requires careful attention because of the magnitude and diversity of the effects, because they occur so early in life, and because those who suffer the harm are involuntarily exposed. These risks are not as well quantified as those to adults. Nevertheless, available evidence indicates that at critical periods in the development of the unborn, for the same dose, risks may be many times greater than those to adults.

There are several factors which mitigate this situation. First, the exposure of most workers under annual limits is relatively evenly distributed over the year, so that only a quarter of a worker's annual dose is delivered to the unborn during any trimester. Second, the mother's body provides considerable shielding of the unborn for most types of exposure. Finally, the total period of potential exposure is small for the unborn compared to that for a worker—a period of months compared to a working lifetime.

It is difficult to provide for protection of the unborn without affecting the rights of women to equal job opportunities. This difficulty is compounded because the critical period for most harm to the unborn occurs soon after conception—during the second and third month after conception, when a woman may not know that she is pregnant. Based on our assessments of the risks and the other factors noted above, we believe that the maximum dose to the unborn should be a factor of ten below the maximum permitted adult workers in any year. This is also the current recommendation of the National

Council on Radiation Protection and Measurements. In Recommendation 8 we propose four alternatives which would, with varying degrees of certainty, achieve this objective.

The first two alternatives rely upon voluntary compliance and, therefore, should have less impact on equal job opportunities for women. The first assumes a woman knows she is pregnant within six weeks of conception, and will then, along with her employer, take appropriate protective action. It therefore does not guarantee that doses to the unborn during the critical early stages of pregnancy will be less than 0.5 rem.

The second alternative adds a voluntary limit on dose rate to women who can bear children in order to protect the unborn whose existence is not yet known. It permits women to hold any job, but encourages women able to bear children not to take those few jobs which potentially involve high dose rates.

The third alternative insures protection of all unborn throughout gestation by making the voluntary requirements of the second mandatory. It would bar women of child-bearing capacity from those few jobs which involve high dose rates.

The final alternative would restrict the exposure of all workers, male and female, to a level which would protect the unborn at the level of the first alternative. This alternative preserves equal job opportunity for women at the cost of causing more total harm. Studies of several high exposure activities show that decreasing the dose limits to this extent would significantly increase the collective dose to workers, and that some current activities would not be possible.

None of these alternatives is completely satisfactory; they each involve either varying degrees of adequacy of protection of the unborn, some sacrifice of equal job opportunity for women, or causing more total harm, or foregoing some of the benefits to society from activities using radiation. We invite public comment on the relative importance to be attached to each of these factors in formulating guidance, and on whether or not the guidance should address this matter now. We would also be happy to receive suggestions for other alternatives.

Limitation of Other Risks

The risk of nonfatal cancer is not only intrinsically less important than that of fatal cancer, but is very much smaller than other nonfatal occupational risks. Thus, we believe the protection provided against fatal cancers includes

adequate protection against nonfatal cancers.

While adequate protection against cataracts of the lens of the eye might be provided by a higher maximum average annual dose than the 5 rem now allowed, no operational difficulty is reported with use of 5 rem as an annual limit. That value is therefore retained in these proposals.

The maximum annual dose for skin of the whole body is maintained at 30 rem, since a need for allowing higher doses has not been demonstrated. However, the current guide permits 75 rem to hands and forearms, or feet and ankles, because of the assumed lower risk when only these portions of the skin and underlying tissue of these extremities are involved. We agree that at low dose rates the risk depends in some degree on the amount of skin and tissue exposed, and that exposure of the extremities is therefore less dangerous than of the whole body. However, for forearms, feet, and ankles such a high value is not needed and we propose that the guides for skin and the whole body apply to these extremities. For the hands a higher value appears to be justified for work in glove boxes. It is proposed to be 50 rem, the limit recommended by the ICRP.

Other Considerations

These recommendations apply to workers exposed to other than normal background radiation on the job. It is sometimes hard to identify such workers, because everyone is exposed to natural sources of radiation and many occupational exposures are small. Regulatory agencies will have to use care in selecting classes of workers whose exposure does not need to be regulated. In selecting such classes we recommend that the agency consider both the collective dose which is likely to be avoided through regulation and the maximum individual doses possible.

The question often arises whether or not exposure for medical purposes and other nonoccupational exposures should be considered in calculating the doses that workers receive within the guides. If there were a threshold for risk of health effects from radiation, this could be an important consideration. However, since we assume that the risk at low doses is proportional to the dose, each exposure must be justified on its individual merits. For this reason, in Note 1 to the recommendations we exclude medical and other nonoccupational exposure from the total calculated occupational radiation exposure of workers.

In many jobs diagnostic x-ray examinations are a routine part of periodic or pre-employment physical

examinations. Some of these examinations are a condition of employment and some are not. Federal radiation protection guidance on use of diagnostic x-rays was issued by the President on February 1, 1978 (43 FR 4377). These recommendations provide that, in general, use of such x-ray examinations should be avoided unless a medical benefit will result to a worker, considering the importance of the x-ray examination in preventing and diagnosing diseases, the risk from radiation, and the cost. Although all of the recommendations in that guidance may be usefully applied to x-ray examinations of workers, Recommendations 1 through 4 are particularly pertinent. Because this matter has been addressed by separate Federal guidance, exposure from such diagnostic x-ray examinations is not included in this guidance for occupational exposure.

Current Federal guidance provides that occupational doses to minors (those below the age of eighteen) be limited to one tenth the RPGs for older workers. We propose no change.

No other general types of exposed workers are singled out for special protection by these recommendations. However, one special class of workers—underground uranium miners—is already subject to a separate Federal guide (36 FR 12921). That guide limits exposure of their lungs to radioactive decay products of radon gas. The Mine Safety and Health Administration regulates exposure of all underground miners in accordance with this guide. We expect to review the guide on the exposure of miners to decay products of radon in the future. Exposure of miners to other radiation is governed by the Federal radiation protection guidance in these proposed recommendations.

We have not addressed the issues of emergency exposures or of whether overdoses in one year should lead to additional restrictions on doses in future years. Such situations must be dealt with on the merits in each case and under the regulatory mandate of the controlling Federal agency. We do not consider it either practical or reasonable to prejudge or prescribe general conditions for such situations beyond the general principles which apply to all radiation exposure that are set forth below in Recommendations 1 and 2.

We recognize, in addition, that some situations may exist which justify planned exposures exceeding the guides. Recommendation 9 provides for this. It requires that the controlling Federal agency fully consider and disclose the reasons for any such exposures.

Estimated Impact of These Proposals

We estimated above that the exposure of 1.1 million workers in 1975 (the latest year for which we have complete statistics) will lead to 15-36 additional premature cancer deaths and comparable numbers of serious mutational effects and nonlethal cancers. If this new guidance is adopted, workers should be harmed less in the future. We are not able to quantify the improvement because we cannot predict how efficiently the guidance will be implemented and we do not know how much of existing exposure is unjustified. However, the proposed recommendations provide a framework of graded minimum requirements to cut down the amount of unjustified exposure, and a recommendation that implementing agencies establish lower regulatory limits for workers who can operate significantly below the new maximum limits. We believe that most workers can. The proposals also reduce the maximum annual and lifetime dose that any workers can get by about 60%.

We have made only a limited assessment of the costs of implementing this proposed guidance. We do not believe it would be prudent to attempt a detailed analysis, because agencies developing regulations to carry out this guidance may use different means, and their specific proposals will be subjected to public review and economic analysis when they are developed.

The principal cost will be that associated with reduced RPGs. In order to comply with a reduced RPG an enterprise can hire more workers, reassign (and, if necessary, retrain) present employees, improve its procedures or technology, or curtail the activity. In general, a mix of these will be used, depending on the value of the reduced RPG, on the cost of each alternative, and on other factors. Since we do not know what mix will be used, for the purpose of developing rough numerical estimates of the upper bounds of costs we have used a simple model based on the costs for hiring new workers only.

From the distribution of doses found in our national survey of exposures for the year 1975, we computed the total excess collective dose between the old RPG of 3 rem per quarter and the proposed RPG of 5 rem per year. Dividing this excess by the value of the proposed new RPG gives the minimum number of workers that must be hired to absorb this dose. The average labor cost, including overhead, for each additional worker was assumed to be \$40,000 per year. This method yields a

cost of about \$35 million per year. We believe the actual cost of meeting the new RPG will be much less.

We have also attempted to evaluate costs if existing workers now receiving lower doses are retrained to do high-dose jobs instead of hiring new workers. Some workers are very difficult to replace (e.g., medical professionals, such as cardiologists and radiologists; and workers in small enterprises with very limited labor pools). However, we believe that most workers can be relatively easily retrained (e.g., medical technicians and skilled laborers, such as welders and pipe fitters) to handle tasks which cause higher exposures. We estimate that workers that can be reassigned to these jobs would require training varying from a few days to a few months. For these workers, the costs are expected to range from a few percent to a few tens of percent of the annual cost of new hires. In addition, these costs are incurred only once instead of annually, as in the case of new hires. We therefore estimate that the costs based on the above new hires model may be as much as ten times too high, for the first year, and an even greater over-estimate in succeeding years. We welcome comments on the costs of implementing these proposals, on whether or not the costs are reasonable, and why.

Proposed Recommendations

We propose nine recommendations as guidance to Federal agencies in the formulation of Federal radiation protection standards for workers, and in their establishment of programs of cooperation with States. In all cases but one we have made single recommendations for public comment. The exception, Recommendation 8, addresses protection of the unborn during gestation. Because this recommendation involves issues that go beyond simple radiation protection of workers, including equality of employment rights and the rights of the unborn, we have proposed four alternatives for public consideration. The recommendations follow:

1. All occupational exposure should be justified by the net benefit of the activity causing the exposure. The justification should include comparable consideration of alternatives not requiring radiation exposure.
2. For any justified activity a sustained effort should be made to assure that the collective dose is as low as is reasonably achievable.
3. The radiation dose to individuals should conform to the numerical Radiation Protection Guides (RPGs) specified below. Individual doses should

be maintained as far below these RPGs as is reasonably achievable and consistent with Recommendation 2.

Radiation Protection Guides

a. The sum of the annual dose equivalent⁶ from external exposure and the annual committed dose equivalent⁷ from internal exposure should not exceed the following values:

Whole body—5 rem
Gonads—5 rem
Lens of eye—5 rem
Hands—50 rem
Any other organ—30 rem

b. Non-uniform exposure of the body should also satisfy the condition on the weighted sum of annual dose equivalents and committed dose equivalents,

H_w , that

$$H_w = \sum_i w_i H_i < 5 \text{ rem},$$

where w_i is a weighting factor, H_i is the annual dose equivalent and committed dose equivalent to organ i , and the sum excludes the gonads, lens of eye, and hands. Recommended values of w_i are:

Breast—0.20
Lung—0.16
Red bone marrow—0.16
Thyroid—0.04
Bone surfaces—0.03
Skin—0.01
Other organs⁸—0.08

c. When both uniform whole-body exposure and nonuniform exposure of the body occur, in addition to the requirements of 3a, the annual uniform whole-body dose equivalent added to the sum of weighted annual dose equivalents from additional nonuniform exposure, H_w , should not exceed 5 rem.

4. The following Minimum Radiation Protection Requirements should be established by appropriate authorities and carried out in the workplace, on the basis of the range of doses anticipated in individual work situations. The numerical values specifying the dose ranges may be adjusted to fit the needs of specific situations by implementing agencies.⁹

⁶ "Dose equivalent" means the quantity expressed by the unit "rem," as defined by the International Commission on Radiation Units (ICRU).

⁷ "Annual committed dose equivalent" applies only to dose equivalents from radionuclides inside the body. It means the sum of all dose equivalents that may accumulate over an individual's remaining lifetime (usually taken as 50 years) from radioactivity that is taken into the body in a given year.

⁸ Applies only to each of the five other organs with highest doses.

⁹ Suggested numerical ranges are: Range A, less than 0.1 RPG; Range B, 0.1-0.3 RPG; Range C, 0.3-1.0 RPG.

Minimum Radiation Protection Requirements

Range A

a. Determine that exposures result only from justified activities and are as low as is reasonably achievable. These determinations may often be made on a generic basis, that is, by considering groups of similar work situations and protective measures.

b. Monitor or otherwise determine individual or area exposure rates to the extent necessary to give reasonable assurance that doses are within the range and are as low as is reasonably achievable.

c. Instruct workers on basic hazards of radiation and radiation protection principles, and on the levels of risk from radiation and appropriate radiation protection practices for their specific work situations. The degree of instruction appropriate will depend on the potential exposure involved.

Range B

The above requirements, plus:

d. Provide professional radiation protection supervision in the work place sufficient to assure that both individual and collective exposures are justified and are as low as is reasonably achievable.

e. Provide individual monitoring and recordkeeping.

Range C

The above requirements, plus:

f. Justify the need for work situations which are expected to make a significant contribution to exposure in Range C and provide professional radiation protection supervision before and while such jobs are undertaken to assure that collective and individual exposures are as low as is reasonably achievable.

g. Carry out sufficient additional monitoring of workers to achieve Recommendation 4f.

h. Once a worker has been exposed in Range C, maintain a lifetime dose record, including at least all subsequent annual doses (as specified in Recommendation 3c) in Ranges B and C.

i. Maintain lifetime doses as low as is reasonably achievable. The accumulation of doses (as recorded under Recommendation 4h) by individual workers should be managed so that their lifetime accumulated dose is less than 100 rem.

5. a. "Radioactivity Intake Factors" (RIFs) should be used to regulate occupational radiation hazards from breathing, swallowing, or immersion in media containing radionuclides. The RIF for a radionuclide is defined as the

maximum annual intake (in curies) for which the committed dose equivalent to a reference person satisfies the Radiation Protection Guides in Recommendation 3. RIFs may be derived for different chemical or physical forms, and for intake by breathing, swallowing, or for external exposure from air containing a radioactive gas. Exposure regulated through use of the RIFs should meet the same Minimum Radiation Protection Requirements as equivalent exposure under the Radiation Protection Guides.

b. When a RIF for a specific radionuclide in a specific chemical or physical form determined on the basis of part (a) is larger than that currently in use, a value no greater than that in current use should be adopted in regulations governing work situations identical or similar to those currently in existence.

6. Federal agencies should establish limits and administrative levels that are below the RPGs and the RIFs, when this is appropriate. Such limits or levels may apply to specific categories of workers or work situations.

7. In addition to any other Federal restrictions, the occupational exposure of individuals younger than eighteen should be limited to one tenth of the Radiation Protection Guides for adult workers.

8. Exposure of the unborn¹⁰ should be restricted more than that of workers. This should include special consideration of ALARA practices for women. Women able to bear children should be fully informed of current knowledge of risks to the unborn from radiation. In addition, employers should assure that protection of the unborn is achieved without loss of job security or economic penalty to women workers. Due to the complexity of the issues involved, we propose four alternative recommendations on numerical limitation of dose to the unborn for public comment. We would be glad to receive other recommendations for dealing with exposure of the unborn.

a. Women are encouraged to voluntarily keep total dose to any unborn less than 0.5 rem during any known or suspected pregnancy; or

b. Women able to bear children are encouraged to voluntarily avoid job situations involving whole-body dose rates greater than 0.2 rem per month, and to keep total dose to the unborn less than 0.5 rem during any known pregnancy; or

c. Women able to bear children should be limited to job situations

¹⁰ "Unborn" here means the fertilized oocyte, the embryo, and the fetus.

involving whole-body dose rates less than 0.2 rem per month. Total dose to the unborn during any known period of pregnancy should be limited to 0.5 rem; or

d. The whole-body dose to both male and female workers should not exceed 0.5 rem during any six month period.

9. In exceptional circumstances the RPGs may be exceeded, for cause, but only if the Federal agency having jurisdiction carefully considers the specific reasons for doing so, and publicly discloses them unless this would compromise national security.

The following notes clarify application of the above recommendations:

1. Occupational exposure of workers does not include that due to (a) normal background radiation and (b) exposure as a patient of practitioners of the healing arts.

2. When the uniform external whole-body exposure occurs in addition to exposure from radioactive materials taken into the body, the requirement of Recommendation 3c may be satisfied by the condition that

$$\frac{H_{ext}}{RPG_{wb}} + \sum_j \frac{I_j}{RIF_j} \leq 1,$$

where H_{ext} is the annual external whole-body dose equivalent, RPG_{wb} is 5 rem, I_j is the intake of radionuclide j , and RIF_j is defined as in Recommendation 5.

3. The values currently specified by the ICRP for quality factors and dosimetric conventions for measurement of the various types of radiation may be used for determining conformance with the RPGs. The model for a reference person and the metabolic models currently specified by the ICRP may be used to calculate the RIFs. We will recommend other factors, conventions, and models when and if they are more appropriate.

4. Numerical guides for emergency exposures are not provided by this guidance. Agencies should follow the general principles established by Recommendations 1, 2, 7, 8, and 9 in dealing with such situations.

5. Procedures for handling overexposures are not addressed by this guidance. The equitable handling of such cases is the responsibility of the employer and the Federal agency having regulatory jurisdiction.

6. Limits for periods other than one year may be derived by Federal agencies from the annual RPGs and RIFs when necessary for administrative

they wish. Questions should be designed to elicit relevant information and should not be repetitious of questions asked by others. The views of questioners should be expressed in their statements and not as prefaces to questions. Such informal questioning will be at the discretion and under the control of the presiding officer.

d. Members of the public who are not able to attend the hearings or prefer not to ask questions themselves may suggest questions to the hearing panel to ask of speakers. These must be submitted no later than 14 days before any hearing to the Director (see "Addresses" above). The panel will decide whether or not to ask these questions.

e. Members of the public may also submit comments during the post-hearing comment period set by the presiding officer. These post-hearing comments should be confined to responses to data and opinions submitted at the hearings or to written comments received by the Agency.

f. In addition to these public hearings, we would appreciate any written comments on these proposals. These will be given equal consideration in formulating final recommendations. The procedure for submitting such written comment is given above under the headings "Dates" and "Addresses."

Participants in the hearings may refer to comment on such written comments, which will be available for public inspection and copying as specified below under "The Public Hearing Record."

5. Opening Statement

At the opening of each hearing, EPA will provide a summary statement of the proposed recommendations and of the major issues involved. At that time speakers and other members of the public can ask questions of the EPA representatives in order to clarify the proposed recommendations and the reasons why EPA is proposing them.

6. The Public Hearing Record

The procedures for filing documents in these hearings will be specified by the presiding officer, except as already provided herein.

The hearing record will include the transcript of oral statements by speakers, the questions and answers, and all written materials filed in connection with these hearings. Items in the public hearing record will be filed under EPA Docket No. A-79-48 and will be available for public inspection and copying as soon as possible following their receipt, at the U.S. Environmental Protection Agency's Central Docket Section, Room 2903B, Mall, 401 M Street,

S.W., Washington, D.C. 20460, and at each of the Agency's ten regional offices (see "Addresses" above).

Dated: January 16, 1981.

Douglas M. Costle,
Administrator.

[FR Doc. 81-2385 Filed 1-22-81; 8:45 am]

BILLING CODE 6560-28-34

purposes. Such limits should be consistent with Recommendation 2 and the three ranges in Recommendation 4.

7. The existing guide for limiting exposure of underground uranium miners to radon decay products is not changed by these recommendations.

These proposed recommendations would provide general guidance for the radiation protection of workers. They would replace that part of existing guidance (see 25 FR 4402 of May 18, 1960) which applies to workers. Individual Federal agencies, with their knowledge of specific worker exposure situations, would use this guidance as the basis upon which to develop detailed standards and regulations to meet their particular statutory obligations. We propose to follow the activities of the Federal agencies as they implement the final Guidance, to issue any necessary clarifications and interpretations, and to promote the coordination necessary for an effective Federal program of worker protection.

Public Hearings

Public hearings on these proposed recommendations will be held as indicated above under the heading "Dates." Because of their major responsibilities to regulate radiation exposures in work places, the Nuclear Regulatory Commission (NRC) and the Occupational Safety and Health Administration (OSHA) will participate in sponsoring these hearings. The following conditions and procedures will govern the conduct of the hearings:

1. Purpose, Type, and Scope

These hearings are to provide additional opportunity for people to express opinions and provide factual information to aid EPA, OSHA, and NRC in carrying out their respective responsibilities for guidance on and regulation of occupational exposure to ionizing radiation. The hearings will be informal and legislative in nature rather than adjudicatory or formal rulemaking hearings. Technical rules of evidence, discovery, subpoena powers, testimony under oath, and similar formalities will not apply.

The issues to be covered by these hearings are those listed above under the heading "Issues Addressed." They include those listed in our advance notice of September 17, 1979 (44 FR 53785) and additional issues suggested since then. As indicated in that notice, both EPA and NRC have been petitioned by the Natural Resources Defense Council, Inc., to revise occupational guidance and standards. The subject matter of these hearings encompasses

the issues raised in those petitions (See 40 FR 50327 of October 29, 1975).

2. Presiding Officer and Panel

The hearings will be conducted by a presiding officer. A six member panel consisting of representatives of EPA, OSHA, and NRC will assist the presiding officer. A principal responsibility of the panel will be to clarify the testimony by eliciting views, comments, and factual information from participants. Members of the panel will not present views or respond to questions on behalf of their agencies. The membership of the panel may vary from time to time.

The presiding officer and panel shall have the joint responsibility to assure a fair and impartial hearing and to encourage the development of testimony that will contribute to informed decision-making. It will not be the function of the presiding officer or the panel to issue an opinion or to make decisions at the conclusion of the hearings. The presiding officer shall conduct the hearings in an orderly, fair, and expeditious manner and make procedural decisions. His functions shall include, but not be limited to, the following:

- a. Regulating the course of the hearings and the conduct of participants, including establishing reasonable time limits for the hearings, establishing the sequence and length of presentations and questioning, and opening and closing each hearing session;
- b. Making determinations concerning procedure and similar matters;
- c. Assuring that questioning of speakers by panel members and others is consistent with the nature and purpose of these hearings;
- d. Making determinations on the relevance of oral testimony and questions to the issues identified as within the scope of the hearings, or, in consultation with the panel, to additional issues pertinent to the proceedings; and, as necessary, terminating irrelevant presentations;
- e. Ruling on late requests to participate;
- f. Deciding how long the hearing record will remain open for written comments and additional data after the end of the oral proceedings.

3. Participation in the Hearings

Persons or organizations who wish to give presentations longer than ten minutes or present extensive data and evidence must give written notice to the Director, Criteria and Standards Division (ANR-460), U.S. Environmental Protection Agency, Washington, D.C.

20460, no later than 28 days prior to the scheduled date of a hearing. The notice should include: (1) the name, address, and telephone number of the participant; (2) the hearing at which they wish to testify; (3) the organization (if any) that they will represent; (4) the amount of time requested; and (5) which of the issues they want to address. Oral presentations will generally be restricted to 30 minutes. Detailed or lengthy material should be summarized orally and presented in full in written submissions. Requests for longer times for oral presentations will be considered only on the basis of a detailed summary of the material to be presented. The Agency will notify participants in advance if their allocated time is less than that requested.

An opportunity will be provided each day of the hearings for persons who have not submitted a notice as specified above to make brief oral statements. A register will be provided at the beginning of each hearing for this purpose. A minimum period will be set aside for such statements in the agenda for each hearing, and the presiding officer may allocate additional time, as necessary. The maximum time allowed for such statements will depend on the number of registrants and the availability of time, but will generally be limited to periods of no more than 5 to 10 minutes each. In order to assist the management of the hearings, persons wishing to make such statements are encouraged to register promptly at the beginning of the hearing.


Attendance at the hearings will be open to all members of the public, and seating will be made available on a first-come first-served basis.

4. Testimony and Written Submission

a. The oral proceedings will be recorded verbatim and a transcript made available promptly for inspection and copying, as specified below under the heading "The Public Hearing Record." It will help the panel if speakers supply copies of their oral testimony before they give it. However, this is not required.

b. Fourteen copies of any written statements and documents on which speakers intend to base their oral statements must be submitted to the Director (see "Addresses" above) no later than 14 days before the beginning of the hearing in which they will testify. We would appreciate if speakers would also provide eight additional copies for the use of the panel.

c. Questions may be directed to speakers by the hearing panel, by other speakers, and by other members of the public. Speakers may respond or not, as



United States
Environmental Protection
Agency

Official Business
Penalty for Private Use
\$300

First-Class Mail
Postage and Fees Paid
EPA
Permit No. G-35

Washington DC 20460

**FEDERAL RADIATION COUNCIL
RADIATION PROTECTION GUIDANCE
FOR FEDERAL AGENCIES**

Memorandum for the President

Pursuant to Executive Order 10831 and Public Law 86-373, the Federal Radiation Council has made a study of the hazards and use of radiation. We hereby transmit our first report to you concerning our findings and our recommendations for the guidance of Federal agencies in the conduct of their radiation protection activities.

It is the statutory responsibility of the Council to " * * * advise the President with respect to radiation matters, directly or indirectly affecting health, including guidance for all Federal agencies in the formulation of radiation standards and in the establishment and execution of programs of cooperation with States * * * "

Fundamentally, setting basic radiation protection standards involves passing judgment on the extent of the possible health hazard society is willing to accept in order to realize the known benefits of radiation. It involves inevitably a balancing between total health protection, which might require foregoing any activities increasing exposure to radiation, and the vigorous promotion of the use of radiation and atomic energy in order to achieve optimum benefits.

The Federal Radiation Council has reviewed available knowledge on radiation effects and consulted with scientists within and outside the Government. Each member has also examined the guidance recommended in this memorandum in light of his statutory responsibilities. Although the guidance does not cover all phases of radiation protection, such as internal emitters, we find that the guidance which we recommend that you provide for the use of Federal agencies gives appropriate consideration to the requirements of health protection and the beneficial uses of radiation and atomic energy. Our further findings and recommendations follow.

Discussion. The fundamental problem in establishing radiation protection guides is to allow as much of the beneficial uses of ionizing radiation as possible while assuring that man is not exposed to undue hazard. To get a true insight into the scope of the problem and the impact of the decisions involved, a review of the benefits and the hazards is necessary.

It is important in considering both the benefits and hazards of radiation to appreciate that man has existed throughout his history in a bath of natural radiation. This background radiation, which varies over the earth, provides a partial basis for understanding the effects of radiation on man and serves as an indicator of the ranges of radiation exposures within which the human population has developed and increased.

The benefits of ionizing radiation. Radiation properly controlled is a boon to mankind. It has been of inestimable value in the diagnosis and treatment of diseases. It can provide sources of

energy greater than any the world has yet had available. In industry, it is used as a tool to measure thickness, quantity or quality, to discover hidden flaws, to trace liquid flow, and for other purposes. So many research uses for ionizing radiation have been found that scientists in many diverse fields now rank radiation with the microscope in value as a working tool.

The hazards of ionizing radiation. Ionizing radiation involves health hazards just as do many other useful tools. Scientific findings concerning the biological effects of radiation of most immediate interest to the establishment of radiation protection standards are the following:

1. Acute doses of radiation may produce immediate or delayed effects, or both.

2. As acute whole body doses increase above approximately 25 rems (units of radiation dose), immediately observable effects increase in severity with dose, beginning from barely detectable changes, to biological signs clearly indicating damage, to death at levels of a few hundred rems.

3. Delayed effects produced either by acute irradiation or by chronic irradiation are similar in kind, but the ability of the body to repair radiation damage is usually more effective in the case of chronic than acute irradiation.

4. The delayed effects from radiation are in general indistinguishable from familiar pathological conditions usually present in the population.

5. Delayed effects include genetic effects (effects transmitted to succeeding generations), increased incidence of tumors, lifespan shortening, and growth and development changes.

6. The child, the infant, and the unborn infant appear to be more sensitive to radiation than the adult.

7. The various organs of the body differ in their sensitivity to radiation.

8. Although ionizing radiation can induce genetic and somatic effects (effects on the individual during his lifetime other than genetic effects), the evidence at the present time is insufficient to justify precise conclusions on the nature of the dose-effect relationship at low doses and dose rates. Moreover, the evidence is insufficient to prove either the hypothesis of a "damage threshold" (a point below which no damage occurs) or the hypothesis of "no threshold" in man at low doses.

9. If one assumes a direct linear relation between biological effect and the amount of dose, it then becomes possible to relate very low dose to an assumed biological effect even though it is not detectable. It is generally agreed that the effect that may actually occur will not exceed the amount predicted by this assumption.

Basic biological assumptions. There are insufficient data to provide a firm basis for evaluating radiation effects for all types and levels of irradiation. There is particular uncertainty with respect to the biological effects at very low doses and low-dose rates. It is not prudent therefore to assume that there is a level of radiation exposure below which there is absolute certainty that no effect may occur. This consideration, in addition to the adoption of the conservative hypothesis of a linear relation between biological effect and the amount of dose, determines our basic approach to the formulation of radiation protection guides.

The lack of adequate scientific information makes it urgent that additional research be undertaken and new data developed to provide a firmer basis for evaluating biological risk. Appropriate member agencies of the Federal Radiation Council are sponsoring and encouraging research in these areas.

Recommendations. In view of the findings summarized above the following recommendations are made:

It is recommended that:

1. There should not be any man-made radiation exposure without the expectation of benefit resulting from such exposure. Activities resulting in man-made radiation exposure should be authorized for useful applications provided in recommendations set forth herein are followed.

It is recommended that:

2. The term "Radiation Protection Guide" be adopted for Federal use. This term is defined as the radiation dose which should not be exceeded without careful consideration of the reasons for doing so; every effort should be made to encourage the maintenance of radiation doses as far below this guide as practicable.

It is recommended that:

3. The following Radiation Protection Guides be adopted for normal peacetime operations:

Type of exposure	Condition	Dose (rem)
Radiation worker:		
(a) Whole body, head and trunk, active blood forming organs, gonads, or lens of eye.	Accumulated dose.....	5 times the number of years beyond age 18.
	13 weeks.....	3.
(b) Skin of whole body and thyroid.....	Year.....	30.
	13 weeks.....	10.
(c) Hands and forearms, feet and ankles.....	Year.....	75.
	13 weeks.....	25.
(d) Bone.....	Body burden.....	0.1 microgram of radium-226 or its biological equivalent.
(e) Other organs.....	Year.....	15.
	13 weeks.....	5.
Population:		
(a) Individual.....	Year.....	0.5 (whole body).
(b) Average.....	30 year.....	5 (gonads).

The following points are made in relation to the Radiation Protection Guides herein provided:

(1) For the individual in the population, the basic Guide for annual whole body dose is 0.5 rem. This Guide ap-

plies when the individual whole body doses are known. As an operational technique, where the individual whole body doses are not known, a suitable sample of the exposed population should be developed whose protection guide for annual whole body dose will be 0.17 rem per capita per year. It is emphasized that this is an operational technique which should be modified to meet special situations.

(2) Considerations of population genetics impose a per capita dose limitation for the gonads of 5 rems in 30 years. The operational mechanism described above for the annual individual whole body dose of 0.5 rem is likely in the immediate future to assure that the gonadal exposure Guide (5 rem in 30 years) is not exceeded.

(3) These Guides do not differ substantially from certain other recommendations such as those made by the National Committee on Radiation Protection and Measurements, the National Academy of Sciences, and the International Commission on Radiological Protection.

(4) The term "maximum permissible dose" is used by the National Committee on Radiation Protection (NCRP) and the International Commission on Radiological Protection (ICRP). However, this term is often misunderstood. The words "maximum" and "permissible" both have unfortunate connotations not intended by either the NCRP or the ICRP.

(5) There can be no single permissible or acceptable level of exposure without regard to the reason for permitting the exposure. It should be general practice to reduce exposure to radiation, and positive effort should be carried out to fulfill the sense of these recommendations. It is basic that exposure to radiation should result from a real determination of its necessity.

(6) There can be different Radiation Protection Guides with different numerical values, depending upon the circumstances. The Guides herein recommended are appropriate for normal peacetime operations.

(7) These Guides are not intended to apply to radiation exposure resulting from natural background or the purposeful exposure of patients by practitioners of the healing arts.

(8) It is recognized that our present scientific knowledge does not provide a firm foundation within a factor of two or three for selection of any particular numerical value in preference to another value. It should be recognized that the Radiation Protection Guides recommended in this paper are well below the level where biological damage has been observed in humans.

It is recommended that:

4. Current protection guides used by the agencies be continued on an interim basis for organ doses to the population.

Recommendations are not made concerning the Radiation Protection Guides for individual organ doses to the population, other than the gonads. Unfortunately, the complexities of establishing guides applicable to radiation exposure of all body organs preclude the Council from making recommendations concern-

ing them at this time. However, current protection guides used by the agencies appear appropriate on an interim basis.

It is recommended that:

5. The term "Radioactivity Concentration Guide" be adopted for Federal use. This term is defined as the concentration of radioactivity in the environment which is determined to result in whole body or organ doses equal to the Radiation Protection Guide.

Within this definition, Radioactivity Concentration Guides can be determined after the Radiation Protection Guides are decided upon. Any given Radioactivity Concentration Guide is applicable only for the circumstances under which the use of its corresponding Radiation Protection Guide is appropriate.

It is recommended that:

6. The Federal agencies, as an interim measure, use radioactivity concentration guides which are consistent with the recommended Radiation Protection Guides. Where no Radiation Protection Guides are provided, Federal agencies continue present practices.

No specific numerical recommendations for Radioactivity Concentration Guides are provided at this time. However, concentration guides now used by the agencies appear appropriate on an interim basis. Where appropriate radioactivity concentration guides are not available, and where Radiation Protection Guides for specific organs are provided herein, the latter Guides can be used by the Federal agencies as a starting point for the derivation of radioactivity concentration guides applicable to their particular problems. The Federal Radiation Council has also initiated action directed towards the development of additional Guides for radiation protection.

It is recommended that:

7. The Federal agencies apply these Radiation Protection Guides with judgment and discretion, to assure that reasonable probability is achieved in the attainment of the desired goal of protecting man from the undesirable effects of radiation. The Guides may be exceeded only after the Federal agency having jurisdiction over the matter has carefully considered the reason for doing so in light of the recommendations in this paper.

The Radiation Protection Guides provide a general framework for the radiation protection requirements. It is expected that each Federal agency, by virtue of its immediate knowledge of its operating problems, will use these Guides as a basis upon which to develop detailed standards tailored to meet its particular requirements. The Council will follow the activities of the Federal agencies in this area and will promote the necessary coordination to achieve an effective Federal program.

If the foregoing recommendations are approved by you for the guidance of Federal agencies in the conduct of their radiation protection activities, it is further recommended that this memorandum be published in the FEDERAL REGISTER.

ARTHUR S. FLEMMING,
Chairman,
Federal Radiation Council.

The recommendations numbered "1" through "7" contained in the above memorandum are approved for the guidance of Federal agencies, and the memorandum shall be published in the FEDERAL REGISTER.

DWIGHT D. EISENHOWER

MAY 13, 1960.

[F.R. Doc. 60-4539; Filed, May 17, 1960;
8:51 a.m.]

25 FR 4402 Vol. 25

FEDERAL RADIATION COUNCIL
RADIATION PROTECTION GUIDANCE
FOR FEDERAL AGENCIES

Memorandum for the President

SEPTEMBER 13, 1961.

Pursuant to Executive Order 10831 and Public Law 86-373, the Federal Radiation Council herewith transmits its second report to you concerning findings and recommendations for guidance for Federal agencies in the conduct of their radiation protection activities.

Background. On May 13, 1960, the first recommendations of the Council were approved by the President and the memorandum containing these recommendations was published in the FEDERAL REGISTER on May 18, 1960. There was also released at the same time, Staff Report No. 1 of the Federal Radiation Council, entitled, "Background Material for the Development of Radiation Protection Standards," dated May 13, 1960.

The first report of the Council provided a general philosophy of radiation protection to be used by Federal agencies in the conduct of their specific programs and responsibilities. It introduced and defined the term "Radiation Protection Guide" (RPG). It provided numerical values for Radiation Protection Guides for the whole body and certain organs of radiation workers and for the whole body of individuals in the general population, as well as an average population gonadal dose. It introduced as an operational technique, where individual whole body doses are not known, the use of a "suitable sample" of the exposed population in which the guide for the average exposure of the sample should be one-third the RPG for the individual members of the group. It emphasized that this operational technique should be modified to meet special situations. In selecting a suitable sample particular care should be taken to assure that a disproportionate fraction of the average dose is not received by the most sensitive population elements. The observations, assumptions, and comments set out in the memorandum published in the FEDERAL REGISTER, May 18, 1960, are equally applicable to this memorandum.

This memorandum contains recommendations for the guidance of Federal agencies in activities designed to limit exposure of members of population groups to radiation from radioactive materials deposited in the body as a result of their occurrence in the environment. These recommendations include: (1) Radiation Protection Guides for certain organs of individuals in the general population, as well as averages over suitable samples of exposed groups; (2) guidance on general principles of control applicable to all radionuclides occurring in the environment; and (3) specific guidance in connection with exposure

of population groups to radium-226, iodine-131, strontium-90, and strontium-89. It is the intention of the Council to release the background material leading to these recommendations as Staff Report No. 2 when the recommendations contained herein are approved.

Specific attention was directed to problems associated with radium-226, iodine-131, strontium-90, and strontium-89. Radium-226 is an important naturally occurring radioactive material. The other three were present in fallout from nuclear weapons testing. They could, under certain circumstances, also be major constituents of radioactive materials released to the environment from large scale atomic energy installations used for peaceful purposes. Available data suggest that effective control of these nuclides, in cases of mixed fission product contamination of the environment, would provide reasonable assurance of at least comparable limitation of hazard from other fission products in the body.

Establishment of the Federal Radiation Council followed a period of public concern incident to discussions of fallout. While strontium-90 received the greatest popular attention, exposures to cesium-137, iodine-131, strontium-89 and, in still lesser degrees to other radionuclides, are involved in the evaluation of over-all effects. The characteristics of cesium-137 lead to direct comparison with whole body exposures for which recommendations by the Council have already been made.

Studies by the staff of the Council indicate that observed concentrations of radioactive strontium in food and water do not result in concentrations in the skeleton (and consequently in radiation doses) as large as have been assumed in the past. However, concentrations of iodine-131 in the diets of small children, particularly in milk, equal to those permitted under current standards would lead to radiation doses to the child's thyroid which, in comparison with the general structure of current radiation protection standards, would be too high. This is because current concentration guides for exposure of population groups to radioactive materials in air, food, and water have been derived by application of a single fraction to corresponding occupational guides. In the case of iodine-131 in milk, consumption of milk and retention of iodine by the child may be at least as great as by the adult, while the relatively small size of the thyroid makes the radiation dose to the thyroid much larger than in the case of the adult. In addition, there is evidence that irradiation of the thyroid involves greater risk to children than to adults.

Recommendations as to Radiation Protection Guides. The Federal Radiation Council has previously emphasized that establishment of radiation protection standards involves a balancing of the benefits to be derived from the controlled use of radiation and atomic energy against the risk of radiation exposure.

In the development of the Radiation Protection Guides contained herein, the Council has considered both sides of this balance. The Council has reviewed available knowledge, consulted with scientists within and outside the Government, and solicited views of interested individuals and groups from the general public. In particular, the Council has not only drawn heavily upon reports published by the International Commission on Radiological Protection (ICRP), the National Committee on Radiation Protection and Measurements (NCRP), and the National Academy of Sciences (NAS), but has had during the development of the report the benefit of consultation with, and comments and suggestions by, individuals from NCRP and NAS and of their subcommittees. The Radiation Protection Guides recommended below are considered by the Council to represent an appropriate balance between the requirements of health protection and of the beneficial uses of radiation and atomic energy.

It is recommended that:

1. The following Radiation Protection Guides be adopted for normal peacetime operations.

TABLE I—RADIATION PROTECTION GUIDES FOR CERTAIN BODY ORGANS IN RELATION TO EXPOSURE OF POPULATION GROUPS

Organ	RPG for individuals	RPG for average of suitable sample of exposed population group
Thyroid.....	1.5 rem per year...	0.5 rem per year.
Bone marrow.....	0.5 rem per year.....	0.17 rem per year.
Bone.....	1.5 rem per year.....	0.5 rem per year.
Bone (alternate guide).	0.003 micrograms of Ra-226 in the adult skeleton or the biological equivalent of this amount of Ra-226.	0.001 micrograms of Ra-226 in the adult skeleton or the biological equivalent of this amount of Ra-226.

It will be noted that the preceding table provides Radiation Protection Guides to be applied to the average of a suitable sample of an exposed population group which are one-third of those applying to individuals. This is in accordance with the recommendations in the first report of the Council concerning operational techniques for controlling population exposure. Since in the case of exposure of a population group to radionuclides the radiation doses to individuals are not usually known, the organ dose to be used as a guide for the average of suitable samples of an exposed population group is also given as an RPG.

Recommendations as to general principles. Control of population exposure from radionuclides occurring in the environment is accomplished in general either by restriction on the entry of such materials into the environment or through measures designed to limit the intake by members of the population of radionuclides already in the environment. Both approaches involve the consideration of actual or potential concentrations of radioactive material in air, water, or food. Controls should be based upon an evaluation of population

exposure with respect to the RPG. For this purpose, the total daily intake of such materials, averaged over periods of the order of a year, constitutes an appropriate criterion.

The control of the intake by members of the general population of radioactive materials from the environment can appropriately involve many different kinds of actions. The character and import of these actions may vary widely, from those which entail little interference with usual activities, such as monitoring and surveillance, to those which involve a major disruption, such as condemnation of food supplies. Some control actions may require prolonged lead times before becoming effective, e.g., major changes in processing facilities or water supplies. The magnitude of control measures should be related to the degree of likelihood that the RPG may be exceeded. The use of a single numerical intake value, which in part has been the practice until now, does not in many instances provide adequate guidance for taking actions appropriate to the risk involved. For planning purposes, it is desirable that insofar as possible control actions to meet contingencies be known in advance.

It is recommended that:

2. The radiological health activities of Federal agencies in connection with environmental contamination with radioactive materials be based, within the limits of the agency's statutory responsibilities, on a graded series of appropriate actions related to ranges of intake of radioactive materials by exposed population groups.

In order to provide guidance to the agencies in adapting the graded approach to their own programs, the recommendations pertaining to the specific radionuclides in this memorandum consider three transient daily rates of intake by suitable samples of exposed population groups. For the other radionuclides, the agencies can use the same general approach, the details of which are considered in Staff Report No. 2. The general types of action appropriate when these transient rates of intake fall into the different ranges are also discussed in Staff Report No. 2. The purpose of these actions is to provide reasonable assurance that average rates of intake by a suitable sample of an exposed population group, averaged over the sample and averaged over periods of time of the order of one year, do not exceed the upper value of Range II. The general character of these actions is suggested in the following table.

TABLE II—GRADED SCALES OF ACTION

Ranges of transient rates of daily intake	Graded scale of action
Range I.....	Periodic confirmatory surveillance as necessary.
Range II.....	Quantitative surveillance and routine control.
Range III.....	Evaluation and application of additional control measures as necessary.

Recommendations on Ra-226, I-131, Sr-90, and Sr-89. The Council has given specific consideration to the effects on man of rates of intake of radium-226, iodine-131, strontium-90 and strontium-89 resulting in radiation doses equal to those specified in the appropriate RPG's. The Council has also reviewed past and current activities resulting in the release of these radionuclides to the environment and has given consideration to future developments. For each of the nuclides three ranges of transient daily intake are given which correspond to the guidance contained in Recommendation 2, above. Routine control of useful applications of radiation and atomic energy should be such that expected average exposures of suitable samples of an exposed population group will not exceed the upper value of Range II. For iodine-131 and radium-226, this value corresponds to the RPG for the average of a suitable sample of an exposed population group. In the cases of strontium-90 and strontium-89, the Council's study indicated that there is currently no known operational requirement for an intake value as high as the one corresponding to the RPG. Hence, a value estimated to correspond to doses to the critical organ not greater than one-third of the RPG has been used.

The guidance recommended below is given in terms of transient rates of (radioactivity) intake in micromicrocuries per day. The upper limit of Range II is based on an annual RPG (or lower, in case of radioactive strontium) considered as an acceptable risk for a lifetime. However, it is necessary to use averages over periods much shorter than a lifetime for both radiation dose rates and rates of intake for administrative and regulatory purposes. It is recommended that such periods should be of the order of one year. It is to be noted that values listed in the tables are much smaller than any single intake from which an individual might be expected to sustain injury.

It is recommended that:

3. (a) The following guidance on daily intake be adopted for normal peacetime operations to be applied to the average of suitable samples of an exposed population group:

TABLE III—RANGES OF TRANSIENT RATES OF INTAKE (MICROMICROCURIES PER DAY) FOR USE IN GRADUATED SCALE OF ACTIONS SUMMARIZED IN TABLE II.

Radionuclides	Range I	Range II	Range III
Radium-226.....	0-2	2-20	20-200
Iodine-131.....	0-10	10-100	100-1,000
Strontium-90.....	0-50	20-200	200-2,000
Strontium-89.....	0-200	200-2,000	2,000-20,000

¹ In the case of iodine-131, the suitable sample would include only small children. For adults, the RPG for the thyroid would not be exceeded by rates of intake higher by a factor of 10 than those applicable to small children.

(b) Federal agencies determine concentrations of these radionuclides in air, water, or items of food applicable to their particular programs which are consistent with the guidance contained herein on average daily intake for the radionuclides radium-226, iodine-131, strontium-90, and strontium-89. Some of the general considerations involved in the derivation of concentration values from intake values are given in Staff Report No. 2.

It is recommended that:

4. For radionuclides not considered in this report, agencies use concentration values in air, water, or items of food which are consistent with recommendations in Radiation Protection Guides and general guidance on intake.

In the future, the Council will direct attention to the development of appropriate radiation protection guidance for those radionuclides for which such consideration appears appropriate or necessary. In particular, the Council will study any radionuclides for which useful applications of radiation or atomic energy require release to the environment of significant amounts of these nuclides. Federal agencies are urged to inform the Council of such situations.

ABRAHAM RIBICOFF,
Chairman,
Federal Radiation Council.

The recommendations numbered "1" through "4" contained in the above memorandum are approved for the guidance of Federal agencies, and the memorandum shall be published in the FEDERAL REGISTER.

JOHN F. KENNEDY.

SEPTEMBER 20, 1961.

SUMMARY OF PROPOSED CHANGES

IN OCCUPATIONAL RADIATION PROTECTION GUIDANCE

<u>Requirement</u>	<u>1960 Guides</u>	<u>Proposed New Guides</u>
1. Justification of exposure	required	required (also consider alternatives to exposure)
2. Optimization of exposure	required	required (include collective dose)
3. Limitation of exposure		
a) Whole body	3 rems/quarter; 5(N-18) cumulative rems, (N = age)	5 rems/year
b) Partial body	individual critical organ limits*	limit on sum of organ risks*
c) Combined internal and external exposure	independent limits	combined limit
4. Radiation Protection Requirements	not specified	in three ranges for instruction, super- vision, monitoring, and recordkeeping (including lifetime dose)
5. Regulatory limits lower than the RPGs for specific job categories	not addressed	recommended
6. Intake guides	Radioactivity Concentration Guides (RCGs)	Radioactivity Intake Factors (RIFs)
7. Exposure of minors	1/10 RPGs	1/10 RPGs
8. Exposure of the unborn	not addressed	four alternative recommendations
9. Exceeding the RPGs	permitted	permitted (disclo- sure now required)

*Some limits are raised and some lowered; some organs are deleted and some added. See the specific guides for numerical values.

T.M. BAAC I
OF DRAFT
10 CFR PART 20
ON THE
SAVANNAH RIVER
PLANT

OPERATIONAL PROBLEMS

ASSIMILATION OF RADIONUCLIDES IN BODY

- PLUTONIUM - ISOTOPIC ABUNDANCE
- AIR SAMPLING
- BIOASSAY - IN VIVO LUNG COUNT
- 50-YEAR DOSE COMMITMENT

INHALATION OF AIRBORNE CONTAMINATION

- PROTECTIVE EQUIPMENT FAILURE
- LOSS OF CONTAINMENT
- PROCEDURE VIOLATION
- FACILITY EVACUATION

3


3

RADIONUCLIDE ASSIMILATIONS

1950 1951 1952 1953 1954



UPTAKE SEVERITY
WHOLE BODY EXPOSURE



ASSIMILATIONS THROUGH OCTOBER 1982

Plutonium Inhalation


injection

1/3

Internal Deposition of Plutonium due to:

INHALATION

PUNCTURES



6

OPERATIONAL PROBLEMS

ASSIMILATION OF RADIONUCLIDES IN BODY

- PLUTONIUM - ISOTOPIC ABUNDANCE
- AIR SAMPLING
- BIOASSAY - IN VIVO LUNG COUNT
- 50-YEAR DOSE COMMITMENT

INHALATION OF AIRBORNE CONTAMINATION

- PROTECTIVE EQUIPMENT FAILURE
- LOSS OF CONTAINMENT
- PROCEDURE VIOLATION
- FACILITY EVACUATION

7 (E)

7

7

ASSIMILATION INVESTIGATION TECHNIQUES

- DETERMINE MODE OF ASSIMILATION; INHALATION
 - PROBABLE RADIONUCLIDES
 - AIRBORNE CONTAMINATION CONCENTRATION
 - DURATION OF EXPOSURE
 - CLOTHING, SKIN, OR NASAL CONTAMINATION
 - WHOLE BODY COUNT
 - URINALYSIS - FECAL ANALYSIS
 - METABOLIC MODELS - DOSE ASSESSMENT
- (7)

8

AIR SAMPLING

PERSONNEL AIR SAMPLERS

- 2 LITERS/MINUTE FOR 8 HOURS
- MINIMUM DETECTABLE - 1×10^{-11} μCi $^{238}\text{Pu/cc}$
- ANNUAL MDA - 25 μCi

ROOM AIR SAMPLERS

- 150 LITERS/MINUTE FOR 8 HOURS
- MINIMUM DETECTABLE - 2×10^{-13} μCi $^{238}\text{Pu/cc}$
- ANNUAL MDA - 0.5 μCi

10 CFR PART 20 APPENDIX B

RADIONUCLIDE

DAC

ALL

- ^{239}Pu 3×10^{-12} $\mu\text{Ci/cc}$ 5 μCi
- ^{241}Pu 1×10^{-10} $\mu\text{Ci/cc}$ 500 μCi
- PLUTONIUM (MIXTURE) 3×10^{-13} $\mu\text{Ci/cc}$ 0.7 μCi

PLUTONIUM

TYPICAL ISOTOPIC ABUNDANCE

<u>ISOTOPE</u>	<u>ABUNDANCE BY WEIGHT</u>	<u>SPECIFIC ACTIVITY</u>	
		<u>ALPHA</u>	<u>BETA</u>
238Pu	.00014	0.0024 Ci/g	—
239Pu	.958	0.0582 Ci/g	—
240Pu	.0575	0.0131 Ci/g	—
241Pu	.0062	—	0.6360 Ci/g
242Pu	.0001	0.0001 Ci/g	—
TOTAL	1.000	0.0737 Ci/g	0.6360 Ci/g

∴ the identity of each radionuclide is known; 0 N.I.

Liver: 50 mem.

UPTAKE SEVERITY LUNG EXPOSURE

FEDERAL ORAL SRP LIMIT

ANNUAL DOSE EQUIVALENT rem

10 9 8 7 6 5 4 3 2 1 0

Legend
☐ PLUTONIUM

5-18



1 2 3 4 5

ASSIMILATIONS THROUGH OCTOBER 1982

10 FEB 80
R-3

RECORDS

- **CONTAIN ALL PARAMETERS USED TO CALCULATE DOSE EQUIVALENT**
- **DOE UPGRADE PROGRAM**

AREAS OF AGREEMENT

OCCUPATIONAL EXPOSURE LIMITS

- **5 REM ANNUAL LIMIT SHOULD NOT BE LOWERED**
- **LIFETIME LIMITS NOT APPROPRIATE**
- **"TWO-TIER" LIMIT NOT APPROPRIATE**

ALARA - DOE

- **ALARA PROGRAM**
- **EQUAL PRIORITY TO INDIVIDUAL
AND COLLECTIVE DOE EQUIVALENT**
- **AUDIT PROGRAM**

ALARA

PROPOSED 10 CFR 20 REVISION


- **ALARA PROGRAM**
- **PRIORITY TO INDIVIDUAL RATHER THAN COLLECTIVE DOSE EQUIVALENT**
- **AUDIT PROGRAM**


TOTAL OCCUPATIONAL EXPOSURE (EXTERNAL + INTERNAL)


<u>WORKER</u>	<u>ACCUMULATED DOSE (REM)</u>	<u>INTERNAL DOSE COMMITMENT STOCHASTIC (REM)</u>	<u>TOTAL WHOLE BODY DOSE (REM)</u>
A	68.5	180	248.5
B	65.1	14	79.1
C	61.1	20	81.1
C	60.4	25	85.4

UNITS AND DEFINITIONS

- **CONSISTENT WITH ICRU
AND ICRP**
- **CONVERSION FACTORS IN
REGULATORY GUIDES**








**DOE AND
DOE CONTRACTOR EMPLOYEES
(82,873 MONITORED)**

> 1 rem
1.53%



**VISITORS
(84,343 MONITORED)**

> 1 rem
0.01%

<u>WORKER</u>	<u>CLASSIFICATION</u>	<u>ACCUMULATED DOSE (REM)</u>	<u>SERVICE</u>	<u>AVERAGE ANNUAL EXPOSURE</u>
A	SEP. OPERATOR	68.5	31	2.2
B	SEP. OPERATOR	65.1	30	2.2
C	SEP. OPERATOR	61.1	29	2.1
D	REACTOR OPERATOR	60.4	36	1.7


WHOLE BODY EXPOSURE EXPERIENCE* WORKERS GREATER THAN 60 REM ALL TIME

<u>WORKER CLASSIFICATION</u>	<u>ACCUMULATED DOSE</u>	<u>SERVICE</u>	<u>AVERAGE ANNUAL EXPOSURE</u>
SEP. OPERATOR	144**	25	5.8
REACTOR INSTR. SP.	76	29	2.6
REACTOR MONITOR	74	26	2.9
SEP. OPERATOR	68.5	31	2.2
REACTOR MONITOR	68.5	27	2.5
REACTOR MONITOR	67.4	30	2.2
REACTOR MONITOR	66.9	25	2.7
REACTOR MONITOR	65.8	26	2.5
SEP. OPERATOR	65.1	30	2.2
REACTOR MONITOR	63.9	35	1.8
REACTOR OPERATOR	61.6	29	2.1
REACTOR OPERATOR	61.2	29	2.1
SEP. OPERATOR	61.1	29	2.1
REACTOR TECH.	60.8	26	2.3
RADIATION CONTROL TECH.	60.6	27	2.2
REACTOR OPERATOR	60.5	33	1.8
REACTOR OPERATOR	60.4	36	1.7
REACTOR MONITOR	60.3	31	2.0
REACTOR MONITOR	60.1	33	1.8

*DATA OBTAINED FROM RL PROGRAMS

**KNOWN ACCIDENT WHERE INDIVIDUAL RECEIVED ABOUT 110 REM

TRENDS IN WHOLE BODY EXPOSURES



*FOR YEARS BEYOND 1968 THE POINTS ABOVE 5 REM REPRESENT ACCIDENTAL EXPOSURES

RADIATION PROTECTION PROGRAM

- **DOE EXPERIENCE**
- **IMPACT ON WORKER PROTECTION**
- **APPARENT LEGAL IMPLICATIONS**

IMPACT ON WORKER PROTECTION

- **OCCUPATIONAL EXPOSURE HISTORY**
- **INCOMPLETE DATA BASE**
- **CALCULATION OF ASSUMED EXPOSURE**
- **ALARA**

APPARENT LEGAL IMPLICATIONS

- **50-YEAR COMMITTED DOSE**
- **TECHNICAL OVEREXPOSURE**
- **INCOMPLETE DATA BASE**

HANFORD WORKERS WITH MEASURED PLUTONIUM DEPOSITIONS

<u>INTERNAL DEPOSITION % OF ²³⁹Pu MPBB</u>	<u>NUMBER OF WORKERS</u>	<u>CALCULATED 50-YEAR DOSE EQUIVALENT COMMITMENT (REM) STOCHASTIC</u>
< 5	114	<20
5-10	25	20-40
10-15	7	40-60
15-20	11	60-80
20-30	4	80-120
30-40	3	120-160
40-50	-	160-200
> 50	4	260-3100
TOTAL CURRENT HANFORD WORKERS WITH PLUTONIUM DEPOSITIONS	168	
TOTAL CURRENT HANFORD RADIATION WORKERS	8164	

STATEMENT

PREPARED FOR DOE OFFICE OF NUCLEAR SAFETY
FOR ACRS SUBCOMMITTEE MEETING, NOVEMBER 12, 1982

J. P. CORLEY

STAFF ENGINEER

BATTELLE, PACIFIC NORTHWEST LABORATORY

I am John Corley, a Staff Engineer with the Radiological Sciences Department of Battelle Memorial Institute's Pacific Northwest Laboratory.

I have been a health physicist for 35 years, for eight of which I was in charge of the environmental surveillance program for the AEC's Hanford Site. For the past eight years I have been responsible for a technical assistance project in the area of radiological environmental protection to first the AEC and now the Department of Energy. As such I have had primary responsibility for the preparation of guides of good practice for radiological environmental surveillance and effluent monitoring. (57a)

It should be understood that my statement presents my own views and does not DOE or Battelle positions.

~~these moves, especially if a significant additional commitment of resources is required.~~

Protection of the public from ionizing radiation involves a parallel set of concerns to ~~those~~ ^{those} for occupational exposures. As recognized by the NRC, however, practical applications of ICRP recommendations to population groups introduces different problems and constraints. In large part, this is due to the lack of specific identification of maximally-exposed individuals (or individuals constituting a "critical group"), ^{a mixed and} the continually-changing population, and the inability to control directly future exposures to the same groups ^{as individuals} ^{General Control} by remedial actions at the source or intervention in the exposure pathways ^{is of course possible.}

~~could will discuss briefly~~
I have listed here (Figure 1) several aspects of the proposed ^{IOCFR20} regulations, both ~~those which~~ generate similar concerns for environmental surveillance as for occupational protection responsibilities; and ~~those which~~ ^{others} engender different responses. It ^{is} ~~may be~~ noted that several of these concerns are inherent in the adoption of ICRP Publication No. 26 recommendations, e.g., the assignment of a 50-year dose commitment to the year of intake and the use of weighting factors to calculate an effective whole body dose equivalent. Others have been introduced in the NRC drafting process, e.g., the use of factored ALIs for population dose estimates and the directed ALARA emphasis,

USE OF 50-YEAR COMMITTED DOSE EQUIVALENT

In principle, The use of 50-year committed dose equivalents from radionuclides with long biological half-lives seems ~~much~~ more appropriate for ~~control~~ ^{assessment} of population exposures than for occupational ~~control~~ ^{doses}. For the latter some capability will exist to substantiate a priori estimates through external and internal monitoring procedures. For members of the public, ~~generally lacking specific identification, continually changing, and with future individual exposures largely uncontrolled except by remedial actions at the source or by intervention in the exposure pathways,~~ ^{used} the committed dose equivalents may be necessary to demonstrate compliance as well as for prediction. As noted earlier ~~that~~ ^{of this principle} acceptance does not extend to use of ~~the~~ ^{committed} effective dose equivalents and requires ~~some~~ additional caveats.

Applying 50yr
is available
availability that
apparently
would be

USE OF WEIGHTING FACTORS - THE "EFFECTIVE COMMITTED DOSE EQUIVALENT"

In principle, the conversion of risks of health effects to individual body organs to an equivalent whole body risk for ~~summation~~ and control purposes is as valid for uncontrolled area populations as for occupational exposures. The practice may indeed be useful ^{for comparison of} ~~as an aid to~~ design analysis, ^{collective health risk is} or ~~as~~ ^{to provide} a trend indicator for a given facility or group of similar facilities with mixed effluents. However, loss of pertinent ^{epidemiological} information will inevitably occur if no other record is maintained of predominant organ dose calculations, ^{especially} where the nuclides and pathways of population exposure are limited. Such masking ^{of} probable risk of health effects to specific body organs (as well as genetic risk) is especially questionable where specific nuclides are

highly concentrated in one body organ. Ready examples would be thyroid doses from radioiodines and bone doses from plutonium. One would find it difficult to ^{evaluate a minor} ~~explain away~~ an apparent excess ~~of~~ ^{incidental solely} cancer on the basis of effective dose equivalents well within limits ^{where no record existed of organ dose data} ~~without~~ ^{without} organ dose data.

With the recognition that the weighting factors recommended involve many assumptions as to physiological parameters, ^{and relative risk} which for diverse population groups would be expected to show large deviations from standard values and for which adequate data is frequently lacking, ^{perhaps} no ready alternative is ^{available} ~~apparent~~ if a single coefficient of risk must be derived ^{for a assessment of total public health risk} for calculational purposes, however, ^{determination} ~~it must be recognized that~~ calculation of an effective ^{committed} whole body dose equivalent may well involve ~~significant~~ increases in effluent and environmental monitoring programs. The potential need ^{for} and cost ^{of} extending specific radionuclide measurements from source ^{facilities} with complex mixtures ^{of nuclides in their effluents} include ~~all those which might contribute significantly to~~ ^{total public health risk} ~~environmental analysis~~ ^{determination} a total risk coefficient, has not really been evaluated. ^{I would also be} concerned about the potentially ^{misplaced emphasis in an effort to reduce}

~~commitments, and warrants some additional caveats.~~

USE OF FRACTIONAL ALI/DAC VALUES

Of greatest concern to those concerned with evaluating population doses is the proposed use of the ICRP's ALI and DAC tables with constant factors to adjust for lower limits, different exposure periods, and an assumed age distribution. Aside from the fact that the ICRP has specifically stated in No. 26 and 30 that these tables should not be used for this purpose, application of standard factors ^{for all nuclides and for all} to the diverse "critical groups" to be found at various licensee facilities will largely negate any claim to more precise control of population exposures. If all such calculated annual intakes were equivalent to less than de minimis levels, one could probably ignore the weakness of the assumptions used. I am not ~~that~~ confident that such is the case.

Figure 1 is taken from a paper by Roy Thompson given at the Vth IRPA meeting, ^(a) and shows some order of magnitude differences in several factors that must be taken into account to adjust a population ALI for just one age group, nuclide, and exposure mode. I suggest that the ability to adjust ALIs for all nuclides and all such factors is some years away. I understand in fact that Committee 2 of the ICRP has been struggling with this problem for some time. ~~For the B₂ H₂ He evaluations of ~~FAST~~ power reactor dose impacts, previously evaluated, four age groups are used.~~

In the interim I suggest that the ICRP in its more recent publications has provided internal dosimetric models which can be ^{used} applied, without recourse to the ALI and especially ^{the} DAC tables. To ^{some} extent these models can be realistically adapted to different age groups, ^{and effective years of exposure to each age group.} they should be. ~~Even so~~

This committee is probably aware that considerable uncertainty exists as to the adequacy of the database for doing so for many radio nuclides, at least to the extent that any better precision of dose and risk calculation can be claimed.

(a) Thompson, R.C. 1980. "An Approach to the Derivation of Radionuclide Intake Limits for Members of the Public", in Radiation Protection - A Systematic Approach to Safety, Proceedings of the Vth International Congress of the IRPA. Pergamon Press, New York.

RADIONUCLIDE-SPECIFIC EXPOSURE ADJUSTMENT
FACTORS FOR ^{239}Pu INHALATION BY THE PUBLIC

PARAMETER	FACTOR FOR:	
	INFANCY	LIFESPAN
ORGAN SIZE	0.1	1
VOLUME INHALED	10.	1
FRACTION DEPOSITED AND/OR RETAINED	2.	1
ENHANCED GASTROINTESTINAL AND/OR POLMONARY ABSORPTION	0.2	1
DISTRIBUTION AND RETENTION IN:		
BONE (2X FOR INFANT)	0.6	1
LIVER (0.5X FOR INFANT)		
G.I. TRACT (100X FOR INFANT)		
FRACTION OF COMMITTED DOSE RECEIVED	40. (W)	1
	4. (Y)	
OVERALL VALUE OF F_j	10. (W)	1
	1. (Y)	

FIGURE 1.

ALARA ~~PRINCIPLE~~ PRIORITIZATION

Section 20.102 of the proposed regulations addresses the prioritization of ALARA efforts. With due respect to my colleagues primarily concerned with occupational protection, I submit that the general public in no way would accept in an either-or situation the principle of minimizing occupational doses, at the expense of somewhat larger ^{doses (and risks) to members of the public.} ~~collective risk.~~ I also submit that the referenced section ignores the ^{population} ~~most~~ ^{members of the public} apt to be affected and to which the population ^{dose} limits are addressed, the maximally-exposed individual (or "critical group" as defined by the ICRP). Proper implementation of the ALARA principle requires ^{consideration of all} ~~balancing all~~ categories of exposure, and indeed involves socio-~~economic~~ - political judgments which presumably the NRC must ^{and should} make, with full consideration of ~~all~~ ^{collective and individual doses, to the worker and to the public.}

either individual or collective,

PROLIFERATION OF LIMITS

(on action levels)

The use of reference levels for special reporting or for initiating investigative action is basically sound and generally accepted as good radiation protection practice. However, those responsible for reporting to the public must be concerned with the continuing proliferation of such levels, which in some instances seem unrelated to previous regulatory efforts and which undoubtedly contribute to public confusion and misunderstanding of the differences between reference levels, ALARA values, and limits. A reference level of 100 mrem ~~has been~~ proposed for members of the public in a recent draft (8/82) of 10CFR20. ~~The proposed reference level of 100 mrem~~ is without antecedent in U.S. practice, and is in addition to other limits applicable to individual members of the public. (Figure 2). These limits include the basic ^{effective} whole-body dose ^{equivalent} limit of 0.5 rem per year, design objectives for light water reactors contained in 10CFR50, Appendix I of 3 to 15 mrem per year depending on pathway, the drinking water limit in 40CFR141 of 4 mrem/yr, and a total dose limit for the bulk of the uranium light water fuel cycle of 25 mrem/yr. Note that I have not even attempted to indicate ^{other} specific organ dose limits. I question the need for still another number other than to conform to ICRP recommendations.

DOSE CRITERIA MAXIMUM EXPOSED INDIVIDUAL




FIGURE 2.

I had hoped ~~that~~ The NRC staff and this Subcommittee ~~will~~ ^{would} recognize that, in practice, any Reference Level is an Action Level, which thereby becomes ~~a~~ Working Limit, which to the public is the Limit. In the proposed regulations, this situation is reinforced by the language of Section 20.301, which states that the basic annual limit for members of the public is 0.5 rem (presumably the effective ^{committed} dose equivalent ~~commitment~~ is intended) ^{and} ~~but~~ applies to the sum of all sources of exposure, licensed and unlicensed, other than natural radioactivity and medical exposures. In Section 20.303, it is quite rightly recognized that "It is impractical, if not impossible, to determine an actual dose (to individual members of the public) precisely", in part because of ^{probable} multiple sources. As a substitute, the Reference Level is offered as a means of demonstrating compliance with the NRC's intent. It seems to me a questionable practice to ^{claim} propose a limit ^(0.5 rem) for the licensee which is ~~not really~~ ^{in reality 5 times} the limit he must ^{really} live with.

The Study part of this sub-section

Then in Section 20.401(c), I find that "a licensee engaged in uranium fuel cycle operations subject to the provisions of 40CFR190" shall comply with its requirements. In addition to limits on releases of specific radionuclides, 40CFR190 specifies annual dose equivalent limits for members of the public, with not only different numerical values (shown in Figure 4), but on what would now be a different basis (annual dose equivalent vs. effective ^{committed} dose equivalent ~~commitment~~). Fortunately very few ~~of~~ of the more than 10000 existing NRC and agreement state licensees would find necessary the double-entry dose bookkeeping. ^{For example, from} ~~According to~~ Battelle-Northwest studies of population doses from nuclear power reactors done for the NRC, some 80% of the dose to the public is from atmospheric releases, nearly all due to radionuclides and radiokrypton. ^{(b) In these cases, the} ~~for which the committed dose equivalent is the annual dose equivalent.~~ ^{For facilities processing transuranics, this would not be the case.}

Several alternative Reference Levels are available. An annual dose-equivalent of 25 mrem to an individual member of the public would be in keeping with the 40CFR190 fuel cycle limit and apply adequately to the large majority of licensees. Another alternative would be to put the Reference ^{level (or} ~~limit)~~ ^{effective} at 170 mrem per year effective ^{committed} dose equivalent ~~commitment~~. There is at least some antecedence for this value in earlier assumptions by the ICRP and the Federal Radiation Council. Although the intent was different, the reasoning was much the same.

(a) Peloquin, R.A., J.D. Schwab, and D.A. Baker. June 1982. Population Dose Commitments Due to Radioactive Releases from Nuclear Power Plant Sites in 1978. NUREG/CR-2201 (PNL-4039). Battelle, Pacific Northwest Laboratory. Richland, WA.

BASIS FOR RISK ESTIMATES

I cannot claim any special expertise in the assessment of public health risk from radiation exposures. However it seems to me that a valid question exists as to whether an assumed distribution of risk for a worker population should be used for a mixed public of varying ages, habits, periods of exposure, and states of health and health care.

EXPANSION OF THE DATA BASE FOR POPULATION DOSE ESTIMATES

I have mentioned ~~several times~~ in the foregoing ~~text~~ a potential need for a significantly expanded data base if the proposed system of dose regulation is to achieve better estimates of population doses. Unfortunately I cannot at this time give you any real data. I can foresee steady employment for a number of computer programmers for some time to come to adapt our existing computerized dose calculations to ICRP models.

SUMMARY

To sum up, I believe that certain provisions of the proposed regulations would permit more consistent and logical assessment and control of population exposures, notably the fixing of de minimis values and the assessment of 50-year committed dose equivalents for the year of intake. ^{whether the necessary data base exists} ~~whether the latter~~ ^{can be justified} ~~would justify~~ ^{without proposed regulation} different systems of record-keeping is open to question. I have major concerns for the proposed conversion system of ALI/DAC tables for dose calculation for members of the public, for the potential loss of epidemiological data and ^{through reliance on} ~~potentially~~ misplaced emphasis on effective committed dose equivalent, and for inappropriate balancing of ALARA considerations.

~~Should you~~
May I pass on a quote from ^{Le Soldat,} my co-worker known at least by reputation to ^{most} of you, ~~the Soldat,~~ referring to the ICRP system adopted for 10CFR20: "My overall impression is that the elegance of the mathematics far exceeds the ~~availability~~ availability of the basic data needed to perform [with confidence] the calculations demanded by the system."

RADIONUCLIDE-SPECIFIC EXPOSURE ADJUSTMENT
FACTORS FOR ^{239}Pu INHALATION BY THE PUBLIC

<u>PARAMETER</u>	<u>FACTOR FOR:</u>	
	<u>INFANCY</u>	<u>LIFESPAN</u>
ORGAN SIZE	0.1	1
VOLUME INHALED	10.	1
FRACTION DEPOSITED AND/OR RETAINED	2.	1
ENHANCED GASTROINTESTINAL AND/OR POLMONARY ABSORPTION	0.2	1
DISTRIBUTION AND RETENTION IN:		
BONE (2X FOR INFANT)	}	1
LIVER (0.5X FOR INFANT)		
G.I. TRACT (100X FOR INFANT)		
FRACTION OF COMMITTED DOSE RECEIVED	40. (W)	1
	4. (Y)	
OVERALL VALUE OF F_J	10. (W)	1
	1. (Y)	

FIGURE 3.

SELECTED DOSE CRITERIA MAXIMALLY EXPOSED INDIVIDUAL




FIGURE 2.

ENO DEFINITION
(SEC 11J OF AEA)

*Peter son
T8*

AN EXTRAORDINARY NUCLEAR OCCURRENCE IS ANY EVENT WHICH:

CAUSES A DISCHARGE OR DISPERSAL OF SOURCE, SPECIAL
NUCLEAR OR BYPRODUCT MATERIAL FROM ITS INTENDED
PLACE OF CONFINEMENT

IN AMOUNTS OFFSITE, OR CAUSING RADIATION LEVELS
OFFSITE, WHICH THE COMMISSION DETERMINES TO BE
SUBSTANTIAL

AND WHICH THE COMMISSION DETERMINES HAS RESULTED
OR WILL PROBABLY RESULT IN SUBSTANTIAL DAMAGES
TO PERSONS OFFSITE OR PROPERTY OFFSITE

REVISED CRITERION FOR "SUBSTANTIAL RELEASES"

- INDIVIDUAL OFFSITE RECEIVES EFFECTIVE WHOLE BODY DOSE OF 5 REM OR MORE

OR

- OFFSITE CONTAMINATION LEVELS EXCEED LIMITS (IN CURRENT PART 140 - NOT CHANGED)

REDUCES 20 REM WHOLE BODY DOSE AND ASSOCIATED ORGAN DOSES TO 5 REM EFFECTIVE DOSE

IF AN ACCIDENT HAD "SUBSTANTIAL RELEASES" THEN IT WOULD HAVE REQUIRED PROTECTIVE ACTIONS

REVISED CRITERION FOR "SUBSTANTIAL DAMAGES"

- "SUBSTANTIAL INJURY" 100 REM TO 5 PEOPLE
SMALLER DOSES TO LARGE POPULATIONS LIMITED BY 1 REM (10,000 PEOPLE
OR MORE)

OR

- DECONTAMINATION REQUIRED OF OFFSITE PROPERTY WORTH \$2,500,000

OR

- LOST EMPLOYMENT OF AT LEAST 25,000 PERSON-DAYS

OR

- EVACUATION OF AT LEAST 100,000 PERSON-DAYS DURATION

PROBLEMS FOUND IN TMI ENO DETERMINATION

1. EVALUATION OF MAGNITUDE OF DAMAGES DIFFICULT
2. INTERPRETATION OF "COULD BE" AND "MIGHT BE"
3. ADEQUACY OF ENO CRITERIA
4. ENO NOT CONSIDERED DURING OR IMMEDIATELY AFTER ACCIDENT

BACKUP

EXISTING CRITERION I FOR "SUBSTANTIAL RELEASES"

PROJECTED DOSE TO INDIVIDUAL OF

30 REM TO THYROID

20 REM TO WHOLE BODY

20 REM TO BONE MARROW

60 REM TO SKIN

30 REM TO OTHER TISSUES

BAIRUP

EXISTING CRITERION I FOR "SUBSTANTIAL RELEASES"

SURFACE CONTAMINATION OF 100M² OR MORE IN EXCESS OF:

	<u>μCi/M²</u>
ALPHA FROM TRANSURANIC ELEMENTS	0.35
ALPHA NON-TRANSURANICS	3.5
BETA OR GAMMA EMISSION	4 mR/HR @ 1 CM AND 7 MG 1CM ² ABSORPTION

BACKUP

EXISTING CRITERION II FOR "SUBSTANTIAL INJURY OR DAMAGE"

1. 5 OR MORE PEOPLE KILLED OR HOSPITALIZED WITH "OBJECTIVE CLINICAL EVIDENCE OF RADIATION INJURY"

OR

2. \$2.5M OF DAMAGE SUSTAINED BY 1 INDIVIDUAL OR \$5M OF DAMAGE SUSTAINED IN TOTAL

OR

3. \$5K OR MORE OF DAMAGE SUSTAINED BY 50 OR MORE PERSONS WITH AT LEAST \$1M SUSTAINED IN TOTAL

BACK UP

Box 13 Thetford
Vermont 05074
July 16, 1982

Ms. Rung C. Tang, Staff Engineer
Advisory Committee on Reactor Safeguards (H1016)
U.S. Nuclear Regulatory Commission
Washington D. C. 20555

RECEIVED
COMMUNICATIONS SECTION
JUL 27 1982
PM
10, 11, 12, 13, 14, 15, 16


Dear Ms. Tang,

As indicated in my letter of July 7, I am forwarding herewith translations of the table and figures from the Kallee paper on KI which I had forwarded to you prior to the June 23 subcommittee meeting.

I have not previously included Kallee's bibliography but I am enclosing a copy of the paper in the original German and the references, which are for the most part obvious, are listed on the final page of the paper.

If the above items are appended to the earlier translation, a complete version of Kallee's paper will be available for the meeting minutes.

Sincerely,


Reginald Muller
Consultant

cc: Dr. Dade W. Moeller

Table and Figures Accompanying Paper by E. Kallee, Medical University Clinic, Tuebingen. Internist (May 1981) Vol. 22, No.5, pp 304-307 (Translated by Ragnwald Muller, ACRS Consultant)

Table 1. Possible Side Effects of a 3-Day Prophylaxis with 300 mg KI. The multiplicity of the listed side effects is rare. (See text)

THYROID

(A) Euthyroids:

Dominant decrease of TT_4 and TT_3 with a rise in TSH or fleeting rise of TT_4 and TT_3 . Iodine goiter and iodine myxedema in adults only after long-term therapy.

(B) Hyperthyroids:

1. Obvious, treated Hyperthyroids: Under Thionamid - Thyreostatika no damaging effect from iodine to worry about. Ferchlorate suppressed by iodide.

2. Latent Untreated Hyperthyroids: Here KI could result in up to a thyroid-toxic crisis in severe hyperthyroids. Endangered are principally persons with multiple adenomas (nodular tumors) and diffuse micro adenomas, but also singular adenomas such as goiter patients.

3. Colloid-poor follicles can resume absorption of colloids because of KI which can result in acute colloidal tumors.

(C) Hypothyroids:

1. Obvious Hypothyroids: No specific thyroid side effects expected.

2. Latent primary Hypothyroids: So-called "Iodine deficiency" can, as a result of iodine saturation be converted to hyperthyroids.

(D) Large Tumors of Unknown Etiology:

Acute volume increase with blockage of the trachea possible.

(E) Pregnancy:

Endangered is solely the fetus, due to tumors or hypothyroidism.

ALLERGIC REACTIONS

(A) Non-specific drug rash, principally in sensitized patients (genuine iodine allergy is rare), facial edema, glottic edema (toxic ?)

(B) Iodine idiosyncrasy with dermatitis herpetiformis Duhring.

(C) Nodous periarteritis with eosinophil

TOXIC EFFECTS

(A) Iodine skin blisters: poxiform hemorrhaging necrotic, can end lethally. Only observed with long-term therapy.

Table 1 (Continued)

(B) Iodine tuberous skin and iodine-stimulated skin growth equally only observed with long-time therapy or locally as a result of pigmentation treatment with 40% KI vaseline.

(C) "Iodine Sniffles" and side-effect sinusitis caused by increased secretion; itching and burning of the eyes; headaches.

(D) Swelling of the salivary glands (Iodine mumps); on awakening - a salty-bitter aftertaste.

(E) Stomach complaints assumed caused by build-up of I_2 from ICl of the stomach juices.

Preventative: Vitamin C, protein-containing nourishment.

(F) Iodide Fever: only at higher doses

PSYCHOLOGICAL EFFECTS


(A) Fear caused by threatening catastrophes can lead to consumption of tranquilizers, sleep inducers, and analgesics, as well as to excessive alcohol or nicotine use. The direct results thereof, or the later effects up to deformities, could be attributed possibly not only to the radioiodine release but also to the iodine prophylaxis.

(B) Stress: Gastritis, stress ulcers, incontinence, leucocytosis reactive psychoses.

(C) Not taking iodine pills or, conversely, harmful overdosing of iodide.

Figure 1

Normalized values of Absorption of ^{131}I in the Human Thyroid




Hours post-application of the radioiodine

The radioiodine absorption in New York was measured in 62 patients with a whole-body counter mainly 24 hours after application of 1.5 nCi ^{131}I Na. (From data of Blum and Eisenbud 1968 (12)). The Tübingen values were obtained from 70 experimentees 6 and 24 hours after 30 μCi ^{131}I Na.

Figure 2

Wolff-Chaikoff Effect: Rise and blockage of new synthesis of Thyroxin (T_4) and Triiodinethyronin (T_3) of the thyroid of rats 4 hours after injection of ^{127}I (Method of Nagataki and Ingbar (16)). In the lower abscissa the iodine quantities converted to 70 kg man from 200-250 g rat data are given in parenthesis. The region indicated for x-ray contrast media is estimated assuming that of a 10 gram given dose of a 60% iodine-content contrast medium, about 0.05-0.5 % will be split off in the form of iodide during the first day.. (The upper abscissa gives the iodine dose for rats in μg . The lower abscissa gives the iodine dose for 70 kg man in mg)

μg ^{127}I hormone per thyroid




Absorption of ^{131}I in the Thyroid

Examples: Eyedrops X-ray contrast media "loading" of thyroid

Figure 3

Absolute iodide absorption by the human thyroid in relation to the serum iodide level (17). (From Oberdisse et al. (1967) Diseases of the Thyroid; 1st ed. Thieme, Stuttgart, p60).



Kurze Informationen

Nutzen und Risiko der Jodprophylaxe bei Kernreaktorunfällen*

E. Kallee

Medizinische Universitätsklinik Tübingen

Jod ist als Schlüsselement der Schilddrüse zugleich ein lebenswichtiges Spurenelement [1]. Der Mensch sollte davon täglich etwa 100 bis 200 µg zu sich nehmen [2, 3]. In den USA und in anderen Jodüberflußgebieten mit hohen Zusätzen von Kaliumjodid (KJ = Kalium jodatum DAB VII; Kalii iodidum Eur. AB I) zum Speisesalz – oder Kaliumjodat (KJO₃) als Backzusatz zum Brot – beträgt die tägliche Jodzufuhr etwa 400 bis 1200 µg. Jodat vernetzt die SH-Gruppen des Klebers oxydativ zu S-S-Brücken und wird während des Backvorgangs zu Jodid reduziert. Gargebackenes Brot enthält also in den USA kein Jodat mehr, sondern nur noch Jodid. In der Bundesrepublik Deutschland ist über die alimentäre Jodaufnahme nur wenig bekannt, aber die Ausscheidung von Jod im Urin liegt mancherorts wahrscheinlich unter 50 µg pro Tag [4, 5].

Der sog. Jodmangelkropf beruht sicher nicht immer auf alimentärem Jodmangel [2, 6-8], unter Jodmangel treten aber stets Strumen auf. Die Schilddrüse enthält hierzulande normalerweise etwa 5-15 mg Jod [3, 9, 10]. Strumen enthalten durchschnittlich etwa die Hälfte, können aber auch viel weniger Jod enthalten. Besonders jodarm sind Schilddrüsen bei latenten und floriden Hyperthyreosen, extrem wenig Jod enthalten toxische Adenome [10, 11]. Die freie Speicherkapazität der Schilddrüse für Jod ist in unserer Gegend auf mindestens 5-10 mg einzuschätzen, bei jodarmen Drüsen entsprechend höher. Einen Parameter hierfür stellt der Radiojodtest dar.

Bei klinisch euthyreoten Probanden speichert die Schilddrüse binnen 24 h hierzulande 60-70% des verabreichten Radiojods. Bei Jodmangelzuständen können die Speicherwerte annähernd 100% erreichen, wobei das Radiojod nachhaltig, oft tagelang, gespeichert bleiben kann.

In Jodüberflußgebieten, beispielsweise in den nordamerikanischen Staaten New York und Massachusetts, ist die freie Jodidbindungskapazität der

Schilddrüse auf die Hälfte bis ein Viertel unserer Werte reduziert [3, 12, 13]. Daher lassen sich US-amerikanische Untersuchungen und Überlegungen zur Jodprophylaxe nur mit erheblichen Korrekturen auf unsere gegenwärtigen Verhältnisse übertragen.

Von entscheidender Bedeutung für das Verständnis des Nutzens und der Gefahren einer Jodprophylaxe ist der Wolff-Chaikoff-Effekt: Bei der Inkubation von Gewebsschnitten von Schafsschilddrüsen in vitro bauen die Zellen zunächst um so mehr Jod in organische Jodverbindungen ein, je höher die Jodkonzentration im Nährmedium ist [14]. Wird eine bestimmte kritische Jodkonzentration überschritten, so nimmt die Bildung organischen Jods wieder ab und kehrt zum Ausgangsniveau zurück. Jodid stimuliert also bei niedrigen bis mittleren Konzentrationen die Hormonsynthese, wogegen hohe Jodidkonzentrationen das Gegenteil bewirken.

Ein ähnlicher Vorgang spielt sich auch in vivo ab [15]. Erhalten Ratten konstante Tracerdosen Radiojod zusammen mit steigenden Mengen Jodid intraperitoneal injiziert, so nimmt die Bildung von Jodhormonen in der Schilddrüse ebenfalls zunächst zu, obwohl die Radiojodspeicherung gleichzeitig zurückgeht (Abb. 2). Das Maximum der Hormonsynthese wird




Abb. 1. Die Radiojodspeicherung in New York wurde bei 62 Patienten mit einem Ganzkörperzähler hauptsächlich 24 h nach Verabreichung von 1,5 nCi ¹³¹I_{Na} gemessen (umgezeichnet nach Blum u. Eisenbud 1968 [12]). Die Tübinger Werte wurden an 70 Probanden 6 und 24 h nach 30 µCi ¹³¹I_{Na} ermittelt [3]

* Gekürzte Fassung eines Vortrags, gehalten auf der Tagung der Vereinigung Deutscher Strahlenschutzärzte in München am 29. November 1980. Alle Vorträge dieser Tagung erscheinen in einem Sammelband beim Georg-Thieme-Verlag, Stuttgart




Abb. 2. Wolff-Chaikoff-Effekt. Steigerung und Blockade der Neusynthese von Thyroxin (T_4) und Trijodthyronin (T_3) der Schilddrüse von Ratten 4 h nach Injektion von $^{127}\text{J}^-$ (modif. nach Nagataki und Ingbar [16]). In der zusätzlichen Abszisse sind die Jodidmengen, die von 200–250 g Ratte auf 70 kg Mensch umgerechnet wurden, in Klammern angegeben. Der für Röntgenkontrastmittel angegebene Bereich ist geschätzt unter der Annahme, daß nach Gabe von 10 Gramm eines 60% Jod enthaltenden Kontrastmittels am ersten Tag etwa 0,05–0,5% in Form von Jodid abgespalten werden




Abb. 3. Absolute Jodidaufnahme der menschlichen Schilddrüse in Abhängigkeit vom Serumjodidspiegel [17]. (Nach Oberdisse et al. (1967). Die Krankheiten der Schilddrüse; 1. Aufl. Thieme, Stuttgart, S 60)

bei einer mittelhohen Jodid-Dosis von 50 μg pro 200–250 g Ratte erreicht. Nach Überschreiten dieser kritischen Dosis kehrt sich der Vorgang analog dem Verhalten in vitro allmählich um, und ab 500 μg sistiert die Hormonsynthese [16]. Bei einer Jodid-Dosis, die ausreicht, die Radiojodspeicherung auf 5% zu supprimieren, findet aber immer noch eine submaximale Hormonsynthese statt, und selbst bei 2% Radiojodspeicherung ist die Hormonbildung noch deutlich erhöht.

Beim Menschen erfolgt der Einbau von Radiojod die Schilddrüse ähnlich wie bei der Ratte. Im Rattenversuch wird das Maximum der Neubildung von organischem Jod bei einer Serumjodidkonzentration von etwa 15 $\mu\text{g/dl}$ erreicht [15]. Da die Jodidkonzentrationen der Dosis-Wirkungskurven von Mensch und Ratte in der Größenordnung gut übereinstimmen, erscheint der Analogieschluß vom Rattenversuch auf den Menschen gerechtfertigt (Abb. 3) [17].

Der Wolff-Chaikoff-Effekt bietet eine naturwissenschaftliche Erklärung für eine schon lange zuvor

bekannte klinische Tatsache: Im physiologischen Bereich von 100 bis 1000 μg täglich ist Jod zur Erhaltung der Gesundheit erforderlich. In Dosen zwischen 1 mg und 50 oder 100 mg täglich kann Jod bei prädisponierten Personen Hyperthyreosen bis hin zum thyreotoxischen Koma auslösen [18, 19]. Diese Reizdosen sind die verhältnismäßig kleinen Jodidmengen, beispielsweise in Augentropfen, oder die mittleren Jodidmengen, welche aus Kontrastmitteln und anderen jodhaltigen Medikamenten wie Clioquinol gewöhnlich frei werden. Im Bereich oberhalb 200–300 mg täglich wird die stimulierende Wirkung mittlerer Joddosen wieder aufgehoben. Eine Überfunktion der Schilddrüse, die durch gefährliche mittlere Jodmengen ausgelöst wurde [20], läßt sich also durch sehr hohe Dosen rückgängig machen [18]. Bei mehr als zweimonatiger Behandlung mit täglichen Dosen von 500–1000 mg KJ und mehr können sogar Jodkropfe mit primärem Myxödem entstehen. Diese verschwinden aber nach Absetzen des KJ spontan [21].

Bei der Wahl der optimalen Joddosis zur Prophylaxe einer Strahlenschädigung der Schilddrüse kommt es darauf an, die Drüse so stark mit Jodid zu sättigen, daß mit einiger Sicherheit weniger als 1% radioaktives Jod in die Drüse gelangt. Zugleich muß sichergestellt sein, daß die gewählte Dosis oberhalb der gefährlich stimulierenden Dosis liegt. Andererseits sollte die Sättigungsdosis unterhalb der lästigen Expektorationsdosis oder gar der direkt toxischen Dosis liegen.

Theoretisch genügen für eine wirksame Blockade der Radiojodspeicherung durch Jodid in den USA 30–100 mg KJ [12, 13], in Griechenland etwa 40 mg [22], und auch in Deutschland wird eine solche Dosis vermutlich in vielen Fällen ausreichen. Da aber die Schilddrüse in Deutschland infolge eines relativen Jodmangels eine etwa zwei- bis vierfach höhere Speicherkapazität besitzt als in den USA, muß die KJ-Dosis entsprechend höher angesetzt werden. Für unsere Verhältnisse erscheint eine Dosis von 300 mg KJ pro Tag – 229 mg Jodid entsprechend – sicher ausreichend, die Radiojodspeicherung in allen Fällen wirksam zu unterdrücken. Zugleich sind bei dieser hohen

ALL INFORMATION CONTAINED HEREIN IS UNCLASSIFIED EXCEPT WHERE SHOWN OTHERWISE
 NATIONAL ARCHIVES REF ID: A61111

Tabelle I. Mögliche Nebenwirkungen einer dreitägigen Prophylaxe mit 300 mg Kaliumjodid pro Tag. Die Mehrzahl der aufgeführten Nebenwirkungen ist selten (vgl. Text)

- Schilddrüse*
- (A) Euthyrosen:
Vorübergehender Abfall von TT_4 und TT_3 mit TSH-Anstieg oder flüchtiger Anstieg von TT_4 und TT_3 . Jodkropf und Jodmyxödem bei Erwachsenen nur durch Langzeittherapie
- (B) Hyperthyrosen:
(1) Manifeste, behandelte Hyperthyrosen: Unter Thionamid-Thyreostatika keine schädlichen Wirkungen von Jodid zu befürchten. Perchlorat wird durch Jodid verdrängt
(2) Latente, unbehandelte Hyperthyrosen: KJ kann hier floride Hyperthyrosen bis hin zur thyreotoxischen Krise auslösen. Gefährdet sind hauptsächlich Träger von multiplen Adenomen („Knotenstruma“) und diffusen Mikroadenomen, aber auch Solitäradenomen sowie Basedow-Patienten
(3) Kolloidarme Follikel können durch KJ wieder Kolloid einlagern, wodurch eine akute Kolloidstruma entstehen kann
- (C) Hypothyrosen:
(1) Manifeste Hypothyrosen: keine schilddrüsenspezifischen Nebenwirkungen zu erwarten
(2) Latente primäre Hypothyrosen: sog. „Jodmangel“ kann durch Jodsättigung in Hyperthyreose umschlagen
- (D) Große Strumen unbekannter Ätiologie:
Akute Volumenzunahme mit Einengung der Trachea möglich
- (E) Gravidität:
Gefährdet ist ausschließlich der Fetus durch Struma und Hypothyreose
- Allergische Reaktionen*
- (A) Unspezifische Arzneimittelalexantheme, vor allem bei sensibilisierten Patienten (echte Jodallergie ist selten). Gesichtsoedeme, Glottisödem (toxisch?)
(B) Jod-Idiosynkrasie bei Dermatitis herpetiformis Duhring
(C) Periarteriitis nodosa mit Eosinophilie
- Toxische Wirkungen*
- (A) Jododerma bulbosum: varicelliform, hämorrhagisch-nekrotisierend, kann letal enden. Bisher nur bei Langzeittherapie beobachtet
(B) Jododerma tuberosum und Jododerma vegetans ebenfalls nur bei Langzeittherapie oder lokal infolge Leukotaxis durch 40%-KJ-Vaseline
(C) „Jodschnupfen“ und Begleitsinusitis durch vermehrte Sekretionsleistung; Jucken und Brennen in den Augen; Kopfschmerzen
(D) Schwellung der Speicheldrüsen (Jod-Mumps); beim Aufwachen salzig-bitterer Mundgeschmack
(E) Magenbeschwerden vermutlich durch Bildung von J_2 aus JCl des Magensaftes
Vorbeugung: Vitamin C, proteinhaltige Nahrung
(F) Jodfieber: nur nach höheren Dosen
- Psyche*
- (A) Angstzustände wegen drohender Katastrophe können zur Einnahme von Beruhigungs- oder Schlafmitteln und Analgetika sowie zu exzessivem Alkoholgenuß und Nikotinabusus etc. verleiten. Deren unmittelbare Folgen oder Spätschäden bis hin zu Mißbildungen werden dann möglicherweise nicht nur der Radiojodexposition, sondern auch der Jodprophylaxe zugeschrieben
(B) Streß: Gastritis, Streßulzera, Inkontinenz, Leukozytose, reaktive Psychosen
(C) Nichteinnahme der Jodidtabletten oder umgekehrt panische Überdosierung von Jodid

Dosis weniger jodinduzierte Hyperthyrosen als bei der scheinbar vorsichtigeren mittleren Dosierung zwischen 30 und 100 mg KJ zu erwarten. Denn unter der hohen Dosierung werden in der Schilddrüse wegen des Wolff-Chaikoff-Effekts keine größeren Hormonvorräte gebildet. Daher ist auch kaum mit einer Ausschüttung von Schilddrüsenhormonen im Sinne eines „escape“-Phänomens oder einer Hormon-„Leckage“ zu rechnen. Die Dosis von 300 mg liegt überdies weit unterhalb der toxischen Grenze und verursacht bei der vorgesehenen kurzfristigen Anwendung keine manifesten Hypothyrosen.

Eine Dosis von 100 mg NaJ reicht selbst in den USA nicht immer zu einer wirksamen Blockade voll aus. Außerdem verfliegt die sättigende Wirkung ziemlich rasch, und 100 mg bewirken bei einer nachträglichen Einnahme nicht viel [23]. Das bedeutet für den Ernstfall, mit der Jodprophylaxe nicht früher als 1–2 h vor und möglichst nicht später als 1–3 h nach einer Radiojodexposition zu beginnen und eine möglichst hohe Initialdosis zu wählen [24].

Unerwünschte Nebenwirkungen einer dreitägigen Behandlung mit jeweils 3×100 mg KJ ($= 229$ mg J^-) werden voraussichtlich nur selten auftreten, und die meisten Nebenwirkungen verschwinden von selbst nach Absetzen der Prophylaxe. In Tabelle I sind alle bisher bekannten möglichen Nebenwirkungen von Jodid in hohen – vorwiegend toxischen – Dosen aufgeführt.

In erster Linie gefährdet sind Menschen mit latenter Hyperthyreose. Auch hinter scheinbar harmlosen „Jodmangelstrumen“ kann sich eine symptomlose Hyperthyreose verbergen. Daher empfiehlt sich hierzulande eine Kontrolle des Thyroxinspiegels und eines Parameters für das FT_4 ab der dritten Woche nach Beendigung der Jodprophylaxe bei allen Personen, die Jodidtabletten eingenommen haben. Solche Kontrollen lassen sich mit modernen Methoden ohne weiteres durchführen, auch wenn tausende oder zehntausende von Proben pro Woche anfallen sollten.

Schwangere sollten möglichst nicht an der Jodprophylaxe teilnehmen, sondern das gefährliche Gebiet

rechtzeitig verlassen. Jedoch müssen notfalls auch Schwangere das Kaliumjodid einnehmen, denn ein fetaler Jodkropf ist im allgemeinen post partum therapeutisch reversibel, ein fetaler Strahlenschaden an der Schilddrüse dagegen wahrscheinlich irreversibel.

Patienten mit Dermatitis herpetiformis Dühring und von der Prophylaxe wegen der notorischen Jod-Idiosynkrasie auszuschließen [27, 28].

Magenbeschwerden können auch bei Gesunden auftreten, vor allem wenn der Magen leer ist. Durch Salzsäure entsteht aus HJ das Chlorjod (JCl), aus dem teilweise elementares J₂ frei wird. Durch reaktionsfreudige anorganische Jodverbindungen kann die Schleimhaut des Magens gebläht und damit gereizt werden. Die Reizerscheinungen lassen sich aber durch Vitamin C (etwa 500 mg pro die) oder durch proteinhaltige Lebensmittel leicht verhüten und beheben. Dagegen müssen erhebliche Magensymptome immer an eine Krankheit denken lassen, die nicht primär mit der Einnahme von Kaliumjodid zusammenhängt.

Aufmerksamkeit verdienen bei Reaktorstörfällen auch psychische Alterationen wegen ihrer somatischen Auswirkungen und versicherungsrechtlichen Folgen. Vor allem bedürfen Streßulzera – im Gegensatz zu jodbedingten Magenbeschwerden – einer intensiven Therapie.

Literatur

1. Reinwein D (1980) Physiologie der Schilddrüse und ihrer Hormone. In: Oberdisse K, Klein E, Reinwein D (Hrsg) Die Krankheiten der Schilddrüse, 2. Aufl. Thieme, Stuttgart, S 47
2. Schmid M, Schulthess C, Bürgi H, Studer J (1980) Jodmangel ist in der Schweiz noch immer endemisch. Schweiz Med Wochenschr 110:1290
3. Kallee E (ältere Lit) (1969) Radioaktive Nuklide – Grundlagen – Diagnostik – Schilddrüse. In: Diem K, Lentner C (Hrsg) Documenta Geigy, Wissenschaftliche Tabellen, 7. Aufl. Geigy Pharma, Basel, S 281, 493
4. Emrich D, Leipert KP, Schreivogel I, Facorro U, Köbberling J (1980) Qualitätskontrolle und Normalbereiche für 10 Schilddrüsen-in-vitro-Parameter. Aktuel Endokrinol 1:245
5. Habermann J, Heinze HG, Horn K, Kantlehner R, Marschner I, Neumann J, Scriba PC (1975) Alimentärer Jodmangel in der Bundesrepublik Deutschland. Dtsch Med Wochenschr 100:937
6. Elfving S (1980) Studies on the naturally occurring goitrogen 5-vinyl-2-thiooxazolidone. Metabolism and antithyroid effect in the rat. Ann Clin Res 12 [Suppl 28]
7. Taterka W (1974) Sind Jodmangel oder Jodfehlverwertung die Ursachen der degenerativen Struma? Praxis 62:783
8. McLaren EH, Alexander WD (1979) Goitrogens. Clin Endocrinol Metab 8:129
9. Riggs DS (1952) Pharmacol Rev 4, zit nach Diem K, Lentner C (Hrsg) Documenta Geigy, Wissenschaftliche Tabellen, 7. Aufl (1969) Geigy Pharma, Basel, S 715

10. Leisner B, Kantlehner R, Igl W, Heinze HG, Lissner J (1980) Die quantitative Fluoreszenzscintigraphie in der Schilddrüsen-diagnostik. Nuklearmedizin 3:249
11. Kallee E, Wahl R, Scherbaum W, Anger K (1978) Selektive Blockade von Schilddrüsenadenomen durch kleine Perchloratdosen. Med Welt 29:1641
12. Blum M, Eisenbud M (1967) Reduction of thyroid irradiation from ¹³¹I by potassium iodide. JAMA 200:1036
13. Sternthal E, Lipworth L, Stanley B, Abreau C, Fang SL, Braverman LE (1980) Suppression of thyroid radioiodine uptake by various doses of stable iodide. N Engl J Med 303:1083
14. Morton ME, Chaikoff IL, Rosenfeld S (1944) Inhibiting effect of inorganic iodide on the formation in vitro of thyroxine and diiodotyrosine by surviving thyroid tissue. J Biol Chem 154:381
15. Wolff J (1980) Physiological aspects of iodide excess in relation to radiation protection. J Mol Med 4:151
16. Nagataki S, Ingbar S (1964) Relation between qualitative and quantitative alterations in thyroid hormone synthesis induced by varying doses of iodide. Endocrinology 74:731
17. Reinwein D, Klein E (1960) Der Einfluß des anorganischen Jodjodes auf den Jodumsatz der menschlichen Schilddrüse. Acta Endocrinol (Kbh) 35:485
18. Kallee E (1974) Therapie thyreotoxischer Krisen. Dtsch Med Wochenschr 99:1369, 1789
19. Steidle B, Grehn S, Seif FJ (1979) Jodinduzierte Hyperthyreose durch Kontrastmittel. Dtsch Med Wochenschr 104:1435
20. Kallee E, Wahl R, Bohner J, Dohm G, Fessler E (1980) Thyrotoxicosis induced by iodine-containing drugs. J Mol Med 4:221
21. Peters G (anonym) (1960) Jod-Myxödem. Med Periskop Ingelheim 10:86
22. Koutras DA, Livadas D (1966) The minimum dose of potassium iodide which inhibits the thyroidal radioiodine uptake. Nuklearmedizin 5:256
23. Tanaka S, Mochizuki Y, Yabumoto E, Iinuma TA, Kumatori T, Yamane T, Akiyama T, Matsusaka N (1968) Protection of thyroid gland and total body from radiation delivered by radioactive iodine. In: Kornberg HA, Norwood WD (eds) Diagnosis and treatment of deposited radionuclides. Excerpta Medica Foundation, Amsterdam, p 298
24. Heinrich HC, Gabbe EE, Meineke B, Whang DH (1966) Quantitative „in vivo“-¹³¹I-Untersuchungen zur vollständigen Hemmung der Gesamtkörper-Inkorporierung und Retention des ¹³¹I-beim Menschen. Atomkernenergie 11:83
25. Nagataki S (1974) Effect of excess quantities of iodide. In: Handbook of physiology, Section 7: Greep RO, Astwood EB (eds) Endocrinology, Vol III: Greer MA, Solomon DH: Thyroid. American Physiological Soc, Washington DC, p 329
26. Seif FJ, Stöckle G, Grehn S, Steidle B (1980) Changes of thyroid hormones, thyrotropin, and prolactin after application of iodinated radiographic media in patients of an endemic goiter area. J Mol Med 4:221
27. Lüders G (1975) In: Kummerle HP, Goossens N (Hrsg) Klinik und Therapie der Nebenwirkungen. Thieme, Stuttgart, S 390, 922
28. Döngemann H (1980) Echte und vorgetäuschte Jod-Allergien. Umweltmed 3:13

Prof. Dr. E. Kallee
Medizinische Universitätsklinik
Ottofried-Müller-Straße 10
D-7400 Tübingen

EPA APPROACH TO DE MINIMIS
For Radioactive Waste

Floyd L. Galpin
Chief, Waste Management Standards Branch
Office of Radiation Programs (ANR-460)

For Presentation at the October 1982 Atomic Industrial Forum Conference
on Radiation Issues for the Nuclear Industry

EPA APPROACH TO De Minimis
For Radioactive Waste
Floyd L. Galpin
Chief, Waste Management Standards Branch
Criteria & Standards Division
Office of Radiation Programs (ANR-460)
U.S. Environmental Protection Agency
401 M Street, S.W.,
Washington, D.C. 20460

PROJECT SCOPE

EPA's present activity, within the context of this Conference session on Exploring the Use of a De Minimis Concept in Radiation Protection, is specifically intended to determine if there are radioactive wastes that are of sufficiently low activity they do not need to be regulated as to their radiation hazard. A potential alternative would be that the wastes could be handled and disposed with only minimal radiation protection controls. We are pursuing this as a part of a broader project to prepare standards and possibly guidance for the disposal of low-level radioactive waste.

In carrying out this activity we are presently avoiding the use of the term "de minimis." This term from the legal profession originates from the Latin quotation "De minimis non curat" meaning, the law is not concerned with trivialities. We have found that some have come to interpret this to mean that "you don't care" or that the risks people face are to be considered as trivialities. Rather than confront people's established misconceptions, we have chosen to use language more directly descriptive of our intentions. We prefer that people have a clear understanding that we have done the analysis and determined a level below which regulation is not warranted or may be minimal.

In describing the scope of the effort I shall point out a couple of aspects that we are not presently pursuing so that there will be no misunderstanding.

We are not developing an across the board regulatory cutoff for all radiation control activities. However, we are following the activities of others pursuing this, which has provided some useful insights for our effort. The most complete listing I have seen of the possible approaches to developing such general criteria are given in the paper "The Feasibility of Establishing a 'De Minimis' Level of Radiation Dose and a Regulatory Cut-off Policy for Nuclear Regulation"⁽¹⁾ prepared by Joyce Davis of the General Physics Corporation for the Edison Electric Institute. Two general bases are suggested for a generic "de minimis." First, one based on biological effects data and the second based on a comparison with background. Neither of these have been found to be directly adaptable to our current effort. As pointed out in the Davis paper itself there is not sufficient data to substantiate any of the biological approaches.

Furthermore, definition of a threshold or similar biological finding is not likely in the near future. The use of background and or its variability provides a useful perspective but is not directly applicable to our problem. A similar approach, which also incorporates the use of cancer incidence and its variability, has been proposed by G. Hoyt Whipple⁽²⁾ which also provides a useful perspective to our considerations. One problem in using background or cancer incidence variability is that they both change with geography and are therefore difficult to apply on a national basis. Another problem is that these approaches do not take into consideration any evaluation of a collective exposure to the population.

Another aspect that is not covered by our current effort is the defining of a truncation value on individual doses for use in calculating a collective population dose. This is quite different than defining a level below which regulation is not warranted. It would be expected that a collective dose truncation on individual doses would be more restrictive than a regulatory cut-off. That is to say, it is appropriate to estimate the population exposure that results from a regulatory cutoff on individual exposures.

Although the present effort to determine a regulatory cut off is restricted to low-level waste disposal, it will probably have implications for some other efforts we are involved in. It is not expected that the level determined would be the same in all cases, but some carry over in approach is probable. Other standards and guidance areas that may be influenced include decommissioning and decontamination standards and Protective Action Guides for recovery and re-entry.

One of the basic reasons that the criteria may not all be the same, in these cases, is that the cost-effective analyses, which determines how much it would cost to control various levels of exposure, may show quite different results. It is conceivable, for instance that remedial costs after a contaminating event, where Protective Action Guides are to be applied, will be much more expensive for a given level of exposure than the costs of planned activities to prevent exposure at the same level from disposal of low-level radioactive wastes. Other practical considerations, such as the measurements to be used in implementation and the determination of critical pathways, may also be very different in each case.

PROJECT AUTHORITIES & APPROACH

The EPA project to set standards for low-level radioactive waste disposal, including the determination of a level below regulatory concern, is being carried out under authorities transferred to EPA by Reorganization Plan No. 3 of 1970.

The first authority, which came from the Atomic Energy Act of 1954, as amended, is for "generally applicable environmental radiation protection standards." Such standards could establish numerical limits on radiation exposure or levels, or concentrations or quantities of radioactive materials, in the general environment outside the boundaries of locations licensed for low-level radioactive waste disposal. This authority was used to set EPA standards for uranium fuel cycle facilities (40 CFR 190). Its use is restricted to Atomic Energy Act materials.

The second authority, which came from the former Federal Radiation Council (42 U.S.C. 2021(h)), is for the EPA Administrator to "advise the President with respect to radiation matters, directly or indirectly affecting health, including guidance for all Federal agencies in the formulation of radiation standards." This authority is the same one that the Federal Radiation Council used to issue reports, numbers one and two, which established the basic limits on exposures used by the Federal agencies today.

Both authorities could be used for setting a level below regulatory concern. We have not decided to use either one of these authorities to the exclusion of the other. We plan to keep our options open as we continue our analysis. It may be that we would want to use both authorities for different aspects.

In carrying out this activity, we are aware of the conclusions of the Task Force on Low-Level Radioactive Waste of the U.S. Radiation Policy Council⁽³⁾ which stated: "that an overall generic 'de minimus' level is not a practical solution to a portion of the waste management problem because, without knowing physical and chemical parameters of the waste involved, it is difficult to establish pathways to humans and resulting doses. Therefore, in order to establish a generic 'de minimus' level, extremely conservative assumptions are dictated which are likely to lead to levels that are so small that they have little practical value in disposing of low activity waste. As an alternative the Task Force endorses the approach of evaluating waste streams on a case-by-case basis...." We agree that considerations of specific categories of waste streams and methodologies of disposal must be a part of the analysis and we are proceeding in that manner. There may even be aspects which will need to be left to a specific licensing consideration. However, we also believe we can at least develop a context within which this can be fostered.

There are several possibilities for the form of expression for a level below regulatory concern. One leading contender for EPA is in terms of an annual individual exposure rate which a cost-benefit analysis has determined to not warrant further reduction. Such criteria could conceptually also be expressed as a collective population exposure, but this would create implementation difficulties.

A regulatory cutoff could be expressed in terms of concentrations or specific activities of radionuclides or defined mixtures of radionuclides which could be disposed of without concern for their radiation hazard. Whether this level of detail is best done by EPA or should be determined by the NRC through regulation and specific licensing requirements is a matter we will discuss in planned interagency meetings. We would also appreciate your comments on this aspect.

Another possible way of accomplishing the purpose, technically, would be to limit the total quantity of radionuclides that might go into some municipal facility, such as a sanitary land fill. This would be difficult to administer however, and it is not clear who would have the authority to enforce this.

PROJECT TECHNICAL ANALYSIS

There are additional reasons why a technical analysis is required, let me just mention a couple. First, a regulatory cutoff must be realistic and accomplish something in terms of reducing the amount of actual radioactive waste that must be handled with full regulatory controls. Unless the potentially excluded waste streams and their disposal options are evaluated, one cannot be sure of accomplishing this.

Secondly, any regulatory cut-off must be shown to be practicable using available management systems and radiation measurement instruments. The necessary measurements for waste segregation must be ones that can be made within the regulatory framework.

The analysis framework we are using follows fairly closely to that described in the IAEA report "Definition of De Minimis Quantities for Release of Low-Level Solid Radioactive Waste Into the Terrestrial Environment From Incineration Plant and Landfill Facilities."⁽⁴⁾ Although we had not read this report when we initiated our technical analysis it was reassuring to see we were so closely in line.

Using the basic waste stream categories established by the NRC we have identified some low activity streams as possible candidates for being "below regulatory concern". We will determine estimates for the cost of disposal of these waste streams with and without their being included below a regulatory cutoff. This must include the differences in transportation costs and the increased cost of segregating the wastes in the case of "below regulatory concern". We also will evaluate the cases of with, and without, special treatment and packaging. Straight sanitary landfill and incineration followed by landfill of the ash will be considered.

For each of the alternatives for which we will make a cost estimate, we will also make a risk estimate, determining maximum individual and population doses. This will also have to consider the exposure for workers at an incinerator or a sanitary landfill who cannot be considered radiation workers.

Most of the information needed for this analysis is available at some level of certainty. Those that are particularly uncertain are the volumes of industrial and institutional wastes that might be effected, the potential cost savings, and the costs of the potential additional waste segregation. Any information you might develop through case studies for specific types of facilities would contribute to this analysis, and would be greatly appreciated.

The analysis described will give us a basis to make some initial judgments on the appropriate level of a regulatory cut-off. At the same time we must evaluate the program implications of the judgments we make. This will include considerations of compatibility and consistency with other present and anticipated radiation standards and regulations. The AIF report "de minimus Concentrations of Radionuclides in Solid Wastes"⁽⁵⁾ should be particularly helpful in this respect. We must also evaluate, through our intra-agency working group, whether our approach has any implications for other EPA standard setting programs. The process has already begun and at this time we see no problems with the general approach.

Because we think that establishing a level "below regulatory concern" for low-level radioactive waste disposal is potentially very important to assisting the nations disposal problems, we are considering proposing it ahead of the complete low-level waste disposal standard. Several considerations must be resolved in making this decision:

- . Will we have an adequate analysis to describe the impact, both in population risks and economics, before we complete the analysis for the whole standard?
- . Will the early establishment of a "level below regulatory concern" or "level requiring minimal control" rule out any viable options for a final standard?
- . Will the additional administrative requirements and hearings delay the final standard issuance beyond an acceptable time?

We have targeted May 1983 to make this decision.

NONTECHNICAL ISSUES

There are several issues that do not lend themselves to technical analysis. We would particularly appreciate discussions with you on these.

We have seen some indication that there may not always be a willingness to take on the administrative difficulties of doing a waste segregation as would be necessary to utilize a regulatory cut-off. Our information base on this is limited, and primarily reflects recent experience with carbon-14 and tritium wastes in scintillation vials and animal carcasses that NRC has deregulated. We understand some facilities still send these to low-level radioactive waste disposal facilities. We realize there have been other difficulties in implementing this regulation such as incompatible DOT labeling requirements and the high cost of disposing of these wastes as hazardous wastes, therefore, it may be too early to make a true evaluation.

There is some question as to whether there is a willingness to take the responsibility for waste segregation where there is the possibility of making an error. We know that even today there are materials placed in low-level radioactive waste containers, not because they really fit that definition, but because they are merely suspect and the disposer did not want to take the chance of being wrong.

One of the most difficult circumstances to evaluate is the potential interactions that may occur with the municipalities and their waste disposal authorities. Will they be willing to accept the definitions established at the Federal level? Similarly, will the waste generator be willing to undergo the difficulties that may result from dealings with such authorities? We have seen instances in recent times when even the best designed sanitary landfills become entangled public issues. Will the specter of having "radioactive waste" placed in such facilities create an even greater issue that the waste generator may not want any part of?

I believe that these questions, and others that have come to your own minds, provide an excellent basis for dialogue. I invite you to let us hear your points of view and questions.

REFERENCES

1. Davis J.P., The Feasibility of Establishing a "De Minimis" Level of Radiation Dose and a Regulatory Cut-off Policy for Nuclear Regulation, General Physics Corporation, Columbia, Maryland, December 31, 1981. (prepared for Edison Electric Institute).
2. Correspondence between G. Hoyt Whipple, Tallahassee, Florida, and Floyd L. Galpin, Environmental Protection Agency, Washington, D.C. May 1982.
3. United States Radiation Policy Council, Report of the Task Force on Low-Level Radioactive Waste, Washington, D.C., August 1980.
4. International Atomic Energy Agency, Definition of De Minimis Quantities for release of Low-Level Solid Radioactive Waste Into the Terrestrial Environment from Incineration Plant and Landfill Facilities. Methodological Implications, IAEA, Vienna, Austria, March 1982.
5. Atomic Industrial Forum, "de minimis" Concentrations of Radionuclides in Solid Wastes, AIF/NESP-016, Atomic Industrial Forum, Washington, D.C., April 1978.

DRAFT

AUG 26, 1982

Enclosure 7

FEDERAL POLICY ON DISTRIBUTION OF POTASSIUM IODIDE
TO THE GENERAL PUBLIC AROUND NUCLEAR POWER PLANT SITES FOR
USE AS A THYROIDAL BLOCKING AGENT

Lay in
T7

The use of potassium iodide (KI) is effective as a thyroidal blocking agent in preventing the accumulation by the thyroid gland of radioiodine which has entered the body through inhalation or ingestion. The radioiodine accumulation in the thyroidal can be reduced to less than 10% of what it would be without a blocking agent by a daily oral intake of 130 milligrams of KI providing administration is started before or simultaneous with the exposure to the radioiodine and treatment continues for at least 48 hours beyond the time of the last exposure. This effectiveness decreases to less than 50% blocking of the radioiodine uptake if the administration of the KI is delayed until 4 hours after the ingestion or inhalation.

It has been proposed that KI be distributed to the population surrounding all commercial nuclear power plant sites so that it could be administered in the event of an accident which results in a large airborne release of radioactivity which includes large quantities of radioiodine. The Food and Drug Administration has evaluated the medical and radiological risks of administering KI for thyroidal blocking under these emergency conditions and has concluded that it is safe and effective and has approved over the counter sale of the drug for this purpose. Recent FDA guidance states that risks from the short term use of relatively low doses of KI for thyroidal blocking in a radiation emergency are outweighed by the risks of radioiodine induced thyroid nodules or cancer at a projected dose to the thyroid gland of 25 REM.

The U.S. Nuclear Regulatory Commission (NRC) and the Federal Emergency Management Agency have already issued guidance to State and local authorities as well as licensees of operating commercial nuclear power plants in NUREG-0654/FEMA-REP-1, Rev. 1 recommending the stockpiling and distribution during emergencies of KI for thyroidal blocking to emergency workers and to institutionalized individuals who might be difficult to evacuate.

This recommendation was made because: (1) the number of individuals for any site is small and requires a limited supply of KI that can be readily distributed; (2) these individuals would be more likely ^{to} be exposed to a radioactive plume in the event of an accident; (3) the medical histories of the limited number of such individuals can be reviewed and the distribution and administration of KI readily controlled; and (4) these individuals can be readily monitored for adverse side effects by medical personnel. This guidance on the distribution and use of KI for all commercial nuclear power plant sites is hereby Federally endorsed as a viable protective action for this limited number of individuals in the event of a catastrophic nuclear power plant accident.

It is recognized that the decision to use KI for thyroidal blocking to protect the public health and safety involves with the State and local health authorities. Therefore, with the exception of the NRC licensee's personnel located onsite during the accident, the decision for use of KI during an actual emergency by all other individuals for whom the use of KI is recommended are the responsibility of these authorities. In addition, because the factors bearing on the desirability of stockpiling and distributing KI for thyroidal blocking of the general population within Emergency Planning Zone for the Plume Exposure Pathway (a radius of approximately 10 miles around the plant) depend heavily on local conditions, this matter is a decision for State and local authorities to make. In deciding whether to distribute and use KI for the general population, these authorities should carefully evaluate advantages and possible problems in implementing this program for the specific nuclear power plant(s) within their jurisdiction.


One of the considerations in deciding whether to implement the use and distribution of KI for the general population is that KI blocking only effectively reduces the radiation exposure of the thyroid gland. While this is an important contribution to the health and safety of the individual, it is not nearly as effective as measures which protect the total body of the individual from radioactivity. Both in-place sheltering and precautionary evacuations can reduce the exposure to the total body. As an example, if a precautionary evacuation of the population can be instituted with little or no radiation exposure, this may be the most effective protective action. However, there are instances where evacuation may not be preferred. Evacuation may be unnecessary because the amount of protection afforded by in-place sheltering is adequate to reduce exposures to values below protective action guideline levels. There are also possible situations when evacuation cannot be accomplished in time to prevent exposing large numbers of individuals to a significant amount of radiation during the evacuation. In those instances where shelter is used because the evacuation cannot be completed in time to avoid a substantial radiation insult, the administration of KI could be a useful ancillary protective action which could provide some additional exposure reduction to the thyroids of the exposed individuals. The use of KI for thyroidal blocking is not an effective means by itself for protecting individuals from an airborne release of radioactivity from a nuclear power plant accident and therefore should be used in conjunction with sheltering, evacuation or other protective methods.

Other considerations and problems to be evaluated by the State and local authorities in deciding whether to institute this program include: (1) whether the KI should

be distributed to the population before the accident occurs or be distributed as soon as possible after the accident occurs; (2) whether evacuation can be completed more quickly than distribution of KI for the particular nuclear power plant site in question; (3) how the KI will be distributed during the emergency; (4) what medical assistance will be available to assist the individuals who may have some adverse reaction to KI; (5) how medical authorities will advise the population to take KI and under what circumstances this advice will be given; (6) if KI is predistributed, what assumptions should be made about its availability; (7) how the authorities will provide KI to transient populations; and (8) whether use of other respiratory devices (e.g., dust masks) may be equally cost-effective.

In summary, the use of KI to prevent radioiodine from accumulating in the thyroid gland can be an effective ancillary protective action during a nuclear power plant accident. Whether KI should be stockpiled and distributed for the general public around a particular site depends on local conditions and a decision on its use during an emergency depends on accident and environmental conditions that may prevail at the time. Its use should be evaluated by each State or local jurisdiction based on the specific conditions and site environment for each operating commercial nuclear power plant. If the decision is made to use KI to protect the general population, specific plans for the distribution, administration and medical assistance should be developed to assure its effectiveness.

DEFINITION OF PROCESS FOR DETERMINING WHETHER
"AN EXTRAORDINARY NUCLEAR OCCURRENCE" HAS OCCURRED
AS GIVEN BY SECTION 11J. OF THE ATOMIC ENERGY ACT OF 1954, AS AMENDED





SUMMARY OF EEI "DE MINIMIS" PROJECT

Introduction

For several years, the radiation scientific community has been discussing the question as to whether there was a level of radiation exposure (or quantity or concentration of radioactive material) that is so trivial that it would represent a cut-off point below which scientists and regulators can ignore the exposure. The possible value of such a regulatory cut-off, a regulatory threshold, continues to be discussed and debated by several radiation standards-setting organizations, by the radiation scientific (medical, biologic, health physics, etc.) community, by regulated users of radiation sources, and by the various state and Federal regulators.

The law has long recognized that there are trivial matters that need not concern it. The maxim, "de minimis non curat lex" (the law does not concern itself with trifles) expresses that principle, and has generally been used in the shorter phrase: de minimis.

Currently, scientists debate the hazards of very low exposures to radiation, arguing whether the effects on people are represented by a biological threshold and whether there is some effect even at very low exposures. Currently, regulatory policy is based on the prudent assumption that effects are possible even from very low exposures and that the effects on populations of people are the same whether the exposures are high for one person but low for the rest or generally even among the population.

However, even current regulatory policy (and generally the statutes under which the regulations have been derived) provide for specific exemptions from regulation of certain categories of radiation exposure, or quantities or concentrations of radioactive material. Maximum exposure standards establish the high level for a range of permitted exposures, with the lower level either set by exemptions or, theoretically, down to zero.

These exemptions are set forth in NRC and EPA regulations, but have been derived without the existence of consistent and uniform criteria. In most instances, it is difficult to identify the bases on which many exemptions were calculated and included in regulations. Compliance inspectors tend to use such arbitrary numbers in regulations as firm and binding on radiation users and issue orders to comply without consideration of alternatives or possible exposure to people and issue citations and fines for failure to comply. A



scientifically derived de minimis level, or set of criteria, would be an essential element in the development of rational, objective, consistent and uniform regulatory cut-off levels.

As a further practical reality, radiation exposures can never reach zero, well below a natural background radiation level. This level varies from place to place and from individual to individual and will exist relentlessly regardless of any additional radiation exposures, no matter how large or small, arising from the activities of man. The variation will depend on many factors, including diet and smoking habits, and results in a potentially wide range of biological effects.

EEl Objectives

EEl funded a study of the feasibility of establishing a de minimis level of radiation dose and a regulatory cut-off policy for nuclear regulation. The report, prepared for EEl in December 1981 by General Physics Corporation, concluded that such a program was feasible using the variation in natural background as one approach. The report further recommended industry initiative in encouraging the radiation regulatory agencies to establish and adopt such a policy.

EEl's objective is to seek mechanisms through which a national regulatory cut-off policy for radiation can be proposed and set in place to assure a consistent and uniform approach to dealing with low level radiation situations, to cease regulating trivial exposures. An Executive Order from the President, with a reasonable time, is desirable to implement such a policy. This Order could be a product of the Presidential Task Force on Regulatory Reform, of an interagency task force established by EPA under its radiation guidance authority, or of other regulatory review authority. A target date of early 1983 would seem appropriate.

Alternatively, or initially, EEl would seek such a regulatory policy within NRC for all licensees including nuclear utilities. A directive from the NRC Commissioners to the NRC staff would be necessary to define the internal NRC generic criteria and then to implement the criteria for all current and pending NRC rulemaking.

A similar regulatory cut-off policy implemented by state radiation control agencies will also be encouraged. The states' radiation control directors have urged such a policy for low-level radioactive wastes.



Development of Criteria

The EEI effort is directed toward the development of consistent and uniform criteria for use by radiation regulatory agencies, whether Federal, state or local. EEI will not propose dose, quantity, concentration, or effluent levels for radiation or radioactivity. The criteria will recognize that below derived de minimis levels there may be some risk but that the risk, when compared to the variation in risks of natural background or to general societal risks, need not be regulated.

EEI will urge the responsible Federal agencies, with input from states, to work together in a timely manner to develop such criteria. In addition, a coordinated industry effort by EEI and AIF should be started to draft and propose such criteria, with input from INPO and EPRI, for consideration by the agencies, or by NRC.

A petition for rulemaking by industry may be in order which could propose that all current and pending NRC regulations that, for example, provide for exemptions be amended simultaneously to require the use of the criteria as the common basis for any decisions on generic or specific exemptions. Other aspects of NRC's rules may require modification as well.

Current and Future Efforts

EEI has provided copies of the December 31, 1981 feasibility study report to many Federal and state regulatory agency contacts and to staff of other interested organizations of radiation users. Very close and cordial cooperation with AIF staff has developed and continues. EEI committees have been provided copies and have been requested to provide comments. Affected AIF committees are being encouraged to review the report and be prepared to reference it in future comments to NRC on a variety of topics.

An effort is underway to identify radiation problems which are currently being over-regulated, in the absence of a national regulatory cut-off policy. Nuclear utility "horror" stories have been solicited from several sources. Estimates of current costs imposed on nuclear utilities and ratepayers because of the absence of this policy, either by NRC or among other Federal or state radiation control agencies, indicate that millions of dollars are being required to satisfy arbitrary regulations.



An initial draft of proposed criteria has been completed and discussed with nuclear utilities' health physicists and others. As one possible action, a draft of a Presidential memorandum to Federal agencies encouraging an interagency task force on de minimis has been prepared along with a draft of a possible Presidential Executive Order implementing the anticipated report of the task force in a timely manner.

To date, contacts have been made with staff members of the Nuclear Regulatory Commission and the Environmental Protection Agency. In addition, EEI staff will discuss the de minimis effort with participants in the 14th Annual Conference of (state) Radiation Control Program Directors (CRCPD) on May 26, 1982.

Other interested groups have also been contacted, including the Atomic Industrial Forum (AIF) and the National Council on Radiation Protection and Measurements (NCRP). A de minimis project has been organized by the Health Physics Society's Committee on State and Federal Legislation.

EEI Consultant Services

EEI continues to contract with General Physics Corporation, Columbia, Maryland, for the services of Joyce P. Davis. Ms. Davis is the author of the feasibility study and combines the technical expertise of a Certified Health Physicist, Professional Engineer and attorney. This unique combination provides EEI with a balanced approach to the scientific and legal arguments and precedents relating to this program.

Comments on the "De Minimis" Concept Presented in
Proposed Revised 10CFR Part 20
(August 1982 Rough Draft)
by Joyce P. Davis, General Physics Corporation

NRC staff is to be congratulated for taking a giant step toward the rationalization of radiation control regulation by its explicit adoption of the concept of de minimis radiation exposures, and its program of lower "cut-off" levels for most regulations. This approach serves to focus the resources of both the regulator and regulatee on those radiation exposures that could have potentially serious consequences, and stop the waste of resources on trivial matters.

We strongly support the de minimis concept and its use by the NRC. We believe, however, that NRC could apply the regulatory cut-off concept even more widely in the proposed part 20. We also believe that the basis for the levels specified in the proposed regulations needs further discussion. Our specific comments follow:

The De Minimis Concept - Regulatory Cut-Off

The idea of a trivial (or de minimis) dose level is part of a larger concept of cut-off levels for all regulations, expressing the lower limits of regulatory concern. In addition to the doses specified as de minimis in this draft, which apply to ALARA and collective doses to the public, NRC has proposed cut-offs for monitoring, reporting, etc., applicable to specific aspects of the regulations. We support such an approach and encourage NRC to develop a de minimis policy and internally consistent cut-off levels for all its regulations.

Acceptable Risk

The NRC's approach to setting de minimis levels for the general population purports to rely on a quantitative risk assessment. The "acceptable" risk used as guidance is a level advanced by the Food and Drug

Administration in a proposed rulemaking to establish an acceptable risk level for the presence of a carcinogen in food - a value of one DES-induced cancer death in a million per lifetime. This is a value proposed by one agency and is not a government-wide guideline. Others, in and outside of the government, have looked at values of risks that could be considered "acceptable," "trivial," or "negligible," based on the apparent unconcern with which they are viewed by the public, and have generally come up with numbers on the order of 10^{-5} to 10^{-6} per year.

Furthermore, most carcinogens, or suspected carcinogens, are substances that are not present in the natural environment in substantial quantity. Radiation, on the other hand, is not only one of the best understood and most detectable of environmental agents, but one that has been naturally present in man's environment since the dawn of human existence.

We do not take issue with the interim use by NRC staff of the FDA value, as quantification of a risk level that is certainly "trivial," in the context of proposing, for comment, levels of de minimis exposure of the general public, recognizing that it is a very conservative value. However we urge NRC to develop its own criteria for the determination of risk or dose levels that can be considered negligible in various regulatory contexts.

The Commission itself has proposed some guidance on quantified risk levels such that "individuals living or working near nuclear power plants should be able to go about their daily lives without special concern by virtue of their proximity to such plants" (emphasis added) (NUREG-0880). This is clearly a definition of a de minimis level. The proposed quantitative guidance for the risk of fatal cancers from accidents at nuclear power plants is an increment of no more than about 2 in a million per year (0.1% of the sum of cancer fatality risks arising from all other causes).

One might argue that the guidance level for the acceptable risk of a facility like a nuclear power plant that has substantial benefits associated with it should be higher than a de minimis level. However, the NRC proposed guidance in question was not based on risk-cost-benefit analysis but on the smallness of the risk relative to the normal incidence of fatal cancers.

Therefore, that proposed guidance level seems of direct applicability to setting de minimis levels for radiation-induced cancers from whatever cause.

A de minimis risk of 2 in a million per year, using the risk coefficient of Table I (which is probably a gross overestimate - see discussion below) would imply a de minimis dose of more than 15 mrem/yr, rather than the 0.1 mrem/yr used in proposed Paragraph 20.303(b)(ii).

Basis for "De Minimis" Level - Application to Calculations Relating to Public Dose

The NRC staff states that it is using a "quantified risk" approach to setting the de minimis level. The acceptable risk level is equated to a dose level by means of the "total risk coefficient" of Table I. There is no discussion of the applicability of that risk coefficient to extremely low doses in the range of 0.1 to 1.0 mrem/yr. Earlier in the discussion, however, at pg. 9, it is stated that "the risk coefficients, which were derived for exposure conditions with doses higher than are expected to occur in the application of this revision, are more likely than not to overestimate the true risk." The context in which these risk coefficients of Table I are introduced, and first used, is the setting of occupational dose limits. These limits are 5,000 to 50,000 times those that are deemed de minimis on page 39. Most radiological health experts would agree, we believe, that the assumption of linearity of risk over the range from high to these extremely low levels is, at best, only an approximate one. In this regard, the use of even two significant figures in the risk coefficient at dose rates in this very low range is unwarranted and misleading. As stated on page 17, "there is substantial reason to believe that for some radiation (x-rays, gamma-rays, electrons) the actual relationship between dose and effects is non-linear, such that the risk for low levels of exposure is actually lower than predicted by the linear assumption." In the subject draft, NRC staff acts on that belief in admonishing licensees to choose lower individual doses, generally, in preference to lower collective doses.

If NRC chooses to use risk coefficients to estimate dose, as shown on page 39, it should make it clear that this is not a true mathematical equation. It is more in the nature of an inequality: A dose of 0.1 mrem per year corresponds to a risk of less than (probably much less than) 10^{-6} cancer deaths per lifetime. The last full sentence on page 39 should therefore state: "Thus, if an individual were to receive an incremental 0.1 mrem per year every year for a lifetime, the estimated incremental risk of cancer death induced by that lifetime increment of radiation would be less than one in one million." (Text changes underlined.)

As an alternative to the use of extrapolated risk coefficients, the de minimis level for the general population could be set by reference to average background radiation dose levels or the variability of background. Whatever the risk associated with background radiation, it is not large enough to be detected, even in sophisticated epidemiological studies. It is generally treated as a negligible risk. A de minimis level of the order of the average annual natural background dose (about 100 mrem) to an individual in the U.S., or a substantial fraction of that dose, would not seem unreasonable. A de minimis level could also be set in relation to one or more measures of the average variability of background radiation in the U.S. over time or space. Such statistical measures could be derived from data already in existence.

An additional advantage of using background levels rather than extrapolated risk coefficients as the basis for a de minimis level lies in the fact that background levels (and their variability) are measured and known to a fair degree of certainty. Their order of magnitude is well documented. Risk coefficients, on the other hand, are "known" only by extrapolation over five or more orders of magnitude.

Other Applications of the "De Minimis" Approach

a. Occupational Levels

The concept of a level of "no regulatory concern" is a broad one and can apply to all regulations. Every time an upper limit is set, there should be a lower cut-off set as well. In particular, as applied to 10CFR20, we believe

that, in addition to cut-off limits for personal monitoring, there should be a de minimis level for occupational exposure that would serve as a floor for occupational ALARA calculations and for truncation of collective occupational dose estimates. Based on the internal logic of the proposed regulations, using the staff assumptions and the proposed de minimis value for dose to the public, it appears that an analogous de minimis level for occupational dose would be about 50 mrem/yr. Because plant populations are small and comprise only adults, a different level for collective doses does not seem appropriate. If these additional de minimis levels were adopted, occupational ALARA calculations would never have to include doses below a level of about 50 mrem/yr (1% of the occupational dose limit) and collective dose calculations could be truncated at about the same level.

This suggestion is consistent with NRC's allowances of a 1% additional dose to overexposed workers. It is, in effect, saying that 1% of the occupational limit is negligible for workers. It would also serve to foster the reduction of relatively larger doses in preference to collective doses, since the contribution of very small doses (below .05 rem) to collective dose calculations would be eliminated.

Suggested Addition to Regulations, Para. 20.21(d)

A de minimis dose level of 50 mrem (.5 mSv) per year may be applied to any individual occupational dose estimate and may be used to truncate collective occupational dose estimates.

b. Waste Disposal

NRC should consider establishing de minimis quantities and concentrations of radioactive materials, in addition to the quantities derived from ALI and DAC tables, for application to radioactive effluents, wastes and scrap. NRC should also consider setting a lower limit on "radioactivity" (e.g., 10CFR Section 71.7 sets 0.002 uCi/gm for shipping) and "contamination." Quantities and concentrations paralleling those in other parts of the regulations (e.g., "exempt" and "unimportant" quantities or fractions thereof) could be set as de minimis. The setting of de minimis levels does not imply that those levels must be met before particular waste materials can be disposed of. For wastes

for which there might be regulatory concern (i.e., those not meeting de minimis criteria), approval would still be required pursuant to 20.1002, and a particular or generic ALARA level, above the de minimis level and consistent with the requirements of part 20, would be involved.

The de minimis guidance for concentrations in air and water (derived from ALI and DAC tables) are useful for airborne and aqueous effluents and wastes. The availability of similar guidance for solutions and dispersions in oil, soil, sludge, resin, concrete, etc., and for contamination levels for protective clothing and similar materials would permit the saving of regulatory and administrative effort and the optimum use of disposal site space. It would also reduce unwarranted shipping and burial costs for wastes that are only nominally radioactive and not at all hazardous.

The concentration of natural radioactivity in rock and other materials might provide a basis for setting de minimis levels for such solid materials.

Comments on Text of the Regulations

Paragraph 20.2 Definitions (Individual definitions should be numbered)

On page 6, item (d):

Alphabetically "de minimis exposure" should be (c) not (d). We suggest, in the second line, "a calculated" be replaced by "an estimated." First of all, "calculated risk" has a special idiomatic meaning not intended here. Secondly, the "calculations," as described above, are very inexact. To avoid misleading implications of accuracy, "estimated" is better.

(page 11)

"Radiation" (a)

"Radioactive material" - we suggest adding a lower limit, i.e., "means material which emits radiation spontaneously, having a specific activity in excess of 0.002 microCurie per gram."

(page 32)

Paragraph 20.303(b) (Suggest re-numbering as 20.304)

The introductory material in section (1) should be deleted. It is ambiguous, since it can be read as permitting the use of the de minimis level in a particular case only if one first determines that there would otherwise be an unwarranted commitment of resources. A de minimis level is one that is so trivial that once it has been set, no such prior determination need be made. If this language is intended to be merely introductory descriptive material, it should not be part of the regulation, but should be put into the statement of considerations. If NRC believes it must appear in the regulation, as a statement of the basis for the regulation, it should be included only as a footnote.

Section (2) should be deleted in its entirety. There is no need for a separate accounting procedure for sub-de minimis doses. If a licensee must prove compliance with this section, he must keep records and do calculations below the de minimis levels and NRC will have to inspect and review them. That is exactly what setting these de minimis levels is meant to prevent. The licensee is responsible for keeping all doses, to everyone, below the applicable limit, ALARA, and generally below the reference level. That is all that is necessary. The de minimis level should be treated, not as a limit, but as an administrative convenience. Any gross misapplication of the de minimis regulations is likely to be readily detected. The cumulation of de minimis levels would be subject to detection long before the reference action levels were reached.

Thus, the section (b) should contain only the items now numbered (i) and (ii).

We believe the values of de minimis dose, used in the August 1982 draft revision, are quite conservative and could be increased by a factor of 10 or more without compromising the triviality of the risks involved.

Nomenclature

Because the term "de minimis" has been used by different people in somewhat different contexts, and because the use of Latin might appear obfuscatory to the public, we believe NRC should denominate the levels it now calls "de minimis" in some other way. They might be called "cut-off" levels, "levels of no regulatory concern," etc. Alternatively they could be called "reference levels" generically, and then specifically denominated by their function, i.e., "minimum termination level for public ALARA calculations," "collective public dose truncation level," "minimum termination level for occupational ALARA calculations," etc.

October 25, 1982

For Presentation at ACRS the Joint Meeting of the ACAS Subcommittee
Reactor Radiological Effects and Site Evaluation, November 12, 1982.

Feasibility and Methodology for Establishing Regulatory Cut-Off Levels

- Joyce P. Davis, General Physics Corporation, Columbia, MD

- I. The "De Minimis" Concept
 - A. The Legal Concept of "De Minimis"
 - B. The Regulatory Concept of "below regulatory concern"
 - C. The concept of negligible risk
 - D. The concept of radiation doses of no concern
- II. The "De Minimis" Program of the Edison Electric Institute
 - A. Initial Feasibility Study
 - B. Document Preparation
 - C. Industry Benefits Questionnaire
 - D. Current Status
 - E. Future Efforts
- III. The Nature of a Regulatory Cut-Off Policy for Low-Level Radiation Doses
 - A. Policy Statement
 - B. Guidance for Implementation
 - C. Criteria for "De Minimis" Levels
 - D. Methodologies for Setting Particular Cut-Off Levels
- IV. Approaches to Setting Cut-Off Levels for Radiation Doses
 - A. Scientific Approaches
 1. Practical Thresholds
 - a. Latency
 - b. Integer Effects
 2. Comparative Approaches
 - a. Non-Detectability
 - (1) Radiation
 - (2) Health Effects

(3) Risks

b. Relation to Background

(1) Background Radiation Doses

(2) Background Health Effects

(3) Background Risks

c. Relative Contribution to Regulated Dose

B. Regulatory Approaches

1. Derivation from Current Standards
2. Derivation for "Safety Goal" quantitative risk guidance value
3. Derivation from expert opinion
4. Derivation from dose, effect, or risk levels deemed "acceptable" to the public
5. Limitation to less than one projected effect
6. Risk-Cost-Benefit Balancing

V. Current Applications

A. 10CFR Part 20

1. "De Minimis" Public Dose - included in August draft
 - ALARA Cut-Off
 - Impacts Truncation
2. "De Minimis" Occupational Doses - not addressed
3. "De Minimis" Effluents and Wastes - included in August draft by implication for water and airborne radionuclides; other media not addressed
4. Definition of "Radioactive" and "Contaminated" - not addressed in August draft.

B. 10 CFR Part 61

1. Category of wastes "Below Class A" not defined

C. NRC Safety Goal

1. "Negligible" risk criterion for accidental deaths.

- D. EPA Re-Entry Criteria
- E. State Regulation

VI. Other Areas of Application

- A. Setting Regulatory Priorities
- B. Guidance for Enforcement
- C. De-Commissioning
- D. Legal Implications
 - 1. Cut-Off for Interests Affected
 - 2. Cut-Off for Compensation
 - 3. Guidance for Reviewing Courts
- E. Public Understanding

VII. Problems

- A. Opposi' Anti-radiation Persons
- B. Scientific "Purism"
- C. Regulatory "Ratcheting"
- D. Accumulation to Significant Levels

VIII. Benefits

- A. Public Assurance
- B. Economic Savings
- C. More Optimum Use of Resources
- D. De-Regulation

References:

"The Feasibility of Establishing a "De Minimis" Level of Radiation Dose and a Regulatory Cut-Off Policy for Nuclear Regulation" by J. P. Davis General Physics Corporation Report GP-R-33040 (December 31, 1981).


Summary of EEI "De Minimis" Project (May, 1982).

ELEMENTS OF A DE MINIMIS POLICY

- IDEA OF CUT-OFF LEVELS
- BASES FOR DETERMINING CUT-OFF LEVELS
- GUIDANCE FOR REGULATORY IMPLEMENTATION

INCREMENTAL DOSE AND RISK - REGULATORY LEVELS

Schematic Diagram - Not to Scale



Survey of previously proposed to Minimize Levels

Name	Definition and Application	Suggested Quantitative Value
Haackus (1980) Ref 1	Level below which exposures are ignored.	Whole body external - 20 - 100 mrem/yr.
Ross (1981, 82) Refs 24, 25	Level of "no concern" Cut-off for ALARA.	3% of natural background.
Wahl (1981) Ref 2	No observable effects on health.	500 mrem/yr for low-LET radiation, as low as 100 mrem/yr.
Wash & Wolcott (1977) Ref 20	Level that individual does not consider in decision making. Derived cut-off level for ALARA and optimization.	10 mrem/yr to organ or to whole body. Cut-off for a single "practice" at .1 mrem/yr.

Name	Definition and Application	Suggested Quantitative Value
Winters & Miller Refs 27, 28	Low dose radiation standard for individual in population.	20 mrem/yr.
NCRP (1979) Ref 19	"de minimis" dose. (draft)	10 mrem/yr.
ICRP Refs 31, 32	Calculation of collective doses.	See calculations when further situations change results by less than a factor of 2.

POSSIBLE BASES FOR DE MINIMIS LEVELS

RISK COMPARISON

- "ACCEPTABLE" RISK
- "NEGLIGIBLE" RISK

BACKGROUND DOSE COMPARISON


- FRACTION OF BACKGROUND
- RELATED TO VARIABILITY OF BACKGROUND

GENERIC BENEFIT/RISK EVALUATION

RELATIVE LEVEL COMPARISON

- FRACTION OF LIMIT
- INCREMENTAL EFFECT ON TOTAL

ADOPTION OF A CURRENT GUIDANCE VALUE



Practical Threshold of Latency





Fig. (c) Examples of Estimated Annual Doses to Individuals in the United States (mrem)




Natural Background Levels and Variability

<u>Area</u>	<u>Population Included</u>	<u>Background Level (mrem/yr) *</u>
U.S. (Atlantic & Gulf Coast)	6,760,000	65 - 70
U.S. (Non-coastal Plains)	46,780,000	80 - 95
U.S. (Colorado Plateau)	1,070,000	125 - 160
U.S. (Leadville, CO)	10,000	235
U.S. (Central Florida & New England Areas)	?	200
Brazil (Coastal Strips)	30,000	500
France (Granite Rock Areas)	7,000,000	180 - 350
India (Kerala & Madras States)	100,000	1300
Niue Island (Pacific)	3,000	1000
Egypt (Northern Nile Delta)	Densely Populated	300 - 400
World (Calculated Average)	2 billion	80 - 90


*Note: Levels given are for external radiation only. Internal doses not included.

From: NIH Publication No. 80-2087




ANNUAL DOSE IN MILLIREMS FROM NATURAL BACKGROUND RADIATION

Variability of State-by State Average Natural Background Levels (Adapted from Adler and Weinberg "An Approach to Setting Radiation Standards", 34 Health Physics, pp 719-720, 6/78)



Schematic Diagram of Application of a Regulatory Cut-Off Level for Non-Occupationally Exposed Individuals Based on Background Variability



Calculation of De Minimis Doses Based on Comparison with Background Cancer Risk (Adapted from "A Practical Threshold for Radiation" by G. H. Whipple)


Numerical Dose Values - Possible Bases for Regulatory Cut-Off Levels


Application	Cut-Off Level
Individual Dose Limit (general population)	500 mrems/yr
Grand Junction, Co. Cut-Off for Remedial Action	440 mrems/yr
Monitoring Threshold for Radiation Workers	1200 mrems/yr 250 mrems/yr
Indoor Contamination Cut-Off for Remedial Action - Cleanup of Inactive Uranium Mill Sites	180 mrems/yr (including background)
Regulatory Cut-Off Level - Negligible Dose	100 mrems/yr
Population Exposure ALARA Guidance for NRC Licenses	100 mrems/yr (proposed)
Guidance for Disposal or Storage of Uranium and Thorium from Past Operations	90 mrems/yr
Dose Limits (general population)	25 mrems/yr

Application	Cut-Off Level
Contamination Level Limit for Decommissioning	25 mrems/yr (suggested)
Population Exposure Reporting Cut-Off for NRC Licensees	25 mrems/yr (proposed)
Dose from Mill Tailings Disposal	14 mrems/yr
Limits on Exposure from Reactor Effluents (general population)	8 mrems/yr
Nuclear Facilities Decommissioning Residual Radioactivity	5 mrems/yr (proposed)
Nuclear Facilities Decommissioning Residual Radioactivity	1 mrem/yr (proposed)
Allowable Dose from Solid Waste Requiring No Regulatory Control or Surveillance	1 mrem/yr (suggested)
Dose with no Significant Environmental Impact	0.2 mrems/yr

Numerical Dose Values - Possible Bases for Regulatory Cut-Off Levels

Application	Cut-Off Level
Cut-Off Dose for Environmental Analyses	0.1 mrem/yr (proposed)
"De Minimis" Level for NEPA Cost-Benefit Balancing	1.12 mrem/yr (average over population)
Cut-Off level for Regulatory Concern	Somewhere between 0.01 mrem and 10 rem.





ALARA Limited by Background

BENEFITS

- PUBLIC ASSURANCE
- ECONOMIC SAVINGS
- OPTIMUM USE OF RESOURCES

HEALTH PHYSICS POLL

Q1	Q2A	Q2B	Q3	Q4A	Q4B	Q4C	Q5
PHD	4.0	NO	UNIV
PHD	5.0	YES	DOE-LAB	500	170.00	170.00	YES
PHD	5.0	YES	UNIV	100	100.00	100.00	NO
PHD	8.0	NO	DOE-LAB	25	5.00	5.00	NO
PHD	10.0	NO	UTILITY	25	25.00	25.00	NO
PHD	11.0	NO	DOE-LAB	125	125.00	125.00	YES
PHD	12.0	NO	DOE-LAB	20	5.00	5.00	NO
PHD	15.0	NO	UNIV	25	5.00	1.00	NO
PHD	15.0	NO	UNIV	25	25.00	25.00	NO
PHD	15.0	NO	DOE-LAB	5	5.00	5.00	NO
PHD	17.0	YES	INDUSTRY	10	5.00	5.00	NO
PHD	20.0	YES	DOE-LAB	15	5.00	5.00	NO
PHD	20.0	NO	DOE-LAB	500	100.00	10.00	YES
PHD	23.0	NO	UNIV	8	3.00	8.00	NO
PHD	24.0	YES	UNIV	5	5.00	5.00	NO
PHD	25.0	YES	UNIV	100	10.00	1.00	NO
PHD	25.0	YES	DOE-LAB	1	1.00	1.00	YES
PHD	27.0	YES	UNIV	30	10.00	10.00	NO
PHD	28.0	YES	UNIV	170	15.00	3.00	NO
PHD	28.0	NO	INDUSTRY	30	15.00	5.00	NO
PHD	30.0	YES	UNIV	5	5.00	5.00	NO
PHD	32.0	YES	DOE-LAB	20	10.00	5.00	NO
PHD	34.0	NO	OTHER	500	170.00	170.00	NO
MS	1.5	NO	UTILITY	1	1.00	1.00	NO
MS	2.0	NO	UTILITY	200	0.01	0.01	NO
MS	4.0	NO	DOE-LAB	1000	100.00	50.00	NO
MS	5.0	NO	UTILITY	25	25.00	25.00	NO
MS	6.0	YES	UNIV	25	25.00	25.00	YES
MS	6.0	YES	UTILITY	10	3.00	1.00	NO
MS	6.0	NO	DOE-LAB	300	100.00	50.00	NO
MS	7.0	YES	UTILITY	10	5.00	1.00	NO
MS	7.0	NO	UTILITY	5	1.00	0.10	NO
MS	7.0	NO	UTILITY	10	1.00	0.10	NO
MS	7.0	NO	UTILITY	100	10.00	0.00	NO
MS	9.0	NO	DOE-LAB	20	10.00	5.00	NO
MS	10.0	NO	DOE-LAB	100	100.00	100.00	NO
MS	10.0	NO	DOE-LAB	500	170.00	170.00	NO
MS	10.0	NO	UTILITY	100	1.00	0.10	NO
MS	12.0	YES	UTILITY	20	2.00	0.20	NO
MS	15.0	YES	DOE-LAB	100	50.00	25.00	NO
MS	15.0	YES	UTILITY	500	170.00	5.00	NO
MS	15.0	NO	DOE-LAB	250	125.00	125.00	NO
MS	15.0	NO	UTILITY	100	1.00	0.10	NO
MS	17.0	YES	DOE-LAB	10	2.00	2.00	NO
MS	20.0	YES	UNIV	20	5.00	5.00	NO
MS	20.0	YES	UTILITY	5	1.00	0.10	NO
MS	20.0	NO	OTHER	100	100.00	100.00	NO
MS	25.0	YES	UNIV	200	200.00	200.00	YES
MS	25.0	YES	DOE-LAB	10	1.00	1.00	NO
MS	25.0	NO	DOE-LAB	5	5.00	1.00	NO
MS	27.0	YES	DOE-LAB	10	5.00	3.00	NO
MS	28.0	YES	UTILITY	10	1.00	0.10	NO
MS	30.0	YES	UNIV	50	50.00	50.00	NO
MS	30.0	YES	DOE-LAB	500	100.00	100.00	NO
MS	32.0	YES	DOE-LAB	100	10.00	1.00	NO
BS	3.0	NO	UTILITY	10	5.00	2.50	NO

HEALTH PHYSICS POLL

Q1	Q2A	Q2B	Q3	Q4A	Q4B	Q4C	Q5
BS	5	NO	DOE-LAB	500	50	50.0	NO
BS	5	NO	UTILITY	5	1	0.1	NO
BS	5	NO	UTILITY	50	20	10.0	NO
BS	7	NO	DOE-LAB	5	1	1.0	NO
BS	7	NO	UTILITY	25	25	25.0	YES
BS	15	NO	UTILITY	10	1	1.0	NO
BS	15	NO	UTILITY	10	10	10.0	NO
BS	20	NO	UTILITY	50	5	5.0	YES
BS	20	NO	UTILITY	50	5	5.0	NO
BS	22	YES	DOE-LAB	100	10	5.0	NO
BS	22	NO	INDUSTRY	500	170	170.0	NO
BS	23	YES	DOE-LAB	100	100	50.0	NO
BS	24	YES	DOE-LAB	300	100	50.0	NO
BS	25	YES	OTHER	170	17	3.0	NO
BS	28	NO	DOE-LAB	50	15	5.0	NO
BS	29	NO	DOE-LAB	30	10	10.0	NO
BS	30	NO	DOE-LAB	200	100	25.0	NO
BS	30	NO	DOE-LAB	500	200	100.0	NO
BS	31	YES	DOE-LAB	50	10	10.0	YES
BS	31	NO	DOE-LAB	250	250	250.0	YES
BS	35	YES	DOE-LAB	10	0	0.0	NO
BS	35	YES	DOE-LAB	10	3	1.0	NO
HS	15	NO	UTILITY	25	25	25.0	NO
HS	28	NO	UTILITY	650	65	6.5	NO

PERCENT RESPONDING

TABLE OF Q1 BY Q4A

Q1	DEGREE	Q4A				TOTAL
		12-19	20-50	51-250	>250	
PHD	1.27	7.59	10.13	5.06	3.80	27.85
MS	1.27	12.66	7.59	12.66	6.33	40.51
BS	0.00	8.86	8.86	6.33	5.06	29.11
HS	0.00	0.00	1.27	0.00	1.27	2.53
TOTAL	2.53	29.11	27.85	24.05	16.46	100.00

PERCENT RESPONDING

TABLE OF Q1 BY Q4C

Q1	DEGREE	Q4C	POPULATION W/IN 50 MILES					TOTAL
			PERCENT	<1	11	12-19	120-50	
PHD			0.00	3.80	16.46	2.53	5.06	27.85
MS			11.39	7.59	6.33	7.59	7.59	40.51
BS			2.53	3.80	12.66	6.33	3.80	29.11
HS			0.00	0.00	1.27	1.27	0.00	2.53
TOTAL			11	12	29	14	13	79
			13.92	15.19	36.71	17.72	16.46	100.00

PERCENT RESPONDING
TABLE OF Q2A BY Q4A

Q2A	YEARS OF EXPERIENCE	Q4A	MAXIMUM EXPOSED INDIVIDUAL	TOTAL
	11	12-19	151-250	1 >250
PERCENT	1.27	1.27	0.00	1.27
<5	0.00	7.59	7.59	2.53
5 TO 9	0.00	6.33	7.59	7.59
10 TO 19	1.27	10.13	8.86	8.86
20 TO 29	0.00	3.60	3.80	3.80
30 AND OVER	2	23	22	19
TOTAL	2.55	29.11	27.85	24.05
				13
				79
				100.00

PERCENT RESPONDING

TABLE OF Q2A BY Q4C

Q2A	YEARS OF EXPERIENCE					TOTAL
	<1	11	12-19	20-50	51-250	
<5	1.27	1.27	1.27	1.27	0.00	5.06
5 TO 9	5.06	3.80	3.80	6.33	2.53	21.52
10 TO 19	3.80	2.53	7.59	5.06	5.06	24.05
20 TO 29	2.53	5.06	20.25	2.53	3.80	34.18
30 AND OVER	1.27	2.53	3.80	2.53	5.06	15.19
TOTAL	11	12	29	14	13	79
	13.92	15.19	36.71	17.72	16.46	100.00

PERCENT RESPONDING
 TABLE OF Q2B BY Q4A

Q2B	CERTIFIED HEALTH PHYSICIST?				Q4A	MAXIMUM EXPOSED INDIVIDUAL
	11	12-19	20-50	51-250		
PERCENT	11	12-19	20-50	51-250	>250	TOTAL
YES	1.27	16.46	8.86	11.39	5.06	43.04
NO	1.27	12.66	18.99	12.66	11.39	56.96
TOTAL	2	23	22	19	13	79
	2.53	29.11	27.85	24.05	16.46	100.00

PERCENT RESPONDING

TABLE OF Q2B BY Q4C

Q2B	CERTIFIED HEALTH PHYSICIST?					TOTAL	
	Q4C	POPULATION W/IN 50 MILES	PERCENT	11	12-19		20-50
YES	1	5.06	8.86	17.72	6.33	5.06	43.04
NO	1	8.86	6.33	18.99	11.39	11.39	56.96
TOTAL	11	12	29	14	13	79	
		13.92	15.19	36.71	17.72	16.46	100.00

PERCENT RESPONDING
TABLE OF Q3 BY Q4A

Q3	FACILITY	Q4A	MAXIMUM EXPOSED INDIVIDUAL	TOTAL		
		12-19	20-50	51-250	>250	
PERCENT	11					
UNIV		0.00	3.80	7.59	5.06	0.00
DOE-LAB		1.27	11.39	8.86	11.39	11.39
OTHER		0.00	0.00	0.00	2.53	1.27
INDUSTRY		0.00	1.27	1.27	0.00	1.27
UTILITY		1.27	12.66	10.13	5.06	2.53
TOTAL		2	23	22	19	13
		2.53	29.11	27.85	24.05	16.46
						79
						100.00

PERCENT RESPONDING

8

TABLE OF Q3 BY Q4C

Q3	FACILITY	Q4C	POPULATION W/IN 50 MILES					TOTAL
			PERCENT <1	11	12-19	120-50	151-250	
UNIV	0.00	2.53	7.59	3.80	2.53	16.46		
DOE-LAB	1.27	7.59	16.46	8.86	10.13	44.30		
OTHER	0.00	0.00	1.27	0.00	2.53	3.80		
INDUSTRY	0.00	0.00	2.53	0.00	1.27	3.80		
UTILITY	12.66	5.06	8.86	5.06	0.00	31.65		
TOTAL	11	12	29	14	13	79		
	13.92	15.19	36.71	17.72	16.46	100.00		



HEALTH PHYSICS POLL ON DEMINIMIS

1. Highest Academic Degree _____
2. (a) Years of Experience _____
(b) ABHP Certified Yes _____ No _____
3. Type of Facility (University, DOE Lab or Plant,
Utility, Other Industry and Other _____) _____
4. Suggested Safe DeMinimis for Off-site for:
 - a) Maximum exposed individual (fence post) _____
 - b) Representative population within 5 miles _____
 - c) Average to total population to 50 miles _____
5. Should person-remS be the governing factor? Yes _____ No _____

Comments: _____

DISTRIBUTION OF RESPONSES

PERCENTAGE




PHD MS RS HS

DEGREE


DISTRIBUTION OF RESPONSES

PERCENTAGE



DISTRIBUTION OF RESPONSES

PERCENTAGE




CERTIFIED HEALTH PHYSICIST?

DISTRIBUTION OF RESPONSES

PERCENTAGE

45
40
35
30
25
20
15
10
5



UNIV

DOE-LAB

OTHER



INDUSTRY

UTILITY

FACILITY

DISTRIBUTION OF RESPONSES

PERCENTAGE




1 5 8 10 15 20 25 30 50 100 125 170 200 250 300 500 650 1000

MAXIMUM EXPOSED INDIVIDUAL


DISTRIBUTION OF RESPONSES

PERCENTAGE




DISTRIBUTION OF RESPONSES

PERCENTAGE



DISTRIBUTION OF RESPONSES

PERCENTAGE



SHOULD PERSON-REMS GOVERN?